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Abstract 
Bromodomains (BRDs) are protein-protein interaction modules responsible for recognition of and 
binding to ε-N-acetylated histone lysines. Following on from the success in drugging the 
Bromodomain and extra-terminal (BET) domain BRDs, there has been significant interest in 
elucidating the biological function of the other ~ 50 BRDs encoded for in the human genome. 
The BRPF (Bromodomain and Plant homeodomain finger containing) proteins function 
endogenously as part of a tetramer involved in regulation of gene transcription, by modulating 
MYST histone acetyl transferase activity. Translocations and aberrant activity of this tetramer have 
been implicated in a number of aggressive forms of acute myeloid leukemia (AML), however the 
role the bromodomain plays in the disease progression is currently unclear. 
To this end, BRPF inhibitors were designed by optimisation of the N-methylquinolin-2(1H)-one (1) 
fragment hit. A credible, tunable SAR model for the BRPF bromodomains, built on the N-
methylquinolin-2(1H)-one core, was developed which has culminated in the synthesis of NI-42 and 
NI-57, BRPF biased and BRPF specific probes respectively. 
Having confirmed the potency and selectivity of NI-42 and NI-57, their pharmacokinetic (PK) 
profiles were thoroughly investigated highlighting excellent oral and IV PK profiles. Subsequently, 
the compounds were employed to interrogate the biological consequences of BRPF bromodomain 
inhibition in a variety of disease models, with some evidence of selective AML cell line growth 
inhibition being observed. 
NI-42 will be of most use when used in conjunction with its inactive control NI-198, providing 
confidence in biological results obtained.  
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1. Introduction 
 
 1.1  Structure of Chromatin 
Deoxyribonucleic acid (DNA), the biological macromolecule that encodes all the information in the 
human genome, is located in the cell’s nucleus and, in order to fit inside the cell, must adopt a 
condensed highly ordered structure called chromatin. 1 
 
 
Chromatin consists of negatively charged DNA, positively charged histone proteins and RNA. It is 
subcomposed of nucleosomes linked by internucleosomal histones. 
The nucleosome consists of 146 DNA base pairs wrapped in a double helix around an octamer of 
histone proteins (Figure 1). The overall structure of the chromatin varies according to the stage of 
the cell cycle as well as DNA and or histone tail modifications.  The importance of the chromatin 
structure lies in its ability to control gene expression depending on the packing adopted: 1 
1. Euchromatin - Chromatin is tightly packed, this makes it difficult for cellular transcription 
machinery to access the DNA leading to low transcriptional activity. 
2. Heterochromatin – DNA is still wrapped around the histones but no longer adopts the 
histone octamer, more resembling ‘beads on a string’. This more open structure is 
associated with transcriptionally active genes. 
Figure 1. Higher order structure of DNA: DNA is wrapped around histone octamers to form nucleosomes 
which aggregate to form chromatin. The tightly packed chromatin allows efficient packing of the DNA into 
the nucleus. Adapted from Shaw et al. 2 
 
2 
 
3. During metaphase of cell meiosis chromatin forms higher order structures involving 
alternative H1 histone analogues for maximum strength. 
 
 1.2  Epigenetics 
Controlling whether the DNA is packed in a closed form (euchromatin) or more open form 
(heterochromatin) is vital to the cell’s ability to control which genes are expressed. The 
mechanisms by which this change in gene transcription is controlled, with no concurrent change in 
gene sequence is called epigenetics. 
Whilst research has typically focussed on the genetic basis for disease there is ample evidence that 
drugging epigenetic processes can provide alternative approaches to challenging diseases like 
cancer,2 inflammation, 3 central nervous system (CNS) diseases 4 and others. 5  
Typically epigenetic phenotype changes are brought about by 3 main mechanisms, which are often 
interlinked (Figure 2): 6 
 
Figure 2. mechanisms for epigenetic phenotypic change showing how they can influence one another. 
Reproduced from Egger et al. 6 
 
1. DNA methylation– A common method for gene silencing, only cytosine nucleobases 
located adjacent to a guanine can be methylated (Figure 3). DNA methylation is highly 
mutagenic, being a frequent cause of C:G to A:T mutations. As a consequence of these CpG 
islands (> 500 base pairs, > 55% C:G content) are evolutionarily conserved  areas of low 
DNA methylation found in promotor regions of the genome. Indeed, abnormal methylation 
of CpG islands is typical in many human cancers and is believed to be a key factor in 
oncogenesis. 6 
3 
 
 
Figure 3. Cytosine methylation: A dynamic process which involves transfer of a methyl from S-
adenosyl methionine (SAM) to cytosine catalysed by DNA methyltransferases (DNMTs). DNA 
demethylation can occur via passive demethylation (concurrent DNA methylation during DNA 
synthesis) or active (independent of DNA synthesis). In both cases it is a multistep process. 
 
DNA methylation is the epigenetic method for long term information transfer and is 
responsible for generational (or even transgenerational) epigenetic heritability.  
 
2. RNA post transcriptional silencing – This is carried out by a diverse set of non-coding 
RNAs (ncRNAs) - functional RNA molecules that are not translated into proteins - which act 
via other epigenetic mechanisms to induce phenotypic change (Figure 2). 
 
3. Histone tail post-translational modification – Histones, the positively charged proteins 
around which the negatively charged DNA wraps have N-terminal tails which can be 
dynamically modified to alter the local structure of DNA. This epigenetic change tends to be 
much more malleable and transient than DNA methylation, however, histone post 
translational modifications (PTM) can also lead to DNA methylation and hence long term 
(transgenerational) genetic changes. 
 
 1.3  Histone Tail Post Translational Modifications 
Histones are positively charged proteins, divided into 5 families H1/5, H2A, H2B, H3 and H4, whose 
primary role is providing the support structure for efficient DNA packing. H1/5 histones link 
nucleosomes, whilst the other 4 families are considered ‘core’ histones responsible for nucleosome 
formation.  
Nucleosomes are linked by internucleosomal histones which can interact with one another via the 
basic N terminals of their tails. In contrast histones interact with DNA through the basic phosphate 
backbone of DNA and the positively charged histone tails. 
N terminal post translational modification (PTM) of these tails can take many forms and can 
dramatically alter the charge and shape of the histone tails and hence the higher order structure of 
the DNA. By affecting the higher order structure of the DNA the series of PTMs, called the ‘histone 
code’, can have a significant effect on gene transcription. 
1.3.1  Readers, Writers and Erasers 
Reading and maintenance of the histone code is carried out by 3 families of proteins: ’readers’, 
‘writers’ and ‘erasers’ which recognise and bind, add, and remove histone PTMs respectively 
4 
 
(Figure 4). There is a unique set of enzymes for each PTM, although some enzymes can catalyse 
modification of differing levels of the same modification i.e., some class I arginine methyl 
transferases can catalyse the formation of both Rme1 and Rme2as.7 
 
Figure 4. The three protein families responsible for the maintenence of the histone code 
1.3.2  Histone PTMs 
The first histone PTMs to be catalogued were lysine acetylation and methylation in 1964 by Allfrey 
et al. 8 Subsequently a wide variety of histone PTMs have been discovered, the most common of 
which are summarized in Figure 5 
 
Figure 5. Common histone PTMs with the PTM in bold 
Lysine Acetylation – A dynamic PTM that reduces the positive charge of the tail leading to 
transcriptionally active heterochromatin. 9 
Phosphorylation – can occur on serine, threonine or tyrosine and like lysine acetylation is 
commonly associated with gene activation.  
Lysine / Arginine Methylation - Lysine can be either mono, di or trimethylated whilst arginine 
can only be mono or dimethylated. However arginine can either be symmetrically dimethylated on 
the terminal nitrogens or asymetrically dimethylated (Figure 5). Unlike acetylation or 
phosphorylation, methylation does not necessarily directly affect the charge of the tails. Hence, 
methylation does not directly affect chromatin spacing. Instead different methylation marks recruit 
proteins to condense chromatin or cause gene transcription. 10 
5 
 
1.3.3  Other Histone Post Translational Modifications 
 A diverse array of less frequent histone tail PTMs have also been catalogued, which either directly 
affect chromatin structure (like acetylation) or recruit chromatin altering proteins in a similar 
manner to histone methylation (Figure 6). 9 
 
Figure 6. Examples of other Histone PTMs 
Ubiquitination and SUMOylation (small ubiquitin-like modifier) are both small proteins usually 
appended to histone lysines. In contrast to other modifications, the addition of a ~ 70 amino acid 
protein is relatively large and these modifications can have drastic effects on chromatin structure. 
Whilst ubiquitinylation can be either repressive or activating, sumoylation is generally repressive. 
11, 12 
In contrast, deimination and proline racemization are examples of PTMs that are both amino acid 
specific and relatively uncommon. There are a number of these specific PTMs whose functions are 
less well understood. 9  
1.3.4 Histone Acetylation  
Acetylation of lysine residues (KAc) on histone tails was one of the first post histone post 
translational modifications to be characterised, in 1964, by Allfrey et al and has long been 
associated with transcriptionally active areas of chromatin. 8 This is a consequence of the lysine 
acetylation eliminating the positive charge on the nitrogen and also blocking the interaction of the 
phosphate backbone with the amine nitrogen (Figure 7) 
6 
 
 
Figure 7. Representation of DNA interacting with histone lysine. a. Positively charged lysine amine can 
interact with negatively charged phosphate from DNA backbone – condensed euchromatin. b. Acetylation 
blocks the interaction between the phosphate and lysine and also removes the amine's positive charge – 
loose heterochromatin 
Three families of enzymes are responsible for maintenance of histone KAc levels: Bromodomains 
(BRDs), Histone Acetyl Transferases (HATs) and Histone Deacetylases (HDACs) which read, write 
and erase KAc marks respectively (Figure 8). KAc is a highly dynamic PTM and a delicate balance 
between the enzymes must be maintained, as aberrant acetylation levels have been implicated in a 
number of different disease states. 13a,13b 
 
Figure 8. Lysine Acetylation. The lysine  ε-nitrogen (red) is acetylated by a HAT (usually with acetyl CoA 
as a cofactor) to give acetylated lysine (green). Acetylated lysine is bound by a BRD (grey) leading to 
transcriptional activation. Lysines are deacetylated by HDACs 
1.3.4.1  Histone Acetylation State and Disease 
HDACs have been linked to several diseases and inhibitors of these enzymes are already in the 
clinic for the treatment of different cancers (Figure 9). Of interest is the fact that many HDAC 
inhibitors contain zinc binding motifs (i.e. hydroxamic acids in Vorinostat and Panobinostat) as a 
consequence of most HDACs having zinc in the binding pocket. 14 
7 
 
 
Figure 9. HDAC inhibitors in the clinic with indications 
The field of BRD inhibitors is, in comparison, fairly new with the first potent inhibitors only 
emerging in 2010 (see below).  Four inhibitors are currently in clinical trials, 3 structurally similar 
compounds for haematological malignancies and RVX-208 for atherosclerosis and cardiovascular 
disease (Figure 10). RVX-208’s differing disease indications can be explained by its selectivity for 
BRD4’s second BRD (BRD4 has 2 BRDs). 15 
 
 
Figure 10. BRD inhibitors with their indications in green 
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Figure 12. Structure of BRPF1 illustrates general structure of a BRD. αZ = green, αA = Blue, αB= yellow, 
αC = Red. (PDB 4QYD) 
Many small molecule inhibitors of HATs have been synthesised but efforts to evaluate these 
compounds in vitro and in vivo have been hampered by very poor cell permeability and stability. 
Currently only two HAT inhibitors have been evaluated in vivo. 16 
1.4  Bromodomains – Acetyl Lysine Readers 
Bromodomains (BRDs) were first characterized in 1992 by Kennison et al as part of the brahma 
(brm) gene, hence the name, in Drosophila. 17 Several years later (1999-2000) several groups 
independently elucidated the BRDs biological role as the recognition of ε-N-acetylated lysines on 
histone tails. 18,19  
Later large scale genome analysis revealed that the human genome encodes for 61 BRDs whose 
biological function is often as part of multiprotein complexes which can contain a wide variety of 
other epigenetic proteins including: HATs, 20 Lysine Demethylases, PHD domains 21 and many 
others.  
Large scale structural analysis of the 61 human BRDs has shown that they can be sorted into 8 
families by sequence alignment (Figure 11). 22 
1.4.1  General Structure 
BRDs consist of ~110 amino acids organized into 4 left handed antiparallel α helices (αZ, αA, αB and 
Figure 11. Bromodomain phylogenetic tree showing BRDs sorted into 8 families by sequence alignment 
9 
 
αc) joined by flexible loop regions (ZA and BC loops) which line the KAc binding pocket (Figure 12). 
It is variation within these loop regions that affords the BRD’s selective binding for different 
acetylated lysines or small molecules.  
Whilst variation is high in the hydrophobic loop regions, the KAc binding pocket is highly conserved 
with key hydrogen bonds being formed with asparagine and a water mediated hydrogen bond to a 
conserved tyrosine. Interestingly the water molecules, despite varying in number from 4-6 are 
crystallographically conserved and very difficult to displace with small molecule inhibitors (Figure 
13). 
 
Figure 13. H4K12Ac bound to BRPF1 Conserved Asp 708 and water mediated H-Bond with Try 665 
shown (PDB 4QYD). 
1.4.2  BRD4 and the BETs 
Whilst the existence and biological functions of BRDs have been known for a number of years their 
roles in disease have remained elusive. In 2006 researchers from Mitsubishi Tanabe identified 
BRD4 as the primary target from an inflammation phenotypic screen of thienodiazepines.. 23 
Further work has associated bromodomains with a range of other diseases including cancers 24 and 
neurodegenerative disease. 25 
 
Figure 14. Structure of (+)-JQ1 and IBET-762. Structurally similar BET inhibitors 
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The first small molecule inhibitors of BRDs were discovered by Zeng et al. in 2002, 26 but significant 
interest in BRDs as therapeutic targets emerged in 2010 when GSK and the Structural Genomics 
Consortium (SGC) independently discovered potent inhibitors inhibitors of BRD4 (Figure 11, 
member of the class I BRDs)  IBET-762, 27 and (+)-JQ1. 28 respectively (Figure 14).  
In large part due to the success of these inhibitors in disease models, and later clinical trials a wave 
of bromodomain and extra terminal domain (BET) inhibitors has since emerged. These inhibitors 
have a variety of chemotypes, acetyl lysine binding mimetics and selectivity profiles and have been 
vital to the scientific communities ability to dissect the biological role of BRD4 and the BETs which 
have been numerous and far reaching (Figure 10). 29, 30 
1.4.3  Class IV Bromodomains 
Following on from the success of BRD4 inhibitors screening campaigns against the other BRD 
families were initiated in the hope of finding selective inhibitors of non-BET BRDs. This would 
allow target validation akin to that of BRD4. Of particular interest was the Class IV BRDs as they had 
been implicated in a number of aggressive diseases with poor prognoses (Figure 15). 
 
Figure 15. BRD Phylogenetic Tree with Class IV BRDs in bold. NB ATAD2B sometimes referred to as 
KIAA 1240 and BRD1 sometimes referred to as BRPF2 
 
1.4.3.1  BRD7/9 
BRD9 has been reported to be part of SWI/SNF BAF type complexes, mutations of which have been 
linked with as many as 19.7% of all human tumors. 31, 32  In addition, mutations of BRD9 specifically 
have been linked with cervical cancer. 33 
BRD7 is also part of SWI/SNF complexes although it is currently believed to be PBAF specific 
subunit, as opposed to BAF for BRD9. BRD7 has also been suggested as a tumour suppressor gene, 
as it allows nuclear translocation of p85α causing a decrease in cellular phosphoinositide 3-kinase 
activity, impairing cell and potentially tumour growth. 34  
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1.4.3.2  ATAD/ATAD2B 
AAA domain-containing protein 2 (ATAD2) is a protein that contains both an AAA+ ATPase domain 
and a bromodomain binding region. Misregulation of its activity has been linked to prostate, lung, 
and triple-negative breast cancers, although it is unknown which domain is responsible for these 
effects. 35a,35b The strong cancer disease association correlates well with ATAD2’s biological 
functions as a coactivator for transcription factors which are responsible for genes involved in 
promoting cell proliferation and survival. 36 Lastly siRNA induced downregulation of ATAD 
expression has been shown to promote cellular apoptosis. 35a 
1.4.4  BRPFs 
The Bromodomain and PHD Finger (BRPF) containing proteins BRPF1, BRPF2 (henceforth BRD1) 
and BRPF3 are a set of bromodomain containing protein in class IV with >65% sequence identity. 37 
They form similar complexes in vivo, with the exception that BRPF1 can form a complex with HAT’s 
monocytic leukemic zinc finger (MOZ/MORF) and HBO1 (human acetylase binding to ORC1), whilst 
BRD1 and BRPF3 can only form complexes with HBO1. In addition BRPF1 has a small N-terminal 
extension of unknown biological effect (Figure 16). 21 BRPF1 was the first of these BRDs to be 
isolated in 1994, 38 but the role the trio play in disease and their potential duplication of function 
and redundancy is only now slowly starting to emerge. 
 
Figure 16. Domain sequence and binding regions for other complex subunits for BRPF1, 2 and 3. 
Reproduced from Yang et al. 21 
1.4.4.1  BRPF3 
Genome wide association studies (GWAS) have linked BRPF3 mutations to a number of different 
diseases. These include the l-citrullin-NO pathway during rodent reproduction, 39 
cholangiocarcinomas (bile duct cancer) which account for 10-20% hepatobiliary cancers 40 and 
synonymous mutation in the trd1 gene locus involved in regulatory T-Cell development in 
nonobese diabetic mice. 41 In addition, specific BRPF3 mutations have also been linked to 
aggressive forms of leukaemia (mean survival time 12 months - adult leukaemia through  E419K 
mutation and paediatric leukaemia through T1031M mutation). 21 
1.4.4.2  BRPF2 (BRD1) 
Many of the disease states associated with BRD1 can be linked with its control of H3K14Ac levels. 
These are controlled by BRD1 bridging and joining HBO1 with its activator protein ING4 (inhibitor 
12 
 
of growth 4). 42 If either HBO1 or BRD1 is depleted in mice knockout studies H3K14Ac levels are 
significantly lowered. Similar depletion of ING4 lowers the H3K14 levels but the effect is not as 
dramatic.  
One effect of lowering H3K14Ac levels is the knockdown of fetal erythropoiesis. The ensuing 
anaemia is thought to be the cause of the unviability of BRD1 knockdown mice. 42-43 Unlike BRD1, 
BRPF3 is not required for survival in fetal mice. 42 
H3K14Ac levels have also been linked to Cd8 (required for killer T-Cell differentiation) expression 
in the thymus. Insufficient acetylation, as a result of lower than normal BRD1 levels, has been 
shown to cause abnormal Cd8 expression in CD4+CD8+ double-positive thymocytes 
(haematopoietic progenitor cell present in the thymus). Deletion of BRD1 by siRNA knockdown 
showed correspondingly low levels of CD8 expression. 44 
In addition to being required in erythropoiesis, BRD1 expression levels have been linked with 
electroconvulsive therapy (ECT) for drug resistant severe depressive disorders. After ECT 
administration, hippocampal BRD1 messenger RNA (mRNA) levels were quantified and a strong 
dose dependence was observed between number of ECT treatments and BRD1 mRNA. .BRD1-S 
(short BRD1 mRNA) showed a positive dose dependence with ECT whilst BRD1-L (long BRD1 
mRNA) showed a negative dose dependence. The observable time period from ECT treatment to 
improved mental status suggests that epigenetic reprogramming may be responsible for improved 
mental status and might represent a novel drug target for psychiatric disease. 45 
1.4.4.3  BRPF1 
BRPF1 is the most characterized member of the BRPF family. BRPF1 exists as 2 splice variants 
BRPF1A and BRPF1B where the splice variant BRPF1A is incapable of binding KAc because of a 12 
amino acid insertion in the ZA loop (unpublished work by the SGC).  
 BRPF1B’s (henceforth BRPF1) biological function has been well characterized in a number of 
different systems and, similarly to the other BRPF members, it performs a bridging role between 
MOZ HAT and the other members of its biologically active tetrameric complex:human ESA1 
associated factor 6 homolog (hEAF6) and inhibitor of growth 5 (ING5) (Figure 17). Each of these 
complex subunits has multiple epigenetic domains highlighted in Figure 17. 
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Figure 17. BRPF1 tetrameric complex showing general structure and linking role of BRPF1. Different 
epigenetic reader domains highlighted reproduced from Poplawski et al. 49  
 
 
The interplay between the reader domains and their control of the MOZ HAT activity is thought to 
begin with the ING5 PHD domain binding H3K4me3 and subsequent recognition of unmodified H3 
by the MOZ tandem PHD domains. This association of the tetrameric complex to chromatin allows 
the MOZ HAT to acetylate H3K14,H4K5, H4K8 and H4K16. Lysine acetylation promotes binding of 
the BRPF1 BRD further strengthens the complex chromatin association, promoting increased HAT 
activity and creating a positive feedback loop. 46 
1.4.4.3.1  BRPF1 and disease 
The MOZ HAT and the complex it forms with BRPF1 was first identified in a chromosomal 
translocations found in a rare subtype of acute myeloid leukemia (AML) associated with a poor 
prognosis (median survival - 6 months). This t(8;16)(p11;p13) translocation involved MOZ  
forming a fusion partner with the CREB binding protein (CBP) HAT in which both HATs retain 
acetylation activity. Indeed overactivity of these two domains in this translocation have been linked 
to leukemogenic transformations and oncogenesis. 47 
MOZ/BRPF translocations have also been identified with the CBP homolog p300, the transcriptional 
intermediary binding factor 2 (TIF2) and the nuclear receptor co-activator 3 (NcoA3) transcription 
factor. Similarly to the CBP translocation, in the p300 translocation both the HAT and the MOZ 
acetyltransferase domains remain intact and functional. The resulting aberrant HAT activity is 
thought to contribute to leukemogenesis and the development of AML. 
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2. Project Aims 
 
When we initiated our research project (Sept. 2012) there was a clear disease association between 
the BRPF proteins and disease. However, there were no small molecule inhibitors of the BRPF 
bromodomains available to the scientific community to ascertain the role that the BRPF 
bromodomains played in this association.  
Thus, it was the aim of this project to:  
1. Develop a fit-for-purpose (potent, selective and cell active) chemical probe for BRPF 
bromodomains. This would allow for the bromodomain target validation and provide 
potential starting points for a future drug discovery program.  
2. Develop the probe by optimisation of the N-methylquinolin-2(1H)-one (1) core. This 
template was chosen as it displayed excellent chemical stability, synthetic tractability and 
evidence of BRD inhibition. 
This was carried out in collaboration with the Structural Genomics Consortium (SGC). 
2.1  N-methylquinolin-2(1H)-one as a BRD inhibitor 
N-methylquinolin-2(1H)-one (1) was first identified as a BRD inhibitor as part of a fragment screen 
carried out by the SGC and Chaikud et al. This highlighted that 1 was a 70 mM hit against the PCAF 
(P300/CBP associated factor) BRD.48 Structural elaboration, by amination at the 6 position gave 2, 
moving activity into the class IV BRDs. Subsequent coupling of the amine to form sulfonamide 3 
narrowed down activity to the BRPF subfamily (Figure 18). 
 
Figure 18. Evolution of fragment hit (1) in class I (top right), to  amine (2) with BRD9 potency (left), to 
sulfonamide (3) with BRPF3 activity (left). 
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2.2  Criteria for a Fit-for-Purpose Chemical Probe 
In order for a chemical probe to provide reliable results a number of generally accepted quality 
criteria must be met. Our initial goals focussed on meeting the criteria set out by the SGC for their 
chemical probes: 49 
1. IC50 or KD < 100 nM against primary target 
2. 30 fold selectivity over members of the same protein class. 100 fold over proteins of other 
classes 
3. Significant cellular activity at 1 μM 
 Should these primary goals be achieved, it was envisaged that the more comprehensive criteria set 
forth by Workman et al could then be systematically investigated (Figure 19): 50a, 53b 
 
Figure 19. Criteria for a chemical probe, reproduced from Workman et al. 50b 
2.2.1  Selectivity  
Profile – Greater than 30-fold selective against all members of the same protein family and greater 
than 100-fold against all other proteins. Suitable selectivity is important as it imparts confidence 
that a phenotypic readout from a biological assay can be unambiguously attributed to inhibition of 
the desired protein.  
Inactive control – Determining the biochemical selectivity of a probe is vital to obtaining reliable 
results, however, it is impossible to screen against all possible intracellular interactions. As such, 
biochemical selectivity may not truly represent the in vitro selectivity. Hence it is desirable to have 
a molecule that is as structurally similar as possible to the probe, yet inactive. This will help confirm 
that phenotypic readouts are a result of interrogation of the protein of interest and not a result of 
off target interactions or assay artefacts. 
Structurally orthogonal probe – in a similar vein to having an inactive control, possession of a 
second probe which is structurally orthogonal in the key binding region of  the protein can also 
validate assay readouts. In the case of BRDs this usually means an alternative KAc mimetic 
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2.2.2  Chemistry 
Aqueous soluble - Compound must be soluble in aqueous media at a sufficient concentration to 
completely inhibit the protein of interest. Otherwise in vitro and in vivo application will be limited. 
Cell permeable (for intracellular targets) – for cellular in vitro models to be reliable, it is necessary 
for the probe to pass through the cell membrane and interact with the proteins within the cell and 
or nucleus. Otherwise, a lack of activity in the assay may be misinterpreted as a lack of interaction 
with the protein of interest. 
Structure and Stability – The well characterized chemical structure along with a reproducible 
synthetic method yielding high purity material, will provide confidence in the material sent for 
testing. In addition, the stability of the probe in test media is vital. 
 2.2.3  Potency  
Biochemical and cellular potency – For BRDs this has been agreed as < 100 nM biochemical assay 
potency and < 1 μM intracellular potency, although the values are very target dependent. Greater 
biochemical than intracellular potency must be achieved to accommodate for the potency decrease 
usually observed between these two settings. As a corollary to this it is important to measure 
intracellular concentration as it may vary greatly from assay concentration and may adversely 
impact results, especially with regard to selectivity windows. 
SAR – closely related structures with defined SAR suggest that potency/phenotypical readouts are a 
result of probe inhibition and not assay noise. 
In vivo profile – if the probe is to be used in vivo the pharmacokinetic profile must ensure that the 
intracellular concentration of the probe is high enough to produce a phenotypical result 
2.2.4  Context 
Genetic corroboration of results – siRNA knockdowns/ knockouts and genetic mutants can provide 
invaluable comparison to data generated from probe studies. 
Availability – Ideally full data on the probe is disclosed with no restrictions on access to material 
2.2.5  JQ1 as an Example of a Fit-for-Purpose Chemical Probe 
(+)-JQ1 (Figure 20) is a probe developed by the SGC and Jay Bradner for the BET proteins. The BET 
proteins includes BRD2, BRD3, BRD4 and BRDT, all members of the Class II BRDs (Figure 11). As 
one of the first bromodomain probes to be discovered (+)-JQ1 fulfils many of the required criteria 
for an excellent chemical probe: 
1. Potency - KD – 49 nM against BRD4(1) and 90 nM against BRD4(2). 
2. Selectivity - > 30 fold selective against all non-BET BRDs, inactive against 55 ion channels and 
receptors. 
3. Solubility - aqueous soluble. 
4. Cell permeability - Localisation to the nucleus and target engagement at < 1 μM confirmed by 
fluorescence recovery after photobleaching (FRAP) assay. 
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5. Inactive control – (-)-JQ1 the enantiomer is inactive against all BRDs and off target proteins. 
6. Orthogonal binding motif - PFI-1 (Figure 20) has very similar selectivity profile with a 1,3-
dimethyl-3,4-dihydroquinazolin-2(1H)-one core as an alternative KAc mimetic .51 
 
 
Figure 20. Structures of BRD4 inhibitors PFI-1 and  (+)-JQ1 
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3. Published Inhibitors of the Class-IV BRDs 
 
 3.1 Designing an inhibitor of a BRD 
The structure of a BRD differs significantly to that of other epigenetic reader domains in that it has 
a comparatively deep, hydrophobic binding pocket. This makes BRDs ideal targets for the design of 
small molecule inhibitors. In contrast, chromodomains, which read methylated lysines have 
charged flat binding pockets consisting of antiparallel strands, making them comparatively difficult 
to drug. 
There are a number of key aspects that need to be addressed when designing a BRD inhibitor: 
1. The most important interaction in the binding pocket of a BRD is that between the  
acetylated lysine and the conserved asparagine and tyrosine residues. As such all BRD 
inhibitors have a warhead that ‘mimics’ this key interaction. Typically this KAc mimic is 
itself an amide, but recently more unusual warheads have been disclosed. A selection of 
KAc mimics is shown in Figure 21. 
 
2. Potency of BRD inhibitors can be increased by designing molecules that interact with the 
so called ‘WPF shelf’. First noticed to be crucial in BRD4 inhibitors this shallow, lipophilic 
shelf contains repeating units of 3 amino acids, one of which is phenylalanine. Variations of 
the 2 other amino acids in the shelf can also allow for selectivity in BRD inhibitors. To date 
only 2 BRD inhibitors have been disclosed which do not intereact with this area of the 
protein, PFI-4 (as well as structurally related GSK5959 and GSK6853) and RVX-208. 52 
 
3. BRD binding pockets contain between 4 and 6 conserved deep pocket water molecules 
which it would be entropically favourable to displace (Figure 13). However, efforts in this 
regard have proved largely unsuccessful and  PFI-3 is currently the only  published 
inhibitor to be deeply enough bound in the pocket to displace the conserved water 
molecules. 53 
 
4. Differences in the ‘gatekeeper’ residue, an amino acid that lies at the entrance to the KAc 
binding pocket, can be exploited to confer selectivity of inhibitors. The gatekeeper residue 
varies in both size and lipophilicity from the small isoleucine in BRD4 to phenylalanine in 
the BRPFs. Indeed, the residue tends not to vary much between families which can make it 
difficult to achieve intrafamilial selectivity. 
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Figure 21. Selection of published KAc mimetics (mimetic in bold). Published inhibitors with this mimetic in 
green 
Many of these criteria have been gainfully employed in the design of inhibitors of the class IV 
bromodomains. An overview of the published inhibitors is presented below. 
 3.2 ATAD2 
WPF Shelf Residues: Arginine, Valine, Phenylalanine 
Gatekeeper Residue: Isoleucine  
With its comparatively shallow and polar binding pocket ATAD2 is considered the most difficult of 
the class IV BRDs to drug. 54 Despite this, high throughput screening (HTS) of fragments has 
facilitated the discovery of several potent inhibitors of this BRD.  
In 2013 the SGC disclosed fragment hits with modest affinity for ATAD2 based on a uracil template 
(4, Figure 22). 55 Subsequently, in 2014, Harner et al disclosed a selection of more potent fragments, 
although several of the more potent fragments were inversely selective for other members of the 
class IV bromodomains. 56 
 
Figure 22. A selection of published fragments that inhibit the ATAD BRD. KAc mimetic in bold 
To date, the most potent ATAD2 inhibitors have been disclosed by GSK, with initial publication of 7, 
a low μM inhibitor. Subsequent lead optimization of 7 yielded 8, which was 10 fold more potent an 
inhibitor of ATAD2. Addition of the pyridine ring at the 5-position maintained both the ligand 
efficiency (LE 7: 0.21, LE 8: 0.20) and the lipophilic ligand efficiency (LLE 7: 6.34, LLE 8: 6.34) . 
Unfortunately, despite maintaining the binding metrics of the lead compound, selectivity of 8 vs 
BRD4, inhibition of which has widespread biological consequences, was insufficient for its use as a 
probe molecule. 57a, 57b  
20 
 
 
Figure 23. GSK inhibitors of ATAD2 KAc mimetic in bold 
 3.3 BRD7/9 
WPF Shelf Residues Glycine, Phenylalanine, Phenylalanine  
Gatekeeper Residue Tyrosine 
There has been significant progress in the development of potent and selective inhibitors of BRD9 
and BRD7. Whilst most of the reported inhibitors in the literature are dual inhibitors of both BRDs, 
Theodoulou et al have also reported I-BRD9, a BRD9 selective inhibitor (Figure 28). 58 
3.3.1 BRD7/9 dual inihibitors 
The SGC and coworkers have published several dual inhibitors of BRD7/9. The first of which, LP99, 
is based on the same core as the work described herein N-methylquinolin-2(1H)-one (1). The core 
was elaborated by addition of a substituted valerolactam ring at the 7 position and a methyl group 
at the 4 position of the quinolin-2-one ring (Figure 24). 
 
Figure 24. Development of LP99 from N-methylquinolin-2(1H)-one. KAc mimetic shown in bold 
LP99 forms the key binding interactions through the C2 carbonyl in the quinolinone A ring 
interacting with the conserved Asn 100 and Tyr 57. In addition, the quinolinone A ring forms a 
beneficial π-stacking interaction with Tyr 106 the gatekeeper residue in BRD9. LP99 has a potency 
of 99 nM by ITC KD, but whilst it is disclosed that there is activity by DSF against BRD7, the potency 
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of the interaction is not quantified. The enantiomer of LP99 (Ent LP-99) is inactive against all BRDs 
and is an excellent negative control for this inhibitor. 51 
The second SGC BRD7/9 inhibitor was developed from the fragment 9, which was also used as a 
starting point towards a BAZ2A/B inhibitor. Substitution of the n-propoxy by a morpholine ring and 
fusion of a pyrrole to the pyridine ring furnished compound 10 (Figure 25). 
 
 
Figure 25. Development of Fragment 7 into BRD7/9 inhibitor 9 
Compound 10 displayed a BRD9 KD of 68 nM and was selective against all other bromodomains, 
including BAZ2A/B. Similarly to LP99 the acetyl was interacting with Asn 100 and Tyr 57, whilst 
forming a π stacking interaction with Tyr 106. 59 
 
Figure 26. Structure of TP472 and its inactive analogue. KAc mimetic in bold 
Recently a number of other BRD7/9 inhibitors have been reported including TP472, developed by 
the SGC in collaboration with Takeda, which is very structurally similar to inhibitor 10.  Also 
mentioned on the SGC website is negative control compound TP472N. TP472 is also slightly more 
potent than 10 with an ITC of 33 nM against BRD9 and 10 fold selectivity over BRD7 for which it 
has a KD of 340 nM. 28  
The last of the BRD7/9 inhibitors disclosed at this time is BI-9564 which is based on a different 
chemotype to the previously reported inhibitors of the same BRD. BI-9564 developed in 
collaboration between the SGC and Böhringer Ingelheim displays potencies of 14 nM and 239 nM 
against BRD9 and BRD7 respectively. 28  
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Figure 27 Structure of BI-9564 KAc mimetic in bold 
3.3.2 BRD9 Selective Inhibitors 
To date, the only BRD9 selective inhibitor is I-BRD9, developed by Theodoulou et al at GSK. 
Screening of the internal GSK compound library indentified thienopyridone (11) which was 100-
fold selective for BRD9 over BRD4. Selectivity was maintained, whilst increasing BRD9 potency by 
replacement of the carboxamide  amidine at the 2 position of the thienopyridone and the 
introduction of an electron withdrawing 2-trifluoromethylbenzene group to fit into the WPF Shelf 
in BRD9. 58 
 
Figure 28. Optimisation of fragment 11 to give I-BRD9 
Measurement of BRD7/9 potency by DiscoverX revealed that I-BRD9 was ~ 200 fold selective for 
BRD9 over BRD7 (BRD9 KD : 2 nM, BRD7 KD : 398 nM). The authors suggest that the origin of this 
selectivity may lie in the replacement of Gly 46 in BRD9 with Ala46 in BRD7, creating a slightly 
larger pocket for the trifluoromethylbenzene group to occupy.   
 3.4 BRPF inhibitors 
WPF Shelf Residues: Asparagine, Isoleucine, Phenylalanine 
Gatekeeper Residue: Phenylalanine  
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Workers at the SGC, GSK and Pfizer have all reported inhibitors of the BRPF bromodomains based 
on the 1,3-dimethyl-1,3-dihydro-2H-benzo[d]imidazol-2-one core.  PFI-4, GSK5959 and GSK6853 
are all BRPF1 specific inhibitor with large structural similarities, 28, 37, 60 whilst OF-1 is a pan BRPF 
inhibitor. 28   
 
Figure 29. Published inhibitors of the BRPF bromodomains. KAc mimetic in bold. 
All of these BRPF1 inhibitors exploit the same key KAc mimetic interactions. The carbonyl bonds 
with Asn708 and via a water mediated hydrogen bond with Tyr665 (Figure 30). Overlaying the 
apo-structure of BRD1 with the cocrystal structure of GSK6853 suggests that the only difference in 
the 2 bromodomains that might account for the exquisite selectivity is BRPF1’s Pro658 which is 
replaced in BRD1 by Ser698 and Asn619 in BRPF3. The advantage of the BRPF1 proline lies in its 
ability to form a stabilising hydrophobic interaction with the 1,3-benzimidazalone ring, an 
interaction serine and asparagine are unable to form (Figure 30).  
 
Figure 30. Cocrystal structure of GSK6853 with BRPF1 (Purple) overlayed with the apostructure of BRD1 
(pale green) highlighting the key binding interactions and the hydrophobic interaction between Pro 658. 
PDB ID: 5G4R 
Whilst the 1,3-benzimidazalone core was able to yield a number of potent and selective BRPF 
inhibitors, the main drawback of this core was its inherent insolubility. It is for this reason that 
Demont et al further developed GSK5959 into GSK6853, derivatising the piperidine ring into a 2-
methylpiperazine for increased aqueous solubility.  
Demont et al have also developed a negative control GSK9311 for GSK6853, which involved N-
ethylating the amide. It was reasoned that the alkylation would inhibit the formation of the internal 
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hydrogen bond whilst also promoting a steric clash between the alkyl group and the piperazine 
ring. Overall these interactions would result in the amide ring being unable to adopt the 
conformation required to fit into the ZA channel and therefore potency would be reduced. This was 
in fact the case, as GSK9311 was 1000-fold less potent against BRPF1. 60 
 
Figure 31. Cocrystal structure of OF-1 and BRPF1 highlighting the key binding interactions. PDB ID: 5FG4 
In contrast to the other BRPF inhibitors OF-1 is a pan-BRPF inhibitor, recording KD’s of 100, 500 
and 2,400 nM against BRPF1, BRD1 and BRPF3 respectively. This is a result of replacing the amide 
moiety for a sulfonamide, which angles the aryl ring into the WPF shelf of BRPF1. As the sequence 
homology between the BRPF bromodomain binding sites is extremely high, without the ability to 
exploit Pro 658, achieving the selectivity of the BRPF1 specific inhibitors is impossible.  
 3.5 BRPF/TRIM24 Inhibitors 
Two further BRPF inhibitors based on the 1,3-benzimidazalone have been published, featuring 
large aryl ether substituents at the 5 position of the benzimidazalone core. Addition of these ethers 
causes these inhibitors to retain BRPF1 whilst gaining appreciable TRIM24 potency.  
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Figure 32. Published dual inhibitors of the TRIM24 and BRPF1 BRDs 
Despite its strong potency against BRPF1 12 was only able to inhibit the TRIM24 BRD-chromatin 
and not the BRPF1 BRD-chromatin association at 1 μM in an in vitro context (FRAP assay). 
Screening of compound 12 in a cancer cell line panel revealed only modest GI50 values (> 10 μM). 61 
In contrast IACS-9571 displays far greater cellular target engagement, recording an EC50 of 50 nM. 
This may be a function of its improved pharmacokinetic profile allowing greater intracellular 
concentration. 62 
 3.6 BRD1/TAF1 Inhibitors 
Recently a collaboration between Bayer and the SGC has disclosed BAY-299 a dual BRD1-TAF1 
BRD inhibitor. BAY-299 has a KD of 6 nM against BRD1 and 13 nM against TAF1(2). In addition 
BAY299N has been synthesised as a negative control. Further details regarding this inhibitor are 
not currently available. 28  
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4. Results and discussion 
 
 4.1  Biological Analysis of compounds 
Compounds were primarily screened against BRDs of interest by two methods. Initial screening 
was carried out by Thermal Shift (TS) at the SGC for qualitative confirmation of binding. 
Subsequent to TS, promising compounds were quantitatively assessed, at DiscoverX, by 
determining a dissociation constant (KD).   
4.1.1  Thermal Shift 
Thermal Shift (TS) measures compound binding to the protein by monitoring the fluorescence 
change of the dye Sypro Orange as a function of temperature. When the protein is folded the 
fluorescence signal from the dye is very low, due to quenching of the signal by the aqueous 
environment; however, on heating and protein unfolding the Sypro Orange binds to hydrophobic 
regions of the protein and a marked increase in fluorescence can be observed. The fluorescence 
intensity is then plotted against temperature, from which the melting temperature or Tm can be 
calculated (Figure 33). The higher ΔTm the more stable compound:protein complex is, which is 
indicative of a higher binding affinity.  
 
Figure 33. Example of a Thermal Shift plot with fluorescence plotted against temperature. The differences 
in the melting temperatures (ΔTm) of the BRD and the BRD with the inhibitor is directly proportional to 
compound affinity. Adapted from Niesen et al. 63 
Despite its excellent characteristics as a high throughput assay (small amounts of protein, fast, 
operational simplicity and good qualitative ordering of compound binding), TS assays suffer from a 
number of important drawbacks. These include qualitative results that do not scale from protein to 
protein, and as Tm is measured by fluorescence, binding of lipophilic compounds to Sypro Orange 
can artificially increase the measured Tm. Although rare, it is also possible for compounds to inhibit 
the fluorescence of Sypro Orange.   
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4.1.2  Dissociation constant (KD) 
Dissociation constants (KD) are a quantitative measure of compound binding by assessing the 
position of the equilibrium between the unbound BRD and inhibitor, and the BRD:inhibitor complex 
(Figure 34).  
 
Figure 34. Graphical representation of a KD. On the left of the equilibrium the BRD (grey) is not bound to 
the inhibitor (purple). On the right of the equilibrium the BRD and inhibitor have formed a complex. A low 
KD indicates that the equilibrium lies to the right. 
Dissociation constants were determined by DiscoverX via a competition assay with an immobilised 
ligand of known affinity, followed by quantitative polymerase chain reaction (qPCR) analysis of the 
tagged BRD still bound to the immobilised ligand.64 Initially, compounds are incubated with 
immobilised ligands of known KD bound to DNA tagged BRDs . Compounds that inhibit the 
bromodomain prevent its binding to the immobilised ligand, thus reducing the amount of protein 
captured on the solid support. KD’s are determined by qPCR measurement of the amount of DNA 
tagged BRD still bound to the known inhibitor and plotting the value obtained versus the 
concentration of the test compound (Figure 35). 
 
Figure 35. Graphical representation of KD determination as carried out by DiscoverX. A. DNA tagged BRD 
(red) is bound to the immobilised ligand (black). b. No competition on introduction of test compound (blue). 
The test compound is not sufficiently potent to displace the bound BRD from the immobilised ligand. c. The 
test compound is sufficiently potent to displace the immobilised ligand and is now bound to the DNA 
tagged BRD. d. qPCR analysis of the the amount of DNA tagged BRD remaining bound to the immobilised 
ligand allows for determination of a KD. Adapted from DiscoverX.65 
The primary advantage of a dissociation constant in comparison to TS is that the quantitative data 
obtained can be compared from protein to protein. Moreover, as nearly the entire bromonome is 
available for screening it is now possible to profile compounds against the entire BRD family 
(protein class) in the same assay format, allowing for meaningful comparison of data. 
However, the assay as carried out by DiscoverX has a couple of drawbacks. Chief amongst these is 
the dependence on having a suitably potent inhibitor as the ‘known affinity ligand’. If the test 
compound is orders of magnititude more potent than the known inhibitor the values derived from 
the assay can be adversely affected. This is due to the fact that the percentage change in the amount 
of ‘known inhibitor’ displaced will be well within the error of the assay beyond a certain point. In 
addition, as dissociation constant determination is a commercial assay, the cost of obtaining all the 
relevant data is can be prohibitively high. 
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4.1.3 Interpretation of Thermal Shift and Dissociation Constant Data 
TS values were compared with those previously determined by the SGC for the relevant protein 
before the values were used for qualitative ranking of compounds. Based on SGC expertise and data 
BRPF1 TS values were then bracketed as follows:  
TS < 2 °C being considered inactive 
2 °C < TS > 5 °C being considered moderately active 
5°C < TS being considered very active 
When assessing dissociation constants as determined by DiscoverX a potency difference of ~ 3 fold 
or greater was considered significant. Ultimately, ITC KD’s as determined by SGC were employed to 
definitively assess compound selectivity and potency. 
 4.2 Lead Compound to BRPF probe – SAR 
4.2.1     Lead compounds and Initial SAR 
 
 
Initial structure activity relationship (SAR) data gathered by the SGC on sulfonamides (unpublished 
data from the SGC) focussing on simple mono or di substitution of the sulfonamide aryl ring was 
inconclusive as to position and electronic effect of different substituents.  
As such our studies began by synthesising simple alkyl, cycloalkyl and benzenesulfonamides in 
order to validate the initial results against BRPF1. Our synthesis is outlined in Scheme 1. 
 
Oxidation with mCPBA in CH2Cl2 gave quinoline-N-oxide in quantitative yield. Preliminary 
conditions for addition to the N-oxide, followed by rearrangement, focussed on tosyl chloride, 
K2CO3 in CHCl3, however reproducing literature conditions afforded 14 in low and variable yield 
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(25 – 51%). 66 Rearrangement with acetic anhydride in acetic acid proved similarly unsuccessful, 
however conditions employing benzoyl chloride and aqueous sodium hydroxide proved 
reproducible and high yielding (78 -84 %, n = 3). 
With reproducible, scalable conditions in hand for the rearrangement to quinolin-2(1H)one (14), 
methylation was either carried out using K2CO3 (small scale ~ 100 mg) or NaH (large scale ~2 g) to 
afford N-methylquinolin-2(1H)one (1) in moderate yields. 
Subsequent nitration by dropwise addition of HNO3 (68%) to a solution of 1 in conc. H2SO4 at 0 °C 
yielded the desired six position nitro isomer (15) as confirmed by 1H NMR (doublet at 8.75 ppm for 
C5H and a doublet of doublets at 8.41 ppm for C7H)  and the literature. 67 Nitro group reduction of 
15 with SnCl2 (either anhydrous or dihydrate) gave amine 2 in good yield. 
4.2.1.1  Simple Alkyl Sulfonamides 
 Amine 2 was then routinely coupled in moderate to good yields with simple alkyl, cycloalkyl or 
benzenesulfonyl chlorides in DCM with pyridine (Scheme 2) to afford 3 and 16-20 for testing of 
inhibition of BRPF1 (Table 1). 
 
Table 1. Biochemical and biophysical evaluation of compounds 3,16-20. a. Tm carried out by Dr Oleg 
Fedorov at the SGC. Experiments carried out at 10 μM, n = 1. b. KD’s determined by DiscoverX. Most KD’s 
were determined using a compound top concentration = 10,000 nM. Dose response curves were 
determined at an 11 point serial dilution. If the initial KD determined was < 0.169 nM (the lowest 
concentration tested), the measurement was repeated with a serial dilution starting at a lower top 
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concentration. Data is the mean of 2 replicates. ClogP’s calculated by ChemBioDraw Ultra 14.0 throughout 
thesis 
Pleasingly, a trend in BRPF1 affinity can be observed, where increasing the length of the carbon 
chain and increasing unsaturation (i.e. Ph) lead to improved binding (Me < Et ~ iPr < cPr ~ c Hex << 
Ph). This can be attributed to the improved lipophilic binding with the WPF shelf on increasing the 
length of the carbon chain and potential π-stacking with phenylalanine on addition of unsaturation. 
The greatly improved potency of the Ph over other compounds can again be attributed to π stacking 
in the WPF shelf. 
4.2.1.2  Simple Aryl Sulfonamide Substitution 
Results for compound 15 were extremely promising, so it was decided that subsequent 
modifications would focus on simple substitution of the sulfonamide aryl ring.  
The initial SGC SAR for BRPF3 (data unpublished) suggested that electron withdrawing 
substituents, especially Cl (Hammett coefficients σmeta: 0.37, σpara: 0.23) 68 were preferred in the 
WPF Shelf. As sequence homology in this area of the protein is very high in the BRPFs, initial 
substitutions focussed on electron withdrawing groups. 37 Thus compounds 21-23 (Scheme 3) 
were synthesised where a substitution of the H by a nitrile was investigated around the phenyl ring. 
A nitrile was chosen as the literature suggested that the  Cl to CN (Hammett coefficients σmeta: 0.56, 
σpara: 0.66) 68 substitution has several  beneficial effects: 
1. Overall negative potential for the nitrile CN compared with the δ+ hole for the chloride. This can 
have a negative impact if the halide is involved in a halogen bond. In addition the nitrile has a 
significantly larger dipole moment at CN = 4.44 D vs Cl = 1.67 D. 
2. Nitriles prefer more hydrophilic open binding regions to chlorides. 69 
3.  Improved logP (logarithm 1-octanol:water partition coefficient.) PhCN = 1.56, PhCl = 2.84 
(ΔLogP = -1.28). Decreasing lipophilicity has beneficial effects on drug like properties such as 
aqueous solubility, metabolic stability and toxicological outcomes.  
 
By calculating the LipE (Lipophilic efficiency): 
 
Lip E = -Log (IC50) – LogP (IC50:  concentration required to inhibit 50% of protein) 
  
Which combines the logP and IC50 analysis have shown that nitriles consistently outperform 
their chloride analogues (Figure 36). 
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Figure 36. Comparison of LipE for ArCN vs. ArCl in drug candidates from literature and Pfizer internal 
database. Values are obtained by calculating: ΔLipE = LipE(CN) – LipE(Cl). Green = ArCN is better (ΔLipE 
> 0.5), Amber = same (0.5 < ΔLipE > -0.5), Red ArCl is better (ΔLipE < -0.5). Reproduced from Jones et 
al.69  
The synthesis of compounds 21-23 initially employed the same conditions as those used for 
compounds 3, 16-20 (Scheme 3). However, significant difficulties were encountered with 
purification of the compounds, as on addition of the sulfonyl chloride a dark red solid, containing an 
unknown contaminant, rapidly precipitated. Attempts at purification were hampered by the 
exceptionally low solubility of this precipitate (~100 mg not soluble in 10 mL of DMF). Thus, 
alternative reaction conditions were investigated where precipitation might be avoided to ease 
purification. 
 
 Eventually, by changing the solvent to DMF and running the reaction at lower concentration (0.2M) 
it proved possible to avoid precipitation and concentrate the reaction directly onto celite ® prior to 
purification by column chromatography.  
In addition to the benzonitriles, a 2,5 dimethylthiophene-3-sulfonamide was synthesised as an 
isostere for the phenyl ring from compound 3. Addition of sulfuryl chloride to DMF at 0 °C to 
preform a chloroimidate which was used to introduce a sulfonyl chloride group by electrophilic 
aromatic substitution on thiophene. Reaction of the crude sulfonyl chloride provided 26 in low 
yield (Scheme 4). 
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Compounds 21-23 and 26 were initially screened against a range of BRDs by Thermal Shift to 
qualititatively determine compound binding (Table 2). 
ID BAZ2A BRD1 BRD4 BRD9 CECR2 PCAF BRPF1B CREBBP TIF1 
21 0.1 0.9 1.3 2.9 0.5 0.2 2.4 0.9 0.9 
22 0.2 1.3 1.9 3.5 0.6 -0.1 3.1 0.9 1.1 
23 0.3 2.4 1.4 2.3 -0.4 0.1 5.2 -0.1 1.1 
26 0.0 1.4 0.9 2.8 0.7 0.2 5.0 0.3 2.1 
 
Table 2. ΔTm results from sulfonamide investigation (°C). Results obtained by Dr Oleg Fedorov at the 
SGC. Experiments carried out at 10 μM, n = 1. Heat map is a scale from Green = low ΔTm – low potency to 
Red = high ΔTm - high potency. 
With regards to BRPF1 inhibition there is a clear preference, amongst the nitriles, for para (23) 
substitution, with the meta nitrile (22) being slightly more potent than the ortho (21) compound. 
The 2,5 dimethylthiophene derivitave (26) was of similar potency to both the Ph (3) and the para 
nitrile (23) compound.  
For BRD1 the order of potency is maintained as 23 > 22 > 21, however there appears to be a much 
larger selectivity for BRPF1 vs BRD9 in compound 23 in comparison to 22. This is because the ΔTm 
for BRD9 for 22 is roughly similar in BRD9 and BRPF1 (Table 2). Thermal shift also suggested that 
all compounds tested had a similar, but appreciable, level of activity against BRD4(1), but that 
otherwise binding against non-class IV BRDs was minimal. 
In light of this data it was decided to quantitatively quantify potency and selectivity of compound 
23 by KD (Table 3). 
 
 
Table 3. Biochemical and biophysical evaluation of compound 23. a. Tm carried out by Dr Oleg Fedorov at 
the SGC. Experiments carried out at 10 μM, n = 1. b. KD’s determined by DiscoverX. Most KD’s were 
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determined using a compound top concentration = 10,000 nM. Dose response curves were determined at 
an 11 point serial dilution. If the initial KD determined was < 0.169 nM (the lowest concentration tested), the 
measurement was repeated with a serial dilution starting at a lower top concentration. Data is the mean of 
2 replicates. 
The trend in potency suggested by the ΔTm results was replicated in the KD’s determined. In 
addition, compound 23 retained the excellent potency against BRPF1 displayed by its des-cyano 
analogue (3). Disappointingly, the reasonable activity against BRD4 hinted at in ΔTm corresponds 
to a 2,800 nM potency and only a 65 fold selectivity window over BRD4. As mentioned previously, 
this selectivity needed to be greater, as BRD4 is known to have a myriad of biological effects. 
Activity against other non-class IV BRDs tested was minimal and all activity against PCAF, where 
the original fragment hit originated from, had disappeared. In addition compound 23 displayed 
excellent physicochemical, druglike properties, with ClogP of 1.96 limiting lipophilicity induced off-
target activity and  a TPSA of 90 Å suggesting excellent cell permeability  
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4.2.2 4-Position Substitution of the Quinolin-2(1H)-one A ring 
 
 
BRD acetyl lysine binding pockets, unlike most protein-protein interaction domains, are deep and 
hydrophobic. As such, exploiting small lipophilic pockets in this region, that vary from BRD to BRD, 
can increase both potency and selectivity. To this end, it was decided to synthesise compounds 
bearing a methyl group at the 4 position, in the hope of serendipitously exploiting such a small 
lipophilic pocket in BRPF1. The required amine was synthesised according to scheme 5. 
 
Heating N-methylaniline with 2,2,6-Trimethyl-4H-1,3-dioxin-4-one in xylene afforded 
oxobutanamide 28 after attack of the amine and spontaneous loss of acetone. 70 This was then 
cyclised by heating in concentrated H2SO4, followed by precipitation on addition of ice water and 
filtration. 71 Nitration was carried out regioselectivity as per the literature, 72 and subsequent 
reduction as  for 2 (Scheme 1).  
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As for amine 2, 31 was coupled with 2, 3 and 4-cyanobenzenesulfonyl chlorides as well as 2,5-
dimethylthiophene-3-sulfonyl chloride using optimised conditions to afford compounds 32-35. 
ID BAZ2A BRD1 BRD4 BRD9 CECR2 PCAF BRPF1B CREBBP TIF1 
32 -0.3 1.6 0.0 1.5 0.0 -0.4 2.5 0.3 0.6 
33 0.2 1.3 1.9 3.5 0.6 -0.1 3.1 0.9 1.1 
34 -0.1 1.2 0.6 2.3 -0.3 -0.3 4.3 0.6 0.3 
35 -1.4 2.1 0.8 2.7 0.3 -1.0 2.8 0.9 -0.7 
 
Table 4. ΔTm results from 4-methyl investigation (°C). Results obtained by Dr Oleg Fedorov at the SGC. 
Experiments carried out at 10 μM, n = 1. Heat map is a scale from Green = low ΔTm – low potency to Red 
= high ΔTm - high potency. 
For the analogues of the two most active compounds from the previous series bearing the 4-CN 
(34) and the 2,5-dimethylthiophene-3-sulfonamide (35) potency with respect to BRPF1 appeared 
to drop between 1 and 2 °C on addition of the 4-methyl group. However, activity against the other 
BRDs remained roughly constant, suggesting lower selectivity for these compounds. For the other 
analogues (32: 2-CN and 33: 3-CN) the potencies and selectivity profiles appear largely unchanged.  
Overall despite the drop for the two most active compounds, the ordering of the compounds in 
potency against BRPF1 on addition of a 4-methyl group remains unchanged 4-CN>thiophene>3-
CN>2CN 
In order to verify the apparent drop in potency by thermal shift a KD was obtained for compound 34 
(BRPF1 KD – 24 nM). This suggested that in contrast to the TS results the introduction of a methyl 
group could be beneficially to potency (compound 23, 4 des-methyl BRPF1 KD – 43 nM). On balance, 
the data is inconclusive as to the effect of adding a methyl group, although it does not appear to be 
disadvantageous, as initially thought. 
4.2.2.1 4-CF3 Substituted Quinolin-2(1H)-one 
As the BRPF binding pocket appeared to accommodate the methyl group further SAR was obtained 
by alteration of the methyl into a trifluoromethyl. This would allow investigation of electron 
withdrawing groups which are located in proximity to the KAc mimetic. 
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The required amine was synthesised by first reacting aniline with ethyl-4,4,4-trifluoroacetoacetate 
at elevated temperatures to form oxobutanamide 37. 72 Elevated temperatures are required for this 
step, as reactions at lower temperatures lead to electrophilic attack of the nitrogen at the ketone 
carbon, which on cyclisation will afford the undesired 1,4 quinolone. Oxobutanamide (37) was 
cyclised in concentrated H2SO4, similarly to the cyclisation of compound 28, to give quinolinone 39. 
72 The nitration followed conditions outlined previously in the literature to give 39 which was 
methylated, reduced and  coupled using standard conditions. 72    
 
 BRPF1 TIF1 BRD4 BRD9 CECR2 CREBBP 
42 3.8 1.4 2.1 3.4 1.0 1.2 
 
Table 5. ΔTm results from 4-trifluoromethyl compound 42 (°C). Results obtained by Dr Oleg Fedorov at the 
SGC. Experiments carried out at 10 μM, n = 1. Heat map is a scale from Green = low ΔTm – low potency to 
Red = high ΔTm - high potency. 
Substitution of the methyl by trifluoromethyl was not well tolerated by the BRPF binding site, as 
the BRPF potency dropped ~ 1 °C whilst affinity for other BRDs has increased by TS. 
It is possible that the negative results for BRPF1 are due to the very electron withdrawing nature of 
the CF3 group (CF3 Hammett coefficients σmeta: 0.43, σpara: 0.53, CH3 Hammett coefficients σmeta: -
0.07, σpara: -0.17 ). 68 Located in close proximity to the C2 carbonyl this would withdraw electron 
density from the carbonyl and have a detrimental effect on compound binding. However, this would 
not explain why the affinity with respect to BRDs other than BRPF1 was not similarly adversely 
effected. 
It is thus likely that the BRPF binding site was unable to sterically accommodate the increased size 
of the CF3 group as well as the other BRDs screened (Taft size parameter Es CH3 = -1.24, CF3 = -2.40). 
28  
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 4.2.3  ‘Reverse’ Sulfonamides 
 
 
Having confirmed the acitivity of the sulfonamides against BRPF1 we next investigated whether 
‘reversing’ the linker altered binding affinity. It was envisaged that reversing the linker would 
primarily have two effects on the compounds: 
1. Electron density in the quinolinone ring and the KAc mimetic would be reduced. This could 
reduce compound affinity (Figure 37). 
 
 
Figure 37. N lone pair can resonate into the 6-sulfonamide group reducing electron density in the KAc 
mimetic. 
 
1. The longer S-C bond (C-N: 147 pm C-S: 182 pm) now linking the quinolinone to the sulfonamide 
would alter the angle and position at which the sulfonamide aryl ring bends into the WPF shelf. 
This could be beneficial both in selectivity and potency. 65 
Synthesis of the required sulfonyl chloride was carried out through adaptation of the conditions of 
Tashima et al by heating N-methylqinolin-2(1H)-one (1) in chlorosulfonic acid to afford 6-
chlorosulfonyl-N-methylquinlin-2(1H)-one (43) in good yield. 73 Regioselectivity, which could 
either be at the 6 or the 8 position was confirmed by the presence of a weak meta-coupled doublet 
at 8.28 ppm in the 1H NMR spectrum. The sulfonyl chloride was then coupled in low to good yields 
with a range of aryl amines (Scheme 7, Table 6). 
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Table 6 Reverse Sulfonamides synthesised 
ID BAZ2A BRD1 BRD4 BRD9 CECR2 PCAF BRPF1B CREBBP TIF1A 
44  1.6     3.5  1.56 
46 0.0 1.0 1.7 3.9 0.5 0.2 2.6 0.1 0.7 
47 0.1 2.0 0.8 1.2 0.2 -0.1 2.3 0.6 1.1 
48 0.5 3.4 1.1 0.9 0.5 0.2 3.0 0.3 1.2 
49 0.0 0.7 0.7 2.5 0.7 0.2 1.2 0.4 0.7 
50 0 0.1 0.9 1.7 0.6 0.2 0.7 0.2 0.2 
 
Table 7. ΔTm results for ‘Reverse sulfonamides’ 46-50 (°C). Results obtained by Dr Oleg Fedorov at the 
SGC. Experiments carried out at 10 μM, n = 1. Heat map is a scale from Green = low ΔTm – low potency to 
Red = high ΔTm - high potency. 
As predicted, reversing the sulfonamide linker reduced compound binding to BRPF1, with Tm 
values decreasing between 1-2 °C. Similarly to the sulfonamide series 21-23 BRPF1 displayed a 
preference for the para substituted compound. KD determination for compound 48 suggested that 
the drop in ΔTm equated to a roughly 50% decrease in potency (23: BRPF1 KD  = 43 nM. 48:  BRPF1 
KD = 100 nM). 
Despite the drop in potency, it was hoped that the reversal of the linker would increase compound 
selectivity. This proved unsuccessful, with 4-CN compound (48) being equipotent against BRPF1 
and BRD1. In addition the Bn analogue (46) had a higher affinity for BRD9 than for BRPF1. In 
general the compounds with the reversed linkers retained potency against BRDs other than BRPF1 
whilst losing potency against BRPF1. This equated to a loss in potency and selectivity suggesting 
that reversing the linker was an unsuccessful avenue of SAR.  
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4.2.4  Substitution of the sulfonamide ring 
 
 
Having determined that the optimal substitution pattern involved a 4-CN substituted sulfonamide, 
we next decided to investigate sulfonamides with a multiply substituted sulfonamide aryl ring. As 
the sulfonyl chlorides bearing a nitrile at the 4 position were not commercially available it was first 
necessary to synthesise the requisite building blocks. 
Sulfonyl chlorides can be synthesised by a variety of routes including: oxidation of the 
corresponding thiol, 74 chlorination of the requisite sulfonic acid, 75 reaction of boronic acids with 
SO2Cl equivalents, 76 electrophilic aromatic substitution with HSO3Cl and the decomposition of 
diazonium chlorides in SO2 saturated solutions. 77 
As a consequence of the synthetic tractability and commercial availability of the required amines it 
was decided to make the sulfonyl chlorides from their respective diazonium chloride salts. 
Typically this involves saturating AcOH with SO2, adding catalytic CuCl and then adding the 
diazonium chloride at low temperature to allow a Sandmeyer reaction to occur.77 Due to the 
expense, toxic nature and difficulty involved in handling SO2 the traditional method was unsuitable 
for our work. Thus it was decided to adopt the method of Hogan et al who had developed a method 
of reacting diazonium chlorides in aqueous solutions that had been saturated with SO2 by 
hydrolysing SOCl2. 78  
The authors reported that this method was well suited to amines bearing mildly electron donating 
groups, but that addition of strongly electron withdrawing, or electron donating groups would 
hinder reaction progress. With this in mind a number of optionally substituted 4-CN amines were 
converted to their sulfonyl chlorides as per Scheme 8. 
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Table 8. Sulfonyl chlorides and sulfonamides synthesised. *indicates commercially available amine. Other 
amines were synthesised by adapting literature procedures (see experimental) a. Yield over 2 steps, 
sulfonyl chloride isolated in a 1:1 ratio with the corresponding chloride and used without further purification 
Yields for sulfonyl chloride formation were generally in line with those reported by Hogan et al. For 
the more electron donating 2-Me (Hammett coefficients σmeta: -0.07, σpara: -0.17) the yield was 
significantly lower, with the sulfonyl chloride being isolated in a 1:1 ratio with the aryl chloride. 
Routine coupling of the synthesised sulfonyl chlorides provided 51d-55d for biological evaluation 
against BRPF1. 
 BRD1 BRD4 BRD9 BRPF1 TIF 
51d n.d. n.d. n.d. 3.6 0.3 
52d 3.1 n.d. 0.4 5.2 n.d. 
53d n.d. n.d. n.d. 6.5 1.4 
54d -2.1 n.d. -0.4 4.3 n.d. 
55d 2.5 2.8 n.d. 4.9 n.d. 
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Table 9. ΔTm results for disubstituted sulfonamides 51d-55d (°C). Results obtained by Dr Oleg Fedorov at 
the SGC. Experiments carried out at 10 μM, n = 1. Heat map is a scale from Green = low ΔTm – low 
potency to Red = high ΔTm - high potency. 
The results indicate that for BRPF potency the most favourable substitution pattern is 2,4 
substituted, with more electron donating, lipophlic substituents being preferred at the 2 position 
(Me>Br>F, in order of ClogP). Interestingly, as measured by TS, the 3Cl-4CN compound (54d) is 
almost equipotent in comparison to the 3,4 Cl (55d) compound, but the nitrile appears to impart 
greatly increased selectivity with decreased lipophilicity. Unfortunately, when assessed by KD 54d 
displayed a potency of 62 nM against BRPF1 and 450 nM against BRD1, suggesting that the nitrile 
did not impart the selectivity hinted at by TS. 
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4.2.5 N alkyl variation 
 
 
Typically the BRD binding pocket can accommodate small changes near the warhead binding site, 
as such it was decided to alter the N-alkyl group on the quinolinone. Preliminary investigation 
focussed on the synthesis of 6-amino-1-ethylquinolin-2(1H)-one (58) is shown in Scheme 9. 
 
Analogously to the synthesis of amine 2, 14 was first alkylated with NaH in DMF and subsequently 
nitrated and reduced to give amine 58 in good yield. Niration regioselectivity was confirmed 
analogously to compound 15.  Subsequent coupling proceeded smoothly to provide sulfonamide 59 
for biological evaluation. 
Attempts at synthesising an N-isopropylated quinolinone were unsuccessful as attempts at 
alkylation of 6-nitroquinolin-2(1H)-one (Synthesised by EB) furnished the O-ethylated compound 
in 82% yield after reaction with 2 iodopropane and crystallisation of the crude reaction material 
from ethanol. 
 BRD1 BRD4(1) BRPF1A 
59 1.6 1.8 4.7 
 
Table 10. ΔTm results for compound 59 (°C). Results obtained by Dr Oleg Fedorov at the SGC. 
Experiments carried out at 10 μM, n = 1. Heat map is a scale from Green = low ΔTm – low potency to Red 
= high ΔTm - high potency. 
Substituting the methyl group for an ethyl group appears to have very little effect on compound 
potency, with KD’s being almost identical between compound 23 (NMe) and 59 (NEt) (23: KD – 47 
nM; 59; KD - 43 nM). The KD values do suggest that ethylating the nitrogen has an advantageous 
effect in compound selectivity as 59 is 8 fold selective over BRD1 whilst 23 is only 5 fold, however 
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as these differences are well within the error of the assay there is insufficient data to suggest that 
this is part of a larger trend. Moreover, the increase in selectivity has come at the expense of a small 
0.57 increase in ClogP (ClogP 29 1.90, ClogP 59: 2.46).Therefore, altering the methyl group to an 
ethyl may be beneficial, but would need to be combined with other modifications to be properly 
investigated. 
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4.2.6  5-Substituted Quinolin-2(1H)-ones 
 
 
Exploration of the quinolinone ring next turned to the B ring by investigating substitution of the 5 
position. This position was chosen as a number of appropriately 5-substittued quinolones were 
readily commercially available, or synthetically tractable. 
4.2.6.1  5 Br Substituted Quinolin-2(1H)-ones 
The first substituent of interest was a bromine, as it was envisaged that the bromine could be used 
as a synthetic handle to synthesise optionally 5 substuted quinolinones. This could occur via either 
metal medidated coupling, metalation and subsequent reaction, or SNAr of 6-nitro-5-bromo-
quinolinone (63). 
 
Formation of 61 by was carried out analogously to compound 14 by oxidation and subsequent 
rearrangement with benzoyl chloride. Nitration, methylation and reduction were also carried out 
using standard conditions.Regioselectivity of the nitration step was confirmed by comparison of the 
spectroscopic data for the reduced amine, 64, with that from the literature. 79 Coupling of the amine 
provided compound 65 for biological evaluation.  
 BAZ2A BRD1 BRD4 BRD9 CECR2 BRPF1 CREBBP TIF1A FALZA 
65 -0.2 3.7 1.0 3.0 0.1 6.2 -0.2 0.1 2.5 
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Table 11. ΔTm results from compound 65 (°C). Results obtained by Dr Oleg Fedorov at the SGC. 
Experiments carried out at 10 μM, n = 1. Heat map is a scale from Green = low ΔTm – low potency to Red 
= high ΔTm - high potency. 
Results appeared very promising, with strong potency against BRPF1 and reasonable selectivity for 
the BRPFs. The only area of concern was strong activity against FALZ2. As a consequence of the 
promising results amine 64 was also coupled with 4’fluorobiphenylsulfonyl chlorde and 
biphenylsulfonyl chloride as in silico docking of compound 23 (work carried out Dr Haider, UCL) 
using published BRPF1 crystal structures suggested that there was more room for optimisation at 
the 4 position on the sulfonamide ring. 
 BRD1 BRD4 BRPF1 
65 3.7 1.0 6.2 
66 4.1 0.5 5.3 
67 4.2 0.4 5.6 
 
Table 12. ΔTm results from 5- Br sulfonamide investigation (°C). Results obtained by Dr Oleg Fedorov at 
the SGC. Experiments carried out at 10 μM, n = 1. Heat map is a scale from Green = low ΔTm – low 
potency to Red = high ΔTm - high potency. 
Results from addition of the second phenyl ring were unproductive, with compounds being slightly 
less potent despite the large increases in lipophilicity (ClogPs 65: 2.31, 66: 4.28, 67: 4.44). In order 
to quantify the potency of 65 of a KD was determined (KD BRPF1 – 340 nM). 
The value of the KD was unexpectedly high, therefore we looked to verify the TS data generated. 
Thus, a new shift was determined at higher concentration (100 μM, TS normally run at 10 μM - 
Figure 38). Higher concentrations were employed, as any abnormalities in the melting curve are 
more readily observed. Indeed, inspection of the melting curve for 65 shows a double melting 
curve, which can be attributed to either compound insolubility, or an abnormal binding mode 
causing aberrations in the protein unfolding.  
 
Figure 38. Melting curve for 65 at 100 μM. Blue - control, Red – Compound 65, Green – Compound 102  
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Subsequent to ascertaining that the initial results for 65 were anomalously high, efforts focussed on 
derivitising the 5 position using the bromine synthetic handle. 
Unfortunately, both 5-bromo-1-methyl-6-nitroquinolin-2(1H)-one (62) and 5-bromo-1-methyl-6-
aminoquinolin-2(1H)-one (63) proved inert to Suzuki coupling conditions (MeB(OH)2, CsCO3 and 
Pd(PPh3)4) in attempts to introduce a methyl group.  Further attempts at SNAr reactions of 
compound 63 were similarly unsuccessful, with compound 63 being inert to both NaOEt and 
NaOMe at elevated temperatures. Metalation of sulfonamide 65 with BuLi at – 78 °C followed by 
reaction with iodomethane was also unsuccessful, furnishing a variety of different amines by TLC.  
As derivitisation was unsuccessful a selection of 5 substituted compounds were synthesised 
starting from simple building blocks 
4.2.6.2  5-Fluoro Substituted Quinolin-2(1H)-ones 
As fluorine atoms can be excellent bioisosteric replacements for hydrogen, it was next decided to 
replace the bromine atom with a fluorine. This should also have the benefit of increasing the 
solubility of the compound in comparison to bromine, as bromines are notorious for their ability to 
impart crystallinity. 
 
Transformation of the amine into a fluorine by literature Balz-Schiemann reaction afforded 5-
fluoroquinoline from 5-aminoquinoline in modest yield. 80 Amine 73 was synthesised via the 
standard reaction sequence depicted in scheme 11. Yields for nitration were slightly lower than 
expected for the nitration of 71 as multiple regioismers were obtained. Coupling of 73 provided 
compound 74 for biological evaluation against BRPF1.  
 BRD1 BRD4 BRPF1 
74 1.4 0.0 2.7 
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Table 13. ΔTm results from compound  74 (°C). Results obtained by Dr Oleg Fedorov at the SGC. 
Experiments carried out at 10 μM, n = 1. Heat map is a scale from Green = low ΔTm – low potency to Red 
= high ΔTm - high potency. 
Although solubility was noticeably improved, binding affinity had decreased significantly on 
addition of the electron withdrawing F. This is potentially a consequence of fluorine withdrawing 
electron density from the quinolinone C2 carbonyl. This would reduce the KAc mimetic’s ability to 
form the key binding interactions and thus reduce affinity. 
4.2.6.3  5-OMe Substituted Quinolin-2(1H)-ones 
As the sulfonamide 74 was hypothesised to be less active as a result of low carbonyl electron 
density a methoxy group was next introduced. The electron donating ability of the ethereal oxygen 
would strengthen any interactions that the acetyl-lysine mimetic makes in the protein (Figure 39).  
 
Figure 39. Ethereal oxygen electron density can resonate into the KAc mimetic 
As previous routes to 5-methoxyquinolin-2(1H)-one (80) proved capricious in our hands a 
synthetic strategy based on Turner et al’s synthesis of napthyridinones was employed. 81 M-
anisidine was first converted into the pivalamide in quantative yield through reaction with the acid 
chloride in pyridine and DCM. 82 With both the methoxy and pivalamide groups acting as ortho 
directing metalation groups for the 2 position, metalation with n-BuLi and reaction with the 
aldehyde equivalent DMF provided N-(2-formyl-3-methoxyphenyl)pivalamide (77) in good yield. 83 
Initially it was decided to introduce a bromine as a synthetic handle at the 4 position at this point in 
the synthesis as the large pivalamide group would sterically hinder electrophilic substitution ortho 
to the amide. 
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Reaction of 77 with NBS in DCM provided the desired regioisomer 78, as confirmed by a NOESY 
interaction between the tert-butyl group and the hydrogen at the 6 position (Figure 40). However, 
as the yield for the reaction was very low it was decided to construct the quinolinone A ring before 
electrophilic substitution was carried out. 
 
Figure 40. NOESY interaction between the tBu group at 1.36 ppm and C6H at 8.52 ppm 
Thus, compound 77 was treated with the pregenerated enolate of tert-butylacetate to form the β-
hydroxyketone (79). 79 was then deprotected, cyclised and dehydrated by heating in a 1:1 mixture 
of HCl (3 M) and 1,4 dioxane to give 5-methoxyquinolin-2(1H)-one (80) in excellent yield. 
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Disappointingly, the yield for nitration of 81 using stoichiometric KNO3 to control mono vs di-
substitution was poor, with the desired regioisomer being isolated in 12%. As for previous nitration 
steps electrophilic substitution could either happen at the 6 or 8 positions of the quinolinone ring. 
Nitration regioselectivity was confirmed by NOESY interaction of the amino group with the 
methoxy methyl group following reduction. Despite the poor yield for nitration, reduction and 
subsequent coupling by standard conditions afforded the desired sulfonamide (84) for biological 
evaluation against BRPF1. 
 BRD1 BRD4 BRPF1 
84 1.5 0.2 3.0 
 
Table 14. ΔTm results from compound 84 (°C). Results obtained by Dr Oleg Fedorov at the SGC. 
Experiments carried out at 10 μM, n = 1. Heat map is a scale from Green = low ΔTm – low potency to Red 
= high ΔTm - high potency. 
Despite the increased electron density of the quinolinone ring, binding affinity was still poor 
(BRPF1 Tm – 2.95 °C). As results for modification of the 5-position were not tolerated, leading to 
lower binding affinity, further optimization in this area was abandoned. 
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4.2.7  7-Substituted Quinolin-2(1H)-ones 
 
4.2.7.1  7-OR Substituted Quinolin-2(1H)-ones 
Efforts at compound optimisation were next directed towards the 7 position. In silico screening by 
our collaborators at the SGC suggested that introduction of a methyl ether at the 7 position could 
improve compound potency. The initial synthetic strategy towards the synthesis of amine 93 is 
outlined in scheme 14. 
 
Biphasic amidation conditions gave compound 85 in quantitative yield which was cyclised via an 
unusual intramolecular Friedel Crafts reaction which, according to the literature, involves the loss 
of a phenyl anion in order to aromatise the quinolin-2(1H)-one A ring (Figure 41). 97 The 
concurrent methyl ether deprotection carried out in the reaction gave quinolinone 86 in modest 
yields, which contained small amounts of the 5-hydroxyquinolin-2(1H)-one (7%) regioisomer after 
crystallization from ethanol.  
 
Figure 41.  Proposed mechanism for the cyclisation of N-(Phenyl)cinnamides 97 
Double methylation using NaH and iodomethane yielded compound 87 in moderate yield. However, 
attempts at nitration were unsuccessful as it proved very difficult to control mono vs di substitution 
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even using nitronium tetrafluoroborate, a mild source of NO2+. In addition, as the products were 
exceptionally insoluble, column chromatography to separate product regioisomers proved 
unsuccessful. 
An alternative approach was thus adopted which would involve the bromination and either 
subsequent amination and coupling, or direct metal mediated cross coupling with the primary 
sulfonamide to provide the desired compound. Unfortunately bromination with NBS in DMF 
proceeded to give the undesired 3-Br isomer (88) in excellent yield. Regioselectivity was confirmed 
by HSQC/HMBC assignment and the lack of a characteristic C3H signal at ~ 6.4 ppm with a strong 
ortho coupling. Instead the signal at 6.79 ppm has a weak meta coupling of 2.3 Hz. Investigation of 
DCM and acetic acid as alternative solvents had little effect on regioselectivity. 
Searching of the literature suggested that it would be possible to synthesise 93 by the sequence 
illustrated in scheme 15. 84 
 
 
Efforts were thus made to synthesise amine 89, which according to literature could be synthesised, 
all be it in 20% yield, from m-anisidine using conditions outlined in scheme 16. 85 Acetylation with 
acetic anhydride in acetic acid gave 45 in quantitative yield. 86 However, reproducing literature 
nitration to give the desired regioisomer proved unsuccessful in our hands, instead exclusively 
isolating a 41% yield of 95a. 85 
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Since amine 96 was commercially available the synthesis was adapted to give Scheme 17. 
 
 
2-ethoxyacraloyl chloride (97) was synthesised following the literature procedure in 2 steps from 
ethyl vinyl ether and oxalyl chloride followed by decarbonylation on heating. 87 Reaction of the 
crude acid chloride with amine 96 gave amide 98 in moderate yields. Cyclization in concentrated 
H2SO4 yielded 99 in quantitave yield which was methylated under standard conditions to give 1-
methyl-6-brome-7-methoxy-quinolin-2(1H)-one  (100) in modest yields. 
Initial attempts at amination by adapting the procedure of Xu et al proved unsuccessful as bromide 
100 proved inert to these conditions. 88 In order to inhibit starting material precipitation on 
addition of NH4OH the ratio of NMP was increased to aid solubilisation. Disappointingly even after 
heating at 110 °C overnight bromide 100 still failed to react.   
Xu et al had also investigated the use of microwave irradiation for the amination of substitutionally 
inert halides with some success. Gratifyingly, on application of microwave conditions the reaction 
proceeded smoothly to the desired amine (93). Unfortunately even after column chromatography 
and prolonged drying under high vacuum it proved impossible to remove NMP from amine 93. 
53 
 
Thus, the crude amine was coupled in low yields with the 2 most promising sulfonyl chlorides using 
standard conditions to give the sulfonamides 101 and 102 for biological evaluation.  
ID BAZ2A BRD1 BRD4 BRD9 CECR2 BRPF1B CREBBP 
101 n.d 1.9 n.d 3.5 n.d 5.3 n.d 
102 -0.1 0.80 -0.3 0.9 0.0 5.6 -0.2 
 
Table 15. ΔTm results from compounds 101 and 102 (°C). Results obtained by Dr Oleg Fedorov at the 
SGC. Experiments carried out at 10 μM, n = 1 Heat map is a scale from Green = low ΔTm – low potency to 
Red = high ΔTm - high potency. 
Whilst both compounds (101 and 102) showed similar levels of potency against BRPF1 compared 
to one another and their des-methoxy analogues (2 and 23) the selectivity of 102 against the other 
class IV BRD family members and other BRDs was greatly improved.  This is potentially a function 
of the sulfonamide NH forming an intramolecular hydrogen with the ether oxygen and orientating 
the sulfonamide in a position favourable for BRPF binding (Figure 42).  
 
Figure 42. Compound 102 showing the internal hydrogen bond between the ethereal oxygen and 
sulfonamide nitrogen. 
With these promising TS results quantitative KD’s were obtained (Table 16). 
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Table 16. Biochemical and biophysical evaluation of compound 102. a. Tm carried out by Dr Oleg Fedorov 
at the SGC. Experiments carried out at 10 μM, n = 1. b. KD’s determined by DiscoverX. Most KD’s were 
determined using a compound top concentration = 10,000 nM. Dose response curves were determined at 
an 11 point serial dilution. If the initial KD determined was < 0.169 nM (the lowest concentration tested), the 
measurement was repeated with a serial dilution starting at a lower top concentration. Data is the mean of 
2 replicates 
102 possessed an excellent probe profile in terms of selectivity and potency. In addition, the ClogP 
of 1.90 combined with PTSA 100 Å2 should impart favourable off-target selectivity and cell 
permeability. However, lack of compound solubility would hinder widespread biological 
application. Compound 102’s insolubility was ascribed to its planarity and the intramolecular 
hydrogen bond between the sulfonamide NH and the ethereal oxygen (Figure 42). 
It was hoped that extending the alkyl ether at the 7 position would detrimentally impact crystal 
packing, thus improving compound solubility whilst retaining the intramolecular hydrogen bond 
for selectivity. The required amines for the 7 alkyl ether analogues were synthesised according to 
scheme 18.  
 
Amidation was carried out analogously to the formation of compound 85 in high yield.  Cyclisation 
was achieved by heating the amide in DMA with AlCl3 under argon at 150 °C  to give the desired 7-
hydroxy-3,4-tetrahydroquinolinone (104) after crystallisation from ethanol. 89 Subsequent 
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literature bromination, employing NBS in DMF afforded the  desired 6-bromo isomer, as evidenced 
by the 2 singlets in the 1H NMR spectrum. 90 Subsequent double methylation was carried out as per 
compound 85. Reaction of methyl ether 106 with BBr3 at -78 °C furnishing phenol 107 in 
reasonable yield. Deprotonation of the phenol with NaH and reaction with the requisite alkyl iodide 
furnished the appropriate 7-alkoxy tetrahydroquinolinone (THQ) in good to excellent yield. The 
THQ was oxidised to the quinolinone by heating a mixture of the THQ with freshly crystallized DDQ 
in DCE at reflux. Whilst purified DDQ was not critical to reaction success it was observed that the 
yield was slightly higher when the purified reagent was employed. With the 6-bromo-7-alkoxy-1-
methylquinolinones in hand amination and subsequent coupling were carried out as per compound 
100 to afford the sulfonamides (111-112) in low yield. 
 
Table 17. Biochemical and biophysical evaluation of compounds 103, 111 and 112. a. Tm carried out by Dr 
Oleg Fedorov at the SGC. Experiments carried out at 10 μM, n = 1. b. KD’s determined by DiscoverX. Most 
KD’s were determined using a compound top concentration = 10,000 nM. Dose response curves were 
determined at an 11 point serial dilution. If the initial KD determined was < 0.169 nM (the lowest 
concentration tested), the measurement was repeated with a serial dilution starting at a lower top 
concentration. Data is the mean of 2 replicates* Compound was assayed again on the same plate to 
provide more meaningful comparison, value is ~2 °C higher than previously recorded. 
After the negative results from the TS assay it was hypothesised that the ether at the 7 position was 
exploiting a small lipophilic pocket that was unable to accommodate a larger alkyl group. Given the 
low Tm values it was thus unusual that the KD’s determined were similar to that determined for 103. 
Although there may not always be a direct correlation between the TS and KD data the magnitude of 
the difference suggests that one of the assays was erroneous. 
4.2.7.2  7-Fluoro Substituted Quinolin-2(1H)-ones 
Replacement of various substituents with a fluorine atom had previously proved unsuccessful in 
terms of BRPF1 potency. However, noticible improvements in solubility had been observed. Thus, 
in an effort to improve the undesirably low solubility of 103 , the ether was replaced with a 
fluorine.  
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In a similar synthetic sequence to scheme 14, 3-fluoroaniline (113) was coupled to form cinnamide 
114 which was subjected to intramolecular cyclisation. 115 was methylated, nitrated to give the 
desired 6-nitro isomer 117. This was confirmed by 1H NMR, with a pair of doublets for C3H and C4H 
as well as doublets for C5H and C8H. The alternative 8-nitro isomer would have displayed a doublet 
of doublets for the C6H proton. Reduction and coupling under standard conditions afforded 
sulfonamide 119 for testing against BRPF1. 
ID BRD1A BRD4A BRPF1B 
119 1.8 0.7 3.8 
 
Table 18. ΔTm results from compounds 119 (°C). Results obtained by Dr Oleg Fedorov at the SGC. 
Experiments carried out at 10 μM, n = 1. Heat map is a scale from Green = low ΔTm – low potency to Red 
= high ΔTm - high potency. 
Substitution of the 7 ether did prove efficacious in terms of solubility, with 119 being soluble at 100 
mM in DMSO which 103 was not. Despite this, the substitution pattern was not investigated further, 
as the compound displayed lower potency and off-target selectivity. Similarly to compound 74 this 
could be a function of lower KAc mimetic electron density, or the lack of intramolecular hydrogen 
bond to preorientate the compound in a mode favourable for BRPF1 binding. 
4.2.8  4,7 Substituted Quinolin-2(1H)-ones 
 
 
 
As it was thought that the ether variation at the 7 position was unproductive, it was decided to 
reintroduce the methyl group at the 4 position. It was hoped that this would retain compound 
selectivity, whilst addressing the solubility issues associated with 103. A merged synthetic strategy 
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from schemes 5 and 17 was employed for the synthesis of 7-methoxy-6-amino-1-methylquinolin 
2(1H)-one (124) which is depicted in scheme 20. 
 
Formation of the oxobutanamide was consistant with previous reactions, although cyclization 
conditions with sulfuric acid were unreproducible, with none of the desired quinolinone being 
isolated.  In contrast, by changing the acid source to polyphosphoric acid (PPA) a quantitative yield 
of 121, with none of the undesired 6-bromo-5-methoxy-4-methylquinolin-2(1H)-one was obtained, 
as evidenced by the two singlets for protons C5H and C8H. PPA was chosen as it has a long history in 
the literature of being an excellent condensation, dehydration and cyclisation reagent. 91 Ensuing 
methylation and amination were carried out as previously described to yield the amine which was 
coupled under standard conditions to provide compound 124. 
ID BRD4A BRD9A CECR2A CREBBPA BRPF1 TIF1A 
124 0.4 1.1 0.3 0.2 7.1 2.2 
 
Table 19. ΔTm results from compound 124 (°C). Results obtained by Dr Oleg Fedorov at the SGC. 
Experiments carried out at 10 μM, n = 1. Heat map is a scale from Green = low ΔTm – low potency to Red 
= high ΔTm - high potency.Heat map is a scale from Green = low ΔTm - inactive to Red = high ΔTm – active. 
Although it was not possible to collect TS data on BRD1 and BRPF3, the general selectivity profile of 
103 was maintained on addition of the methyl group at the 4 position, whilst maintaining the 
potency against BRPF1. 
 Quinolinone C2-cabonyl acts as acyl-lysine mimic forming H-
bond with Asn
708
 (2.8 Å). 
 Only direct polar interaction 
 Quinolinone C2-cabonyl participates in water H-
bonding network through to Tyr
665
 
58 
 
 
Table 20. Biochemical and biophysical evaluation of compound 124. a. Tm carried out by Dr Oleg Fedorov 
at the SGC. Experiments carried out at 10 μM, n = 1. b. KD’s determined by DiscoverX. Most KD’s were 
determined using a compound top concentration = 10,000 nM. Dose response curves were determined at 
an 11 point serial dilution. If the initial KD determined was < 0.169 nM (the lowest concentration tested), the 
measurement was repeated with a serial dilution starting at a lower top concentration. Data is the mean of 
2 replicates 
Determination of the KD’s indicated that 124 was more selective than 102 with respect to BRD1 
and BRPF3, but less selective for BRD9. The promising KD’s merited further investigation, thus an 
ITC KD (experiment carried out by Cynthia Tallant at the SGC) was determined. Disappointingly this 
gave a value of 423 nM against BRPF1, suggesting that the competition assay KD’s determined by 
DiscoverX were overestimating binding by approximately 10 fold. 
Despite the disappointing affinity, it was observed that 124 possessed marginally better solubility 
than 102. 102 required sonication to dissolve and then was observed to precipitate from DMSO 
after 7 days, which was not the case for 124 (~ 100 mM). The added soluibility allowed for the 
determination of a cocrystal structure of 124 with BRPF1. 
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Figure 43. Cocrystal structure of compound 124 with BRPF1 (1.65 Å) . Data obtained by Cynthia Tallant at 
the SGC. Diagram created in PyMOL. a. 124 in BRPF1 highlighting the binding interactions between the 
quinolinone A ring and F714 and the KAc mimetic with N708 and W665 b. View of 124 in BRPF1 looking 
down F714, highlighting the π-stacking between F714 and the quinolinone A ring. c. Surface of BRPF1 
showing the pocket available at the 3-position. d. Superimposed crystal structures of 124 and 1-
methylquinolin-2(1H)-one (14- light blue) showing same binding mode, but ‘tilting’ of F714 in 14 structure 
(light blue)  
The crystal structure highlights a number of key interactions: 
1. As expected, the quinolinone C2-carbonyl acts as an acetyl lysine mimetic. The amide forms a 
hydrogen bond (2.8 Å) with Asn 708. This is the only direct polar interaction of the molecule 
(Figure 43a). 
2. The C2-carbonyl interacts with the conserved Tyr 665 via a water mediated H-bonding 
network (Figure 43a). 
3. Quinolinone A-ring forms parallel, face-centered π-π stack with Phe 714  ‘gatekeeper’ residue 
(3.6 Å) (Figure 43b). 
4. Quinolinone A-ring sandwiched between Phe 714 and Val 657 (Figure 43a). 
5. Benzonitrile forms perpendicular, T-shaped C-H-π interaction with Phe 714 (5.0 Å) (Figure 
43a). 
6. Overlaying a cocrystal structure of the fragment bound to BRPF1 (obtained later in the 
project) illustrated that elaboration into the sulfonamide caused Phe 714 to tilt such that it 
can now π-stack with the quinolinone A ring ( Figure 43d). 
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By obtaining a cocrystal structure of compound 124 with BRPF1 it was possible to shift from 
systematic to a structure guided SAR approach. Through analysis of the key inhibitor interactions a 
number of further areas of optimisation were prioritised. 
1. The quinolinone was orientated such that the 4-methyl group was pointing into open space, 
not picking up any interactions. Further investigation of this group was unlikely to provide 
the extra potency required. 
2. Analysis of the polar surface of the binding site suggested C3 position modification might be 
able to exploit a small lipophilic pocket (Figure 43c). 
3. Aromaticity of the quinolinone A-ring and the sulfonamide ring was important to maintain 
the π stacking with phenylalanine. 
4. Increasing the electron density of the benzonitrile aromatic ring might strengthen the T-
shaped π bond. 
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4.2.9  3-Substituted Quinolin-2(1H)-ones 
 
Further attempts at investigating the sterically demanding area of the binding pocket next focussed 
on altering the 3 position, as the cocrystal structure of 124 and BRPF1 showed that there was a 
small lipophilic pocket in this area. 
4.2.9.1  3-Me Substituted Quinolin-2(1H)-ones 
As the lipoplic pocket available appeared to be quite small the first subsituent investigated was a 
methyl group. The required quinolin-2(1H)-one was synthesised according to Scheme 21. 
 
The required 3-methylquinolin-2(1H)-one (125) was synthesised as per the synthesis of scheme 1, 
by oxidation of the 3-methylquinoline with mCPBA and subsequent rearrangement of the N-oxide 
with benzoyl chloride. In contrast to scheme 1, the quinolinone was first nitrated to afford 127, 92 
as this would facilitate corroboration of the data generated from the investigation of the N-alkyl 
group. The undesired 8-nitro isomer was not observed in the 1H NMR as there was no doublet of 
doublets for the C6 proton. Alkylation under standard conditions yielded 128a-b in reasonable to 
good yield, however issues were encountered with the reduction step. Application of the previously 
employed SnCl2 lead to a complex mixture of products, so the conditions of Fish et al were instead 
adopted to yield the amine (129a-b) in moderate yield. 92 Sulfonamidation afforded compounds 
130 (henceforth referred to as NI-42) and 131 for biological evaluation. 
Initial evaluation of NI-42 by TS highlighted excellent potency against, and selectivity for, the class 
IV BRDs (Figure 44). Whilst NI-42 did not meet the selectivity criteria for a BRPF probe, it was 
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found to be almost equipotent against all class IV BRDs, further profiling was carried out as it was 
envisaged that it could be employed as a pan class IV BRD probe. 
 
Figure 44. Graph showing bromonome screening of NI-42 by TS. Tm carried out by Dr Oleg Fedorov at the 
SGC. Experiments carried out at 10 μM, n = 3 
The first thing of note, is the lower values of TS in comparison with other compounds screened. 
This is a result of differences in assay execution when profiling one compound against the entire 
bromonome. When many compounds are screened the individual compounds are added to the 
wells containing the BRD of interest, whereas when profiling a single compound the BRD is instead 
added to the well containing the compound. The net effect of this reversal of addition is that the 
results obtained from the BRD wide screen tend to be lower, and more accurate as a result of a 
more consistent compound concentration. 
NI-42 was extremely selective for the class IV BRDs, with the highest ΔTm outside the class IV 
family being 0.69 °C recorded for TAF1L, with previous TS data from the SGC indicating that these 
values corresponded to KD values greater than 1 μM. With this data in hand KD’s were determined to 
further confirm compound selectivity. 
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Table 21. Biochemical and biophysical evaluation of NI-42. a. Tm carried out by Dr Oleg Fedorov at the 
SGC. Experiments carried out at 10 μM, n = 1. b. KD’s determined by DiscoverX. Most KD’s were 
determined using a compound top concentration = 10,000 nM. Dose response curves were determined at 
an 11 point serial dilution. If the initial KD determined was < 0.169 nM (the lowest concentration tested), the 
measurement was repeated with a serial dilution starting at a lower top concentration. Data is the mean of 
2 replicates. c. ITC Kd’s determined by Cynthia Tallant at the SGC, n = 1. 
The data from the TS assay was corroborated by the both DiscoverX and ITC KD’s , with NI-42 being 
potent against the Class IV’s, but inactive against BRDs outside this family. There was a surprisingly 
high KD for BRD7, for which TS data can be misleading due to this BRDs very low melting 
temperature (melts partially at RT). Also of note is that the drop in potency from the Dx platform to 
the ITC was far lower (~5 fold) than that for compound 124. 
For the N-ethylated compound (131) the BRPF1 ΔTm of 5.5 suggests that, in combination with the 
favourable 3-methyl group, an ethyl group is not well tolerated by the BRPF binding site. However, 
KD determination (BRPF1 KD: 15 nM) suggested that the drop in potency was not as large as the TS 
value suggests, corroborating the data from compound  59. 
As envisaged, the introduction of a methyl group at the 3 position of the A ring was exploiting a 
small hydrophobic pocket near the KAc binding site. As a consequence of this, the binding the 
potency of NI-42 is improved approximately 5-fold in comparison to its des-methyl compound 23 
(BRPF1 KD 23: 43 nM NI-42: 7.9 nM). 
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4.2.9.2  3-Et Substituted Quinolin-2(1H)-ones 
We next investigate the size of the hydrophobic pocket at the 3 position by synthesising the 3-Ethyl 
substituted quinolinone (Scheme 22). 
 
For the synthesis of the required nitroquinolinone (134) an alternative route, based on that of Wu 
et al was employed. 93 This involved the reaction of 2-chloro-4-nitrobenzaldehyde (132) with 4,4-
dimethyl-2-propyl-4,5-dihydrooxazole (133). The reaction proceded by formation of the enamine 
from the oxazole, followed by nucleophilic attack on the aldehyde carbon. Dehydration is followed 
by the oxazole carrying out SNAr at the carbon bearing the chlorine substituent, followed by ring 
opening. Loss of a proton followed by ether hydrolysis furnishes the desired 3 alkyl quinolinone 
(Figure 45). 
 
Figure 45. Proposed mechanism for quinolinone formation from 4,4-dimethyl-2-alklyl-4,5-dihydrooxazoles 
and 2-halo-4-nitrobenzaldehydes 
Methylation, reduction and coupling were carried via the standard procedures to provide 
compound 137 for biological evaluation. 137 recorded a ΔTm of 4.7 °C and a KD of 180 nM against 
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BRPF1 suggesting that the hydrophobic pocket at the 3 position was unable to accommodate larger 
alkyl groups. 
4.2.9.3  3-Br Substituted Quinolin-2(1H)-ones 
Increasing the 3 position substituent size from a methyl to an ethyl group resulted in a drop in 
compound potency, suggesting that the binding pocket was unable to accommodate the larger ethyl 
group. A compound with a 3-Br was next synthesised as a marginally smaller (Br Taft size 
parameter ES: -1.16, Me ES: -1.23) 65, more lipophilic replacement for the methyl. Synthesis of the 
desired sulfonamide was carried out as per scheme 23. 
 
Oxidation and rearrangement employing standard conditions provided 3-bromoquinolin-2(1H)-
one, which was nitrated to afford 141 using HNO3 in H2SO4. The 6-nitro isomer regioselectivity was 
confirmed analogously to 127. Methylation, reduction and coupling of the crude amine afforded 
sulfonamide 143 for biological evaluation against BRPF1. 
Sulfonamide 143 recorded a KD of 7.9 nM against BRPF1, equipotent to the 3-Me analogue (NI-42). 
However, the complete profile of NI-42 was superior to the 3-Br sulfonamide (143) as it displayed 
lower lipophilicity (3-Br ClogP – 2.88, 3-Me ClogP – 2.46) and hence improved lipophilic efficiency. 
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4.2.10   Substitution of the Sulfonamide ring II 
 
 
Having determined the ideal substitution of the quinolinone ring to be 1,3-dimethyl-6-
aminoquinolinone, further sulfonamide substitution was now investigated utilising this core. The 
most promising substitution pattern from investigation with the 6-amino-1-methylquinolin-2(1H)-
one (2) core involved the electron donating methyl group at the 2 position. As the co-crystal 
structure of 124 corroborated this SAR, highlighting a T-shaped π stacking interaction between the 
sulfonamide aryl ring and Phe 714, it was decided to prioritise the synthesis of 2-methoxy-4-
cyanobenzenesulfonyl chloride (148). This would retain the 4-cyano group for selectivity, whilst 
introducing a 2-methoxy group for its electron donating abilities. 
 
Substitution of the fluorine by SNAr with NaOR provided 145a-b in excellent yields which were 
reduced in modest yield in alkyl alcohol at reflux with SnCl2 to furnish the required amines (146a-
b). Unfortunately, application of the previously employed conditions for conversion of the amine to 
the sulfonyl chloride were unsuccessful for compound 146a, failing to yield any of the desired 
compound. This was in agreement with the literature observations of poor conversion for electron 
donating substituents, 78 thus optimisation of the various reaction parameters was required (Table 
22). 
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Table 22. Optimization of the Sandmeyer transformation of amine 146a into 2-methoxy-4-
cyanobenzenesulfonyl chloride (148). a. ratio of sulfonyl chloride:aryl chloride b. indicates use of freshly 
purified CuCl c. reaction run under these conditions 4 times. Yields = 0%, 0%, 10% and 33%. All other 
reactions n=1 . d. optimised conditions used for 2-ethoxy-4-cyanoaniline (146b). e. optimised conditions 
used for 2-methoxy-4-chloroaniline (151), n = 2. 
Efforts initially focussed on encouraging a faster reaction, as in previous successful reactions on 
addition of the diazonium salt the reaction was visibly rapid (the reaction would darken and then 
would return to pale green in ~15 minutes, followed shortly thereafter by precipitation of the 
product). Increasing the amount of SOCl2, in the hopes of increasing the SO2 concentration, proved 
partially successful isolating the sulfonyl chloride in low yield. Doubling the reaction concentration 
proved unsuccessful, whilst using freshly purified CuCl appeared to have a small benefit. The most 
successful modification involved decreasing the temperature to -15 °C during diazonium addition, 
followed by allowing the reaction to stir at -5 °C and then RT.  This suggests that the limiting factor 
may be instability of the corresponding diazonium salt. Disappointingly even using optimised 
conditions the reaction proved capricious, failing to yield any sulfonyl chloride in half of the 
attempts. 
Attempts to synthesise 2-ethoxy-4-cyanobenzenesulfonyl chloride (149) using the optimised 
conditions were successful, however the yield was low and an unidentified third product was 
formed during the reaction. Despite this sufficient quantities of the sulfonyl chloride were 
synthesised for coupling.  
Further application of the conditions to 2-methoxy-4-chloroaniline (151) failed to yield any of the 
desired sulfonyl chloride in two attempts. 
With the required sulfonyl chlorides in hand a selection of sulfonamides were synthesised in order 
to investigate the effect of T-shaped π stacking on potency in the 3-methyl-6-sulfonamide series. 
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Table 23. Biochemical and biophysical evaluation of compounds 152-154. a. Tm carried out by Dr Oleg 
Fedorov at the SGC. Experiments carried out at 10 μM, n = 1. b. KD’s determined by DiscoverX. Most KD’s 
were determined using a compound top concentration = 10,000 nM. Dose response curves were 
determined at an 11 point serial dilution. If the initial KD determined was < 0.169 nM (the lowest 
concentration tested), the measurement was repeated with a serial dilution starting at a lower top 
concentration. Data is the mean of 2 replicates. 
Overall the KD and TS data indicate a general trend that increasing the electron density of the 
sulfonamide ring increases compound affinity. However, the differences between compounds 152, 
NI-42 and 153 are all within the error of the assay, thus absolute ranking of the compounds is not 
possible.  Despite this, addition of the nitrile from compound 153 to 154 (henceforth referred to as 
NI-57) did appear to be beneficial in both assay formats 
As Fish et al had synthesised 153 as an inhibitor of BRD4 compound selectivity for BRPF1 was next 
assessed.92 
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Table 24. Biochemical and biophysical evaluation of compound 153. a. Tm carried out by Dr Oleg Fedorov 
at the SGC. Experiments carried out at 10 μM, n = 1. b. KD’s determined by DiscoverX. Most KD’s were 
determined using a compound top concentration = 10,000 nM. Dose response curves were determined at 
an 11 point serial dilution. If the initial KD determined was < 0.169 nM (the lowest concentration tested), the 
measurement was repeated with a serial dilution starting at a lower top concentration. Data is the mean of 
2 replicates. 
In terms of potency against BRPF1 and selectivity versus BRD1 NI-42 and 153 had almost identical 
profiles. However, 153 was also a moderately potent inhibitor of BRD4 (BRD4(1) KD: 600 nM), 
providing only a 66 fold selectivity window, much lower than the > 200 fold selectivity of NI-42. 
Given the importance of BRD4 selectivity this compound was not profiled further. 
4.2.10.1  NI-57 
Since introduction of the nitrile had previously been successful in imparting selectivity for BRPF1 
(cf 101 vs 102), following on from the promising TS and KD data, NI-57 was profiled by TS against 
the available bromonome (Figure 46).  
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Figure 46. Graph showing bromonome screening of NI-57 by TS. Tm carried out by Dr Oleg Fedorov at the 
SGC. Experiments carried out at 10 μM, n = 3. Red = Class IV BRD 
As for NI-42, NI-57 proved very selective for the class IV BRDs by thermal shift, although unlike NI-
42 there were indications that the NI-57 may be sufficiently selective for the BRPFs to be 
considered a BRPF probe. (ΔTm BRPF1-BRD9 NI-57: 7.6 °C, NI-42: 5.98 °C, ΔTm BRPF1-BRD7 NI-57: 
4.1 °C, NI-42: 3.0 °C). Therefore, NI-57 was further profiled by DiscoverX KD against the entire BRD 
class (Table 25). 
Determination of the selectivity by DiscoverX KD’s indicated that NI-57 met the SGC selectivity 
criteria to be considered a BRPF specific probe. That is: 
1. < 100 nM in potency in a biophysical assay. 
2. 30 fold selective for the BRPF BRDs with respect to other class IV BRDs. 
3. 100 fold selective over non-class IV BRDs. 
BRD KD (nM) 
Selectivity vs 
BRPF1 (× fold) 
BRD KD (nM) 
Selectivity vs 
BRPF1 (× 
fold) 
ATAD2A >50,000 >12,500 BRD3(2) >50,000 >12,500 
ATAD2B >50,000 >12,500 BRD4(1) 3,300 825 
BAZ2A >50,000 >12,500 BRD4(1,2) 15,000 3750 
BAZ2B 9,400 2350 BRD4(2) >50,000 >12,500 
BRD1 46 11.5 BRD4(full-length) 4,900 1225 
BRD2(1) 5,900 1475 BRD7 100 25 
BRD2(1,2) 12,000 3000 BRD8(1) >50,000 >12,500 
BRD2(2) >50,000 >12,500 BRD8(2) >50,000 >12,500 
BRD3(1) 7,200 1800 BRD9 160 40 
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BRD3(1,2) 12,000 3000 BRDT(1) 4,800 1200 
BRDT(1,2) >50,000 >12,500 PBRM1(5) 11,000 2750 
BRDT(2) >50,000 >12,500 PCAF 4,200 1050 
BRPF1 4 1 SMARCA2 >50,000 >12,500 
BRPF3 110 27.5 SMARCA4 41,000 10250 
CECR2 12,000 3000 TAF1(2) 4,900 1225 
CREBBP 13,000 3250 TAF1L(2) 5,500 1375 
EP300 15,000 3750 TRIM24(Bromo) 1,600 400 
FALZ 2,300 575 TRIM24(PHD,Bromo) 5,600 1400 
GCN5L2 4,100 1025 TRIM33(PHD,Bromo >50,000 >12,500 
PBRM1(2) >50,000 >12,500 WDR9 >50,000 >12,500 
 
Table 25. Bromonome KD panel for NI-57 . KD’s determined by DiscoverX. Most KD’s were determined 
using a compound top concentration = 10,000 nM. Dose response curves were determined at an 11 point 
serial dilution. If the initial KD determined was < 0.169 nM (the lowest concentration tested), the 
measurement was repeated with a serial dilution starting at a lower top concentration. Data is presented 
as the mean of 2 replicates. Red = Class IV BRD. 
However, as the DiscoverX KD’s had overestimated potency and selectivity for previous compounds, 
it was decided to determine KD’s by ITC in order to corroborate the data. 
 
Table 26. Biochemical and biophysical evaluation of NI-57 . a. Tm carried out by Dr Oleg Fedorov at the 
SGC. Experiments carried out at 10 μM, n = 1. b. KD’s determined by DiscoverX. Most KD’s were 
determined using a compound top concentration = 10,000 nM. Dose response curves were determined at 
an 11 point serial dilution. If the initial KD determined was < 0.169 nM (the lowest concentration tested), the 
measurement was repeated with a serial dilution starting at a lower top concentration. Data is the mean of 
2 replicates. c. ITC carried out by Cynthia Tallant at the SGC, n = 1 
Changing the assay from a competition KD to an ITC KD lowered potency against all bromodomains. 
As for previous compounds the BRPF1 potency was most affected, dropping ~8 fold, similar to the 
drop seen for 124. The decreases in potency for the other BRPF members, BRD1 and BRPF3, were 
both between 3 and 4, whilst BRD9 was in between at 5.5. Nonetheless, despite the large drop in 
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potency affecting compound selectivity, NI-57 was still able to meet the probe criteria outlined by 
the SGC. 
 
 
Figure 47. Cocrystal structure of NI-57 with BRPF1 (2.10 Å) . Data obtained by Cynthia Tallant at the 
SGC. Diagram created in PyMOL. a. NI-57 in BRPF1 highlighting the binding interactions between the KAc 
mimetic with N708 and W665 b. Surface of BRPF1 with NI-57 bound c. NI-57 bound to BRPF1 looking 
down F714. d. Superimposed crystal structures of NI-57 and 1-methylquinolin-2(1H)-one (14- light blue) 
showing same binding mode, but ‘tilting’ further forward of F714 in 14 structure (light blue) e. 
Superimposed crystal structures of NI-57 and 124 (light blue) showing how the quinolinone ring has 
flipped.d. 2 dimensional representation of the interactions between NI-57 and the BRPF1 binding pocket. 
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Having obtained a cocrystal structure of NI-57 with BRPF1, the first thing of note was that the 
interactions between the acetyl-lysine mimetic and the BRPF1 binding pocket were maintained 
from 124 to NI-57. That is, the quinolinone carbonyl interacts directly with Asn 708 and via a water 
mediated hydrogen bond network with Tyr 665 (Figure 47a). 
The first difference between the 2 crystal structures is highlighted in Figure 47b and c where, 
unlike 124 where Phe 714 forms a face-face π-stacking interaction with the quinolinone A-ring the 
aromatic ring, Phe 714 for NI-57 is now tilted forward in a similar manner to that in the cocrystal 
structure of fragment 14 with BRPF1 (Figure 47d). Moreover the postulated T-shaped π-stacking 
interaction for 124 is no longer possible for NI-57. 
Of particular note, is the overlayed cocrystal structures of NI-57 and 124, where it can be seen that 
the quinolinone ring has ‘flipped’, the N-alkyl group is now occupying the pocket formerly occupied 
by the 4-methyl group of 124. Consequently, the NI-57 sulfonamide aryl ring does not occupy the 
same area of the WPF shelf as 124, bending in ‘lower’ than its 124 counterpart.  
The cocrystal structure does not indicate why addition of the methyl ether to the sulfonamide aryl 
ring imparts greater potency and selectivity. There was no indication of an intramolecular 
hydrogen bond between the sulfonamide NH and the ether oxygen, or the T-shaped π-stacking 
which might have benefitted from the increased electron density of the aryl ring. Moreover, the 
methyl group does not appear to be binding in any hydrophobic pockets. 
4.2.11  3-Me,7-OMe Substituted Quinolin-2(1H)-ones 
 
On addition of a methyl ether at the 7 position of the quinolinone ring previous compounds had 
increased in both potency and selectivity. Inspection of the crystal structure  (vide supra) showed 
that it was possible that the ethereal oxygen would be able to form an intramolecular hydrogen 
bond similar to that hypothesised to be responsible for the selectivity of compound 102. 
Thus 3-methyl-7-methoxy-6-sulfonamidequinolinones were synthesised according to scheme 26, in 
the hope of increasing the selectivity of NI-57 against BRD7 and BRD9. 
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Table 27. Biochemical and biophysical evaluation of compounds 161-170. a. Tm carried out by Dr Oleg 
Fedorov at the SGC. Experiments carried out at 10 μM, n = 1. b. KD’s determined by DiscoverX. Most KD’s 
were determined using a compound top concentration = 10,000 nM. Dose response curves were 
determined at an 11 point serial dilution. If the initial KD determined was < 0.169 nM (the lowest 
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concentration tested), the measurement was repeated with a serial dilution starting at a lower top 
concentration. Data is the mean of 2 replicates. c. prepared by catalytic hydrogenation of compound 168. 
Reaction of compound 94 in a double Vilsmeier type reaction afforded 2-chloro-7-
methoxyquinoline-3-carbaldehyde (155) in reasonable yield. 94 Hydrolysis of the 2-chloroquinoline 
in 3 M HCl provided the 3-formylquinolinone (156), 95 which was reduced with triethylsilane in 
TFA. Methylation, bromination, amination and coupling with the sulfonyl chloride were carried out 
as for previous reaction schemes. As for 105 the selectivity of the bromination step was confirmed 
by the presence of two singlets in the 1H NMR spectrum, where the alternative 8-bromo isomer 
would have shown 2 doublets.  
ID BRPF1B TIF1A BRD4 BRD9 CECR2 CREBBP 
161 9.4 0.8 2.6 4.2 -0.5 1.5 
162 8.8 0.5 1.1 3.5 0.0 1.3 
163 9.9 1.0 1.0 4.4 0.6 2.1 
164 12.7 n.d. n.d. n.d. n.d. n.d. 
165 9.5 n.d. n.d. 5.3 0.1 n.d. 
166 11.0 n.d. n.d. 6.3 0.4 n.d. 
167 Interferes with assay 
168 6.6 n.d. n.d. 2.9 0.2 n.d. 
169 7.7 n.d. n.d. 2.8 0.0 n.d. 
170 3.8 n.d. n.d. 5.7 -3.5 n.d. 
 
Table 28. ΔTm results from sulfonamide investigation 161-170 (°C). Results obtained by Dr Oleg Fedorov 
at the SGC. Experiments carried out at 10 μM, n = 1. Heat map is a scale from Green = low ΔTm – low 
potency to Red = high ΔTm - high potency. 
The SAR generated for this core was consistent with that from previous series. Investigation of 
different groups at the 4-position of the sulfonamide ring suggested that a nitrile was the most 
favourable. Electron donating substituents (4-Me – 169  and 4-NH2 –170) proved less potent. 
Indeed, compound 170 with a 4-NH2 group was also inversely selective against BRD9 by TS. 
Decreasing electron donating ability relative to the nitrile was similarly ineffective, with 4-NO2 
(168) recording a Tm of 6.6 °C. 
Addition of electron donating groups at the 2 position again appeared favourable, with all 2-
position substituents recording appreciable thermal shifts. The data does imply that extension of 
the alkyl group from a methyl to an ethyl on the 2 position ether (164 R = Me BRPF1 ΔTm: 12.73 °C, 
165 R = Et BRPF1 ΔTm: 9.5 °C) is not beneficial, but there is insufficient data to confirm this 
hypothesis. 
Following on from the promising Tm and KD data sulfonamide 164 was assayed against the available 
bromonome by TS. 
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Figure 48. Graph showing bromonome screening of compound 164 by TS. Tm carried out by Dr Oleg 
Fedorov at the SGC. Experiments carried out at 10 μM, n = 3. Red = Class IV BRD 
Results from the bromonome assay (Figure 48) indicated that, in contrast to previous compounds, 
addition of the methyl ether at the 7 position was counterproductive at improving compound 
selectivity. Selectivity was especially poor against key selectivity target, the class II BRDs (BRD2: 
2.2 °C, BRD3: 2.3 °C and BRD4: 2.6 °C). Inspection of the cocrystal structures of 124 and NI-57 
suggests that if the sulfonamide orientates itself in such a manner as to form an internal hydrogen 
bond the inhibitor core will have to ‘flip’ again. As the potency against the class IV BRDs has been 
retained, but the non-class IV BRD potency has increased, the methoxy group promoted ring flip 
orientates the sulfonamide in a position more favourable for binding to other BRDs (Figure 49).  
 
Figure 49. Binding mode of compound 124 on the left showing how the quinolinone ring ‘flips’ to the 
binding mode of NI-57 in the middle. The hypothesised ring flip of compound 164 back into the original 
orientation as a consequence of the internal hydrogen bond is shown on the right  
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 4.3  Inactive control 
Having successfully synthesised NI-57, a BRPF selective chemical probe, and NI-42 a tool 
compound for the class IV BRDs, we next turned our efforts towards the synthesis of inactive 
control compounds to help validate any biological results obtained. Several areas of the inhibitor 
were modified in these efforts  
 4.3.1  8-Fluoro Substituted Quinolin-2(1H)-ones 
 
Initial attempts at producing an inactive analogue focussed on modification of the 8 position. It was 
envisaged that substitution of this site could interact with the 1 position alkyl group potentially 
causing the unfavourable torsion in the quinolinone ring, thus inhibiting binding. 96 Alternatively 
introduction, of electron withdrawing modifications could interact unfavourably with the proximal 
acetyl lysine mimetic, as had been observed for previous compounds. 
 Methylation of the unalkylated NH quinolinones was extremely low yielding, as a consequence of 
the peri-interactions between the 8 substituent and the approaching nucleophile. As a consequence 
of the steric clash almost exclusively O-alkylated product was isolated (or hydrolysed on silica). 
In order to assess whether the 8 position substitution was tolerated, the sterically undemanding F 
was chosen as a starting point. 
 
Reaction of 2-fluoroaniline (171) with α-methylcinnamoyl chloride (172) provided the appropriate 
cinnamide (173) which was cyclised in excellent yield using the previous employed conditions. 
Methylation afforded the required 8-fluoro-1,3-dimethylquinline-(1H)2-one (175) in good yield. 
Surprisingly nitration of this compound appeared to provide almost exclusively the unwanted 5-
nitro regioisomer.  This was unexpected as whilst both the fluoro and the amide are ortho/para 
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directing substituents the amide is usually the more powerful of the 2 (σpara F: 0.06, NHCOMe: -
0.15). 68 The 5-NO2 assignment was based upon the following data: 
1. The C6H-C7H coupling of 8.9 Hz is of a magnitude consistent with protons ortho to one 
another 
2. The C7H-CF and C6H-CF coupling constants of 14 and 3.8 Hz respectively are consistent  is 
consistent with substituents ortho and meta to a fluorine atom 
3. Although not conclusive no proton interaction was observed in a NOESY between C4H and a 
possible C5H (Figure 50) 
 
Figure 50. potential NOESY interaction between 4 and 5 position hydrogens 
This was promising with respect to the hypothesis that the 8 substituent might cause ring torsion, 
as the reduced orbital overlap of the para directing amide might be responsible for the lack of 
desired 6-position nitration. 
Thus, in order to be sure of synthesising a compound with the correct regiochemistry the route was 
repeated, but starting with 2-fluoro-4-bromoanline, which could eventually be subjected to 
standard amination conditions.  
 
Standard amide formation conditions provided the appropriate cinnamide (178), although for this 
analogue issues were encountered on Friedel-Crafts cyclisation. TLC indicated substantial 
quantities of debrominated quinolinone, 8-fluoro-3-methylquinolin-2(1H)-one (174), in the 
supernatent. This was unexpected, as literature cyclization of N-(4-bromophenyl)cinnamamide 
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proceeded in 55% yield and cyclisation of the des-bromo cinnamide (173) was near quantitative. 
Despite these issues sufficient quantities of 180 were isolated to allow for methylation, amination 
and coupling to provide sulfonamides 182 and 183 for biological evaluation. 
 
Table 29. Biochemical and biophysical evaluation of compounds 182 and 183. a. Tm carried out by Dr Oleg 
Fedorov at the SGC. Experiments carried out at 10 μM, n = 1. b. KD’s determined by DiscoverX. Most KD’s 
were determined using a compound top concentration = 10,000 nM. Dose response curves were 
determined at an 11 point serial dilution. If the initial KD determined was < 0.169 nM (the lowest 
concentration tested), the measurement was repeated with a serial dilution starting at a lower top 
concentration. Data is the mean of 2 replicates. * Yield over 2 steps from 180. 
The biological evaluation for these 2 compounds produced conflicting data. Thermal shift suggested 
that these compounds had significant drops in potency, however the KD determined for compound 
183 suggested that the drop in potency (~4 fold) was compariately modest. Whilst it is likely that 
the compounds had dropped somewhat in potency introduction of a fluorine at the 8 position was 
sufficiently tolerated to be unproductive for the synthesis of an inactive analogue.  
4.3.2  Sulfonamide N – alkylation 
 
Alkylation of the sulfonamide nitrogen was carried out by simple deprotonation with sodium 
hydride and subsequent reaction with the appropriate alkyl iodide in DMF 
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Table 30. Biochemical and biophysical evaluation of compounds 184-188. a. Tm carried out by Dr Oleg 
Fedorov at the SGC. Experiments carried out at 10 μM, n = 1. b. KD’s determined by DiscoverX. Most KD’s 
were determined using a compound top concentration = 10,000 nM. Dose response curves were 
determined at an 11 point serial dilution. If the initial KD determined was < 0.169 nM (the lowest 
concentration tested), the measurement was repeated with a serial dilution starting at a lower top 
concentration. Data is the mean of 2 replicates 
Methylation was first carried out on compound 23 and caused a ~20 fold decrease in compound 
potency (23 BRPF1 KD: 43 nM, 184 BRPF1 KD: 910 nM). Similar drops in potency were observed for 
methylation of compounds 102 and NI-57. Clearly, whilst the sulfonamide NH involved is 
favourable, it is not vital to compound binding.  
It was hoped that introducing a larger alkyl group would introduce a steric clash which would 
prevent the sulfonamide adopting the required orientation to bend into the WPF shelf. Thus NI-57 
was ethylated (187) and isopropylated (188) however the drops in potency were similar to those 
observed for compound methylation. 
4.3.3  1-methyl-3,4-dihydroquinolin-2(1H)-one Core 
Early SAR generated by the SGC suggested that the BRPF inhibition was reduced by reduction of the 
quinolinone A ring to form a 6-amino-1-methyl-3,4-dihydroquinolin-2(1H)-one core. Compounds 
synthesised early in the project (Dr Elliott Bayle) confirmed this, so a partially reduced NI-57 was 
synthesised to investigate the effect this might have on BRPF inhibition 
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Table 31. Compounds synthesised by Dr. Elliott Bayle by hydrogenation. Biochemical and biophysical 
evaluation of compounds 189 and 190. a. Tm carried out by Dr Oleg Fedorov at the SGC. Experiments 
carried out at 10 μM, n = 1 
Whilst the effect of reducing the quinolinone A-ring double bond appeared to have a greater effect 
for NI-57 on potency than for the earlier compound 23, the reduction was not large enough to 
afford the desired inactive analogue. 
4.3.4  1,3-Alkyl Variation 
 
As it had been previously shown that introducing larger and longer alkyl chains at the 1 and 
especially the 3 positions of the quinolinone ring was detrimental to potency, it was next decided to 
investigate bigger alkyl groups at both positions, to probe the steric demands in proximity to the 
KAc binding site. 
As the 3 position variation had led to a greater decrease in potency (NI-42 to 137 potency dropped 
23 fold) it was decided to synthesis the 3 Et analogue of NI-57, in order to determine whether the 
decrease in potency was mimicked for this sulfonamide. 
82 
 
 
Table 32a. Biochemical and biophysical evaluation of compound 191. a. Tm carried out by Dr Oleg 
Fedorov at the SGC. Experiments carried out at 10 μM, n = 1 
Pleasingly the observed 30 fold decrease in affinity for BRPF1 was similar to that recorded for NI-
42 to 137. 
As increasing the size of the 3-alkyl group from Me to Et had proved effective at decreasing the 
potency we next extended the alkyl group to an isopropyl group. The sulfonamide was synthesised 
according to Scheme 30. 
 
The N-(phenyl)-3-chloropropanamide (192) was synthesised as for compound 103 and cyclised by 
intramolecular Friedel-Crafts with AlCl3 in chlorobenzene. Alpha-amide alkylation with LDA and 
isopropyl bromide provided 3-isopropyl-3,4-dihydroquinolin-2(1H)-one (194) in moderate yield. 
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Methylation, employing the standard protocol, was followed by oxidation by DDQ in DCE at reflux. 
Oxidation was incomplete after 2 days with 4 eq. of DDQ accounting for the low isolated yield of the 
desired quinolinone 196. Initial nitration conditions employing sulfuric acid as the solvent with 
stoichiometric KNO3 provided a variety of regioisomers. However, switching the solvents to the 
milder acetic acid provided the required 6-nitroisomer (197) in reasonable yield after 
crystallisation from ethanol. The quinolin-2(1H)-amide is ortho or para directing, thus nitration 
would be expected at either the 6 or 8 positions on the ring. The appearance in the NMR of a 
doublet with a meta coupling at 8.49 ( J = 2.5 Hz) corresponding to C5H, a doublet of doublets at 
8.37 with ortho and meta couplings (J = 9.2, 2.5 Hz) corresponding to C7H, and a doublet with meta 
coupling at 7.43 (J = 9.2 Hz) corresponding to C8H is consistent with nitration at the desired 6 
position. Reduction with SnCl2 with concentrated HCl and subsequent coupling afforded the two 
sulfonamides (199-200) for testing against BRPF1 (Table 32). 
 
Table 33. Biophysical evaluation of compounds 199 and 200. KD’s determined by DiscoverX. Most KD’s 
were determined using a compound top concentration = 10,000 nM. Dose response curves were 
determined at an 11 point serial dilution. If the initial KD determined was < 0.169 nM (the lowest 
concentration tested), the measurement was repeated with a serial dilution starting at a lower top 
concentration. Data is the mean of 2 replicates 
Altering the alkyl group at the 3-position for the larger isopropyl was more effective at impeding 
compound binding for the analogue of NI-42 (199), than for the analogue of NI-57 (200). Despite 
the significant drop in compound affinities for all three BRPF BRDs, even for compound 199 the 
difference was insufficient to be considered a true inactive control. Nonetheless, the results 
highlighted that further alteration of the alkyl groups in this area could prove fruitful for design of 
an inactive control. Therefore, it was decided to synthesise the 1,3 ethyl compound which would be 
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tractable from the previously synthesised 3-ethyl-6-nitroquinolin-2(1H)-one (135). The synthetic 
strategy utilised for synthesis of the desired sulfonamides is outlined in Scheme 31  
 
Ethylation was carried out as for previous compounds, however unlike the N-methyl compound 
(135) SnCl2 was employed as a reductant prior to sulfonamidation.  
Ethylation of both the 1 and 3 positions of the quinolinone was successful in creating an inactive 
control for NI-42. Compound 203 (henceforth NI-198) has affinity reduced by      > 1,000 fold 
against all 3 members of the BRPF family and the rest of the class IV BRDs. Further profiling against 
BRD4 and representative BRDs from the other BRD families established that NI-198 showed 
minimal affinity for the other BRDs. 
 
Table 34. Biophysical evaluation of compound NI-198. KD’s determined by DiscoverX. Most KD’s were 
determined using a compound top concentration = 10,000 nM. Dose response curves were determined at 
an 11 point serial dilution. If the initial KD determined was < 0.169 nM (the lowest concentration tested), the 
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measurement was repeated with a serial dilution starting at a lower top concentration. Data is the mean of 
2 replicates 
Whilst the same motif was more effective than the 3-isopropyl compound at reducing compound 
affinity, the effect was not so drastic for 1,3 Et analogue of NI-57. Compound 204 was only 62.5 
times less potent against BRPF1. This was surprising as it was hypothesised that the compounds 
would have identical binding modes, and would therefore be similarly affected by changes in such 
close proximity to the KAc mimetic. 
 
Table 35. Biophysical evaluation of compound 204. KD’s determined by DiscoverX. Most KD’s were 
determined using a compound top concentration = 10,000 nM. Dose response curves were determined at 
an 11 point serial dilution. If the initial KD determined was < 0.169 nM (the lowest concentration tested), the 
measurement was repeated with a serial dilution starting at a lower top concentration. Data is the mean of 
2 replicates 
 
  
86 
 
 4.4 Second Generation Inhibitors 
We next focussed on generating BRPF inhibitors based on alternative cores, with the aim of 
designing inhibitors with different selectivity profiles. 
4.4.1  2,4-dimethyl-1,4-dihydroisoquinolin-3(2H)-ones 
As reduction of the quinolinone A ring did not appear to have a drastic effect on potency, the core 
was altered to the 7-amino-2,4-dimethyl-1,4-dihydroisoquinolin-3(2H)-one. 
 
Synthesis of the required 7 substituted 2-methyl-1,4-dihydroisoquinolin-3(2H)-one was carried out 
as per the procedure of Ulysse et al. 97 Whilst the formation of the acid chloride and subsequent 
reaction with aqueous methylamine proceeded as described, for the strongly electron withdrawing 
nitro group the Pictet-Spengler type reaction failed to furnish any of the cyclised product. Thus the 
nitro group was exchanged for a bromine for which transformation into the N-methylamide and 
subsequent cyclisation were successful (207). This was followed by alpha-amide alkylation with 
LDA and iodomethane in modest yield. Amination via the standard procedure provided the crude 
amine which was coupled to give sulfonamide 210 for biological evaluation against BRPF1 
Unfortunately, the sulfonamide 210 only inhibited BRPF1 with a ΔTm of 3.61 °C and thus this series 
was not further investigated 
4.4.2  Napthyridin-2(1H)-ones 
Substitution of one of the carbon atoms in the quinolinone ring for a nitrogen, to make a 
napthyridinone, could alter the physicochemical properties of the final sulfonamides quite 
drastically depending which carbon on the ring was substituted (Table 35). The two properties 
most affected would be the pKa of the sulfonamide nitrogen, and the ClogP.  
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If the sulfonamide is ortho to the napthyridinone nitrogen it would result in a significantly more 
acidic sulfonamide proton. Moreover according to in silico predictions the ClogP would decrease by 
up to 1 log unit depending on where in the ring the nitrogen is substituted. 
 
Table 36. Position of nitrogen in the quinolone-1(2H)-one and the effect on CLogP 
As the most synthetically tractable of the desired napthyridinones the 4 position was the first 
investigated 
 
Nitration and subsequent methylation, reduction and coupling of 4-quinaxalinol (214) was carried 
out using standard conditions outlined in Scheme 33. Problems were encountered during the 
reduction step, as the strongly acidic conditions appeared to promote rapid amine degredation, but 
shortening of the reaction times lead to sufficient quantities being isolated for coupling. 
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ID BAZ2A BRD1 BRD4 BRD9 BRPF1B BRPF3 CECR2 CREBBP FALZ 
215 0.0 -0.1 -0.2 1.6 2.4 0.6 0.0 -0.9 -0.8 
 
Table 37. ΔTm results for 215 (°C). Results obtained by Dr Oleg Fedorov at the SGC. Experiments carried 
out at 10 μM, n = 1. Heat map is a scale from Green = low ΔTm – low potency to Red = high ΔTm - high 
potency. 
The replacement of the carbon at the 4-position with a nitrogen resulted in a substantial drop in 
potency against BRPF1 by TS (23 BRPF1 ΔTm 5.2 °C). In addition, this drop in potency was not 
propagated throughout the class IV BRDs, as BRD9 potency had only dropped 0.65 °C. As a 
consequence the selectivity window was likely to be smaller for compound 215. 
The next napthyridinones to be synthesised were those where the nitrogen replaced the carbon at 
the 5 and 7 positions respectively. Similar synthetic strategies were employed for both analogues.  
 
For the 5-position analogue, the literature procedures of Grongsaard et al and Turner et al were 
combined. 81,81, 98  Thus, 3-amino-6-chloropyridine (216) was first brominated in DMF in good yield, 
followed by installation of the tert-butylcarbonate group as an ortho directing metallating group. 
Deprotonation of the amide with MeLi was followed by lithium-halogen exchange with BuLi to 
provide an anion for reaction with the aldehyde equivalent DMF. The subsequent aldol reaction, 
cyclisation and methylation were identical to those in Scheme 13. 
Synthesis of the 6-chloro-1-methyl-1,7-naphthyridin-2(1H)-one followed a similar route, with 
initial reaction of the amine with the ortho directing tert-butylcarbonate group. Without the 
bromine group to guide lithium halogen exchange at the 2 position of the ring the butyl lithium 
deprotonates the ring at the 4 position.  Ensuing reactions followed the outline in Scheme 35. 
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With compounds 221 and 225 in hand, conditions were next investigated for aminoloysis of the 2-
chloropyridine moiety. Both compounds 221 and 225 proved inert to reaction with aqueous and 
methanolic (2 M and 7 M) ammonia, even at elevated temperatures (130 °C for methanolic, 160 °C 
for aqueous). Employing the previously successful microwave conditions with catalytic Cu2O was 
also ineffective. 
Direct cross-coupling with 2-methoxy-4-cyanobenzenesulfonamide (227) was thus attempted. 
Unfortunately despite screening several catalysts and conditions the starting material also proved 
inert to coupling conditions. 
Preparation of the 6-chloro-1-methyl-1,8-napthyridone (232a) followed an adaptation of literature 
procedure, involving initial bromination at the 2 position to provide compound 229a. Subsequent 
Heck coupling with methyl acrylate, followed by cyclisation with methanolic sodium methoxide 
provided 231a in good yield. Reaction with iodomethane yielded the required core for 
sulfonamidation. 99 Unfortunately, like the other 6-chloronapthyridones it proved inert to the 
coupling conditions attempted. Therefore the halogen was substituted for the more labile bromine, 
with a near identical synthetic strategy employed 
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Reaction of the 6-bromo-1-methyl-1,8-napthryidone (232b) using the standard microwave 
conditions proved successful and the crude amine was coupled to provide 233 for biological 
evaluation against BRPF1. Dissociation constant determination showed that 234 was an 870 nM 
inhibitor of BRPF1, approximately 18 times less potent than its quinolinone analogue (23) 
 The three 6-chloronapthyridones were also tested in an attempt to quantify the effect of the 
nitrogen on BRPF binding  
 
Table 38. Biophysical evaluation of compound napthyridone fragments. KD’s determined by DiscoverX. 
Most KD’s were determined using a compound top concentration = 10,000 nM. Dose response curves 
were determined at an 11 point serial dilution. If the initial KD determined was < 0.169 nM (the lowest 
concentration tested), the measurement was repeated with a serial dilution starting at a lower top 
concentration. Data is the mean of 2 replicates 
 
91 
 
In general the addition of the nitrogen appears to have decrease binding affinity relative to the 
unaltered quinolinone ring with the 8 nitrogen being especially unfavourable. It was thus 
unsurprising that compound 234 recorded a KD of 870 nM. 
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 4.5 Hybrid inhibitors 
During the course of our project a number of BRPF1 inhibitors were published in the literature, 
most notably the structurally similar BRPF1 specific inhibitors from Pfizer (PFI-4) and GSK 
(GSK5959 and GSK6853) and the pan-BRPF inhibitor from the SGC (OF-1) (see section 3.4). 
 
 
Figure 51. Overlayed cocrystal structures of BRPF1 with NI-57 and published BRPF inhibitors. a. Overlay 
of NI-57 and GSK6853 crystal structures highlighting the identical binding interactions, but different binding 
modes (PDB ID: 5G4R) b. NI-57 and OF-1 highlighting similar binding modes in the WPF shelf and 
identical binding interactions (PDB ID: 5FG4) 
Overlaying the crystal structures of the published inhibitors highlights that the acetyl lysine 
mimetics form identical binding interactions, but that as expected the amide from the Pfizer and 
GSK probes does not bend into the WPF shelf like the sulfonamides of NI-57 and OF-1. Of particular 
note is that the 2 cores, the benzo[d]imidazole-2-one and the quinolin-2(1H)-one cores appear to 
overlay well with the 6 position nitrogen occupying the same area of the protein for both cores. 
4.5.1  1,3-Dihydro-2H-benzo[d]imidazol-2-one Acetyl Lysine Mimetic 
The main disadvantages of the SGC pan BRPF inhibitor OF-1 were that it had modest BRD4 
inhibition, as well as very low solubility. It was thought that by hybridising the OF-1 1,3-Dihydro-
2H-benzo[d]imidazol-2-one core with the sulfonyl chloride from NI-57 it might be possible to 
create a more soluble and selective inhibitor 
For synthetic tractability the unsubstituted benzo[d]imidazole-2-one was first synthesised 
according to Scheme 37.  
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Reaction of 1,2-Diamino-4-nitrobenzene (235) with 1,1’-carbonyldiimidazole in DMF gave 
compound 236 in good yield, 100 which was methylated under standard conditions. Reduction of 
the nitro group with palladium on carbon provided the amine (238) in excellent yield which was 
coupled using the previously employed procedure.  
Sulfonamide 239 was evaluated by KD which indicated a potency of 230 nM against BRPF1. 
Similarly to literature compounds based on the same core, sulfonamide 239 displayed very poor 
solubility as ~4 mg required heating and extensive sonication to dissolve in around 500 μL of 
DMSO.   
Synthesis of the hybrid inhibitor containing the 5-OMe group was attempted according to Scheme 
38.  
 
Attempts at literature nitration of 240, which could then be reduced and coupled, were 
unsuccessful in our hands, exclusively isolating the polynitrated compound. Bromination of 
compound 240 which could then be methylated and coupled, either via the amine or directly to the 
sulfonamide was thus carried out. Bromination and methylation proceeded smoothly, however 
attempts at direct coupling with the sulfonamide or transformation into the amine were 
unsuccessful. Later, GSK published a route to the 7OR-6NO2-benzo[d]imidazole-2-one however, as 
the methoxy group was unlikely to drastically improve solubility, efforts to synthesise this hybrid 
were not pursued.    
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4.5.2  Quinolin-2(1H)-one Hybrids  
The first hybrids synthesised were those that combined the 6-amino-7-methoxy-1-methylquinolin-
2(1H)-one (93) core with the sulfonamides from OF-1, (2-methyl-4-bromobenzenesulfonyl 
chloride) and NI-57 (2-methoxy-4-cyanobenzensulfonyl chloride-148). 
 
Table 39. Biochemical and biophysical evaluation of compounds 243 and 244. a. Tm carried out by Dr Oleg 
Fedorov at the SGC. Experiments carried out at 10 μM, n = 1. b. KD’s determined by DiscoverX. Most KD’s 
were determined using a compound top concentration = 10,000 nM. Dose response curves were 
determined at an 11 point serial dilution. If the initial KD determined was < 0.169 nM (the lowest 
concentration tested), the measurement was repeated with a serial dilution starting at a lower top 
concentration. Data is the mean of 2 replicates. *Yield over 2 steps from 100. 
Hybridising with the OF-1 sulfonamide, to give compound 243 yielded a sulfonamide which 
appeared to be more potent by TS, but wider screening with this assay indicated that the compound 
was significantly less selective (data not shown). 
Efforts at improving the solubility and increasing the potency of the excellent selectivity seen 
previously for this core, by coupling to 2-methoxy-4-cyanobenzenesulfonyl chloride (244) proved 
ineffective, as there was no increase in potency and selectivity was largely similar. 
 
4.5.3  PFI-4 Hybrids 
We next turned towards amalgamating PFI-4 and NI-57, by retaining the 1-methylquinolin-2(1H)-
one core lysine mimetic, but substituting the sulfonamide for the 2-methoxybenzamide and 
installing the 7-pyrrolidine ring. It was envisaged that 2 analogues would need to be synthesised, as 
unlike the 1,3-dihydro-2H-benzo[d]imidazol-2-one core, the 1-methylquinolin-2(1H)-one is not C2 
symmetric (Figure 52). 
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Figure 52. C2 Symmetry of the 1,3-Dihydro-2H-benzo[d]imidazol-2-one core and the 2 required 
regioisomers required to investigate the PFI-4 and NI-57 hybrid  
The first analogue to be synthesised was the 6-amide N-(1,3-dimethyl-2-oxo-7-(pyrrolidin-1-yl)-
1,2-dihydroquinolin-6-yl)-2-methoxybenzamide (252). The polysubstituted ring structure was 
efficiently accessed using the synthetic strategy outlined in Scheme 40. 
 
Literature nitration of 245 yielded 246 in excellent yield, which was subjected to the cyclisation 
conditions previously employed in Scheme 22. 101 Methylation via standard conditions was 
followed by an Ullman/SNAr replacement of the bromine with pyrrolidine. Reduction of the nitro 
group in moderate yield preceded coupling with 2-methoxybenzoyl chloride to give 252 for 
evaluation against BRPF1. 
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Table 40. Biochemical and biophysical evaluation of compound 252 a. Tm carried out by Dr Oleg Fedorov 
at the SGC. Experiments carried out at 10 μM, n = 1. b. KD’s determined by DiscoverX. Most KD’s were 
determined using a compound top concentration = 10,000 nM. Dose response curves were determined at 
an 11 point serial dilution. If the initial KD determined was < 0.169 nM (the lowest concentration tested), the 
measurement was repeated with a serial dilution starting at a lower top concentration. Data is the mean of 
2 replicates 
Given the low potency against BRPF1 and poor selectivity against other BRDs, amide 252 is clearly 
unable to adopt the correct binding orientation to achieve the profile observed for PFI-4. The 
inability of the amide to bind in the channel may be a result of the quinolinone ring flipping. Thus 
synthesis of the alternative regioisomer was attempted according to Scheme 41. 
 
The initial strategy focussed on reduction of the nitro group from compound 249 to give aniline 
253 which could then be converted into the pyrrolidine by heating with base and 1,4-diiodobutane. 
Disappointingly the reduction of the nitro group either failed to yield the amine, or gave an 
intractable mixture of products, depending in conditions employed.  
 Therefore, the alternative strategy of cyclising the amine 129a prior to bromination with NBS was 
investigated. Cyclisation was required prior to bromination as previous work in our lab had shown 
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that bromination of 129a exclusively provided the undesired 5-Br regioisomer. Cyclisation with 
1,4-diiodobutane with Cs2CO3 yielded the pyrrolidine in good yield, however reaction of 254 with 
NBS was extremely slow, failing to go to completion regardless of the number of equivalents of NBS 
and reaction time. Therefore 255 was isolated in only 12% yield. Attempts at cross coupling with 2-
methoxybenzamide (256) were unsuccessful, as were attempts at installation of an amine group via 
the previously employed Cu catalysed microwave amination 
It was hoped that one method for promoting the correct conformation of the quinolinone would be 
to remove the methyl group at the 3 position. A synthetically identical procedure to that used for 
252 was utilised, which is outlined in scheme 42 
 
Substituting the 2-ethyl-dihydrooxazole for the methyl analogue afforded the unmethylated 
quinolinone which was subjected to the same conditions as for scheme 40 for pyrrolidine 
substitution, reduction and coupling 
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Table 41. Biochemical and biophysical evaluation of compound 261. a. Tm carried out by Dr Oleg Fedorov 
at the SGC. Experiments carried out at 10 μM, n = 1. b. KD’s determined by DiscoverX. Most KD’s were 
determined using a compound top concentration = 10,000 nM. Dose response curves were determined at 
an 11 point serial dilution. If the initial KD determined was < 0.169 nM (the lowest concentration tested), the 
measurement was repeated with a serial dilution starting at a lower top concentration. Data is the mean of 
2 replicates 
 
Amide 261 is less potent, but in general it is more selective against the class IV BRDs. However, the 
selectivity against the key selectivity target BRD4 is significantly lower. As a consequence of its low 
inhibition of BRPF1 this series of inhibitors was not investigated further. 
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5. NI-57 and NI-42: BRPF Probes 
 
With their favourable potency and selectivity profiles NI-42 and NI-57  were both deemed suitable 
for use as BRPF biased and BRPF specific probes respectively of the class IV BRDs (Tables 21 and 
26 respectively). Initially NI-57 was confirmed to engage with BRPF1 in an intracellular setting 
before both compounds their pharmacokinetic (PK) profiles extensively profiled. Subsequently, 
both compounds were employed in in vitro and in vivo settings to determine the consequences of 
BRPF BRD inhibition.  
 
 5.1 Large Scale Synthesis of NI-57 
Whilst synthesis of the 6-amino-1,3-dimethylquinolin-2(1H)-one (129a) core for NI-57 (Scheme 
44) was reasonably efficient (21% over 5 steps, chromatography free), the capricious nature of the 
sulfonyl chloride synthesis and difficulty in product purification required improvement. This would 
allow the synthesis of NI-57 on the scale necessary to be able to provide the material for biological 
evaluation. 
Thus, alternate strategies were investigated for the synthesis of 2-methoxy-4-
cyanobenzenesulfonyl chloride (148). It was hoped that with a cleaner product profile for the 
sulfonyl chloride it might be possible to carry out purification of the target sulfonamide without the 
need to employ column chromatography. 
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Initially 3-methoxybenzonitrile (262) was treated with HSO3Cl at 0 °C, however no reaction was 
observed so the reaction mixture was then heated to 40 and then 60 °C, leading to a complex 
mixture of products. Literature synthesis of the structurally similar 3-methoxy-4-
cyanobenzenesulfonyl chloride involved reaction of the primary formamide with HSO3Cl, followed 
by dehydration of the amide to provide the nitrile. Adaptation of these conditions also failed to 
provide any of the desired sulfonyl chloride. 102 
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Eventually, work carried out in our lab (Scheme 44, work carried out by Dr. Elliott Bayle, checking 
in progress for Org Synth) devised a 4 step synthesis of 148 starting from 2-methoxy-4-
cyanophenol (266) involving a key Newman-Kwart rearrangement, followed by hydrolysis and 
oxidation to provide the required sulfonyl chloride. Moreover modification of the coupling 
conditions, by reducing the equivalents of sulfonyl chloride and replacing pyridine with DABCO, 
afforded analytically pure NI-57 without the need for purification. 
 5.2 On-target engagement 
Having confirmed the potency and selectivity of NI-57 in biophysical assays we next sought to 
confirm that the compound engaged with the BRPF bromodomains in an in vitro setting. 
The first assay run was a cellular thermal shift assay (CETSA), which involved incubating cells with 
the inhibitor of interest before heating the cell to denature the protein, causing it to precipitate. The 
quantity of protein remaining in solution can then be determined by lysing the cells, centrifugation 
to remove denatured protein and subsequent analysis to quantify the amount of soluble protein. 
Similarly to TS, the inhibitor binding to the protein increases the protein stability. As a consequence 
the protein does not denature on heating and can thus be detected in greater quantities in the 
soluble protein fraction. 
 
Figure 53. CETSA analysis of NI-57 showing binding to BRPF1B but not BRPF1A. GAPDH is used as a 
positive control. Work carried out at the SGC (C057 is the compound ID for NI-57 in this experiment 
Analysis of the western blot indicates that NI-57 interacts with BRPF1B, but not the inactive splice 
variant BRPF1A. This can be seen by the disappearance of BRPF1A from the soluble fraction with 
the increase in temperature, which is not observed when NI-57 is added to the cells (Figure 53). 
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Figure 54. FRAP assay data confirming in vitro target engagement of NI-57 to BRPF1 and BRD1 at 1 μM. 
Work carried out at the SGC  
Fluorescence recovery after photobleaching (FRAP) was utilised to confirm in vitro binding to 
BRD1 and further confirm BRPF1 binding. This assay assesses protein diffusion by monitoring the 
fluorescence of green fluorescent protein. After photobleaching the BRPF will diffuse back into the 
bleached area. The rate of diffusion is retarded by BRD binding to acetylated chromatin. If however, 
the BRD is bound to an inhibitor the recovery time is significantly reduced. Introduction of SAHA 
(an HDAC inhibitor) increases the acetylated lysine levels, increasing recovery time and 
exacerbating the difference between the cells with and without the inhibitor. For both 
bromodomains there was accelerated recovery after photobleaching (BRD1: ~2 fold faster 
recovery at 1 μM, BRPF1: ~2 fold faster recovery at 1 μM) indicating that NI-57 is inhibiting the 
association of BRPF1/BRD1 to the chromatin in the nucleus (Figure 54). 
 5.3 Pharmacokinetic Profiles 
Prior to investigation of in vivo effects of BRPF inhibition it was necessary to confirm that both NI-
42 and NI-57 possessed suitable PK profiles. The first parameter tested was cellular permeability 
via a Caco-2 assay (Table 41). 
 
Table 42. Caco-2 assay results for NI-57 and NI-42. Assay carried out at 10 μM at 37 °C, data is 
presented as the mean of two results with the standard deviation in brackets. A to B is apical to basolateral 
layer and B to A is basolateral to apical layer. 
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The results show that both compounds are cell permeable, showing excellent apical to basolateral 
(A to B) diffusion, suggesting that ~90% of both compounds would be absorbed in the intestine. 65 
However, given that the efflux ratio (B to A/A to B) is greater than 2, it is possible that the 
compounds are substrates for active efflux from the cell. Further investigation, involving 
remeasurement of the data in the presence of an active efflux inhibitor, would be required to 
confirm the hypothesis. 65 
Having confirmed that the compounds were cell permeable we next determined in vitro compound 
stability, by measuring both human and murine liver microsomal stability. Data from the assay 
would help determine the phase I stability of both compounds by assessing the extent to which they 
are metabolised by the cytochrome P450 (CYP) proteins. 
 
Table 43. Human and Mouse liver microme stability studies for NI-42 and NI-57. Work carried out by Anne 
Cheasty at Cancer Research UK  
Both compounds showed low clearance in both mice and human liver microsomes. In particular the 
value for human microsomal stability is promising, with values below 8.6 considered low clearance. 
103 This bodes well for their in vivo stability (Table 42).  
In order to be able to traverse the cell membrane it is important that the compound is not bound to 
the plasma proteins in the blood. 
 
Table 44. Human and Mouse plasma protein binding studies studies for NI-42 and NI-57. Work carried out 
by Anne Cheasty at Cancer Research UK. a. Due to 50 ng/mL limits of detection by LCMS the values for 
NI-57 may vary from true values.   
Analysis of the plasma protein binding (PPB) in humans and mice suggests that both compounds 
have high PPB percentages, although NI-42’s values are not as high as those of NI-57. Furthermore, 
the levels of PPB for NI-57 may not be as high as recorded, as sensitivity issues were encountered 
with the LCMS analysis for this assay. Indeed the US Federal Drug Administration recommend that 
when PPB free drug fractions of less than 1% are recorded that the value be arbitrarily set at 1% as 
a consequence of uncertainty at these low values. 104 
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Having confirmed that both compounds had promising initial in vitro PK profiles in vivo data was 
collected to support future experiments. Both compounds were tested by intravenous injection (IV 
1 mg/kg 5 mL/kg) and orally (P.O. 3 mg/kg). 
 
Table 45. In vivo mouse PK for NI-42 and NI-57. Studies carried out on Female CD-1 mice, data the 
average of 2 replicates. Work carried out by Anne Cheasty at Cancer Research UK.  
Following an intravenous dose of 1 mg/kg NI-57 shows low clearance (21 ml/min/kg) with a 
reasonable 1.4 l/kg volume of distribution. The low in vitro clearance value of 0.2 ml/min/kg 
combined with the t½ of 1.2 hours suggest that the compound possesses good mouse in vitro 
stability. 
Oral dosing of 3 mg/kg highilighted that NI-57 had a maximum concentration (Cmax) of 0.63 μM 
after 2 hours (Tmax). The area under the curve between 0 and 7 hours (AUC0-7h) was calculated as 
651 ng.h/ml, whilst the oral bioavailability was 29%. 
For NI-42 the IV clearance was even lower than NI-57, at 4 mL/min/kg, although the Vss was 
slightly lower at 0.7 L/kg. As a consequence of the low clearance the t½ was slightly longer at 2h, 
but similarly to NI-57, NI-42 posesses very low in vivo clearance. 
Following oral administration of NI-42 a Cmax of 4 μM was observed at 1 hour. This allowed for the 
calculation of an oral bioavailability of 49% and a AUC0-24h  of 5692 ng.h/ml. Taken as a whole, the 
oral and IV administration profile of NI-42 was superior to that of NI-57. 
The CYPs play a major role in drug metabolism. As such, it is important to assay which CYPs a drug 
interacts with, as compounds with similar CYP profiles can effect one anothers plasma levels over 
time. Thus, to avoid unfavourable drug-drug interactions it is vital to know which CYPs a compound 
inhibits. 
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Table 46. Cytochrome P450 inhibition for NI-42 and NI-57. Data is presented as the average of 2 
replicates with standard deviation in brackets. Work carried out at Cyprotex. 
In comparison to their ITC KD’s the CYP inhibition of both compounds was minimal, with most 
inhibitions being greater than 1,000 times the KD of the inhibitor for BRPF1.  The exception was NI-
42 and CYP2C9 for which NI-42 had an IC50 of 854 nM (Table 45). The above CYPs were chosen as 
they represent 5 of the 7 major human CYP isoforms. 65 
 5.4 Safety 
Having assessed the probe PK profiles, cardiac ion channel inhibition was next investigated to 
determine compound safety. The most important of the channels assayed was hERG, inhibition of 
which can lead to fatal tachyarrhythmia. A number of other major ion channels were also tested 
(Table 46). 
 
Table 47. Ion channel inhibition of NI-42 and NI-57 at 30 μM. Data is presented as the average of 12 
replicates. Work carried out at Eurofins 
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Determination of inhibition at a single concentration (30 μM) showed that the inhibition of ion 
channels in both compounds was pleasingly low. 
NI-57 off-target selectivity was determined by a screen of 56 different kinases and  GCPRs by 
CEREP. There was no significant binding at the test concentration of 10 μM, with the highest 
observed inhibition being 37% (see Apendix). 
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6. Biological evaluation 
 
Having confirmed their suitable biochemical profiles (potency, selectivity, in vitro target 
engagement etc) and PK profiles NI-42 and NI-57 were investigated in a number of in vitro and in 
vivo experiments to determine the biological consequences of BRPF BRD inhibition.  
 6.1 BIOMAP 
BIOMAP is a proprietary screening platform operated by DiscoverX which profiles a compound in 
more than 30 human derived disease cell lines and 48 disease models. The assay gives more than 
200 readouts indicating areas of potential biological effect. The combined fingerprint of these 
biological effects can then be compared to the database of known drugs to suggest a potential mode 
of action.  
 
Figure 55. BIOMAP profile of NI-57  
When profiled in this comprehensive assay NI-57 failed to give any substantial readouts. There was 
a modest increase in IL-8, which is involved in inflammation, and MMP9, a protein involved in 
tissue remodelling, was also slightly activated. The data on the whole suggests that the global 
effects of BRPF1 bromodomain inhibition might be minimal. However, the assay also indicates that 
NI-57 has a safe in vitro profile. 
 6.2 COPD 
In collaboration with AstraZeneca NI-57 was utilised to investigate the role BRPF inhibition might 
play in chronic obstructive pulmonary disease (COPD). COPD is characterised by progressive and 
irreversible airflow limitation and one of the potential causes is thought to be epigenetic changes. 
It was hoped that inhibition of the BPRF bromodomains might reduce the immune response and 
subsequent inflammation caused by M-2 macrophages. In vitro analysis of NI-57 showed that there 
was a decrease in M2 associated genes CCL-17 and CCL-22, suggesting that BRPF1 inhibition could 
reduce the inflammation caused by COPD. 105 
 6.3 Cancer Panels 
BRPF has been implicated in a number of cancers, particularly AML. NI-57 was screened in both the 
National Institute of Health (NIH) cancer panel and a proprietary AstraZeneca cancer panel. 
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Figure 56. NCI-60 cancer cell line panel showing inhibition of cancer cell line growth at 10 μM. Different 
colors are indicative of different types of cancer, leukemia, lung cancer, colon cancer, CNS cancer, 
melanoma, ovarian, renal, prostate, breast  
Growth inhibition for the NCI cancer panel was run at a concentration of 10 μM. As such, even the 
highest inhibitions recorded, around 25%, were modest. Although the data displayed no clear 
trends, there was a suggestion that AML cell line growth may be preferentially arrested by BRPF 
inhibition.  
These findings are in line with the associations between BRPFs and this types of cancer and 
prompted screening in a more targeted AML cell line panel at Cancer Research UK to confirm these 
findings (Table 47). 
 
Table 48. GI50’s from CRUK AML cell lines  
 
Whilst inhibitions were modest, it was hoped that a larger screen of cell lines would prove more 
revealing. Thus both NI-42 and NI-57 were screened in AstraZeneca’s more comprehensive cancer 
cell line panel (CLIMB panel). The results from this panel were disappointing for NI-57 indicating 
no GI50 values below 10 μM (Figure 57). NI-42 performed slightly better, recording values below 
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5μM in 12 cell lines. Further analysis of the data, focussing on the AML cell lines, highlighted that 
NI-42 modestly and selectively inhibited AML cancer cell lines. 
 
Table 49. NI-42 inhibition of AML cell lines a. cancer cell lines exhibit MLL translocations 
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Figure 57. AZ CLIMB panel for NI 42 (Red) and NI-57 (blue. Cancer cell lines ranked by the inhibition of NI-42, with the strongest inhibition on the left
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 6.4 BRPF Inhibition and Osteoclastogenesis 
NI-57 and its potential role in preventing osteoclastogenesis was investigated by the SGC by 
incubating the probe with bone marrow mononuclear cells which were then induced to 
differentiate. Inhibition of osteoclastogenesis could provide treatments for diseases caused by 
osteoclast overexpression, such as osteoporosis.  
 Incubation of NI-57 with bone marrow cells caused significant reductions in the number of 
multinucleated TRAP-positive cells. Further analysis of biomarkers that signify inhibition of 
osteoclastogenesis found significant reductions in levels of: tartrate-resistant acid phosphatase 
(TRAP), the late-phase osteoclast marker cathepsin K (CATK), the proton generator 
carboanhydrase II (CA2), the key transcription factor NFATC1 and OC-STAMP, an essential cell-cell 
fusigen. Overall, the data indicated that inhibition of the BRPF BRDs caused significant reductions in 
osteoclastogenesis. 
Significant reductions of MMP9 secretion were also noted, an observation consistent with the 
BIOMAP results. MMP9 is a protein that is secreted by osteoclasts to promote bone matrix 
degradation, which is of potential interest as MMP9 levels are upregulated in a number of invasive 
tumors. 
 
Figure 58. Imaging showing NI-57 inhibition of osteoclastogenesis. Blue cells indicate TRAP-positive cells  
On the left DMSO control on the right dosing with NI-57. Work carried out by Julia Maier at the SGC  
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7. Conclusion 
When we initiated our research project there was a clear link between the BRPF proteins and 
disease. However, there were no small molecules available to the scientific community to determine 
the role that the BRPF BRDs play in this disease association. As such, we set out, in collaboration 
with the SGC, to design and synthesise a fit for purpose, selective potent and cell permeable probe 
for the BRPF BRDs to validate this link. 
Starting from the N-methylquinolin-2(1H)-one (1) core we have developed a consistent SAR model, 
by investigation of all the possible positions on both of the quinolone rings and the sulfonamide 
aryl ring, both in isolation and combination (Figure 59). Our work culminated in the synthesis of 
NI-42 and NI-57, BRPF biased and BRPF specific BRD probes respectively. Following on from this 
we were able to modulate the activity and design inactive analogue NI-198. 
 
Figure 59. SAR Model generated for N-methylquinolin-2(1H)-one (1) core modifications on the potency 
against and selectivity for BRPF1.  Substituent effect is primarly measured by potency. Comparisons made 
where possible by comparing identical cores. Different colours indicate comparison was made in reference 
to a different core 
With NI-57 having satisfied our initial goals of meeting the SGC criteria (30 fold selectivity against 
members of the same family, > 100 fold selectivity otherewise, potency < 100 nM and in vitro target 
engagement at < 1 μM), we next fulfilled the more stringent criteria outlined by Workman et al 
(Figure 61). 50b 
 7.1 Further work 
Despite strong evidence that aberrant behaviour of the BRPF proteins is involved in a number of 
aggressive leukaemias, incubation of both NI-42 and NI-57 produced only modest effects in several 
AML cell lines. As such, it is possible that BRPF protein’s primary role is as a scaffolding protein for 
its endogenous tetramer.  
During the course of our studies Winter et al proposed tethering BET inhibitor JQ1 (see above) to a 
phthalimide linker, which on binding to the BRD will target the protein for E3-ligase promoted 
degradation (Figure 60) . 106 
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Figure 60. Strategy of Winter et al for promoting BRD degradation. JQ1 in green, pthalimide for E3 ligase 
binding in purple 
By tethering NI-57 to a similar phthalmide conjugate it will be possible to investigate whether 
cellular degradation of BRPF will have the desired effect on AML cell lines. This could easily be 
achieved by conjugation of the tether to the primary formamide of NI-57 to give compound 272, 4-
(N-(1,3-dimethyl-2-oxo-1,2-dihydroquinolin-6-yl)sulfamoyl)-3-methoxybenzamide – 270, BRPF1 
KD: 5 nM, which can be synthesised in high yield without purification from NI-57.  
Furthermore by investigating the effects of BRPF protein degradation with pan BRPF and BRPF1 
specific probes it may be possible to elucidate whether the BRPF proteins have redundant 
functions. 
114 
 
 
 
Figure 61. Probe criteria of Workman et al as demonstrated by NI-57 and NI-42. 50b
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8. Experimental 
 
All chemicals were purchased from commercially available sources and used without further 
purification unless otherwise specified. Organic solvents used such as ethyl acetate (EtOAc), 
dichloromethane (DCM), Tetrahydrofuran (THF), methanol (MeOH), ethanol (EtOH) were provided 
by Fisher Scientific, while N,N-dimethylformamide (DMF) 99.8% was purchased from Ratburn 
Chemicals. The deuterated CDCl3 and DMSO-d6 were provided by Sigma Aldrich. Dry solvents were 
purchased from Acros 
1H and 13C NMR spectra were recorded at ambient temperature in deuterated solvents (CDCl3 or 
DMSO-d6) on a Bruker Avance 400 or 500 NMR Spectrometer. Chemical shifts are reported in parts 
per million (ppm) downfield from tetramethylsilane (TMS) reference using the residual protonated 
solvent as an internal standard (1H: δ (CDCl3) = 7.26 ppm, δ (DMSO-d6) = 2.50 ppm and 13C: δ 
(CDCl3) = 77.0 ppm, δ (DMSO-d6) = 39.4 ppm). Data for 1H NMR is given as follows: chemical shift, 
integration, multiplicity, coupling constants (J, given in Hertz (Hz)). Splitting patterns that could not 
be interpreted or easily visualised were recorded as multiplets (m) or broad peaks (br). 2D NMR 
techniques HSQC, HMQC and HMBC) were also utilised for the assignment of 1H and 13C NMR 
signals.  
The progress of reactions was monitored by thin layer chromatography (TLC) performed on 
Keiselgel 60 F254 (Merck) silica plates and visualised by exposure to UV light at 254 nm.  
Infrared (IR) spectra were recorded on a PerkinElmer FT–IR SpectrumTM 100, while melting points 
were determined in open capillary tubes on a digital melting point apparatus SMP10 (Stuart™). IR 
absorption peak values are expressed in cm-1 and melting points are given in °C and are 
uncorrected. 
High-resolution mass spectra (HRMS) were recorded on a Thermo Navigator mass spectrometer 
coupled to an HPLC instrument using electrospray (ES) ionisation and time-of-flight (TOF) mass 
spectrometry.  
System A: Analytical reverse-phase high-performance liquid chromatography (HPLC) was carried 
out on a XSELECT™ CSH™ C-18 column 2.5 μm 6 x 50 mm. HPLC experiments were performed with 
gradient conditions: initial fixed composition 5% B to 50% B over 20 min, then increased to 95% B 
over 2 min, held for 2 min at 95% B, then returned to 5% B in 1 min. Total duration of gradient run 
was 25 min. Eluents used were solvent A (H2O with 0.02% TFA) and solvent B (MeCN with 0.02% 
TFA). Flow rate: 1.00 mL/min 
 
General Procedure A: Preperation of quinolin-2(1H)-ones from quinolines 
To a stirred solution of quinoline (1 eq.) in DCM (1 mL/mmol) at 0 °C was added 3-
chloroperbenzoic acid (77 % w/w, 1 eq.) portionwise over 10 minutes. The resulting solution was 
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allowed to warm to room temperature and then stirred overnight. After completion of the reaction 
the solution was washed with sodium hydroxide (1.0 M, 3 × volume of DCM) and the aqueous phase 
extracted with DCM (3 mL/mmol). The organic layers were combined and dried over anhydrous 
MgSO4, filtered and the solvent removed under reduced pressure to yield the appropriate 
quinolone-N-oxide which was used in the next step without further purification. 
To a stirred solution of quinolone-N-oxide in DCM (2 mL/mmol) was added sodium hydroxide (1.0 
M, 1.5 mL/mmol) and the resulting biphasic mixture was cooled to 0 °C. To this was added, under 
rapid agitation, benzoyl chloride (1.2 eq.) dropwise. The suspension was stirred for 2 hours and the 
resulting precipitate was collected by filtration, washed with water (50 mL) and dried under 
vacuum to give the desired quinolinone. 
General Procedure B: N alkylation of quinolin-2(1H)-ones 
To a solution of quinolin-2(1H)-one (1 eq.) in dry DMF (2 mL/ mmol) under an argon atmosphere 
was added NaH (60% w/w, 1.2 eq.) in one portion. Upon the completion of gas evolution, the 
appropriate iodoalkane (1.2 eq.) was added in 1 portion and the resulting solution was stirred 
overnight. Excess sodium hydride was quenched by the addition of water (3 × vol. of DMF). If 
precipitation was observed the precipitate was isolated by filtration, washed with water and dried 
to afford the desired N-alklyquinolinone. 
 Otherwise, the solution was extracted with ethyl acetate (3 × vol. of DMF), washed with water and 
then brine.  The organic phase was dried over anhydrous MgSO4, filtered and then concentrated 
under reduced pressure. The crude solid was purified by column chromatography to afford the 
desired N-alklyquinolinone. 
General Procedure C: Nitration of quinolin-2(1H)-ones 
To a suspension of the appropriate quinolinone (1 eq.) in concentrated H2SO4 (2 mL/ mmol) at –5 
°C was added HNO3 (70% w/w, 0.5 mL/mmol) dropwise. The resulting yellow solution was stirred 
at this temperature for 2.5 hours before being allowed to warm to room temperature. The solution 
was next poured over crushed ice and the resultant suspension stirred for 5 minutes. The 
precipitate was collected by filtration and dried under vacuum to give the appropriate 6-
nitroquinolinone. 
General Procedure D: Reduction of 6-nitroquinolin-2(1H)-ones with SnCl2 
To a suspension of the appropriate 6-nitroquinolinone (1 eq.) in concentrated HCl (5 mL/mmol) 
was added SnCl2·2H2O (5 eq.) and the resulting suspension was stirred overnight. Sodium 
hydroxide was added with cooling until the pH had reached ~pH 10.  The aqueous solution was 
then extracted with DCM (3 × 100 mL) and the organic layers were combined and the solvent 
removed under reduced pressure to give the appropriate 6-aminoquinolinone. 
General procedure E: Coupling of amines to sulfonyl chlorides 
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To a solution of amine (1 eq.) in DMF (0.2 M, minimum 1 mL) was added pyridine (2 eq.) and the 
resulting solution was stirred for 5 minutes and then sulfonyl chloride (1.5 eq.) was added. The 
resulting solution was stirred overnight and then diluted with acetone (~20 mL).  Celite ® was 
added and the suspension was concentrated under reduced pressure. Purification of the crude solid 
by column chromatography afforded pure sulfonamide.  
General procedure F: Coupling of amines to 1-methyl-2-oxo-1,2-dihydroquinoline-6-sulfonyl 
chloride 
To a solution of 1-methyl-2-oxo-1,2-dihydroquinoline-6-sulfonyl chloride (100 mg, 0.39 mmol, 1.1 
eq.) and pyridine (31 mg, 32 μL, 1.1 eq.) in DCM (5 mL) was added the appropriate amine (0.35 
mmol, 1 eq.) and the resulting solution was stirred overnight. After this time the organic solvents 
were removed under reduced pressure and the residue purified by column chromatography (ethyl 
acetate: hexane) to give pure product 
General Procedure G: Preperation of 6-nitroquinolin-2(1H)-ones from 2-halo-5-
nitrobenzaldeyhdes 
The appropriate 2-halo-4-nitrobenzaldehyde (1 eq.) and the appropriate 4,4-dimethyl-2-alkyl-4,5-
dihydrooxazole (1 eq.) were dissolved in NMP (0.75 mL/mmol) and Xylenes (0.4 mL/mmol) and 
sodium bisulfate (0.1 eq.) was added. A Dean-Stark apparatus was attached and the mixture slowly 
heated to 200 °C and maintained at this temperature for 90 mins and then raised to 225 °C for 45 
mins. After this time the reaction was allowed to cool to RT, added to water (10 × vol of NMP), 
filtered and dried to give the desired 3-alkyl-6-nitroquinolinone. 
General Procedure H: Sulfonamide N alkylation 
To a solution of sulfonamide (1.0 eq.) in dry DMF (3 mL) under an argon atmosphere, was added 
NaH (60% in mineral oil, 1.2 eq.) in one portion. Upon the completion of gas evolution, the 
appropriate iodoalkane (1.2 eq.) was added in 1 portion and the resulting solution was stirred 
overnight. Excess sodium hydride was quenched by the addition of water (30 mL) and the aqueous 
solution was extracted with EtOAc (3 × 50 mL). The organic fractions were pooled, dried over 
anhydrous MgSO4, filtered and concentrated onto celite ®. Purification of the residue by column 
chromatography provided the desired N-alkylated sulfonamide. 
General Procedure I: Oxidation of tetrahydroquinolin-2(1H)-ones with DDQ 
To a solution of the appropriate of tetrahydroquinolinone (1 eq.) in dry DCE (5 mL/mmol) under an 
argon atmosphere was added freshly crystallised DDQ (3 eq.) and the resulting dark suspension 
was stirred at reflux for 3 hours before being allowed to cool to RT. NaOH (1.0 M, 25 eq.) was added 
with stirring and the mixture was extracted with EtOAc (3 × 100 mL). The organic fractions were 
pooled, washed with NaOH (3 × 100 mL), saturated brine, dried over anhydrous Mg SO4, filtered 
and concentrated to provide the quinolinone which was either used without further purification or 
purified by column chromatography. 
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General Procedure J: Microwave conversion of bromides to amines 
The appropriate arylbromide (1 eq.) was dissolved in NMP (1.5 mL) in a Biotage 10 mL microwave 
vial. Cu2O (0.1 eq.) and NH4OH (28–30% NH3 , 2 mL) were added and the vial was sealed and heated 
at 110 °C under microwave irradiation for 3 hours. After cooling to RT the solution was filtered 
through a pad of celite and washed with DCM (20 mL). The filtrate was washed with an aqueous 
lithium chloride solution (0.5 M, 10 mL) and the organic fractions were combined and concentrated 
under reduced pressure. The resulting residue was purified by column chromatography to give a 
solution of the amine in NMP. 
General Procedure K: Synthesis of Cinnamides: 
A solution of the appropriate aniline (1 eq.) and potassium carbonate (1.5 eq.) in acetone (1 
mL/mmol of amine) and water (2 mL/mmol of amine) was cooled to 0 °C and cinnamoyl chloride 
(1.25 eq.) was added portionwise over 10 minutes. Sitrring was continued for 1 hour at 0 °C  and 
then warmed to RT and stirred for 1 hour. The product was isolated by filtration and either purified 
by crystallisation or used without further purification. 
General Procedure L: Cyclisation of Cinnamides 
A solution of the appropriate cinnamide (1 eq.) in chlorobenzene (7.5 mL/mmol) was cooled to 0 °C 
and aluminium chloride (3 eq.) was added portionwise. The resulting suspension was slowly 
heated to 120 °C and maintained at that temperature for 3 hours. After this time the solution was 
cooled to RT and poured over ice water. The precipitate was removed by filtration and dried to give 
the crude quinolin-2(1H)-ones which were either crystallised or used without further purification. 
General Procedure M: Preparation of Quinolin-2(1H)-ones from 2-N-
protectedbenzaldehydes   
Step 1 To a solution of diisopropylamine  (2.1 eq.) in dry ether (1.25 mL/mmol) under an argon 
atmosphere at –78 °C was added n-butyllithium solution (1.6 M in hexane, 2.1 eq.) and the solution 
was stirred for 30 minutes. Tert-butyl acetate (2.1 eq.) was added dropwise and the solution was 
allowed to stir for 30 minutes.  The appropriate benzaldehyde (1.0 eq.) in dry ether (1 mL/mmol) 
was added dropwise and the bright yellow solution was allowed to warm to RT over 2 hours. 
Ammonium chloride solution (1.0 M, 20 mL) was added and the reaction mixture stirred for a 
further 10 minutes. The aqueous layer was separated and extracted twice with ether. The combined 
organic layers were washed with water and brine, dried over anhydrous MgSO4, filtered and the 
solvent removed under reduced pressure to provide the β-hydroxyester, which was used without 
further purification in the next step.  
Step 2 Crude β-hydroxyester was dissolved in 1,4 dioxane (1 mL/mmol of benzaldehyde from step 
1) and HCl (3M, 1 mL/mmol of benzaldehyde from step 1). The solution was heated at reflux for 4 
hours and then allowed to cool to RT. The precipitated product was collected by filtration and dried 
under vacuum to yield the quinolin-2(1H)-one. 
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General Procedure N: Reduction of Nitroaryl Compounds in MeOH  
The appropriate nitroaryl (1 eq.) was dissolved in MeOH (5 mL/mmol) and SnCl2·2H2O (5 eq.) was 
added and resulting suspension heated at reflux for 4 hours. The solution was allowed to cool to RT, 
basified to pH 9 with sat NaHCO3 , filtered and extracted with EtOAc (3 × 50 mL) to give a crude 
solution of amine which was either purified or used crude in the next step. 
General Procedure O: Synthesis of Sulfonyl Chlorides 
Sulfonyl chlorides were prepared from the appropriate amines by adapting the procedure of Hogan 
et al. 78 
Step 1: Thionyl chloride (0.4 mL/mmol of amine) was added dropwise to rapidly stirred H2O (2 
mL/mmol) at -10 °C whilst maintaining the temperature below -5 °C (Caution addition of thionyl 
chloride is very exothermic). On completion of thionyl chloride addition the resulting solution was 
allowed to gradually warm to ~17 °C overnight and then freshly purified CuCl (0.1 eq.) was added 
to form a yellow green solution. 
Step 2: The appropriate amine (1 eq.) was suspended in HCl (37% w/w, 1.5 mL/mmol) and heated 
to 50 °C for 45 minutes with rapid stirring. The resulting suspension was cooled to -5 °C and NaNO2 
(1.05 eq.) in the minimum amount of H2O was added dropwise at such a rate that the internal 
temperature did not exceed 0 °C. The dark solution of aryldiazonium chloride was then stirred at 0 
°C for 30 mins. 
Step 3: The solution from step 1 was cooled to -5 °C (-15 °C for 146a and 146b) and then the 
solution from step 2 was added at such a rate that the temperature did not exceed 0 °C. On 
completion of addition the solution was stirred at 0 °C for 30 mins and then allowed to warm to RT 
and stirred until precipitation of the target sulfonyl chloride was observed. Sulfonyl chlorides were 
isolated by filtration, washed with water, dried under vacuum and then used without further 
purification in the next step. 
General Procedure P: Synthesis of 2-(acrylate)-anilines 
The appropriate 2-haloaniline (1 eq.), the appropriate acrylate (2 eq.) triethylamine (4 eq.), 
Pd(OAc)2 (0.05 eq.) and P(Ph)3 (2 eq.) were dissolved in dry DMF (5 mL/mmol) under an argon 
atmosphere and heated to 110 °C for 18 hours. After this time the solution was allowed to cool to 
RT, diluted with H2O and extracted with EtOAc. The organic fractions were combined, washed with 
sat. brine, dried over anhydrous MgSO4, filtered and concentrated under reduced pressure. 
Purification of the crude solid by column chromatography provided the pure acrylate. 
General Procedure Q: Cyclisation of Acrylates 
The appropriate acrylate was dissolved in dry MeOH (5 mL/mmol) and NaOMe (5 eq.) was  added. 
The suspension was heated at reflux for 6 hours and allowed to cool to RT. The suspension was 
diluted with H2O and filtered to provide analytically pure napthyridone. 
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Quinlin-2(1H)-one (14): Prepared according to general procedure A from quinoline (1.0 g, 7.75 
mmol) to give the title compound (0.88 g, 6.13 mmol, 78% over 2 steps) as a colourless solid: mp 
195 – 196 °C (ethanol);1H NMR (400 MHz, DMSO-d6):  ppm 11.75 (1H, br, s), 7.90 (1H, d, J = 9.5 
Hz), 7.65 (1H, dd, J = 7.8, 1.6 Hz), 7.49 (1H, t, J = 8.1 Hz), 7.35–7.26 (1H, m), 7.22–7.09 (1H, m), 6.50 
(1H, d, J = 9.5 Hz); 13C NMR (126 MHz, DMSO-d6):  ppm 161.7, 140.2, 138.8, 130.3, 127.8, 121.9, 
121.7, 119.1, 115.1. The above data is in agreement with that previously reported in the literature. 
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1-Methylquinolin-2(1H)-one (1)  Prepared by general procedure B from 13 (530 mg, 3.63 mmol). 
Purification of the residue by column chromatography (3:2 ethyl acetate:hexane) gave the title 
compound (382 mg, 2.51 mmol, 69%) as a pale yellow solid: mp 70 – 71 °C (ethyl acetate-hexane) 
1H NMR (400 MHz, DMSO-d6):  ppm 7.91 (1H, d, J = 9.5 Hz), 7.72 (1H, dd, J = 7.7, 1.5 Hz), 7.67–7.61 
(1H, m), 7.53 (1H, d, J = 8.5 Hz), 7.30–7.25 (1H, m), 6.62 (1H, d, J = 9.5 Hz), 3.62 (3H, s);  13C NMR 
(126 MHz, CDCl3):  ppm 162.3, 140.0, 139.0, 130.6, 128.8, 122.1, 121.8, 120.7, 114.1, 29.4.  The 
above data is in agreement with that previously reported in the literature. 108 
 
1-Methyl-6-nitroquinolin-2(1H)-one (15) : Prepared by general procedure C from 1 (1.20 g, 7.55 
mmol) to give the title compound (1.34 g, 6.57 mmol, 87%) as a yellow solid: mp 218 - 219 °C 
(ethanol); 1H NMR (400 MHz, DMSO-d6):  ppm 8.75 (1H, d, J = 2.7 Hz, C5H), 8.41 (1H, dd, J = 9.4, 2.7 
Hz, C7H), 8.16 (1H, d, J = 9.5 Hz, C4H), 7.73 (1H, d, J = 9.4 Hz, C8H), 6.81 (1H, d, J = 9.5 Hz, C3H), 3.68 
(3H, s, C11H); 13C NMR (101 MHz, DMSO-d6): δ ppm 161.7, 149.3, 140.9, 128.1, 124.6, 123.8, 123.3, 
115.3, 62.1, 14.3. Data are in agreement with the literature. 67 
 
6-Amino-1-methylquinolin-2(1H)-one (2): Prepared according to general procedure D from 15 
(180 mg, 0.88 mmol) to give the title compound (0.85 mmol, 97%) as a bright yellow solid: 1H NMR 
(400 MHz, CDCl3):  ppm 7.45 (1H, d, J = 9.5 Hz), 7.13 (1H, d, J = 8.9 Hz), 6.90 (1H, dd, J = 8.9, 2.7 
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Hz), 6.76 (1H, d, J = 2.7 Hz), 6.60 (1H, d, J = 9.5 Hz), 3.66–3.58 (5H, m); 13C NMR (101 MHz, CDCl3): δ 
ppm 160.9, 141.2, 138.1, 132.6, 122.3, 121.7, 119.4, 115.2, 112.8, 29.4.  
 
N-(1-methyl-2-oxo-1,2-dihydroquinolin-6-yl)benzenesulfonamide (3) Prepared by general 
procedure E from 2 (20 mg, 0.11 mmol), purified by column chromatography (acetone:hexane 3:7) 
to give the title compound (16 mg, 0.06 mmol, 47%): mp 201-204 °C (acetone-hexane); IR (neat) 
νmax: 3080, 1641, 1581, 1485, 1310, 1157, 1091, 979, 989, 819, 754, 687, 592, 567, 506, 474 cm-1;  
1H NMR (400 MHz, DMSO-d6):  ppm 10.32 (1H, br. s), 7.83 (1H, d, J = 9.6 Hz), 7.76 (1H, s), 7.64–
7.50 (3H, m), 7.46–7.39 (2H, m), 7.31 (1H, dd, J = 10.4, 2.0 Hz), 6.58 (1H, d, J = 9.4 Hz), 3.54 (3H, s); 
13C NMR (126 MHz, DMSO-d6):  ppm 160.7, 139.2, 138.7, 136.8, 132.9, 131.7, 129.3, 126.6, 124.3, 
121.8, 120.3, 120.1, 115.6, 29.0; HRMS: m/z ESI- [Found (M-H)- 313.033 C11H12N2O3S requires (M-
H)- 313.0725]; HPLC: Retention time (system A): tR= 9.92 min. Purity: >95%. 
 
 
N-(1-methyl-2-oxo-1,2-dihydroquinolin-6-yl)methanesulfonamide (16): Prepared by general 
procedure E from 2 (20 mg, 0.11 mmol), purified by column chromatography (acetone:hexane 3:7) 
to give the title compound  (16 mg, 0.06 mmol, 59%) as a pale yellow solid: mp 239-242 °C 
(acetone-hexane); IR (neat) νmax: 3129, 2925, 1635, 1580, 1565, 1422, 1319, 1148, 1119, 971, 815, 
776, 735, 655, 542, 513, 467, 410 ; 1H NMR (400 MHz, DMSO-d6):  ppm 9.79 (1H, s, NH), 7.91 (1H, 
d, J = 9.3 Hz, C4H), 7.58 - 7.52 (2H, m C5H and C8H), 7.46 (1H, dd, J = 9.6, 2.5 Hz, C7H), 6.63 (1H, d, J = 
9.3 Hz, C3H), 3.60 (3H, s C11H), 2.99 (3H, s, C12H); 13C NMR (126 MHz, DMSO-d6):  ppm 160.4 C2, 
138.6 C4, 136.8 C10, 132.4 C6, 124.4 C7, 121.8 C3, 120.5 C9, 119.7 C5, 115.7 C8, 39.5 (Assigned by 
HSQC) C12, 28.3 C11; HRMS: m/z NSI+ [Found (M+H)+ 253.0648 C11H12N2O3S requires (M+H)+ 
253.0569]; HPLC: Retention time (system A): tR= 4.27 min. Purity: >95%. 
 
N-(1-methyl-2-oxo-1,2-dihydroquinolin-6-yl)ethanesulfonamide (17) Prepared by general 
procedure E from 2 (20 mg, 0.11 mmol). Purified by column chromatography (acetone-hexane 3:7) 
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to give the title compound  (21 mg, 0.07 mmol, 64%) as a pale yellow solid: mp 195-199 °C 
(acetone-hexane); IR (neat) νmax: 3130, 2931, 1640, 1566, 1420, 1313, 1233, 1141, 977, 881, 818, 
768, 527, 470 cm-1;  1H NMR (400 MHz, DMSO-d6):  ppm 9.86 (1H, s, NH), 7.90 (1H, d, J = 9.3 Hz, 
C4H), 7.56 - 7.51 (2H, m, C5H and C8H), 7.47 (1H, dd, J = 10.4, 2.0 Hz, C7H), 6.62 (1H, d, J = 9.3 Hz, 
C3H), 3.60 (3H, s, C11H), 3.08 (2H, q, J = 7.3 Hz, C12H), 1.21 (3H, t, J = 7.3 Hz, C13H); 13C NMR (126 
MHz, DMSO-d6):  ppm 160.3 C2, 138.9 C4, 136.6 C10, 132.5 C6, 123.9 C7, 121.8 C3, 120.5 C9, 119.2 C5, 
115.8 C8, 44.9 C12, 29.1 C11, 8.0 C13; HRMS m/z NSI+ [Found (M+H)+ 267.0802 C11H12N2O3S requires 
(M+H)+ 267.0725]; HPLC: Retention time (system A): tR= 3.94 min. Purity: >95%. 
 
N-(1-methyl-2-oxo-1,2-dihydroquinolin-6-yl)propane-2-sulfonamide (18) Prepared by 
general procedure E from 2 (20 mg, 0.11 mmol), purified by column chromatography 
(acetone:hexane 3:7) to give the title compound  (13 mg, 0.05 mmol, 43%) as a brown solid: mp 
191-193 °C (acetone-hexane); IR (neat) νmax : 3084, 2933, 1622, 1572, 1486, 1306, 1259, 1139, 
1121, 984, 886, 754, 695, 672, 586, 492, 473, 446, 411 cm-1; 1H NMR (400 MHz, DMSO-d6):  ppm 
9.85 (1H, s, NH), 7.90 (1H, d, J=9.6 Hz, C4H), 7.57 - 7.45 (3H, m, C5H,C7H and C8H), 6.61 (1H, d, J = 9.3 
Hz, C3H), 3.59 (3H, s C11H), 3.22 (1H, quin, J = 6.8 Hz, C12H), 1.25 (6H, d, J = 6.8 Hz, C13H); 13C NMR 
(126 MHz, DMSO-d6):  ppm 160.7 C2, 138.8 C4, 136.5 C10, 132.7 C6, 123.7 C7, 121.8 C3, 120.5 C9, 
118.9 C5, 115.8 C8, 51.2 C12, 29.0 C11, 16.1 C13; HRMS m/z NSI+ [Found (M+H)+ 281.0954 
C11H12N2O3S requires (M+H)+ 281.0882]; HPLC: Retention time (system A): tR= 5.53 min. Purity: 
>95%. 
 
N-(1-methyl-2-oxo-1,2-dihydroquinolin-6-yl)cyclopropanesulfonamide (19) Prepared by 
general procedure E from 2 (20 mg, 0.11 mmol), purified by column chromatography 
(acetone:hexane 3:7) to give the title compound  (31 mg, 0.10 mmol, 97%) as a bright yellow solid: 
mp: 181-182 °C (acetone-hexane); IR (neat) νmax: 3095, 2928, 1639, 1570, 1481, 1310, 1143, 978, 
882, 809, 584, 525, 471 cm-1; 1H NMR (500 MHz, DMSO-d6):  ppm 9.79 (1H, s, NH), 7.91 (1H, d, J = 
9.5 Hz, C4H), 7.57 (1H, s, C5H), 7.54 (1H, d, J  =  9.5 Hz, C8H), 7.49 (1H, d, J  =  8.5 Hz, C7H), 6.63 (1H, d, 
J  = 9.5 Hz, C3H), 3.61 (3H, s, C11H), 0.91 (4H, br. s); 13C NMR (126 MHz, DMSO-d6): δ ppm 160.1 C2, 
138.8 C4, 136.8 C10, 132.4 C6, 124.7 C7, 121.8 C3, 120.4 C9, 120.2 C5, 115.6 C8 , 29.3 C12, 29.1 C11, 4.9 
C13; HRMS m/z ESI+ [Found (M+H)+ 279.0800, C13H14N2O3S requires (M+H)+ 279.0825]; HPLC: 
Retention time (system A): tR= 4.99 min. Purity: >95%. 
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N-(1-methyl-2-oxo-1,2-dihydroquinolin-6-yl)cyclohexanesulfonamide (20): Prepared by 
general procedure E from 2 (20 mg, 0.11 mmol), purified by column chromatography 
(acetone:hexane 3:7) to give the title compound  (20 mg, 0.06 mmol, 59%) as a pale yellow solid:  
mp 169-172 °C (acetone-hexane); IR (neat) νmax: 3098, 2933, 1640, 1620, 1572, 1483, 1332, 1308, 
1258, 1142, 1121, 980, 882, 807, 758, 706, 604, 585, 526, 492, 472, 412 cm-1; 1H NMR (400 MHz, 
DMSO-d6):  ppm 9.85 (1H, s), 7.90 (1H, d, J = 9.6 Hz), 7.56 - 7.45 (3H, m), 6.61 (1H, d, J = 9.6 Hz), 
3.59 (3H, s), 3.04 – 2.82 (1H, m), 2.03 (2H, d, J = 11.1 Hz), 1.75 (2H, d, J = 12.6 Hz), 1.57 (1H, d, J = 
11.6 Hz), 1.51 - 1.32 (2H, m), 1.26 - 1.02 (3H, m); 13C NMR (126 MHz, DMSO-d6):  ppm 160.7, 
138.9, 136.4, 132.7, 123.6, 121.8, 120.5, 118.8, 115.8, 58.8, 29.0, 26.0, 24.7, 24.3; HRMS m/z ESI+ 
[Found (M+H)+ 321.1267, C16H20N2O3S requires (M+H)+ 321.1195]; HPLC: Retention time (system 
A): tR= 8.06 min. Purity: >95%. 
 
 
 
2-Cyano-N-(1-methyl-2-oxo-1,2-dihydroquinolin-6-yl)benzenesulfonamide (21): Prepared by 
general procedure E from 2 (100 mg, 0.55 mmol). Purified by column chromatography (ethyl 
acetate) to give the title compound (114 mg, 0.34 mmol, 61%) as an off white solid:   mp 231 – 234 
°C (ethyl acetate-hexane); IR (neat) νmax: 3185, 2225, 1646, 1578, 1500, 1408, 1348, 1309, 1162, 
1098, 956, 933, 908, 820, 797, 712, 681, 638, 590, 531, 472, 417; 1H NMR (400 MHz, DMSO-d6):  
ppm 8.19 (1H, t,  J= 1.5 Hz), 8.15–8.07 (1H, m), 8.04–7.96 (1 H, m), 7.87 (1H, d, J = 9.5 Hz), 7.81–7.71 
(1H, m), 7.50–7.40 (2H, m), 7.31 (1H, s), 6.60 (1H, d, J = 9.5 Hz), 3.54 (3H, s); 13C NMR (126 MHz, 
DMSO-d6): δ ppm 161.0, 142.5, 138.9, 138.7, 131.9, 130.8, 128.0, 127.9, 127.6, 124.1, 122.7, 122.1, 
119.6, 118.2, 116.1, 112.1, 29.4; HRMS m/z ESI+ [Found (M+H)+ 340.0678 C17H13N3O3S requires 
(M+H)+ 340.0751]; HPLC: Retention time (system A): tR= 9.28 min. Purity: >95%. 
 
 
 
125 
 
3-Cyano-N-(1-methyl-2-oxo-1,2-dihydroquinolin-6-yl)benzenesulfonamide (22): Prepared by 
general procedure E from 2 (100 mg, 0.55 mmol), purified by column chromatography (ethyl 
acetate) to give the title compound (88 mg, 0.26 mmol, 46%) as an off-white solid: mp 256-257  °C 
(ethyl acetate); IR (neat) νmax:1637, 1565, 1503, 1462, 1436, 1416, 1336, 1239, 1204, 1156, 1124, 
1087, 1062, 976, 934, 904, 873, 802, 715, 82, 625, 583, 560, 495, 472 cm-1; 1H NMR (400 MHz, 
DMSO-d6):  ppm 10.53 (1H, br. s), 8.19 (1H, t, J = 1.5 Hz), 8.11 (1H, dt, J =7.8, 1.3 Hz), 8.03–7.97 
(1H, m), 7.87 (1H, d, J = 9.5 Hz), 7.80 –7.72 (1H, m), 7.48–7.41 (2H, m), 7.33–7.26 (1H, m), 6.63 (d, J 
= 9.5 Hz,), 3.55 (3H, s); 13C NMR (126 MHz, DMSO-d6): δ ppm 160.6, 140.3, 138.7, 137.2, 136.6, 
131.1, 130.9, 130.8, 130.2, 124.7, 121.9, 120.8, 120.4, 117.4, 115.8, 112.5, 29.0; HRMS m/z ESI+ 
[Found (M+H)+ 340.0678 C17H13N3O3S requires (M+H)+ 340.0751]; HPLC: Retention time (system 
A): tR= 9.21 min. Purity: >95%. 
 
 
4-Cyano-N-(1-methyl-2-oxo-1,2-dihydroquinolin-6-yl)benzenesulfonamide (23): Prepared by 
general procedure E from 2 (100 mg, 0.55 mmol), purified by column chromatography (ethyl 
acetate) to give the title compound (77 mg, 0.23 mmol, 41%) as an off white solid: mp: >300 °C; IR 
(neat) νmax: 3091, 2846, 1644, 1574, 1523, 1435, 1338, 1274, 1159, 1091, 952, 905, 871, 844, 663, 
649, 584, 556, 496 cm-1;  1H NMR (400 MHz, DMSO-d6):  ppm 10.59 (1H, br. s), 8.06–8.01 (2H, m), 
7.91–7.84 (3H, m), 7.47–7.42 (2H, m), 7.30 (1H, d, J = 2.6 Hz), 6.60 (1H, d, J = 9.5 Hz), 3.55 (3H, s); 
13C NMR (126 MHz, DMSO-d6): δ ppm 160.8, 146.1, 143.2, 136.6, 133.3, 127.9, 124.5, 122.0, 120.1, 
118.0, 117.2, 116.3, 116.0, 29.0; HRMS m/z ESI+ [Found (M+H)+ 340.0755 C17H13N3O3S requires 
(M+H)+ 340.0751]; HPLC: Retention time (system A): tR= 9.33 min. Purity: >95%. 
 
2,5-Dimethylthiophene-3-sulfonyl chloride (25) Dry DMF (211 mg, 2.9 mmol, 1.3 eq.) was 
added to flame dried flask and cooled to 0 °C. SO2Cl2 (392 mg, 2.9 mmol, 1.3 eq.) was added 
dropwise and the resultant yellow solution was stirred for 20 minutes at 0 °C. After this 2,5 
dimethylthiophene (250 mg, 2.23 mmol, 1 eq.) was added and the solution heated to 97 °C for 2 
hours before being allowed to cool back down to RT. The volatile solvents were removed under 
reduced pressure and the residue dissolved in DCM, washed with 5% NaHCO3, dried over 
anhydrous MgSO4, and filtered. The solvent was removed under reduced pressure to give the title 
compound (310 mg, 1.47 mmol, 66%) as a viscous black oil which was used without further 
purification.  
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2,5-Dimethyl-N-(1-methyl-2-oxo-1,2-dihydroquinolin-6-yl)thiophene-3-sulfonamide (26): 
Prepared by general procedure E from 2 (100 mg, 0.55 mmol), purified by column chromatography 
(ethyl acetate: hexane 2:8-4:6) to give the title compound  (59 mg, 0.17 mmol, 31%) as an off-white 
solid: mp 201-204 °C (ethyl acetate-hexane); IR (neat) νmax: 3120, 2921, 2851, 1637, 1564, 1498, 
1457, 1428, 1414, 1377, 1308, 1227, 1140, 1117, 1054, 1029, 939, 929, 898, 831, 805, 756, 698, 
636, 587, 533, 499, 470, 424 cm-1;  1H NMR (400 MHz, DMSO-d6):  ppm 10.23 (1H, br. s), 7.87 (1H, 
d, J = 9.6 Hz, C4H), 7.47 (1H, d, J = 9.1 Hz, C8H), 7.41 (1H, d, J = 2.5 Hz, C5H), 7.32 (1H, dd, J = 9.1, 2.5 
Hz, C7H), 6.88 (1H, d, J = 1.3 Hz, C13H), 6.60 (1H, d, J = 9.3 Hz, C3H), 3.56 (3H, s, C11H), 2.40 (3H, s, 
C18H), 2.31 (3H, s, C17H); 13C NMR (126 MHz, DMSO-d6): δ ppm 160.7, 142.4, 138.7, 136.8, 136.3, 
133.6, 131.7, 125.1, 124.2, 121.8, 120.3, 120.0, 115.6, 29.0, 14.5, 13.7; HRMS m/z ESI- [Found (M-
H)- 347.0782 C11H12N2O3S requires (M-H)- 347.0881]. 
 
N-Methyl-3-oxo-N-phenylbutanamide (28) To a solution of N-methylaniline (3 g, 26.5 mmol, 1 
eq.) in xylenes as added 2,2,6-Trimethyl-4H-1,3-dioxin-4-one (3.77 g, 26.5 mmol, 1 eq.) and the 
resulting solution was heated at reflux for 3 hours. After this time the solution was allowed to cool 
to RT and the solvent removed under reduced pressure. The crude oil was purified by column 
chromatography (ethyl acetates:hexane 4:1) to give the title compound (3.02 g, 15.6 mmol, 59%) as 
a dark red oil:  1H NMR (400 MHz, CDCl3): δ ppm 14.26 (0.2 H, br. s), 7.45 - 7.39 (2H, m), 7.38 - 7.32 
(1H, m), 7.22 - 7.16 (2H, m), 4.68 (0.2H, br. s), 3.35 - 3.24 (5H, m), 2.09 (2H, s), 1.79 (0.7H, s); 13C 
NMR (126 MHz, CDCl3): δ ppm 202.4, 166.4, 143.5, 129.9, 128.3, 127.2, 49.90 , 37.31, 30.33.  The 
above data is in agreement with that previously reported in the literature. 109 
 
1,4-Dimethylquinolin-2(1H)-one (29) Concentrated sulfuric acid (10 mL) was cooled to 0 °C and 
28 (3 g, 15.6 mmol 1 eq.) was added dropwise, the flask was fitted with a calcium chloride guard 
tube and then heated to 95 °C for 2 hours. After this time the solution was cooled to RT and then 
poured over crushed ice and stirred for 30 minutes. The resultant precipitate was filtered, washed 
with water and dried under vacuum to give the title compound (1.83 g, 10.5 mmol, 58%) as a 
purple solid: mp 132-134 °C (water); 1H NMR (400 MHz, CDCl3): δ ppm 7.73 (1H, dd, J = 8.1, 1.5 
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Hz), 7.60 (1H, ddd, J = 8.5, 7.1, 1.5 Hz), 7.40 (1H, d, J = 8.6 Hz), 7.31 - 7.25 (1H, m CHCl3 overlap), 
6.62 (1H, d, J = 1.0 Hz), 3.73 (3H, s), 2.49 (3H, d, J = 1.0 Hz); 13C NMR (126 MHz, CDCl3): δ ppm 
162.1, 146.4, 139.8, 130.4, 125.2, 121.9, 121.4, 121.2, 114.2, 29.2, 18.9. The above data is in 
agreement with that previously reported in the literature. 110 
 
1,4-Dimethyl-6-nitroquinolin-2(1H)-one (30):  Prepared according to general procedure C from 
29 (1g, 5.78 mmol, 1 eq.) to give the title compound (1.15 g, 5.27 mmol, 91%) as a pale yellow solid 
: 1H NMR:  (400 MHz, DMSO-d6):  ppm 8.42 (1H, d, J = 8.3 Hz, C7H), 8.05 (1H, s, C5H), 7.96 (1H, s, 
C3H), 7.09 (1H, d, J = 8.6 Hz, C8H), 3.60 (s, 3H, C11H), 2.19 (s, 3H, C12H). The above data is in 
agreement with that previously reported in the literature. 111 
 
6-Amino-1,4-dimethylquinolin-2(1H)-one (31): Prepared according to general procedure D 
from 30 (900 mg, 4.12 mmol) to give the title compound (603 mg, 3.2 mmol, 78%) as a golden 
solid: mp 162-164 °C (DCM);  1H NMR  (400 MHz, CDCl3):  ppm 7.45 (1H, d, J = 8.1 Hz), 6.77 (1H, 
s), 6.65 (1H, s), 6.60 (1H, d, J = 8.2 Hz), 3.69–3.60 (5H, m), 2.10 (s, 3H); 13C NMR (126 MHz, CDCl3) δ 
ppm 161.6, 145.4, 141.1, 133.2, 122.4, 121.6, 119.1, 115.5, 109.7, 29.2, 19.0. 
 
 
 
2-Cyano-N-(1,4-dimethyl-2-oxo-1,2-dihydroquinolin-6-yl)benzenesulfonamide (32): 
Prepared by general procedure E from 31 (100 mg, 0.53 mmol), purified by column 
chromatography (ethyl acetate) to give the title compound  (39 mg, 0.09 mmol, 17%) as a white 
solid: 1H NMR (400 MHz, DMSO-d6): δ ppm 10.65 (1H, s), 8.91 (1H, d, J = 5.3 Hz), 8.02 - 7.96 (3H, 
m), 7.50 - 7.24 (3H, m), 6.54 (1H, s), 3.52 (3H, s), 2.31 (3H, s); HRMS m/z ESI- [Found (M-H)- 
352.0740 C18H15N3O3S requires (M-H)- 352.0756]. 
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3-Cyano-N-(1,4-dimethyl-2-oxo-1,2-dihydroquinolin-6-yl)benzenesulfonamide (33): 
Prepared by general procedure E from 31 (100 mg, 0.53 mmol), purified by column 
chromatography (ethyl acetate) to give the title compound  (46 mg, 0.13 mmol, 25%) as a yellow 
solid: mp 248 – 250 °C (ethyl acetate-hexane); IR (neat) νmax: 2915, 2849, 1640, 1579, 1488, 1417, 
1374, 1343, 1305, 1156, 1084, 970, 885, 795, 728, 678, 580, 498 cm-1;  1H NMR (400 MHz, DMSO-
d6): δ ppm 10.53 (1H, s), 8.20 (1H, s), 8.11 (1H, d, J = 7.8 Hz), 8.01 (1H, d, J = 8.1 Hz), 7.77 (1H, t, J = 
7.6 Hz), 7.46 - 7.40 (2H, m), 7.32 (1H, dd, J = 9.0, 2.4 Hz), 6.53 (1H, s), 3.52 (3H, s), 2.31 (3H, s); 13C 
NMR (126 MHz, DMSO-d6): δ ppm 160.4, 145.5, 136.8, 136.5, 131.2, 130.8, 130.2, 124.4, 121.2, 
120.9, 117.4, 117.3, 116.0, 112.5, 28.8, 18.1; HRMS m/z ESI- [Found (M-H)- 352.0749 C18H15N3O3S 
requires (M-H)- 352.0756]. 
 
4-Cyano-N-(1,4-dimethyl-2-oxo-1,2-dihydroquinolin-6-yl)benzenesulfonamide (34): 
Prepared by general procedure E from 31 (100 mg, 0.53 mmol), purified by column 
chromatography (ethyl acetate) to give the title compound  (73 mg, 0.21 mmol, 43%) as a white 
solid mp 281-282 °C (ethyl acetate); IR (neat) νmax: 2915, 2849, 2776, 1637, 1616, 1564, 1482, 
1339, 1309, 1283, 1159, 1091, 979, 869, 835, 815, 732, 702, 660, 628, 578, 546, 519, 499, 441  cm-1; 
1H NMR (400 MHz, DMSO-d6): δ ppm 8.04 (2H, d, J = 8.3 Hz), 7.90 (2H, d, J = 8.3 Hz), 7.48–7.39 (2H, 
m), 7.31 (1H, dd, J = 9.0, 2.4 Hz), 6.54 (1H, s), 3.53 (3H, s), 2.31 (3H, s); 13C NMR (126 MHz, DMSO-
d6) δ ppm 160.4, 145.5, 143.3, 136.9, 133.5, 127.5, 124.4, 121.2, 120.9, 117.5, 117.4, 116.0, 115.3, 
28.8, 18.1; HRMS m/z ESI- [Found (M-H)- 352.0749 C18H15N3O3S requires (M-H)- 352.0756]  
 
 
 
N-(1,4-dimethyl-2-oxo-1,2-dihydroquinolin-6-yl)-2,5-dimethylthiophene-3-sulfonamide 
(35) : Prepared by general procedure E from 26 (100 mg, 0.53 mmol), purified by column 
chromatography (EtOAc:hexane ; 1:1) to give the title compound  (88 mg, 0.24 mmol, 44%) as a 
white solid: mp 250-251 °C (decomposed); 1H NMR (400 MHz, DMSO-d6): δ ppm 7.46 (1H, d, J = 9.1 
Hz), 7.40 (1H, d, J = 1.8 Hz),7.33 (1H, dd, J = 9.0, 1.9 Hz), 6.90 (1H, s), 6.54 (1H, s), 3.54 (3H, s), 2.41 
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(3H, s), 2.36 - 2.28 (6H, app s); 13C NMR (126 MHz, DMSO-d6): δ ppm 160.4, 142.6, 138.7, 136.7, 
136.8, 133.7, 131.8, 124.9, 124.2, 122.0, 120.8, 120.1, 115.5, 29.0, 28.1, 14.4, 13.7.  
 
4-(Trifluoromethyl)quinolin-2(1H)-one (38) Prepared according to the procedure of van 
Oeveren et al from aniline (2.6 g, 27.9 mmol, 1 eq.) and 4,4,4 trifluoroacetoacetate (5.0 g, 27.1 
mmol, 0.97 eq.) to give the title compound (2.2 g,  10.3 mmol, 38%) as a colourless solid: 1H NMR 
(500 MHz, DMSO-d6): δ ppm 7.72 (1H, d, J = 8.2 Hz), 7.65 (1H, t, J = 7.6 Hz), 7.46 (1H, d, J = 7.9 Hz), 
7.33 (1H, t, J = 7.6 Hz), 6.99 (1H, s); 13C NMR (126 MHz, DMSO-d6): δ ppm 159.9, 139.7, 136.4 (q, J = 
31 Hz), 131.7, 124.1, 123.4, 122.9, 122.7 (q, J = 277 Hz) 121.8 (q, J = 5 Hz), 116.4, 112.6. The above 
data is in agreement with that previously reported in the literature. 72 
 
6-Nitro-4-(trifluoromethyl)quinolin-2(1H)-one (39) Prepared according to the procedure of 
van Oeveren et al from 38 (1.0 g, 4.69 mmol, 1 eq.) to give the title compound (874 mg, 3.38 mmol, 
72 %)  as yellow needles: 1H NMR (500 MHz, DMSO-d6): δ ppm 12.85 (1H, br. s., NH), 8.47 (1H, dd, J 
= 9.0, 2.4 Hz, C7H), 8.43 (1H, s, C5H), 7.58 (1H, d, J = 9.1 Hz, C8H), 7.21 (1H, s, C3H); 13C NMR (126 
MHz, DMSO-d6): δ ppm 160.1, 143.9, 141.9, 136.0, 136.0 (q,  J = 31 Hz), 126.2, 124.4 (q, J = 5 Hz), 
122.3 (q, J = 277 Hz) 120.1, 117.5, 112.4. The above data is in agreement with that previously 
reported in the literature. 72 
 
 
 
1-Methyl-6-nitro-4-(trifluoromethyl)quinolin-2(1H)-one (40) Prepared according to general 
procedure B from 39 (500 mg, 1.94 mmol). Crude product was crystallised from EtOH to give the 
title compound (488 mg, 1.78 mmol, 94%) as colourless needles: 1H NMR (500 MHz, CDCl3): δ ppm 
8.80 (1H, s), 8.54 (1H, dd, J = 9.3, 2.4 Hz), 7.59 (1H, d, J = 9.5 Hz), 7.26 (1H, s), 3.84 (3H, s); 13C NMR 
(126 MHz, CDCl3): δ ppm 160.0, 144.2, 142.1, 136.9 (q, J = 33 Hz), 126.3, 123.3 (q, J = 5 Hz), 122.0 (q, 
J = 5 Hz), 120.1 (q, J = 278 Hz), 115.7, 114.8, 30.6. The above data is in agreement with that 
previously reported in the literature. 112  
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6-Amino-1-methyl-4-(trifluoromethyl)quinolin-2(1H)-one (41) Prepared according to general 
procedure D from 40 (272mg, 1 mmol)  to give the title compound (129 mg, 0.53 mmol, 53%) as a 
yellow solid: mp 171-172 °C (DCM); 1H NMR (500 MHz, CDCl3): δ ppm 7.29 (1H, d, J = 9.1 Hz), 7.11 - 
7.08 (2H, m), 7.06 (1H, dd, J = 8.8, 2.5 Hz), 3.81 (2H, br. s.), 3.72 (3H, s); 13C NMR (126 MHz, CDCl3): 
δ ppm 159.8, 141.9, 136.0 (q,  J = 31 Hz), 133.9, 122.3 (q, J = 275 Hz), 121.6 (q,  J = 5 Hz), 120.4, 
116.2, 116.0, 109.6 (q,  J = 3 Hz), 29.9. The above data is in agreement with that previously reported 
in the literature. 112  
 
4-Cyano-N-(1-methyl-2-oxo-4-(trifluoromethyl)-1,2-dihydroquinolin-6-
yl)benzenesulfonamide (42) Prepared according to general procedure E from 41 (24 mg, 0.1 
mmol). Purified by column chromatography (acetone:hexane ; 3:7) to give the title compound (18 
mg, 0.044 mmol, 44%) as colourless needles: mp 258-259 °C (acetone-hexane);   1H NMR (500 
MHz, DMSO-d6): δ ppm 10.77 (1H, br. s. NH), 8.06 (2H, d, J = 8.3 Hz, C15H), 7.88 (2H, d, J = 8.3 Hz, 
C14H), 7.64 (1H, d, J = 9.1 Hz, C8H), 7.48 (1H, dd, J = 9.1, 2.5 Hz, C7H), 7.45 (1H, s, C3H), 7.11 (1H, s, 
C5H), 3.61 (3H, s, C11H); 13C NMR (126 MHz, DMSO-d6): δ ppm 158.7, 142.9, 137.7, 134.4 (q,  J = 31 
Hz), 133.5, 131.8, 127.4, 125.8, 122.1 (q, J = 272 Hz), 122.1 (q, J = 4 Hz), 117.4, 117.3, 116.4, 115.5, 
114.2, 29.7; HRMS: m/z ESI- [Found (M-H)- 406.0474 C18H12N3O3SF3 requires (M-H)- 406.0473]; 
HPLC: Retention time (system A): tR= 10.04 min. Purity: >95%. 
 
1-Methyl-2-oxo-1,2-dihydroquinoline-6-sulfonyl chloride (43): A solution of 1 (400 mg, 2.55 
mmol, 1 eq.)  in chlorosufonic acid (4 mL) was heated at 95 °C for 3 hours. After completion of the 
reaction the solution was cooled to 0 °C and added dropwise to ice water (~100 g, Caution very 
violent reaction!) The resulting precipitate was filtered, washed with water and dried under 
reduced pressure to give the title compound (503 mg, 1.96 mmol, 77 %) as an off-white solid: 1H 
NMR (400 MHz, CDCl3): δ ppm 8.28 (1H, d, J = 2.0 Hz, C5H), 8.19 (1H, dd, J = 9.1, 2.3 Hz, C5H), 7.79 
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(1H, d, J = 9.6 Hz, C4H), 7.56 (1H, d, J = 9.1 Hz, C8H), 6.89 (1H, d, J = 9.6 Hz, C3H), 3.80 (3H, s, C11H); 
13C NMR (126 MHz, CDCl3): δ ppm 161.8, 144.2, 138.3, 137.4, 128.4, 128.3, 124.3, 120.3, 115.4, 30.0. 
 
1-Methyl-2-oxo-N-phenyl-1,2-dihydroquinoline-6-sulfonamide (44); From 43 (100 mg, 0.39 
mmol, 1.1 eq.) and aniline (33 mg, 0.35 mmol, 1 eq.) using general procedure F. Purified by column 
chromatography (2:8 ethyl acetate:hexane) to give the title compound (82 mg, 0.27 mmol, 79%) as 
a colourless solid: mp 246-247 °C (ethyl acetate-hexane); IR (neat) νmax : 3120, 3081, 3050, 2965, 
2844, 1641, 1575, 1498, 1418, 1306, 1222, 1149, 1117, 1095, 1095, 936, 911, 762, 698, 690, 635, 
594, 505, 476 cm-1;  1H NMR (400 MHz, DMSO-d6):  ppm 10.31 (1H, s, NH), 8.17 (1H, d, J = 2.0 Hz, 
C5H), 8.03 (1H, d, J = 9.6 Hz, C4H), 7.90 (1H, dd, J = 9.0, 2.1 Hz, C7H), 7.67 (1H, d, J = 9.1 Hz, C8H), 7.25 
- 7.19 (2H, m, C14H), 7.14 - 7.09 (2H, m, C13H), 7.01 (1H, tt, J = 7.3, 1.1 Hz, C15H), 6.70 (1H, d, J = 9.6 
Hz, C3H), 3.60 (3H, s, C11H); 13C NMR (126 MHz, DMSO-d6):  ppm 161.0, 142.2, 138.9, 137.6, 132.5, 
129.2, 128.1, 127.9, 124.1, 122.6, 120.0, 119.5, 115.9, 29.; HRMS m/z ESI- [Found (M-H)- 313.0635 
C16H14N2O3S requires (M-H)- 313.0647] ; HPLC: Retention time (system A): tR= 8.29 min. Purity: 
>95%. 
 
N,1-dimethyl-2-oxo-N-phenyl-1,2-dihydroquinoline-6-sulfonamide (45): From 43 (100 mg, 
0.39 mmol, 1.1 eq.) and N-methylaniline (36 mg, 0.35 mmol, 1 eq.) using general procedure F. 
Purified by column chromatography (1:9 - 2:8 ethyl acetate: hexane) to give the title compound (77 
mg, 0.23 mmol, 71%) as a yellow solid: mp 149 -152 °C (ethyl acetate-hexane); IR (neat) νmax : 
1654, 1582, 1491, 1454, 1418, 1348, 1146, 1054, 860, 819, 758, 690, 636, 566, 507 cm-1;  1H NMR 
(400 MHz, DMSO-d6): δ ppm 8.07 (1H, d, J = 9.6 Hz, C4H), 8.04 (1H, d, J = 2.0 Hz, C5H), 7.70 - 7.64 
(1H, m, C8H), 7.58 (1H, dd, J = 9.0, 2.2 Hz, C7H), 7.39 - 7.26 (3H, m, C15H/ C16H), 7.15 - 7.11 (2H, m, 
C14H), 6.75 (1H, d, J = 9.5 Hz, C8H), 3.64 (3H, s, C11H), 3.17 (3H, s, C12H); 13C NMR (126 MHz, DMSO-
d6):  ppm 161.1, 142.5, 141.1, 139.1, 129.1, 128.9, 128.8, 128.6, 127.3, 126.3, 122.6, 119.7, 115.5, 
38.0, 29.4; HRMS m/z ESI- [Found (M+Cl)- 363.0567 C17H16N2O3S requires (M+Cl)- 363.0570]; 
HPLC: Retention time (system A): tR= 9.31 min. Purity: >95%. 
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N-Benzyl-1-methyl-2-oxo-1,2-dihydroquinoline-6-sulfonamide (46) From 43 (100 mg, 0.39 
mmol, 1.1 eq.) and benzylamine (38 mg, 0.35 mmol, 1 eq.) using general procedure F. Purified by 
column chromatography (2:8 ethyl acetate: hexane) to give the title compound (100 mg, 0.30 mmol, 
86%) as a colourless solid: mp 168 -170 °C (ethyl acetate-hexane); IR (neat) νmax: 3091, 2854, 
1642, 157, 1458, 1328,1154, 789, 732, 9, 640, 591, 506 cm-1;  1H NMR (400 MHz, DMSO-d6): δ ppm 
8.23 - 8.15 (2H, m, NH/C5H), 8.06 (1H, d, J = 9.6 Hz, C4H), 7.96 (1H, dd, J = 9.0, 2.1 Hz, C7H), 7.70 (1H, 
d, J = 9.1 Hz, C8H), 7.25 - 7.16 (5H, m, C14H/ C15H/ C16H), 6.74 (1H, d, J = 9.3 Hz, C3H), 4.00 (2H, d, J = 
6.3 Hz, C12H), 3.65 (3H, s, C11H); 13C NMR (126 MHz, DMSO-d6): δ ppm  161.1, 141.9, 139.1, 137.3, 
133.7, 128.2, 128.1, 127.6, 127.6, 127.1, 122.4, 119.6, 115.7, 46.1, 29.4; HRMS m/z ESI- [Found (M-
H)- 327.0791 C17H16N2O3S requires (M-H)- 327.0804]; HPLC: Retention time (system A): tR= 8.26 
min. Purity: >95%. 
 
 
1-Methyl-2-oxo-N-phenethyl-1,2-dihydroquinoline-6-sulfonamide (47) From 43 (100 mg, 0.39 
mmol, 1.1 eq.) and phenethylamine (42 mg, 0.35 mmol, 1 eq.) using general procedure F. Purified 
by column chromatography (2:8 ethyl acetate: hexane) to give the title compound (86 mg, 0.23 
mmol, 72%) as a colourless solid: mp 159 -160 °C (ethyl acetate-hexane); IR (neat) νmax: 3107, 
2858, 1642, 1574, 1450, 1313, 1152, 1118, 1672, 896, 813, 754, 699, 636, 590, 510, 472, 435 cm-1; 
1H NMR (400 MHz, DMSO-d6): δ ppm 8.17 (1H, d, J = 2.0 Hz, C5H), 8.07 (1H, d, J = 9.6 Hz, C4H), 7.93 
(1H, dd, J = 9.0, 2.1 Hz, C7H), 7.74 (1H, br. s. NH), 7.70 (1H, d, J = 9.1 Hz, C8H), 7.28 - 7.11 (5H, m, 
C15H/ C16H/ C17H), 6.73 (1H, d, J = 9.6 Hz, C3H), 3.65 (3H, s, C11H), 3.05 – 2.95 (2H, m, C12H), 2.69 (2H, 
t, J = 7.5 Hz, C13H); 13C NMR (126 MHz, DMSO-d6):  ppm 161.1, 141.9, 139.1, 138.6, 133.4, 128.6, 
128.2, 128.1, 127.5, 126.3, 122.4, 119.6, 115.7, 44.1, 35.2, 29.4; HRMS m/z ESI- [Found (M-H)- 
341.0954 C18H18N2O3S requires (M-H)- 341.0960]; HPLC: Retention time (system A): tR= 9.05 min. 
Purity: >95%. 
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N-(4-cyanophenyl)-1-methyl-2-oxo-1,2-dihydroquinoline-6-sulfonamide (48): From 43 (100 
mg, 0.39 mmol, 1.1 eq.) and 4-aminobenzonitrile (41 mg, 0.35 mmol, 1 eq.) using general procedure 
F. Purified by column chromatography (3:7 - 1:1 ethyl acetate: hexane) to give the title compound 
(47 mg, 0.14 mmol, 39%) as a colourless solid; mp 290-292 °C (decomposed); IR (neat) νmax : 3128, 
3050, 2937, 2876, 2221, 1646, 1575, 1503, 1349, 1303, 1159, 1098, 918, 836, 788, 690, 648, 01, 
599, 512, 475; 1H NMR (400 MHz, DMSO-d6): δ ppm 11.11 (1H, br. s. NH), 8.31 (1H, d, J = 2.0 Hz, 
C5H), 8.08 (1H, d, J = 9.6 Hz, C4H), 7.96 (1H, dd, J = 9.0, 2.1 Hz, C7H), 7.73 – 7.67 (3H, m, C8H/ C13H), 
7.27 (2H, d, J = 8.6 Hz, C14H), 6.74 (1H, d, J = 9.3 Hz, C3H), 3.61 (3H, s, C11H); 13C NMR (126 MHz, 
DMSO-d6):  ppm 161.0, 142.6, 142.1, 138.9, 133.7, 131.9, 128.0, 127.9, 122.8, 119.6, 118.7, 118.5, 
116.2, 105.4, 29.4; HRMS m/z ESI- [Found (M-H)- 338.0591 C17H13N3O3S requires (M-H)- 338.0599]; 
HPLC: Retention time (system A): tR= 8.10 min. Purity: >95%. 
 
N-(3-cyanophenyl)-1-methyl-2-oxo-1,2-dihydroquinoline-6-sulfonamide (49): From 43 (100 
mg, 0.39 mmol, 1.1 eq.) and 3-aminobenzonitrile (41 mg, 0.35 mmol, 1 eq.) using general procedure 
F. Purified by column chromatography (3:7 - 1:1 ethyl acetate: hexane) to give the title compound 
(59 mg, 0.17 mmol, 50%) as a white solid: mp 234 -236 °C (ethyl acetate-hexane); 1H NMR (400 
MHz, DMSO-d6): δ ppm 8.63 (1H, d, J=2.0 Hz), 8.47 (1H, dd, J=9.3, 2.8 Hz), 8.34 (1H, dd, J=8.1, 2.0 
Hz), 8.28 (1H, d, J=2.5 Hz), 7.96-7.88 (m, 4H), 6.73 (1H, s), 3.66 (3H, s); 13C NMR (126 MHz, DMSO-
d6): δ ppm 161.1, 142.9, 137.8, 137.5, 132.1, 131.0, 128.1, 127.3, 127.1, 125.2, 123.8, 122.0, 119.9, 
117.2, 116.5, 112.5, 29.3; HRMS m/z ESI- [Found (M-H)- 338.0593 C17H13N3O3S requires (M-H)- 
338.0599]. 
 
N-(2-cyanophenyl)-1-methyl-2-oxo-1,2-dihydroquinoline-6-sulfonamide (50): From 43 (100 
mg, 0.39 mmol, 1.1 eq.), 2-aminobenzonitrile (41 mg, 0.35 mmol, 1 eq.), 4-(Dimethylamino)pyridine 
(4 mg, 0.4 mmol, 0.1 eq.)  and pyridine (31 mg, 32 μL, 1.1 eq.) were dissolved in DCM and heated at 
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reflux overnight. The solvent was removed under reduced pressure  and the residue purified by 
column chromatography (1:9 - 1:1 ethyl acetate: hexane) to give the title compound (18 mg, 0.05 
mmol, 15%) as a brown solid: IR (neat) νmax :1639, 1570, 1496, 1464, 1440, 1418, 1352, 1314, 
1287, 1237, 1157, 1117, 1097, 1048, 935, 909, 832, 816, 787, 690, 648, 601, 599, 512, 475 cm-1; 1H 
NMR (400 MHz, DMSO-d6): δ ppm 10.62 (1H, br. s. NH), 8.14 (1H, d, J = 2.0 Hz, C5H), 8.05 (1H, d, J = 
9.6 Hz,  C4H), 7.90 (1H, dd, J = 9.1, 2.3 Hz, C7H), 7.84 - 7.79 (1H, m, C14H), 7.73 (1H, d, J = 9.1 Hz, C8H), 
7.59 (1H, td, J = 7.8, 1.5 Hz, C16H), 7.40 (1H, td, J = 8.1, 0.8 Hz, C15H), 7.07 (1H, d, J = 8.1 Hz, C17H), 
6.74 (1H, d, J = 9.3 Hz, C3H), 3.64 (3H, s, C11H); 13C NMR (126 MHz, DMSO-d6): δ ppm 161.1, 142.4, 
139.1, 138.6, 134.1, 134.0, 132.5, 128.3, 128.0, 127.2, 126.3, 122.6, 119.6, 116.6, 115.9, 109.9, 29.4; 
HRMS m/z ESI- [Found (M-H)- 338.0591 C17H13N3O3S requires (M-H)- 338.0599]. 
 
4-Cyano-2-fluorobenzenesulfonyl chloride (51c) Prepared by general procedure O from 4-
cyano-2-fluoroaniline (2.0 g, 14.7 mmol) to give the title compound (2.66 g, 12.2 mmol, 83%) as an 
orange solid: 1H NMR (500 MHz, CDCl3): δ ppm 8.16 (1H, dd, J = 8.0, 6.8 Hz), 7.75 - 7.66 (2H, m); 13C 
NMR (126 MHz, CDCl3): δ ppm 158.2 (d, J = 264.9 Hz), 135.5 (d, J = 13.7 Hz), 130.4, 128.6 (d, J = 5.5 
Hz), 121.9 (d, J = 23.8 Hz), 120.9 (d, J = 9.2 Hz), 115.2. 
 
4-Cyano-2-fluoro-N-(1-methyl-2-oxo-1,2-dihydroquinolin-6-yl)benzenesulfonamide (51d) 
Prepared according to general procedure E from 2 (20 mg, 0.11 mmol). Purified by column 
chromatography (acetone:hexane ; 2:8-3-7) to give the title compound (31 mg, 0.09 mmol, 79%) as 
a pink solid: mp 282 -284 °C (acetone-hexane); 1H NMR (500 MHz, DMSO-d6): δ ppm 8.10 (1H, d, J = 
10.1 Hz, C14H), 7.95 (1H, t, J = 7.7 Hz, C17H), 7.87 – 7.81 (2H, m, C16H/ C4H), 7.47 - 7.39 (2H, m, 
C8H/C5H), 7.33 (1H, dd, J = 9.1, 2.5 Hz, C7H), 6.58 (1H, d, J = 9.5 Hz, C3H), 3.55 (3H, s, C11H); 13C NMR 
(126 MHz, DMSO-d6): δ ppm 160.7, 157.5 (d, J = 263.0 Hz), 138.7, 137.2, 131.6 (d, J = 14.7 Hz), 
131.3, 130.5, 129.4 (d, J = 4.6 Hz), 124.6, 121.9, 121.6 (d, J = 25.7 Hz), 120.6, 120.4, 117.4 (d, J = 10.1 
Hz), 116.4, 115.8, 29.0; HRMS: m/z FTMS- [Found (M-H)- 356.0508 C17H12FN2O3S requires (M-H)- 
356.0505]; HPLC: Retention time (system A): tR= 7.92 min. Purity: 94%. 
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4-Amino-3-bromobenzonitrile (52a)  Prepared according to the procedure of Suh et al  from 4-
cyanoaniline (250 mg, 1.27 mmol) to give the title compound (158 mg, 0.80 mmol, 63%) as an off-
white solid: 1H NMR (500 MHz, CDCl3): δ ppm 7.71 (1H, d, J = 1.6 Hz), 7.39 (1H, dd, J = 8.4, 1.7 Hz), 
6.76 (1H, d, J = 8.2 Hz), 4.67 (2H, br. s.).  The above data is in agreement with that reported 
previously in the literature. 113 
 
4-Cyano-2-bromobenzenesulfonyl chloride (52c)  Prepared by general procedure O from 52a 
(150 g, 0.76 mmol) to give the title compound (114 mg, 0.41 mmol, 54%) as a brown solid: 1H NMR 
(500 MHz, DMSO-d6): δ ppm 8.12 (1H, d, J = 1.6 Hz), 8.03 (1H, d, J = 7.9 Hz), 7.83 (1H, dd, J = 8.0, 1.6 
Hz); 13C NMR (126 MHz, DMSO-d6): δ ppm 151.1, 137.1, 131.1, 129.5, 120.2, 117.2, 112.6. 
 
2-Bromo-4-cyano-N-(1-methyl-2-oxo-1,2-dihydroquinolin-6-yl)benzenesulfonamide (52d) 
Prepared according to general procedure E from 2 (20 mg, 0.11 mmol). Purified by column 
chromatography (acetone:hexane ; 2:8-3:7) to give the title compound (33 mg, 0.08 mmol, 71%) as 
a colourless solid: mp 262 -263 °C (acetone-hexane); 1H NMR (400 MHz, DMSO-d6): δ ppm 10.65 
(1H, s, NH), 8.16 (1H, d, J = 8.3 Hz, C17H), 8.03 (1H, d, J = 1.5 Hz, C14H), 7.88 (1H, d, J = 9.6 Hz, C4H), 
7.79 (1H, dd, J = 8.2, 1.6 Hz, C16H), 7.51 - 7.41 (2H, m, C8H/ C5H), 7.31 (1H, dd, J = 8.8, 2.5 Hz, C7H), 
6.61 (1H, d, J = 9.6 Hz, C3H), 3.56 (3H, s, C11H); 13C NMR (126 MHz, DMSO-d6): δ ppm 160.7, 144.5, 
138.7, 137.4, 136.5, 135.9, 130.5, 127.5, 125.8, 125.0, 122.0, 121.2, 120.5, 116.1, 115.9, 114.9, 29; 
HRMS: m/z NSI+ [Found (M+H)+  417.9856 C17H12BrN3O3S requires (M+H)+  417.7983]; HPLC: 
Retention time (system A): tR= 9.19 min. Purity: >95%. 
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4-Amino-3-methylbenzonitrile (53a) Prepared by general procedure N from 4-nitro-3-
methylbenzonitrile (1.0 g, 6.0 mmol). Crystallized  (Et2O:Hexane ; 1:2) to give the title compound 
(615 mg, 4.6 mmol, 77%) as colourless needles: 1H NMR (500 MHz, CDCl3): δ ppm 7.38 – 7.31 (2H, 
m), 6.66 (1H, d, J = 8.8 Hz), 4.10 (2H, br. s.), 2.18 (3H, s); 13C NMR (126 MHz, CDCl3): δ ppm 148.7, 
134.2, 131.6, 122.1, 120.3, 114.2, 100.7, 17.0. The above data is in agreement with that previously 
reported in the literature. 114 
 
4-Cyano-2-methylbenzenesulfonyl chloride (53c) Prepared by general procedure O from 53a 
(500 mg, 3.78 mmol) to give a crude solid of the crude title compound (128 mg) as an orange solid 
which was used without further purification.  
 
4-Cyano-2-methyl-N-(1-methyl-2-oxo-1,2-dihydroquinolin-6-yl)benzenesulfonamide (53d) 
Prepared according to general procedure E from 2 (20 mg, 0.11 mmol). Purified by column 
chromatography (acetone:hexane ; 2:8-3-7) to give the title compound (5 mg, 0.01 mmol, 12%) as a 
yellow solid: mp 271 -273 °C (acetone-hexane); 1H NMR (400 MHz, DMSO-d6): δ ppm 7.96 (1H, d, J 
= 8.3 Hz, C17H), 7.90 (1H, s, C14H), 7.90 – 7.70 (2H, m, C16H/C4H), 7.47 - 7.19 (3H, m, C8H/C5H/C7H), 
6.57 (1H, d, J = 9.1 Hz, C3H), 3.53 (3H, s, C11H), 2.64 (3H, s, C18H); 13C NMR (126 MHz, DMSO-d6): δ 
ppm 160.7, 138.7, 138.3, 136.1, 130.2, 129.9, 124.0, 121.9, 120.4, 119.8, 117.5, 115.8, 115.2, 29.0, 
19.5; HRMS: m/z FTMS- [Found (M-H)- 352.0764 C18H15N3O3S requires (M-H)- 352.0756]; HPLC: 
Retention time (system A): tR= 8.48 min. Purity: >95%. 
 
4-Cyano-3-chlorobenzenesulfonyl chloride (54c)  Prepared by general procedure O from 3-
chloro-4-cyanoaniline (500 mg, 3.29 mmol) to give the title compound (535 mg, 2.27 mmol, 69%) 
as a colourless solid: 1H NMR (500 MHz, CDCl3): δ ppm 8.19 (1H, d, J = 7.9 Hz), 7.96 – 8.06 (m, 2H). 
The above data is in agreement with that previously reported in the literature. 78 
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3-Chloro-4-cyano-N-(1-methyl-2-oxo-1,2-dihydroquinolin-6-yl)benzenesulfonamide (54d) 
Prepared according to general procedure E from 2 (20 mg, 0.11 mmol). Purified by column 
chromatography (acetone:hexane ; 2:8-3:7) to give the title compound (30 mg, 0.08 mmol, 73%) as 
a colourless solid: mp 245 °C (decomposed); 1H NMR (400 MHz, DMSO-d6): δ ppm 8.16 (1H, d, J = 
8.1 Hz, C16H), 8.03 (1H, d, J = 1.5 Hz, C13H), 7.88 (1H, d, J = 9.6 Hz, C4H), 7.79 (1H, dd, J = 8.2, 1.6 Hz, 
C17H), 7.49 - 7.42 (2H, m, C8H/C5H), 7.31 (1H, dd, J = 9.1, 2.5 Hz, C7H), 6.61 (1H, d, J = 9.3 Hz, C3H), 
3.56 (3H, s, C11H); 13C NMR (126 MHz, DMSO-d6): δ ppm 160.7, 144.6, 138.7, 137.4, 136.5, 135.9, 
130.5, 127.5, 125.8, 125.0, 121.9, 121.2, 120.5, 116.1, 115.9, 115.0, 29.0; HRMS: m/z FTMS- [Found 
(M-H)- 372.0219 C17H12ClN3O3S requires (M-H)- 372.0221]; HPLC: Retention time (system A): tR= 
9.19 min. Purity: >95%. 
 
3,4-Dichloro-N-(1-methyl-2-oxo-1,2-dihydroquinolin-6-yl)benzenesulfonamide (55d) 
Prepared according to general procedure E from 2 (20 mg, 0.11 mmol). The crude solution was 
added to H2O (10 mL) and filtered. Purification of the crude solid by crystallisation (MeOH) gave 
the title compound (38 mg, 0.10 mmol, 91%) as a colourless solid: mp 230 - 232 °C (methanol); 1H 
NMR (400 MHz, DMSO-d6):  ppm 10.62–10.32 (1H, br. s, NH), 7.95 (1H, d, J = 2.2 Hz, C13H), 7.88 
(1H, d, J = 9.5 Hz, C4H), 7.83 (1H, d, J = 8.5 Hz, C16H), 7.65 (1H, dd, J = 8.5, 2.2 Hz, C17H), 7.48 – 7.42 
(2H, m, C8H/ C5H), 7.31 (1H, dd, J = 9.0, 2.6 Hz, C7H), 6.60 (1H, d, J = 9.5 Hz, C3H), 3.55 (3H, s, C11H); 
13C NMR (126 MHz, DMSO-d6): δ ppm 160.7, 139.5, 138.7, 137.3, 136.1, 132.2, 131.7, 130.9, 128.4, 
126.8, 124.8, 121.9, 120.9, 120.4, 115.8, 29.0; HRMS: m/z FTMS- [Found (M-H)- 380.9871 
C17H12Cl2N2O3S requires (M-H)- 380.9868]; HPLC: Retention time (system A): tR= 10.34 min. Purity: 
>95%. 
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1-Ethylquinolin-2(1H)-one (56) Prepared by general procedure B from 14 (1.0 g, 6.8 mmol) 
Purification by column chromatography (1:1 ethyl acetate:hexane) gave the title compound (759 
mg, 4.39 mmol, 66%) as a colourless oil. 1H NMR (400 MHz, DMSO-d6): δ ppm 7.90 (1H, d, J = 9.6 
Hz), 7.73 (1H, d, J = 7.6 Hz), 7.66–7.56 (2H, m), 7.27 (1H, t, J = 7.8 Hz), 6.61 (1H, d, J = 9.6 Hz), 4.29 
(2H, q, J = 7.1 Hz), 1.22 (3H, t, J = 7.1 Hz). The above data is in agreement with that previously 
reported in the literature. 115 
 
1-Ethyl-6-nitroquinolin-2(1H)-one (57) To a suspension of 56 (759 mg, 4.39 mmol, 1.0 eq.) in 
concentrated H2SO4 (5 mL) at –5 °C was added KNO3 (444 mg, 4.39 mmol, 1.0 eq.) portionwise and 
the resulting yellow solution was stirred at this temperature for 1 hour before being allowed to 
warm to room temperature. The solution was poured over crushed ice, stirred for 10 minutes and 
the precipitate collected by filtration and dried under vacuum to give the title compound (804 mg, 
3.68 mmol, 84%) as a pale yellow solid: 1H NMR (400 MHz, DMSO-d6): δ ppm 8.71 (1H, d, J = 2.8 Hz, 
C5H), 8.37 (1H, dd, J = 9.4, 2.5 Hz, C7H), 8.13 (1H, d, J = 9.6 Hz, C4H), 7.77 (1H, d, J = 9.6 Hz, C8H), 6.77 
(1H, d, J = 9.6 Hz, C3H), 4.30 (2H, q, J = 7.1 Hz, C11H), 1.22 (3H, t, J = 7.1 Hz, C12H); 13C NMR (126 MHz, 
DMSO-d6): δ ppm 160.7, 142.8, 141.3, 139.3, 125.1, 124.9, 122.9, 120.0, 115.5, 37.3, 12.6. 
 
6-Amino-1-ethylquinolin-2(1H)-one (58) Prepared according to general procedure D from 57 
(500 mg, 2.29 mmol, 1.0 eq.) to give the title compound (428 mg, 2.29 mmol, quant.) as a bright 
yellow solid: mp 158 - 159 °C (DCM); 1H NMR (400 MHz, DMSO-d6): δ ppm 7.67 (1H, s), 7.30 (1H, d,  
J= 9.1 Hz), 6.96 (1H, dd, J = 9.1, 2.5 Hz), 6.80 (1H, d, J = 2.5 Hz), 6.47 (1H, d, J = 9.4 Hz), 5.08 (2H, br. 
s), 4.20 (2H, q, J = 7.1 Hz), 1.18 (3H, t, J = 7.1 Hz); 13C NMR (126 MHz, CDCl3): δ ppm 161.3, 141.1, 
138.1, 132.3, 122.3, 122.0, 119.5, 115.1, 112.9, 37.0, 12.8. 
 
4-Cyano-N-(1-ethyl-2-oxo-1,2-dihydroquinolin-6-yl)benzenesulfonamide (59)  Prepared by 
general procedure E from 58 (50 mg, 0.27 mmol). Purified by column chromatography 
(acetone:hexane ; 2:8-3:7) to give the title compound (43 mg, 0.12 mmol, 45 %) as an off-white 
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solid: mp 239 - 240 °C (acetone-hexane); 1H NMR (400 MHz, DMSO-d6): δ ppm 10.58 (1H, br. s, 
NH), 8.04 (2H, d, J = 8.3 Hz, C15H), 7.90 (2H, d, J = 8.3 Hz, C14H), 7.85 (1H, d, J = 9.6 Hz, C4H), 7.50 (1H, 
d, J = 9.1 Hz, C8H), 7.44 (1H, d, J = 2.3 Hz, C5H), 7.29 (1H, dd, J = 9.0, 2.4 Hz, C7H), 6.58 (1H, d, J = 9.6 
Hz, C3H), 4.20 (2H, q, J = 6.9 Hz, C11H), 1.16 (3H, t, J = 6.9 Hz, C12H); 13C NMR (126 MHz, DMSO-d6): δ 
ppm 160.3, 143.3, 138.8, 136.1, 133.5, 130.7, 127.4, 124.8, 121.9, 120.9, 120.7, 117.5, 115.6, 115.4 , 
36.6, 12.5; HRMS: m/z ESI- [Found (M-H)- 352.0768 C18H15N3O3S requires (M-H)-  352.0756]; HPLC: 
Retention time (system A): tR= 8.39 min. Purity: >95%. 
 
5-Bromoquinolin-2(1H)-one (61) Prepared according to general procedure A from 3-
bromoquinoline (2.5 g, 12.0 mmol)  to give the title compound (2.37 g, 10.60 mmol, 88%) as a 
colourless solid: 1H NMR (400 MHz, DMSO-d6): δ ppm 11.98 (1H, br. s), 8.03 (1H, d, J = 9.9 Hz), 
7.49–7.46 (1H, m), 7.42 (1H, t, J = 7.9 Hz), 7.34 (1H, d, J = 8.6 Hz), 6.64 (1H, d, J = 9.9 Hz); 13C NMR 
(126 MHz, DMSO-d6): δ ppm 161.5, 140.2, 138.1, 131.4, 125.6, 123.7, 121.7, 117.8, 114.8. The above 
data is in agreement with that previously reported in the literature. 116  
 
5-Bromo-1-methylquinolin-2(1H)-one (62) Prepared according to general procedure B from 61 
(1.25 g, 5.58 mmol) to give the title compound (625 mg, 2.62 mmol, 47%) as a colourless solid: 1H 
NMR (CDCl3): δ ppm 8.39 (1H, d, J = 8.0 Hz), 7.84 (1H, d, J = 8.1 Hz), 7.30 (1H, dd, J = 8.1, 7.9 Hz), 
7.13 (1H, d, J = 7.9 Hz), 6.81 (1H, d, J = 7.9 Hz), 3.58 (3H, s). The above data is in agreement with 
that previously reported in the literature. 117  
 
5-Bromo-1-methyl-6-nitroquinolin-2(1H)-one (63) Prepared according to general procedure C 
from 62 (500 mg, 2.1 mmol) to give the title compound (315 mg, 1.11 mmol, 53%) as a yellow 
solid: 1H NMR (400 MHz, DMSO-d6): δ ppm 8.26 (1H, d, J = 10.1 Hz), 8.21 (1H, d, J = 9.4 Hz), 7.77 
(1H, d, J = 9.4 Hz), 6.91 (1H, d, J = 9.9 Hz), 3.68 (3H, s).  
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6-Amino-5-bromo-1-methylquinolin-2(1H)-one (64) Prepared according to general procedure 
D from 63 (300 mg, 1.06 mmol) to give the title compound (185 mg, 0.73 mmol, 69%) as a bright 
yellow solid: mp 175 – 178 °C (DCM); 1H NMR (400 MHz, DMSO-d6): δ ppm 7.98 (1H, d, J = 9.9 Hz, 
C4H), 7.39 (1H, d, J = 9.1 Hz, C8H), 7.18 (1H, d, J = 9.1 Hz, C7H), 6.66 (1H, d, J = 9.9 Hz, C4H), 5.39 (2H, 
br. S, NH), 3.58 (3H, s, C11H); 13C NMR (126 MHz, CDCl3): δ ppm 161.2, 139.7, 137.1, 134.1, 123.1, 
120.3, 119.0, 114.4, 108.0, 29.8. The above data is in agreement with that previously reported in the 
literature. 79 
 
N-(5-bromo-1-methyl-2-oxo-1,2-dihydroquinolin-6-yl)-4-cyanobenzenesulfonamide (65)  
Prepared by general procedure E from 63 (20 mg, 0.08 mmol). Purified by column chromatography 
(acetone:hexane ; 6:4) to give the title compound (10 mg, 0.02 mmol, 28%) as a yellow solid: mp 
240 - 242 °C (acetone-hexane); 1H NMR (400 MHz, DMSO-d6): δ ppm 10.46 (1H, br. s, NH), 8.11–
7.96 (3H, m, C14H/C4H), 7.84 (2H, d, J = 8.3 Hz, C13H), 7.57 (1H, d, J = 9.4 Hz, C8H), 7.40 (1H, d, J = 9.1 
Hz, C7H), 6.73 (1H, d, J = 9.9 Hz, C3H), 3.61 (3H, s, C11H); 13C NMR (126 MHz, DMSO-d6): δ ppm 160.3, 
144.6, 139.6, 137.6, 133.5, 130.8, 129.0, 127.4, 123.3, 122.4, 119.4, 117.7, 115.3, 115.2, 29.6; HRMS: 
m/z ESI- [Found (M-H)- 415.9703, C19H17N3O4SBr requires (M-H)- 415.9705]; HPLC: Retention time 
(system A): tR= 8.45 min. Purity: >95%. 
 
N-(5-bromo-1-methyl-2-oxo-1,2-dihydroquinolin-6-yl)-[1,1'-biphenyl]-4-sulfonamide (66) 
Prepared by general procedure E from 63 (20 mg, 0.08 mmol). Purified by column chromatography 
(EtOAc:hexane ; 1:1) to give the title compound (18 mg, 0.04 mmol, 47%) as a colourless solid: mp 
227 - 228 °C (ethyl acetate-hexane); 1H NMR (400 MHz, DMSO-d6): δ ppm 10.14 (1H, s), 8.04 (1H, d, 
J = 9.9 Hz), 7.88 (2H, d, J = 8.6 Hz), 7.81 - 7.71 (4H, m), 7.57 (1H, d, J = 9.3 Hz), 7.50 (2H, t, J = 7.1 Hz), 
7.44 (2H, t, J = 9.1 Hz), 6.73 (1H, d, J = 9.9 Hz), 3.61 (3H, s); 13C NMR (126 MHz, DMSO-d6): δ ppm 
160.3, 144.2, 139.4, 139.2, 138.2, 137.6, 130.2, 129.6 , 129.1, 128.6, 127.4, 127.3, 127.0, 123.2, 
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122.0, 119.4, 115.2, 29.5; HRMS: m/z ESI- [Found (M-H)- 467.0070, C22H17N2O3SBr requires (M-H)- 
467.0065]; HPLC: Retention time (system A): tR= 11.78 min. Purity: >95%. 
 
N-(5-bromo-1-methyl-2-oxo-1,2-dihydroquinolin-6-yl)-4'-fluoro-[1,1'-biphenyl]-4-
sulfonamide (67) Prepared by general procedure E from 63 (20 mg, 0.08 mmol). Purified by 
column chromatography (EtOAc:hexane ; 1:1) to give the title compound (21 mg, 0.04 mmol, 54%) 
as a colourless solid: mp 219 - 220 °C (ethyl acetate-hexane); 1H NMR (400 MHz, DMSO-d6): δ ppm 
10.14 (1H, s), 8.05 (1H, d, J = 9.9 Hz), 7.86 (2H, d, J = 8.3 Hz), 7.83 - 7.74 (4H, m), 7.57 (1H, d, J = 9.1 
Hz), 7.43 (1H, d, J = 9.3 Hz), 7.34 (2H, t, J = 8.8 Hz), 6.73 (1H, d, J = 9.9 Hz), 3.61 (3H, s); 13C NMR 
(126 MHz, DMSO-d6): δ ppm 163.4, 161.5, 160.3, 143.1, 139.3 (d, J=21.1 Hz), 137.6, 134.7 (d, J = 2.7 
Hz), 130.2, 129.6, 129.2 (d, J=8.2 Hz), 127.3 (d, J=15.6 Hz), 123.2, 122.0, 119.3, 116.1, 115.9, 115.1, 
29.6; HRMS: m/z ESI- [Found (M-H)- 484.9977, C22H16N2O3SF requires (M-H)- 484.9981]; HPLC: 
Retention time (system A): tR= 11.78 min. Purity: >95%. 
 
5-Fluoroquinoline (69) To a suspension of 5-aminoquinoline (2.50 g, 17.36 mmol, 1 eq.) in 
48percent HBF4 (20 mL) at 0°C was added portionwise sodium nitrite (1.32 g, 19.09 mmol, 1.1 eq.). 
The resulting solution was stirred for 1 hour at 0 °C and  then poured into EtOAc:Et2O (1:1, 50 mL). 
The diazonium tetrafluoroborate salt was filtered, washed with Et2O (100 mL) and dried under 
vacuum.  
Xylene (80 mL) was heated to reflux and the tetrafluoroborate salt was added portionwise and then 
stirred at reflux for 2 hours before being cooled to RT. The xylene was decanted off and the residue 
was dissolved in HCl (1M, 50 mL). The solution was neutralized with NaHCO3 and  extracted with 
EtOAc (3 × 50 mL). The extracts were combined, dried over anhydrous Na2SO4, filtered and the 
solvent removed under reduced pressure. The residue was purified by column chromatography 
(EtOAc:Hexane 1:99 – 2:98) to give the title compound (970 mg, 6.50 mmol, 38%) as a pink oil:  1H 
NMR (400 MHz, CDCl3): δ ppm 8.99 (1H, dd, J = 4.2, 1.6 Hz), 8.47 (1H, d, J = 8.3 Hz), 7.95 (1H, d, J = 
8.6 Hz), 7.67 (1H, td, J = 8.2, 6.1 Hz), 7.49 (1H, dd, J = 8.3, 4.3 Hz), 7.28 - 7.21 (1H, m); 13C NMR (126 
MHz, CDCl3): δ 158.1 (d, J = 252.4 Hz), 151.2, 149.0, 129.7, 129.0 (d, J = 9.0 Hz), 124.8 (d, J = 5.1 Hz), 
121.3 (d, J = 3 Hz), 119.0, 110.0 (d, J = 19.2 Hz). The above data is in agreement with that previously 
reported in the literature. 118  
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5-Fluoroquinolin-2(1H)-one (70) Prepared by general procedure A from 69 (950 mg, 6.46 mmol) 
to give the title compound (864 mg, 5.30 mmol, 82%) as a pale pink solid: 1H NMR (400 MHz, 
DMSO-d6) δ ppm 12.04 – 11.95 (1H, br. s.), 7.99 (1H, d, J = 9.6 Hz), 7.51 (1H, d, J = 6.3 Hz), 7.14 (1H, 
d, J = 8.3 Hz), 7.04 - 6.95 (1H, m), 6.57 (1H, d, J = 9.9 Hz). 
 
5-Fluoro-1-methylquinolin-2(1H)-one (71) Prepared by general procedure B from 70 (700 mg, 
4.30 mg)  to give the title compound (534 mg, 3.00 mmol, 70%) as a pale pink solid: 1H NMR (400 
MHz, DMSO-d6): δ ppm 8.01 (1H, d, J = 9.6 Hz), 7.65 (1H, td, J = 8.4, 6.4 Hz), 7.39 (1H, d, J=8.6 Hz), 
7.13 (1 H, ddd, J=9.7, 8.2, 0.8 Hz), 6.69 (1 H, d, J=9.9 Hz), 3.63 (3 H, s).  
 
5-Fluoro-1-methyl-6-nitroquinolin-2(1H)-one (72)  Prepared by general procedure C from 71 
(400 mg, 2.26 mmol).  The crude solid was crystallised (Acetone) to give the title compound (217 
mg, 0.97 mmol, 43 %) as a yellow solid that was used without further purification.  
 
5-Fluoro-1-methyl-6-aminoquinolin-2(1H)-one (73)  Prepared by general procedure D from 72 
(100 mg, 0.45 mmol) to give the title compound (45 mg, 0.24 mmol, 54 %) as a bright yellow solid: 
1H NMR (500 MHz, DMSO-d6): δ ppm 8.21 (1H, dd, J = 9.0, 5.8 Hz), 8.12 (1H, d, J = 9.8 Hz), 7.34 (1H, 
t, J = 8.7 Hz), 6.85 (1H, d, J=9.5 Hz), 3.50 (2H, br. s.), 3.29 (3H, s).  
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4-Cyano-N-(5-fluoro-1-methyl-2-oxo-1,2-dihydroquinolin-6-yl)benzenesulfonamide (74) 
Prepared by general procedure E from 73 (30 mg, 0.16 mmol). Purified by column chromatography 
(acetone:hexane ; 2:8 – 3:7) to give the title compound (44 mg, 0.13 mmol, 80%): 1H NMR (400 
MHz, DMSO-d6): δ ppm 10.54 (1H, br. s, NH), 8.06 (2H, d, J = 8.6 Hz, C14H), 7.92 - 7.82 (3H, m, 
C13H/C4H), 7.45 - 7.37 (1H, m C7H), 7.33 (1H, d, J = 9.6 Hz, C8H), 6.66 (1H, d, J = 9.6 Hz, C3H), 3.58 
(3H, s, C11H); 13C NMR (126 MHz, DMSO-d6): δ ppm 161.2, 154.1 (d, J = 244.6 Hz), 150.9, 144.7 (d, J 
= 13.4 Hz), 135.5, 135.4, 128.9 (d, J = 18 Hz), 126.2, 122.7, 119.2 , 117.0, 116.0, 102.6, 102.2, 29.2; 
HRMS: m/z ESI- [Found (M-H)- 356.0496 C17H12N3O3SF3 requires (M-H)- 356.0505]. 
 
N-(3-methoxyphenyl)pivalamide (76)  3-methoxyaniline (5.0 g, 40.65 mmol, 1 eq.) and pyridine 
(3.5 g 44.72 mmol, 1.1 eq.) were dissolved in DCM (50 mL) and cooled down to 0 °C. Pivaloyl 
chloride (5.4 g, 44.72 mmol, 1.1 eq.) was added dropwise with rapid stirring, the solution was 
allowed to warm to RT and then stirred overnight. HCl (1M, 50 mL) was added and the aqueous 
phase extracted with DCM (3 × 100 mL), the organic fractions were pooled, dried over anhydrous 
MgSO4 and concentrated under reduced pressure to give the title compound (8.4 g, 40.60 mmol, 
quant.) as an off-white solid: 1H NMR (500 MHz, CDCl3): δ ppm 7.42 (1H, t, J = 1.9 Hz), 7.34 (1H, br. 
s.), 7.22 (1H,app. t, J = 8.2 Hz), 6.96 (1H, d, J = 7.9 Hz), 6.68 (1H, dd, J = 8.2, 2.2 Hz), 3.83 (3H, s), 1.34 
(9H, s); 13C NMR (126 MHz, CDCl3): δ ppm 176.6, 160.2, 139.3, 129.6, 111.8, 110.4, 105.3, 55.3, 39.7, 
27.6. The above data is in agreement with that previously reported in the literature. 82 
 
N-(2-formyl-3-methoxyphenyl)pivalamide (77)  Prepared according to the procedure of Bertani 
et al 83 starting from 76 (5.0 g, 24.15 mmol). Purification by column chromatography 
(EtOAc:hexane ; 1:19 – 3:17) gave the title compound (4.14 g, 17.63 mmol, 73%) as a colourless 
solid: 1H NMR (500 MHz, CDCl3): δ ppm 11.93 (1H, br. s.), 10.55 (1H, s), 8.38 (1H, d, J = 8.5 Hz), 7.53 
(1H, app. t, J = 8.5 Hz), 6.65 (1H, d, J = 8.2 Hz), 3.94 (3H, s), 1.37 (9H, s); 13C NMR (126 MHz, CDCl3): 
δ ppm 193.3, 178.7, 163.2, 142.8, 137.9, 112.1, 111.2, 104.8, 55.9, 40.5, 27.6. The above data is in 
agreement with that previously reported in the literature. 83 
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N-(4-bromo-2-formyl-3-methoxyphenyl)pivalamide (78) To a solution of 77 (500 mg, 2.13 
mmol, 1 eq.) in DCM (10 mL) was added NBS (378 mg, 2.13 mmol, 1 eq.) in portion. The resulting 
solution was stirred at RT overnight, diluted with H2O and extracted with EtOAc (3 × 50 mL). The 
organic fractions were pooled, dried over anhydrous MgSO4, filtered and concentrated under 
reduced pressure. Purification by column chromatography (EtOAc:hexane ; 1:19-1:9) provided the 
title compound (147 mg, 0.47 mmol, 22%) as a brown solid: mp 77 – 78  °C (ethyl acetate-hexane); 
1H NMR (500 MHz, CDCl3): δ ppm 11.68 (1H, br. s., NH), 10.41 (1H, d, J=0.6 Hz, C13H), 8.53 (1H, d, 
J=9.1 Hz, C5H), 7.75 (1H, d, J=9.5 Hz, C6H), 3.99 (3H, s, C7H), 1.36 (9H, s, C12H); 13C NMR (126 MHz, 
CDCl3): δ ppm 193.5, 178.6, 161.4, 142.0, 141.2, 117.3, 116.9, 109.4, 63.5, 40.6, 27.5. 
 
5-Methoxyquinolin-2(1H)-one (80) Prepared by general procedure M from 77 (1.0 g, 4.26 mmol, 
1.0 eq.) to yield the title compound (672 mg, 3.84 mmol, 90% over 2 steps) as a fluffy colourless 
solid: mp 183 – 185 °C (1,4 dioxane-HCl (3M)) 1H NMR (400 MHz, DMSO-d6): δ ppm 11.71 (1H, br. 
s), 8.03 (1H, d, J = 9.6 Hz), 7.43 (1H, t, J = 8.2 Hz), 6.90 (1H, d, J = 8.3 Hz), 6.74 (1H, d, J = 8.3 Hz), 6.42 
(1H, d, J = 9.9 Hz), 3.90 (3H, s); 13C NMR (126 MHz, DMSO-d6): δ ppm 161.9, 155.5, 140.1, 134.1, 
131.3, 120.4, 109.2, 107.7, 102.6, 55.8. The above data is in agreement with that previously 
reported in the literature. 119 
 
5-Methoxy-1-methylquinolin-2(1H)-one (81) Prepared by general procedure B from 80 (500 
mg, 2.86 mmol). Purified by column chromatography (EtOAc:hexane ; 2:8) to give the title 
compound (345 mg, 1.83 mmol, 64 %) as  a colorless solid: mp 132 -133 °C; 1H NMR (400 MHz, 
DMSO-d6): δ ppm 8.07 (1H, d, J = 9.6 Hz) 7.57 (1H, t, J = 8.5 Hz) 7.11 (1H, d, J = 8.6 Hz) 6.87 (1H, d, J 
= 8.1 Hz) 6.55 (1H, d, J = 9.9 Hz) 3.93 (3H, s) 3.60 (3H, s); 13C NMR (126 MHz, CDCl3): δ ppm 162.5, 
156.5, 141.3, 133.2, 131.1, 120.0, 111.3, 106.8, 102.8, 55.8, 29.8. The above data is in agreement 
with that previously reported in the literature. 87 
145 
 
 
5-Methoxy-1-methyl-6-nitroquinolin-2(1H)-one (82) To a solution of 81 (270 mg, 1.43 mmol, 1 
eq.) in concentrated sulfuric acid (5 mL) cooled to –5 °C was added potassium nitrate (144 mg, 1.43 
mmol, 1 eq.) portionwise and the resulting yellow solution was stirred at this temperature for 1 
hour before being allowed to warm to room temperature. The solution was poured over crushed 
ice, stirred for 10 minutes and the precipitate collected by filtration and dried under vacuum.  The 
crude solid was purified by column chromatography (1:9–2:8 ; acetone:hexane) to give the title 
compound as a pale yellow solid (48 mg, 0.2 mmol, 14%): 1H NMR (400 MHz, DMSO-d6): δ ppm 
8.23 (1H, d, J = 9.6 Hz, C7H) 8.15 (1H, d, J = 9.9 Hz, C4H) 7.49 (1H, d, J = 9.3 Hz, C8H) 6.79 (1H, d, J = 
9.9 Hz, C13H) 3.99 (3H, s, C12H) 3.66 (3H, s, C13H); 13C NMR (126 MHz, DMSO-d6): δ ppm 160.8, 
151.3, 144.3, 139.6, 136.2, 133.2, 122.5, 115.0, 111.3, 64.1, 29.8. 
 
4-Cyano-N-(5-methoxy-1-methyl-2-oxo-1,2-dihydroquinolin-6-yl)benzenesulfonamide (84) 
The required amine was synthesised by general procedure D from 82 (40 mg, 0.2 mmol)  and then 
coupled crude via general procedure E. Purified by column chromatography (acetone:hexane ; 1:9 – 
6:4) to give the title compound (16 mg, 0.04 mmol, 22% over 2 steps) as a pale yellow solid 1H NMR 
(400 MHz, DMSO-d6): δ ppm 10.19 (1H, s) 8.10–8.02 (2 H, m) 7.97–7.85 (3H, m) 7.39 (1H, d, J = 9.1 
Hz) 7.26 (1H, d, J = 9.3 Hz) 6.61 (1H, d, J = 9.6 Hz) 3.59–3.56 (6H, m). 
 
N-(3-methoxyphenyl)cinnamamide (85) :A solution of 3-methoxyaniline (14.3 g, 13.06 mL, 116.2 
mmol, 1 eq.) and potassium carbonate (24.1 g, 174.3 mmol, 1.5 eq.) in acetone (120 mL) and water 
(240 mL) was cooled to 0 °C and cinnamoyl chloride (24.2 g, 145.3 mmol, 1.25 eq.) was added 
portionwise over 10 minutes. Sitrring was continued for 1 hour at 0 °C  and then warmed to RT and 
stirred for 1 hour. The resulting precipitate was filtered, washed with water and dried under 
vacuum to give the title compound (30.2 g, 116.4 mmol, quant.) as a brown solid: mp 110 – 112 °C 
(ethanol); 1H NMR (400 MHz, DMSO-d6): δ ppm 10.20 (1H, s), 7.67 - 7.54 (3H, m), 7.50 - 7.38 (4H, 
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m), 7.27 - 7.20 (2H, m), 6.84 (1H, d, J=15.7 Hz), 6.69 - 6.63 (1H, m), 3.76 (3H, s); 13C NMR (126 MHz, 
DMSO-d6): δ ppm 163.5, 159.1, 140.3, 140.1, 134.7, 129.8, 129.6, 129.0, 127.7, 122.2, 111.5, 108.7, 
105.0, 54.9. The above data is in agreement with that previously reported in the literature. 120 
 
7-Hydroxyquinolin-2(1H)-one (86): A solution of 85 (25.3 g, 100 mmol, 1 eq.) in chlorobenzene 
(750 mL) was cooled to 0 °C and aluminium chloride (80 g, 600 mmol, 6 eq,) was added 
portionwise over 30 minutes. The resulting suspension was slowly heated to 120 °C and 
maintained at that temperature for 3 hours. After this time the solution was cooled to RT and 
poured over ice water (~ 2kg). The precipitate was removed by filtration and dried to give the title 
compound (14.9g, 6:1 7OH:5OH by 1H NMR) which was recrystallised from ethanol to give the title 
compound (13:1 9.31 g, 58 mmol, 58% contained 7% 5-OH regioisomer) as a brown solid: 1H NMR 
(400 MHz, DMSO-d6): δ ppm 11.48 (1H, br. s.), 10.08 (1H, s), 7.73 (1H, d, J = 9.3 Hz), 7.44 (1H, d, J = 
8.6 Hz), 6.69 (1H, d, J = 2.3 Hz), 6.62 (1H, dd, J = 8.3, 2.3 Hz), 6.22 (1H, d, J = 9.6 Hz); 13C NMR (126 
MHz, DMSO-d6): δ ppm 162.3, 159.6, 140.8, 140.1, 129.3, 117.5, 112.4, 111.5, 99.8. The above data is 
in agreement with that previously reported in the literature. 120 
 
7-Methoxy-1-methylquinolin-2(1H)-one (87) : To a suspension of 86 (7.3 g, 45 mmol, 1 eq.) in 
dry DMF (100 mL) under an argon atmosphere was added NaH (60%, 4.35 g , 108.8 mmol, 2.4 eq.) 
in 4 portions over 20 minutes. Upon completion of gas evolution iodomethane (15.45 g, 6.8 mL, 
108.8 mmol, 2.4 eq.) was added dropwise portion and the resulting solution was stirred overnight. 
Excess sodium hydride was quenched by the addition of water (20 mL) and the solvents were 
removed under reduced pressure. The residue was dissolved in ethyl acetate (200 mL), washed 
with water and then brine.  The organic phase was dried over anhydrous MgSO4, filtered and then 
concentrated under reduced pressure. The crude solid was purified by column chromatography 7:3 
hexane:acetone) to give the title compound (4.63g, 24 mmol, 54%) as a pale pink solid ; 1H NMR 
(400 MHz, CDCl3): δ ppm 7.61 (1H, d, J = 9.6 Hz), 7.48 (1H, d, J = 8.3 Hz), 6.86 - 6.82 (1H, m), 6.81 
(1H, d, J = 2.3 Hz), 6.57 (1H, d, J = 9.3 Hz), 3.94 (3H, s), 3.71 (3H, s); 13C NMR (126 MHz, CDCl3) δ 
ppm 162.8, 161.8, 141.7, 138.7, 130.0, 118.6, 114.9, 109.6, 98.7, 55.6, 29.6. The above data is in 
agreement with that previously reported in the literature. 121 
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3-Bromo-7-methoxy-1-methylquinolin-2(1H)-one (88) :  87 (2g, 10.10 mmol, 1 eq.) was 
dissolved in DMF (25 mL) and NBS (1.98 g, 11.11 mmol, 1.1 eq.) was added in one portion. The 
resulting solution was stirred overnight and then poured onto crushed ice and stirred for 30 
minutes. The precipitate was filtered, washed with water (~100 mL) and dried under vacuum to 
the title compound (2.50 g, 9.31 mmol, 92%) as a pink solid: 1H NMR (400 MHz, CDCl3) δ ppm 8.06 
(1H, s, C4H), 7.45 (1H, d, J=8.6 Hz, C5H), 6.87 (1H, dd, J=8.6, 2.3 Hz, C6H), 6.79 (1H, d, J=2.3 Hz, C8H), 
3.95 (3H, s, C12H), 3.78 (3H, s, C11H); 13C NMR (126 MHz, DMSO-d6) δ ppm 161.7, 157.6, 140.8, 
140.6, 129.7, 114.1, 112.3, 110.8, 98.8, 55.7, 30.8. 
 
N-(3-methoxyphenyl)acetamide (94) : 3-methoxyaniline (10g, 50.4 mmol, 1 eq.) was dissolved in 
acetic acid (20 mL) and acetic anhydride (5.7 g, 55.8 mmol, 1.1 eq.) was added dropwise. The 
resulting solution was stirred overnight and then poured onto crushed ice and stirred for 30 mins. 
The resulting precipitate was filtered, washed with water and dried under vacuum to give the title 
compound (13.2 g, 80.9 mmol, quant.) as a brown solid: 1H NMR (400 MHz, CDCl3): δ ppm 7.50 (1H, 
br. s.), 7.28 (1H, s), 7.21 (1H, t, J = 8.1 Hz), 6.99 (1H, d, J = 7.8 Hz), 6.67 (1H, dd, J = 8.2, 1.6 Hz), 3.80 
(3H, s), 2.18 (3H, s); 13C NMR (126 MHz, CDCl3): δ ppm , 161.7, 141.7, 138.7, 130.1, 118.6, 109.7, 
98.8, 55.7, 29.5. The above data is in agreement with that previously reported in the literature. 86 
 
N-(5-methoxy-2-nitrophenyl)acetamide (95a) : To a solution of 94 (5 g, 30.3 mmol, 1 eq.) in 
acetic acid (90 mL) at 0 °C was added a premixed solution of nitric acid (70%, 5.45 g, 3.9 mL, 60.6 
mmol, 2 eq.) in acetic anhydride (6 mL) dropwise maintaining the temperature below 5 °C. Stirring 
was continued for 3 hours at 0 °C and the solution was poured onto crushed ice. The aqueous layer 
was extracted with ethyl acetate (3 × 100 mL) and the combined organic fractions were pooled, 
dried over anhydrous magnesium sulfate, filtered and concentrated under reduced pressure. The 
crude residue was purified by column chromatography (EtOAc:hexane ; 1:9-1:1) to give the title 
compound (2.58 g, 12.2 mmol, 41 %) as bright orange crystals: mp 122 – 124 °C (ethyl acetate-
hexane) 1H NMR (400 MHz, CDCl3): δ ppm 10.78 (1H, br. s., NH), 8.44 (1H, d, J = 2.8 Hz, C6H), 8.21 
(1H, d, J = 9.3 Hz, C3H), 6.66 (1H, dd, J = 9.3, 2.8 Hz, C4H), 3.92 (3H, s, C10H), 2.30 (3H, s, C9H); 13C 
NMR (126 MHz, CDCl3): δ ppm 169.4, 165.8, 137.8, 129.4, 128.1, 110.6, 104.1, 56.1, 25.9. The above 
data is in agreement with that previously reported in the literature. 85 
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(E)-3-ethoxyacryloyl chloride (97) Oxalyl chloride (12.9 mL, 150 mmol, 1.5 eq.) was cooled to 0 
°C and ethyl vinyl ether (9.56 mL, 100 mmol, 1 eq.) was added dropwise. The solution was allowed 
to warm to RT and then stirred overnight. The volatiles were removed under reduced pressure and 
the residue was heated under a positive pressure of argon to 110 °C to give the title compound 
(9.73 g, 73 mmol, 73%) as a black oil that was used without further purification. 
 
(E)-N-(4-bromo-3-methoxyphenyl)-3-ethoxyacrylamide (98) To a solution of 3-methoxy-4-
bromoaniline (1.01 g, 5.00 mmol, 1 eq.) and pyridine (474 mg, 484 µL, 6 mmol, 1.2 eq.) in DCM (20 
mL) was added 97 (432 mg, 6 mmol, 1.2 eq.). The solution was stirred for 3 hours, the solvent 
removed under reduced pressure and the residue purified by column chromatography (1:9–6:4 ; 
ethyl acetate:Hexane) to give the title compound (885 mg, 2.95 mmol, 59%) as sticky brown solid: 
1H NMR (400 MHz, DMSO-d6):  ppm 9.86 (1H, s), 7.55–7.47 (2H, m), 7.44 (1H, d, J = 8.6 Hz), 7.11 
(1H, dd, J = 8.6, 2.3 Hz), 5.51 (1H, d, J = 12.1 Hz), 3.96 (2H, q, J = 6.9 Hz), 3.83 (3H, s), 1.27 (3 H, q, J = 
7.6 Hz); 13C NMR (126 MHz, CDCl3): δ ppm 165.2, 161.7, 156.2, 138.8, 132.9, 112.6, 105.6, 104.5, 
98.7, 67.6, 56.2, 14.7. 
 
6-Bromo-7-methoxyquinolin-2(1H)-one (99) Concentrated sulphuric acid (8 mL) was cooled to 
0 °C and 98 (880 mg, 2.93 mmol) was added portionwise. The dark solution was allowed to stir for 
20 minutes and was then poured onto ice. The resulting precipitate was filtered, washed with water 
and dried under vacuum to afford the title compound (745 mg, 2.93 mmol, quant.) as a brown solid: 
mp >300 °C (water); 1H NMR (400 MHz, DMSO-d6):  ppm 7.94 (1H, s), 7.80 (1H, d, J = 9.6 Hz), 6.94 
(1H, s), 6.37 (1H, d, J = 9.6 Hz), 3.89 (3H, s). 
 
6-Bromo-7-methoxy-1-methylquinolin-2(1H)-one (100) Prepared by general procedure B from 
99 (200 mg, 0.81 mmol, 1 eq.) Purification by column chromatography (1:4 ethyl acetate:hexane) 
gave the title compound (132 mg, 0.50 mmol,  56%) as a pale yellow solid: 1H NMR (400 MHz, 
DMSO-d6):  ppm 8.00 (1H, s), 7.81 (1H, d, J = 9.6 Hz), 7.04 (1H, s), 6.49 (1H, d, J = 9.6 Hz), 4.02 (3H, 
s), 3.64 (3H, s); 13C NMR (126 MHz, CDCl3): δ ppm 162.3, 157.6, 141.0, 137.7, 132.3, 119.5, 115.6, 
105.9, 97.1, 56.5, 29.6. 
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6-amino-7-methoxy-1-methylquinolin-2(1H)-one (93): Prepared by general procedure J from 
100 (200 mg, 0.76 mmol, 1.0 eq.). The resulting residue was purified by column chromatography 
(7:3–3:7 hexane:acetone) to give the title compound as a solution in NMP: Relevant  1H NMR (400 
MHz, DMSO-d6)  ppm 7.63 (1H, d, J = 9.3 Hz) 6.86 (2H, d, J = 11.4 Hz) 6.36 (1H, d, J = 9.3 Hz) 4.77 
(2H, s) 3.95 (3H, s) 3.60 (3H, s). 
 
N-(7-methoxy-1-methyl-2-oxo-1,2-dihydroquinolin-6-yl)benzenesulfonamide (101) 
Prepared by general procedure E from a solution of 93 in NMP (39 mg, 0.19 mmol). Purified by 
column chromatography (acetone:hexane ; 3:7 – 1:1) to give the title compound (24 mg, 0.07 mmol, 
37% over 2 steps) as a colourless solid: mp 236-237 °C (acetone-hexane); IR (neat) νmax: 3200, 
1697, 1591, 1430, 1397, 1350, 1324, 1250, 1165, 1119, 1054, 823, 777, 666, 634, 598, 558, 506 cm-
1; 1H NMR (400 MHz, DMSO-d6):  ppm 9.62 (1H, s, NH), 7.83 (1H, d, J = 9.4 Hz, C4H), 7.71 (2H, d, J = 
7.3 Hz), 7.64–7.48 (4H, m, C14H/C15H), 6.83 (1H, s, C8H), 6.45 (1H, d, J = 9.3 Hz, C3H), 3.58 (6H, app. s, 
C12H/ C11H); 13C NMR (126 MHz, DMSO-d6): δ ppm 161.2, 155.2, 140.4, 139.5, 138.7, 132.5, 128.8, 
126.6, 126.3, 120.3, 118.2, 113.3, 97.5, 55.8, 29.2; HRMS: m/z ESI- [Found (M-H)- 343.0739, 
C17H16N2O4S requires (M-H)- 343.0753]; HPLC: Retention time (system A): tR= 7.79 min. Purity: 
>95%. 
 
4-Cyano-N-(7-methoxy-1-methyl-2-oxo-1,2-dihydroquinolin-6-yl)benzenesulfonamide (102) 
Prepared by general procedure E from a solution of 93 in NMP (39 mg, 0.19 mmol). Purified by 
column chromatography (acetone:hexane ; 3:7 – 6:4) to give the title compound (15 mg, 0.04 mmol, 
21% over 2 steps) as a colourless solid: mp 291-292 °C (acetone-hexane);  1H NMR (400 MHz, 
DMSO-d6):  ppm 9.99 (1H, br. s, NH), 8.03 (2H, d, J = 8.3 Hz, C15H), 7.89–7.80 (3H, m, C14H/C4H), 
7.60 (1H, s, C5H), 6.83 (1H, s, C8H), 6.46 (1H, d, J = 9.6 Hz, C3H), 3.58 (3H, s, C12H), 3.54 (3H, s, C11H); 
13C NMR (126 MHz, DMSO-d6): δ ppm 161.2, 155.6, 144.7, 140.0, 138.7, 133.0, 127.6, 127.4, 119.3, 
118.3, 117.8, 114.8, 113.4, 97.6, 55.7, 29.2; HRMS: m/z NSI+ [Found (M+H)+ 370.0855, C17H16N2O4S 
requires (M+H)+ 370.0854]; HPLC: Retention time (system A): tR= 6.17 min. Purity: >95%. 
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3-Chloro-N-(3-methoxyphenyl)propanamide (103) – 3-methoxyaniline (10.00 g, 81.3 mmol, 1 
eq.) was dissolved in toluene (20 mL) and NaHCO3 (10.29 g, 122 mmol, 1.5 eq.) was added. The 
resulting suspension was cooled to 0 °C and 3-chloropropionyl chloride (10.33 g, 81.3 mmol, 1 eq.) 
was added dropwise with rapid stirring. On completion a further 10 mL of toluene was added and 
the suspension was heated to 50 °C for 2 hours and then poured with stirring onto 3N HCl (50 mL). 
The precipitate was filtered, washed with H2O  and toluene and then dried to give the title 
compound (13.70 g, 64.2mmol, 79%) as a brown solid  that was used without further purification. 
Analytical sample purified by column chromatography (EtOAc:hexane,  1:4). 200 mg of crude solid 
gave 187 mg of the title compound as white needles:  1H NMR (500 MHz, CDCl3): δ ppm 7.33 (1H, 
br. s.), 7.23 (1H, t, J = 2.5 Hz), 7.14 (1H, t, J = 8.2 Hz), 6.91 (1H, d, J = 7.6 Hz), 6.61 (1H, dd, J = 8.5, 1.9 
Hz), 3.81 (2H, t, J = 6.4 Hz), 3.73 (3H, s), 2.74 (2H, t, J=6.4 Hz); 13C NMR (126 MHz, CDCl3): δ ppm 
167.7, 160.2, 139.0, 130.4, 112.1, 110.6, 106.0, 55.3, 40.6, 39.9. The above data is in agreement with 
that previously reported in the literature. 122 
 
7-Hydroxy-3,4-dihydroquinolin-2(1H)-one (104) -  103 (15.0 g, 70.2 mmol. 1.0 eq.) was 
dissolved in N,N-dimethylacetamide (12 mL) and cooled to 0 °C. AlCl3 (37.4 g, 281 mmol, 4 eq.) was 
added portionwise and the resulting solution was fitted with a calcium chloride guard tube and 
heated to 150 °C for 2 hours. On completion the reaction was allowed to cool to ~60 °C and then 
poured over ice (~300 g) and stirred for 20 mins. The precipitate was filtered, washed with H2O 
dried and then crystallized (EtOH) to give the title compound (6.16 g, 37.80 mmol, 54%) as a pale 
pink solid:  1H NMR (500 MHz, DMSO-d6): δ ppm 9.93 (1H, br. s), 9.25 (1H, s), 6.92 (1H, d, J = 7.9 
Hz), 6.33 (1H, d, J = 2.5 Hz), 6.31 (1H, dd, J = 8.2, 2.5 Hz), 2.73 (2H, t, J = 7.4 Hz), 2.39 (2H, t, J = 7.3 
Hz); 13C NMR (126 MHz, DMSO-d6): δ ppm 170.3, 156.4, 139.0, 128.1, 113.7, 108.6, 102.3, 30.8, 23.9. 
The above data is in agreement with that previously reported in the literature. 89 
 
6-Bromo-7-hydroxy-3,4-dihydroquinolin-2(1H)-one (105) – Synthesised according to the 
method of Hu et al from 104 (2.0 g, 12.3 mmol) and NBS (2.4 g, 13.5 mmol, 1.1 eq.) to give the title 
compound (1.71 g, 7.12 mmol, 58%) as a colourless powder:  1H NMR (500 MHz, DMSO-d6): δ ppm 
10.08 (2H,app. s), 7.25 (1H, s), 6.54 (1H, s), 2.76 (2H, t, J = 7.6 Hz), 2.39 (2H, t, J= 7.6 Hz) ; 13C NMR 
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(126 MHz, DMSO-d6): δ ppm 170.2, 152.8, 138.5, 131.2, 115.9, 103.1, 101.0, 30.5, 23.6. The above 
data is in agreement with that previously reported in the literature. 90 
 
6-Bromo-7-methoxy-1-methyl-3,4-dihydroquinolin-2(1H)-one (106) – 105 (1.1 g, 4.6 mmol, 1 
eq.) was dissolved in dry DMF (9 mL) under argon and NaH (60% in mineral oil, 405 mg, 10.1 
mmol, 2.2 eq.) was added in 1 portion with rapid stirring. After gas evolution had ceased the 
solution was cooled to 0 °C and iodomethane (1.5 mL, large excess) was added dropwise. The 
resulting solution was stirred overnight and then poured onto ice and stirred for 20 mins. The 
precipitate was filtered, washed with water and crystallized (MeOH) to give the title compound 
(905 mg, 3.36 mmol, 73%) as colourless needles: mp 159 – 161 °C (methanol); 1H NMR (500 MHz, 
CDCl3): δ ppm 7.34 (1H, s), 6.55 (1H, s), 3.94 (3H, s), 3.39 (3H, s), 2.85 (2H, t, J = 7.9 Hz), 2.66 (2H, t, 
J = 7.9 Hz); 13C NMR (126 MHz, CDCl3): δ ppm 170.1, 155.2, 141.0, 131.8, 119.6, 104.4, 100.0, 56.5, 
31.7, 29.7, 24.2. The above data is in agreement with that previously reported in the literature. 90 
 
6-Bromo-7-hydroxy-1-methyl-3,4-dihydroquinolin-2(1H)-one (107) –  106 (500 mg, 1.85 
mmol, 1 eq.) was dissolved in dry THF (9 mL) and the resulting solution was cooled to – 78 °C. BBr3 
(1.0 M in heptane, 5.56 mmol, 3 eq.) was added dropwise and the solution was then allowed to 
warm to RT and stirred for 3 hours. The solution was poured over ice and the precipitate filtered, 
washed with H2O and dried to give the title compound  (287 mg, 1.12 mmol, 61%) as yellow solid: 
mp 191 – 193 °C (water); 1H NMR (500 MHz, DMSO-d6): δ ppm 10.16 (1H, s), 7.31 (1H, s), 6.66 (1H, 
s), 3.18 (3H, s), 2.76 (2H, t, J = 7.4 Hz); 13C NMR (126 MHz, DMSO-d6): δ ppm 169.3, 152.9, 140.6, 
130.9, 118.3, 103.5, 101.5, 31.3, 28.9, 23.2. 
 
6-Bromo-7-ethoxy-1-methyl-3,4-dihydroquinolin-2(1H)-one (108a) – 107 (100 mg, 0.39 
mmol, 1 eq.) was dissolved in dry DMF (2 mL) under an argon atmosphere and NaH (60% in 
mineral oil, 17 mg, 0.43 mmol, 1.1 eq.) was added in one portion. Upon completion of gas evolution 
iodomethane (61 mg, 0.43 mmol, 1.1 eq.) was added in one portion and the resulting solution was 
stirred overnight. H2O (10 mL) was added and the resulting solution was extracted with EtOAc (3 × 
20 mL). The organic fractions were pooled, washed with saturated brine (3 × 20 mL), dried over 
anhydrous MgSO4, filtered and concentrated under reduced pressure to give the title compound 
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(112 mg, 0.39 mmol, quant.) as a pale yellow solid: mp 109 -111 °C (DMF-water); 1H NMR (500 
MHz, CDCl3): δ ppm 7.31 (1H, s), 6.53 (1H, s), 4.12 (2H, q, J = 6.9 Hz), 2.83 (2H, t, J = 7.9 Hz), 2.63 
(2H, t, J = 7.9 Hz), 1.49 (3H, t, J = 6.9 Hz); 13C NMR (126 MHz, CDCl3): δ ppm 170.3, 154.7, 140.9, 
131.7, 119.7, 105.1, 101.6, 65.5, 31.8, 29.6, 24.2, 14.8. 
 
6-Bromo-7-isopropoxy-1-methyl-3,4-dihydroquinolin-2(1H)-one (108b) Prepared as per 
compound 108a  from 107 (100 mg, 0.39 mmol) and 2-iodopropane (74 mg, 0.43 mmol, 1.1 eq.) to 
give the title compound (73 mg, 0.25 mmol, 63 %): mp 101 -103 °C (DMF-water); 1H NMR (500 
MHz, CDCl3): δ ppm 7.23 (1H, s), 6.49 (1H, s), 4.45 (1H, spt, J = 6.0 Hz), 3.25 (3H, s), 2.75 (2H, t, J = 
7.9 Hz), 2.56 (2H, t, J = 7.9 Hz), 1.32 (6H, d, J = 6.0 Hz); 13C NMR (126 MHz, CDCl3): δ ppm 170.2 , 
153.9, 140.8, 131.8, 120.4, 107.0, 104.6, 73.3, 31.8, 29.7, 24.3, 22.1. 
 
6-Bromo-7-ethoxy-1-methylquinolin-2(1H)-one (109a)  Prepared by general procedure I from 
108a (80 mg, 0.28 mmol) to give the title compound (79 mg, 0.28 mmol, quant) as a pale yellow 
solid: mp 174 - 175 °C (DCM); 1H NMR (500 MHz, CDCl3): δ ppm 8.06 (1H, s), 7.45 (1H, d, J = 8.8 
Hz), 6.86 (1H, dd, J = 8.5, 2.2 Hz), 6.80 (1H, d, J = 2.2 Hz), 4.17 (2H, q, J = 6.9 Hz), 3.78 (3H, s), 1.51 
(3H, t, J = 6.9 Hz); 13C NMR (126 MHz, CDCl3): δ ppm 161.4, 158.8, 141.1, 140.3, 129.5, 114.7, 113.7, 
110.7, 99.4, 64.0, 31.1, 14.3. 
 
6-Bromo-7-isopropoxy-1-methylquinolin-2(1H)-one (109b) Prepared by general procedure I 
from 109b (60 mg, 0.20 mmol) to give the title compound (60 mg, 0.20 mmol, quant) as a pale 
yellow solid: mp 1157 - 159 °C (DCM); 1H NMR (500 MHz, CDCl3): δ ppm 8.02 (1H, s), 7.51 (1H, d, J 
= 8.9 Hz), 6.84 (1H, dd, J = 8.6, 2.1 Hz), 6.80 (1H, d, J = 2.1 Hz), 4.45 (1H, spt, J = 6.0 Hz), 1.32 (6H, d, J 
= 6.0 Hz); 13C NMR (126 MHz, CDCl3): δ ppm 161.0, 158.8, 139.6, 139.5, 130.0, 114.9, 114.6, 110.9, 
99.0, 65.2, 29.8, 22.2. 
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4-Cyano-N-(7-ethoxy-1-methyl-2-oxo-1,2-dihydroquinolin-6-yl)benzenesulfonamide (111) 
The required amine was prepared by general procedure J from 109a (50 mg, 0.18 mmol). 
Purification of the residue by column chromatography (acetone:hexane ; 3:7-4:6) provided the 
amine as a solution in NMP. Coupling of the crude amine by general procedure E and purification of 
the residue by column chromatography (acetone:hexane ; 4:6 – 6:4) provided the title compound 
(12 mg, 0.03 mmol, 17% over 2 steps): mp 228 – 230 °C (acetone-hexane); 1H NMR (500 MHz, 
DMSO-d6): δ ppm 9.96 (1H, br. s, NH), 8.03 (2H, d, J = 7.9 Hz, C16H), 7.87 (1H, d, J = 9.5 Hz, C4H), 7.81 
(2H, d, J = 7.9 Hz, C15H), 7.63 (1H, s, C5H), 6.81 (1H, s, C8H), 6.45 (1H, d, J = 9.1 Hz, C3H), 3.87 (2H, q, J 
= 6.3 Hz, C12H), 3.56 (3H, s, C11H), 1.06 (3H, t, J = 6.8 Hz, C13H); 13C NMR (126 MHz, DMSO-d6): δ ppm 
161.2, 154.8, 144.7, 140.0, 138.7, 133.0, 127.7, 127.4, 119.3, 118.2, 117.7, 114.8, 113.3, 97.9, 64.0, 
29.2, 13.8; HRMS: m/z ESI- [Found (M-H)- 382.0862, C19H17N3O4S requires (M-H)- 382.0862]; HPLC: 
Retention time (system A): tR= 8.08 min. Purity: >95%. 
 
4-Cyano-N-(7-isopropoxy-1-methyl-2-oxo-1,2-dihydroquinolin-6-yl)benzenesulfonamide 
(112) The required amine was prepared by general procedure J from 109b (50 mg, 0.17 mmol). 
Purification of the residue by column chromatography (acetone:hexane ; 3:7-4:6) provided the 
amine as a solution in NMP. Coupling of the crude amine by general procedure E and purification of 
the residue by column chromatography (acetone:hexane ; 4:6 – 6:4) provided the title compound 
(16 mg, 0.04 mmol, 24% over 2 steps): mp 209-210 °C (acetone-hexane); 1H NMR (400 MHz, 
DMSO-d6): δ ppm 9.87 (1H, br. s. NH), 8.03 (2H, d, J = 8.6 Hz, C16H), 7.84 - 7.78 (3H, m, C15H/C4H), 
7.64 (1H, s, C5H), 6.80 (1H, s, C8H), 6.44 (1H, d, J = 9.6 Hz, C3H), 4.67 (1H, spt, J = 6.0 Hz, C12H), 3.55 
(3H, s, C11H), 1.01 (6H, d, J = 6.1 Hz, C13H); 13C NMR (126 MHz, DMSO-d6): δ ppm 161.2, 153.5, 144.8, 
139.9, 138.7, 133.1, 127.7, 127.5, 119.8, 118.1, 117.7, 114.8, 113.1, 98.5, 70.0, 29.2, 20.9; HRMS: 
m/z ESI- [Found (M-H)- 396.1015, C20H19N3O4S requires (M-H)- 396.1018]; HPLC: Retention time 
(system A): tR= 9.51 min. Purity: >95%. 
 
N-(3-fluorophenyl)cinnamamide (114)  Prepared by general procedure K from 2-fluoroaniline 
(4.0 g, 36.03 mmol) to give the title compound (8.07 g, 33.51 mmol, 93%) as a colourless solid: 1H 
NMR (400 MHz, DMSO-d6): δ ppm 10.43 (1H, s), 7.82 - 7.58 (4H, m), 7.50 - 7.32 (5H, m), 6.95 - 6.87 
(1H, m), 6.83 (1H, d, J = 15.7 Hz). The above data is in agreement with that previously reported in 
the literature. 123 
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7-Fluoroquinolin-2(1H)-one (115) Prepared by general method L from 114 (5.00 g, 20.58 
mmol). Crystallised (EtOH) to give the title compound (2.05 g, 12.6 mmol, 61%) as a pink solid 
(contains 24% 5-F isomer by 1H NMR):  1H NMR (400 MHz, DMSO-d6): δ ppm 11.82 (1 H, br. s.), 
7.91 (1 H, d, J = 9.6 Hz), 7.73 (1 H, dd, J = 8.5, 6.2 Hz), 7.10 – 6.99 (2H, m), 6.46 (1H, d, J = 9.6 Hz). 
Used without further purification. 
 
7-Fluoro-1-methylquinolin-2(1H)-one (116) Prepared by general procedure B from 115 (1.00 g, 
6.13 mmol). Purified by column chromatography (acetone:hexane ; 1:19 – 1:9) to give the title 
compound (836 mg, 4.72 mmol, 77%) (contains 11% 5-F isomer by 1H NMR) as a pale pink solid: 1H 
NMR (400 MHz, CDCl3): δ ppm 7.91 (1H, d, J = 9.3 Hz), 7.79 (1H, dd, J = 8.6, 6.6 Hz), 7.40 (1H, dd, J = 
11.6, 2.3 Hz), 7.14 (1H, td, J = 8.6, 2.5 Hz), 6.57 (1H, d, J = 9.6 Hz), 3.58 (3H, s). Used without further 
purification. 
 
7-Fluoro-1-methyl-6-nitroquinolin-2(1H)-one (117) Prepared by general procedure C from 116 
(700 mg, 3.95 mmol). Crystallised (EtOH) to give the title compound (300 mg, 1.34 mmol, 34%) as a 
yellow solid: 1H NMR (400 MHz, DMSO-d6): δ ppm 8.51 (1H, d, J = 8.3 Hz), 7.88 (1H, d, J = 9.6 Hz), 
7.51 (1H, d, J = 14.1 Hz), 6.53 (1H, d, J = 9.6 Hz), 3.40 (3H, s).  
 
7-Fluoro-1-methyl-6-aminoquinolin-2(1H)-one (118)  Prepared by general procedure D from 
117 (100 mg, 0.45 mmol) to give the title compound (33 mg, 0.17 mmol, 39%) as a bright yellow 
solid: 1H NMR (500 MHz, CDCl3): δ ppm 7.52 (1H, d, J = 9.8 Hz), 7.06 (1H, d, J = 12.6 Hz), 6.95 (1H, d, 
J = 9.1 Hz), 6.64 (1H, d, J = 9.5 Hz), 3.78 (2H, br. s.), 3.66 (3H, s); 13C NMR (126 MHz, CDCl3): δ ppm 
161.9, 153.8 (d, J = 244.7 Hz), 137.7, 133.7 (d, J = 10.1 Hz), 130.2 (d, J = 13.7 Hz), 121.1 (d, J = 3.7 
Hz), 117.7 (d, J = 2.7 Hz), 114.8 (d, J = 5.5 Hz), 101.7 (d, J = 24.7 Hz), 29.6. 
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4-Cyano-N-(7-fluoro-1-methyl-2-oxo-1,2-dihydroquinolin-6-yl)benzenesulfonamide (119) 
Prepared according to general procedure E from 118 (20 mg, 0.10 mmol). Purified by column 
chromatography (acetone:hexane ; 3:7 – 6:4) to give the title compound (31 mg, 0.08 mmol, 83%) 
as a colourless solid: mp >300 °C (acetone-hexane); 1H NMR (400 MHz, DMSO-d6): δ ppm 10.52 
(1H, br. s, NH), 8.06 (2H, d, J = 8.6 Hz, C14H), 7.92 (1H, d, J = 9.6 Hz, C4H), 7.87 (2H, d, J = 8.6 Hz, C13H), 
7.65 (1H, d, J = 8.6 Hz, C5H), 7.41 (1H, d, J = 12.6 Hz, C8H), 6.59 (1H, d, J = 9.6 Hz, C3H), 3.53 (3H, s, 
C11H); 13C NMR (126 MHz, DMSO-d6): δ ppm 160.9, 157.8 (d, J = 250.2 Hz), 143.9, 139.7 (d, J = 11.0 
Hz), 138.5, 133.4, 128.3, 127.4, 120.8, 117.6 , 116.9, 115.3, 102.8, 102.6, 29.5; HRMS: m/z ESI- 
[Found (M-H)- 356.508 C17H12N3O3SF requires (M-H)- 356.505]; HPLC: Retention time (system A): 
tR= 7.79 min. Purity: >95%. 
 
N-(4-bromo-3-methoxyphenyl)-3-oxobutanamide (120) To a solution of 4-bromo-3-
methoxyaniline (2.5 g, 12.32 mmol, 1 eq.) in xylenes (25 mL) at 110 °C was added 2,2,6-Trimethyl-
4H-1,3-dioxin-4-one (1.93 g, 13.55 mmol, 1.1 eq.). The solution was stirred for 2 hours and allowed 
to cool to RT. The solvents were removed under reduced pressure and the residue purified by 
column chromatography (8:2–6:4; hexane:ethyl acetate) to yield the title compound (2.32 g, 8.14 
mmol, 66%) as a brown oil: 1H NMR (400 MHz, CDCl3): δ ppm 9.07 (1H, br. s), 7.30 (1H, t, J = 2.2 
Hz), 7.24 (1H, t, J = 8.1 Hz), 7.06 (1H, dd, J = 8.0, 1.1 Hz), 6.70 (1H, dd, J = 8.2, 1.9 Hz), 3.83 (3H, s), 
3.61 (2H, s), 2.35 (3H, s). 
 
6-Bromo-7-methoxy-4-methylquinolin-2(1H)-one (121) A mixture of 120 (1.21 g, 4.05 mmol) 
and polyphosphoric acid (10 g) was heated at 90 °C for 2 hours. The reaction mixture was allowed 
to cool to approximately 60 °C and then ice was added until a freely stirring mixture was achieved. 
The precipitate was isolated by filtration and dried under vacuum to yield the title compound (1.05 
g, 3.90 mmol 96%) as a colourless solid: mp 257 - 259 °C (water); 1H NMR (400 MHz, DMSO-d6): δ 
ppm 7.87 (1H, s), 6.94 (1H, s), 6.27 (1H, s), 3.89 (3H, s), 2.38 (3H, s); 13C NMR (126 MHz, DMSO-d6): 
δ ppm 161.7, 156.5, 147.2, 139.7, 128.7, 118.8, 114.7, 104.5, 98.1, 56.3, 18.4. 
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6-Bromo-7-methoxy-1,4-dimethylquinolin-2(1H)-one (122)  was prepared according to general 
procedure B from 121 (500 mg, 1.88 mmol). Product precipitated by addition of H2O, filtered and 
dried to give the title compound (275 mg, 0.98 mmol, 52%) as a pale yellow solid: 1H NMR (400 
MHz, DMSO-d6): δ ppm 7.92 (1H, s), 7.02 (1H, s), 6.41 (1H, s), 4.02 (3H, s), 3.62 (3H, s), 2.39 (3H, d, J 
= 0.5 Hz); 13C NMR (126 MHz, DMSO-d6): δ ppm 162.2, 157.3, 145.3, 140.7, 129.4, 119.1, 116.3, 
105.7, 97.2, 56.4, 28.7, 18.4. 
 
6-Amino-7-methoxy-1,4-dimethylquinolin-2(1H)-one (123) Prepared by general procedure J 
from 122 (100 mg, 0.35 mmol, 1 eq.).The resulting residue was purified by column 
chromatography (7:3–3:7 hexane:acetone) to give the title compound as a crude solution solution 
in NMP. Relevant 1H NMR (400 MHz, DMSO-d6): δ ppm 6.96 (1H, s), 6.87 (1H, s), 6.29 (1H, s), 4.82–
4.76 (2H, br. s), 3.95 (3H, s), 3.59 (3H, s), 2.31 (3H, s). 
 
4-Cyano-N-(7-methoxy-1,4-dimethyl-2-oxo-1,2-dihydroquinolin-6-yl)benzenesulfonamide 
(124) Prepared by general procedure E from a solution of 123 in NMP (75 mg, 0.35 mmol). Purified 
by column chromatography (acetone:hexane ; 2:8 – 1:1) to give the title compound (28 mg, 0.07 
mmol, 20% over 2 steps) as a pale yellow solid: mp 260 - 262 °C (acetone-hexane);1H NMR (500 
MHz, DMSO-d6): δ ppm 10.05 (1H, br. s, NH), 8.04 (2H, d, J = 8.2 Hz, C16H), 7.83 (2H, d, J = 8.5 Hz, 
C15H), 7.52 (1H, s, C5H), 6.84 (1H, s, C8H), 6.40 (1H, s, C3H), 3.56 (6H, m, C11H/ C13H), 2.34 (3H, s, 
C12H); 13C NMR (126 MHz, DMSO-d6): δ ppm 160.9, 155.5, 145.8, 144.7, 139.7, 133.0, 127.5, 124.1, 
119.3, 118.0, 117.7, 114.8, 113.8, 97.8, 55.7, 29.0, 18.3; HRMS: m/z NSI+ [Found (M+H)+ 384.1012 
C19H17N3O4S requires M+ 384.0940]; HPLC: Retention time (system A): tR= 7.21 min. Purity: >95%. 
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3-Methylquinolin-2(1H)-one (126) Prepared according to general procedure A from 3-
methylquinoline (5.0 g, 35.0 mmol) to give the title compound (3.78 g, 23.8 mmol, 69%) as a 
colourless solid: 1H NMR (400 MHz, DMSO-d6): δ 11.72 (1H, br. s.), 7.75 (1H, s), 7.56 (1H, d, J = 7.8 
Hz), 7.41 (1H, t, J = 8.3 Hz),7.29 (1H, d, J = 8.3 Hz), 7.14 (1H, t, J = 7.5 Hz), 2.09 (3H, s); 13C NMR (126 
MHz, DMSO-d6): δ 162.4, 137.9, 136.3, 129.8, 129.0, 126.9, 121.6, 119.4, 114.7, 16.5. The above data 
is in agreement with that previously reported in the literature. 124 
 
3-Methyl-6-nitroquinolin-2(1H)-one (127) Prepared according to the procedure or Fish et al 
from 126 (3.0 g, 18.9 mmol)  to give the title compound (3.0 g, 14.6 mmol, 77%) as a pale yellow 
solid: 1H NMR (400 MHz, DMSO-d6): δ 12.12 (1H, s, NH), 8.63 (1H, s, C5H), 8.38 (1H, d, J = 8.7 Hz, 
C7H), 8.08 (s, 1H, C3H), 7.66 (1H, d, J = 8.8 Hz, C8H), 2.16 (3H, s,  C11H); 13C NMR (125 MHz, DMSO-
d6): δ 161.8, 143.0, 141.2, 135.1, 131.4, 123.9, 123.6, 119.9, 115.8, 17.0. The above data is in 
agreement with that previously reported in the literature. 92 
 
1,3-Dimethyl-6-nitroquinolin-2(1H)-one (128a) Prepared according to general procedure B 
from 127 (1.0 g, 4.90 mmol) to give the title compound (588 mg, 2.70 mmol, 54%) as a pale yellow 
solid: mp 196 -198 °C (DMF-water);;1H NMR (400 MHz, DMSO-d6): δ 8.63 (1H, s), 8.35 (1H, d, J = 
8.8 Hz), 8.03 (1H, s), 7.7 (1H, d, J = 8.8 Hz), 3.71 (3H. s) 2.16 (3H, s); 13C NMR (126 MHz,  DMSO-d6): 
δ 161.8, 142.9, 141.4, 135.3, 131.2, 123.9, 123.5, 119.7, 115.7, 30.1, 17.4. The above data is in 
agreement with that previously reported in the literature. 92 
 
1-Ethyl-3-methyl-6-nitroquinolin-2(1H)-one (128b) Prepared by general procedure B from 127 
(500 mg, 2.45 mmol) to give the title compound (470 mg, 2.0 mmol, 83%) as a pale yellow solid: 
mp 241 – 243 °C (DMF-water); 1H NMR (500 MHz, CDCl3): δ ppm 8.45 (1H, d, J = 2.5 Hz), 8.37 (1H, 
dd, J = 9.5, 2.5 Hz), 7.66 (1H, s), 7.45 (1H, d, J = 9.5 Hz), 4.43 (2H, q, J = 7.1 Hz), 2.32 (3H, d, J = 0.9 
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Hz), 1.41 (3H, t, J = 7.1 Hz); 13C NMR (126 MHz, CDCl3): δ ppm 162.2, 142.1, 141.9, 135.1, 132.8, 
124.0, 123.9, 120.5, 114.3, 38.3, 17.7, 12.7. 
 
 
6-Amino-1,3-dimethylquinolin-2(1H)-one (129a) Prepared according to the procedure of Fish 
et al from 128a (500 mg, 2.29 mmol) to give the title compound (319 mg, 1.70 mmol, 74%) as a 
golden powder: 1H NMR (500 MHz, DMSO-d6): δ 7.55 (1H, s), 7.21 (1H, d, J = 8.8 Hz), 6.87 (1H, d, J = 
8.8 Hz), 6.71 (1H, s), 5.04 (2H, br. s), 3.56 (3H, s) 2.08 (3H, s); 13C NMR (126 MHz, DMSO-d6): δ 
160.9, 143.6, 135.0, 130.5, 128.7, 120.9, 117.7, 115.0, 110.0, 29.2, 17.5. The above data is in 
agreement with that previously reported in the literature. 92 
 
6-Amino-1-ethyl-3-methylquinolin-2(1H)-one (129b) Prepared by general procedure D from 
128b (250 mg, 1.08 mmol) to give the title compound  (135 mg, 0.67 mmol, 62%) as a yellow solid: 
mp 173 - 175 °C (DCM); 1H NMR (500 MHz, CDCl3): δ ppm 7.42 (1 H, s), 7.21 (1 H, d, J = 8.8 Hz), 
6.94 (1 H, dd, J = 8.8, 2.5 Hz), 6.82 (1 H, d, J = 2.5 Hz), 4.36 (2 H, q, J = 7.0 Hz), 3.79 (1 H, br. s.), 2.26 
(3 H, s), 1.36 (3 H, t, J = 7.3 Hz); 13C NMR (126 MHz, CDCl3): δ ppm 161.8, 140.7, 134.9, 131.6, 130.6, 
122.1, 118.3, 114.8, 112.3, 37.5, 17.8, 12.9. 
 
4-Cyano-N-(1,3-dimethyl-2-oxo-1,2-dihydroquinolin-6-yl)benzenesulfonamide (130 – NI-42) 
Prepared according to general procedure E  from 129a (188 mg, 1.00 mmol). Purified by column 
chromatography (acetone:hexane ; 3:7 – 4:6) to give the title compound (129 mg, 0.37 mmol, 39%) 
as a colourless solid: mp 279 – 282 °C (acetone-hexane); 1H NMR (400 MHz, DMSO-d6):  ppm 
10.52 (1H, br. s), 8.03 (2H, d, J = 8.6 Hz, C15H), 7.88 (2H, d, J = 8.6 Hz, C14H), 7.73 (1H, s, C4H), 7.41 
(1H, d, J = 9.1 Hz, C8H), 7.34 (1H, d, J = 2.3 Hz, C5H), 7.23 (1H, dd, J = 9.0, 2.4 Hz, C7H), 3.58 (3H, s, 
C11H), 2.10 (3H, s,  C12H); 13C NMR (126 MHz, DMSO-d6): δ ppm 161.4, 143.3, 136.3, 135.0, 133.5, 
130.8, 130.0, 127.4, 123.5, 120.3, 119.9, 117.5, 115.5, 115.3, 29.4, 17.3; HRMS: m/z NSI+ [Found 
(M+H)+ 354.908 C18H15N3O3S requires (M+H)+ 354.0912]; HPLC: Retention time (system A): tR= 
8.91 min. Purity: >95%. 
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4-Cyano-N-(1-ethyl-3-methyl-2-oxo-1,2-dihydroquinolin-6-yl)benzenesulfonamide (131) 
Prepared according to general procedure E from 129b (25 mg, 0.13 mmol). Purified by column 
chromagraphy (acetone:hexane ; 1-9 - 3-7) to give the title compound (22mg, 0.06 mmol, 48%) as a 
pale pink solid: mp 263 – 264 °C (acetone-hexane); 1H NMR (500 MHz, DMSO-d6): δ ppm 10.55 (1H, 
s, NH), 8.04 (2H, d, J = 8.2 Hz, C16H), 7.89 (2H, d, J = 8.5 Hz, C15H), 7.73 (1H, s, C4H), 7.46 (1H, d, J = 9.1 
Hz, C8H), 7.35 (1H, d, J = 2.2 Hz, C5H), 7.23 (1H, dd, J = 9.1, 2.5 Hz, C7H), 4.22 (2H, q, J = 6.9 Hz, C11H), 
2.09 (3H, s, C13H), 1.16 (3H, t, J = 6.9 Hz, C12H); 13C NMR (126 MHz, DMSO-d6): δ ppm 160.9, 143.4, 
135.1, 135.1, 133.5, 130.7, 130.0, 127.4, 123.6, 120.6, 120.0, 117.5, 115.3, 115.3, 36.9, 17.2, 12.6; 
HRMS: m/z ESI- [Found (M-H)- 366.0923 C19H17N3O3S requires (M-H)-  366.0912];  HPLC: Retention 
time (system A): tR= 9.40 min. Purity: >95%. 
 
4,4-Dimethyl-2-propyl-4,5-dihydrooxazole (133) Prepared according to the method of Meyers 
et al from butyric acid (5.0 g, 61.7 mmol) to give the title compound (6.18 g, 43.8 mmol, 71%) as a 
colourless oil: 1H NMR (400 MHz, CDCl3): δ ppm 3.91 (2H, s), 2.24 (2H, t, J = 7.5 Hz), 1.67 (2H, sxt, J 
= 7.4 Hz), 1.28 (6H, s), 0.98 (3H, t, J = 7.3 Hz). The above data is in agreement with that published 
previously in the literature. 125 
 
3-Ethyl-6-nitroquinolin-2(1H)-one (134) – Prepared by general procedure G from 2-chloro-5-
nitrobenzaldehyde (2.50 g, 13.5 mmol, 1 eq.) and 133 (1.90 g, 13.5 mmol, 1 eq.) to give the title 
compound (2.62 g,12.0 mmol, 89%) as a brown solid: mp >300 °C (NMP - water); 1H NMR (500 
MHz, DMSO-d6): δ ppm 12.29 (1H, s), 8.64 (1H, d, J = 2.5 Hz), 8.28 (1H, dd, J = 9.1, 2.5 Hz), 7.97 (1H, 
s), 7.42 (1H, d, J = 9.1 Hz), 1.19 (3H, t, J=7.4 Hz) (NB Et CH2 overlaps with DMSO peak); 13C NMR 
(126 MHz, DMSO-d6): δ ppm 162.1, 142.1, 141.4, 137.4, 134.5, 124.0, 123.5, 118.9, 115.6, 22.8, 12.3. 
 
3-Ethyl-1-methyl-6-nitroquinolin-2(1H)-one (135) Prepared according to general procedure B 
from 134 (1.20 g, 5.50 mmol) to give the title compound (1.0 g, 4.34 mmol, 79%) as a brown solid, 
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which was used without further purification 1H NMR (500 MHz, DMSO-d6): δ ppm 8.58 (1H, d, J = 
2.5 Hz), 8.19 (1H, dd, J = 9.0, 2.5 Hz), 7.94 (1H, s), 7.41 (1H, d, J = 9.0 Hz), 1.18 (3H, t, J=7.4 Hz) (NB 
Et CH2 overlaps with DMSO peak) 
 
6-Amino-3-ethyl-1-methylquinolin-2(1H)-one (136) Prepared according to the procedure of 
Fish et al from 135 (500 mg, 1.03 mmol) to give the title compound (129 mg, 0.63 mmol  31%) as a 
black solid that was used without further purification. 
 
4-Cyano-N-(3-ethyl-1-methyl-2-oxo-1,2-dihydroquinolin-6-yl)benzenesulfonamide (137) 
Prepared according to general procedure E from 136 (30 mg, 0.15 mmol). Purified by column 
chromatography to give the title compound (30 mg, 0.08 mmol, 55% or 17% over 2 steps from 
135): mp 245 – 246 °C (acetone-hexane); 1H NMR (400 MHz, DMSO-d6): δ ppm 10.57 (1H, s, NH), 
8.04 (2H, d, J = 8.6 Hz, C15H), 7.88 (2H, d, J = 8.6 Hz, C14H), 7.69 (1H, s, C4H), 7.46 - 7.35 (2H, m, 
C8H/C5H), 7.22 (1H, dd, J = 8.8, 2.5 Hz, C7H), 3.57 (3H, s, C11H), 1.15 (3H, t, J = 7.5 Hz, C13H) NB CH2 
overlaps with DMSO; 13C NMR (126 MHz, DMSO-d6): δ ppm 160.9, 143.3, 136.1, 135.3, 133.5, 133.5, 
130.8, 127.4, 123.6, 120.4, 120.2, 117.5, 115.5, 115.3, 29.4, 23.7, 12.5; HRMS: m/z ESI- [Found (M-
H)- 366.0915 C19H17N3O3S requires (M-H)-  366.0912]; HPLC: Retention time (system A): tR= 9.83 
min. Purity: >95%. 
 
3-Bromoquinolin-2(1H)-one (139) Prepared by general procedure A from 3-bromoquinoline (2.5 
g, 12.0 mmol) to give the title compound (2.13 g, 9.50 mmol, 79%) as a colourless solid: 1H NMR 
(500 MHz, DMSO-d6): δ ppm 12.33 (1H, br. s.), 8.51 (1H, s), 7.68 (1H, d, J = 7.6 Hz), 7.55 (1H, t, J = 
7.6 Hz), 7.39 (1H, d, J = 8.2 Hz), 7.22 (1H, t, J = 7.6 Hz); 13C NMR (126 MHz, DMSO-d6) δ ppm 157.6, 
141.7, 138.1, 130.7, 127.3, 122.3, 119.4, 117.0, 115.2. The above data is in agreement with that 
previously reported in the literature. 126 
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3-Bromo-6-nitroquinolin-2(1H)-one (140) Prepared according to general procedure C from 139 
(1.0 g, 4.5 mmol) to give the title compound (615 mg, 2.3 mmol, 51%) as a pale yellow solid: 1H 
NMR (500 MHz, DMSO-d6): 12.84 (1H, br. s.), 8.75 (1H, s), 8.71 (1H, d, J = 2.6 Hz), 8.39 – 8.33  (1H, 
m), 7.49 (1H, d, J = 8.8 Hz). 
 
3-Bromo-1-methyl-6-nitroquinolin-2(1H)-one (141) Prepared by general procedure B from 
140 (250 mg, 0.93 mmol). Crystallised from acetone to give the title compound (86 mg, 0.31 mmol, 
33%) as a pale yellow solid; 1H NMR (500 MHz, DMSO-d6): δ ppm 8.78 (1H, s, C4H), 8.76 (1H, d, J = 
2.8 Hz, C5H), 8.44 (1H, dd, J = 9.3, 2.7 Hz, C7H), 7.78 (1H, d, J = 9.1 Hz, C8H), 3.77 (3 H, s, C11H); 13C 
NMR (126 MHz, DMSO-d6): δ ppm 157.5, 143.1, 141.8, 140.7, 125.1, 124.0, 119.6, 118.5, 116.4, 31.5. 
 
N-(3-bromo-1-methyl-2-oxo-1,2-dihydroquinolin-6-yl)-4-cyanobenzenesulfonamide (143) 
The required amine was prepared by general procedure D from 141 (40 mg, 0.14 mmol) to give 
crude amine which was coupled by general procedure E. Purified by column chromatography 
(acetone:hexane ; 2:8 -6:4) to give the title compound (28 mg, 0.07 mmol, 48% over 2 steps) as an 
orange solid: mp >300 °C (acetone-hexane); 1H NMR (400 MHz, DMSO-d6): δ ppm 10.64 (1H, s, NH), 
8.52 (1H, s, C4H), 8.03 (2H, d, J = 8.3 Hz, C14H), 7.89 (2H, d, J = 8.4 Hz, C13H), 7.50 – 7.46 (2H, m, C8H/ 
C5H), 7.33 (1H, dd, J = 9.1, 2.5 Hz, C7H), 3.64 (3H, s, C11H); 13C NMR (126 MHz, DMSO-d6): δ ppm 
157.0, 143.2, 140.4, 136.5, 133.5, 131.4, 127.4, 125.0, 120.3, 119.8, 117.5, 117.4, 116.3, 115.4, 30.9; 
HRMS: m/z ESI- [Found (M-H)- 415.9711, C17H12N3O3SBr requires (M-H)- 415.9705]; HPLC: 
Retention time (system A): tR= 9.39 min. Purity: >95%. 
 
3-Methoxy-4-nitrobenzonitrile (145a) 3-fluoro-4-nitrobenzonitrile (5.00 g, 30.1 mmol) was 
dissolved in dry THF and cooled to 0 °C. Sodium methoxide (4.87 g, 90.3 mmol, 3 eq.) was added in 
one portion with vigorous stirring and the resulting suspension was stirred at 0 °C for 3 hours, 
neutralised with HCl (2M), and washed with EtOAc (3 × 50 mL). The organic fractions were pooled, 
dried over anhydrous MgSO4, filtered and concentrated under reduced pressure to give the title 
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compound (5.65 g, 30.1 mmol, quant) as a pale yellow solid: mp 122 - 123 °C (ethyl acetate); 1H 
NMR (500 MHz, CDCl3): δ ppm 7.90 (1H, d, J = 8.8 Hz), 7.41 - 7.34 (2H, m), 4.04 (3H, s); 13C NMR 
(126 MHz, CDCl3): δ ppm 152.7, 142.4, 126.1, 124.2, 117.4, 117.1, 116.9, 57.0. The above data is in 
agreement with that previously reported in the literature. 127 
 
 
3-Ethoxy-4-nitrobenzonitrile (145b) Prepared analogously to compound 145a from 3-fluoro-4-
nitrobenzonitrile (3.00 g, 18.1 mmol) and sodium ethoxide (3.69 g, 54.2 mmol, 3 eq.) to give the 
title compound (3.02 g, 15.7 mmol, 87%) as an orange solid: mp 121 - 123 °C (ethyl acetate); 1H 
NMR (500 MHz, CDCl3): δ ppm 7.86 (1H, d, J = 8.8 Hz), 7.38 - 7.33 (2H, m), 4.24 (2H, q, J = 6.9 Hz), 
1.53 (3H, t, J = 6.9 Hz); 13C NMR (126 MHz, CDCl3): δ ppm 152.0, 142.8, 125.8, 123.9, 117.9, 117.1, 
116.9, 66.2, 14.3. 
 
4-Amino-3-methoxybenzonitrile (146a) Prepared by general procedure M from 145a (5.00 g, 
28.0 mmol). Purified by column chromatography (EtOAc:Hexane ; 3:7) to give the title compound 
(20.8 mmol, 3.08 g, 74%) as a dark red solid; 1H NMR (500 MHz, CDCl3): δ ppm 7.15 (1H, dd, J = 8.0, 
1.4 Hz), 6.99 (1H, s), 6.68 (1H, d, J = 7.9 Hz), 4.31 (2H, br. s.), 3.90 (3H, s); 13C NMR (126 MHz, 
CDCl3): δ ppm 146.2, 141.1, 126.7, 120.3, 113.6, 113.0, 99.6, 55.5. The above data is in agreement 
with that previously reported in the literature. 128  
 
4-Amino-3-ethoxybenzonitrile (146b) Prepared by general procedure N from 145b (2.5 g, 13.02 
mmol) to give the title compound (910 mg, 5.60 mmol, 43%)  as an orange solid: 1H NMR (500 
MHz, CDCl3): δ ppm 7.12 (1H, dd, J = 8.2, 1.6 Hz), 6.96 (1H, d, J = 1.6 Hz), 6.68 (1H, d, J = 8.2 Hz), 4.34 
(2H, br. s.), 4.08 (2H, d, J = 6.9 Hz), 1.47 (3H, t, J = 6.9 Hz); 13C NMR (126 MHz, CDCl3): δ ppm 145.5, 
141.1, 126.5, 120.4, 113.8, 113.6, 99.6, 64.2, 14.7.  
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4-Cyano-2-methoxybenzenesulfonyl chloride (148) Prepared by general procedure O from 
146a (500 mg, 3.38 mmol) to give a crude solid of the title compound (480 mg) as an orange solid: 
Relevant 1H NMR (500 MHz, CDCl3): δ ppm 8.11 (1H, d, J = 8.2 Hz), 7.49 (1H, d, J = 8.2 Hz), 7.41 (1H, 
s), 4.15 (3H, s). 
 
4-Cyano-2-ethoxybenzenesulfonyl chloride (149)  Prepared by general procedure O from 146b 
(1.0 g, 6.2 mmol) to give a crude solid of the title compound (417 mg) as an orange solid Relevant 
1H NMR (500 MHz, CDCl3): δ ppm 8.09 (1H, d, J = 8.2 Hz), 7.40 (1H, dd, J = 8.2, 1.6 Hz), 7.38 (1H, s), 
4.35 (2H, q, J = 7.0 Hz), 1.61 (3H, t, J = 6.9 Hz)  
 
 
 
4-Chloro-2-methoxyaniline (151) Prepared according to the procedure of Diab et al from 2-
methoxy-4-chloro-nitroaniline (1.0 g, 5.33 mmol). Purified by column chromatography (ethyl 
acetate:hexane ; 1:1) to give the title compound (660 mg, 4.21 mmol, 79%) as a dark red oil: 1H 
NMR (400 MHz, CDCl3): δ ppm 6.75 - 6.81 (2H, m), 6.61 - 6.67 (1H, m), 3.86 (3H, s), 3.78 (2H, br. s.); 
13C NMR (101 MHz, CDCl3): δ ppm 147.5, 134.8, 122.7, 120.7, 115.2, 111.1, 55.7. The above data is 
in agreement with that published previously in the literature129 
 
N-(1,3-dimethyl-2-oxo-1,2-dihydroquinolin-6-yl)cycloHexaneulfonamide (152) Prepared 
according to general procedure E  from 129a (20 mg, 0.11 mmol). Purified by column 
chromatography (acetone:hexane ; 1:19 – 1:9) to give the title compound (28 mg, 0.08 mmol, 79%) 
as a colorless solid: mp 158 - 160 °C (acetone-hexane); mp 177 - 178 °C (acetone-hexane); 1H NMR 
(400 MHz, DMSO-d6): δ ppm 9.81 (1H, s, NH), 7.78 (1H, s, C4H), 7.51 – 7.26 (3H, m, C5H/ C8H/ C7H), 
3.62 (3H, s, C11H), 3.00 – 2.91 (1H, m), 2.12 (3H, s, C12H), 2.02 (2H, d, J = 11.4 Hz), 1.74 (2H, d, J = 
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10.6 Hz), 1.57 (1H, d, J = 13.9 Hz), 1.41 (2H, m), 1.27 - 1.04 (3H, m); 13C NMR (126 MHz, DMSO-d6): 
δ ppm 161.4, 135.5, 135.2, 132.6, 129.8, 122.3, 120.4, 118.0, 115.5, 58.7, 29.4, 26.0, 24.7, 24.3, 17.3; 
HRMS: m/z ESI- [Found (M-H)- 333.1272 C17H22N2O3S requires (M-H)- 333.1273]; HPLC: Retention 
time (system A): tR= 9.37 min. Purity: >95%. 
 
N-(1,3-dimethyl-2-oxo-1,2-dihydroquinolin-6-yl)-2-methoxybenzenesulfonamide (153) 
Prepared according to general procedure E from 129a (20 mg, 0.11 mmol). Purified by column 
chromatography (acetone:hexane ; 1:9) to give the title compound (25 mg, 0.07 mmol, 65%) as a 
yellow solid: mp 221 - 222 °C (acetone-hexane); 1H NMR (400 MHz, DMSO-d6): δ ppm 9.97 (1H, s, 
NH), 7.72 (1H, dd, J = 7.8, 1.8 Hz, C18H), 7.67 (1H, s, C4H), 7.57 - 7.50 (1H, m, C16H), 7.35 (1H, d, J = 9.1 
Hz, C8H), 7.31 - 7.25 (2H, m, C5H/C7H), 7.16 (1H, d, J = 7.8 Hz, C17H), 6.99 (1 H, td, J = 7.6, 1.0 Hz, 
C15H), 3.91 (3H, s), 3.54 (3H, s), 2.07 (3H, d, J = 1.0 Hz); 13C NMR (126 MHz, DMSO-d6): δ ppm 161.4, 
156.3, 135.6, 135.0, 135.0, 131.9, 130.2, 129.8, 126.1, 122.5, 120.1, 120.0, 118.4, 115.2, 112.7, 56.0, 
29.3, 17.2; HRMS: m/z FTMS- [Found (M-H)- 357.0921 C18H18N2O4S requires M- 357.0909]; HPLC: 
Retention time (system A): tR= 8.56 min. Purity: >95%. 
 
 
 
4-Cyano-N-(1,3-dimethyl-2-oxo-1,2-dihydroquinolin-6-yl)-2-methoxybenzenesulfonamide 
(154 – NI-57) Prepared according to general procedure E  from 129a (20 mg, 0.11 mmol). Purified 
by column chromatography (acetone:hexane ; 2:8 – 4:6) to give the title compound (9 mg, 0.02 
mmol, 24%) as a colourless solid: mp 246 – 247 °C (acetone-hexane); 1H NMR (400 MHz, DMSO-d6) 
δ ppm 10.26 (1H, s, NH), 7.86 (1H, d, J = 8.1 Hz,  C14H), 7.73 (1H, d, J = 1.3 Hz, C17H), 7.70 (1H, s, C4H), 
7.47 (1H, dd, J = 8.1, 1.3 Hz, C15H), 7.37 (1H, d, J = 9.1 Hz, C8H), 7.30 (1H, d, J = 2.5 Hz, C5H), 7.26 (1H, 
dd, J = 9.1, 2.5 Hz, C7H), 3.98 (3H, s, C19H), 3.56 (3H, s, C11H), 2.08 (3H, d, J = 1.0 Hz, C12H); 13C NMR 
(126 MHz, DMSO-d6): δ ppm 161.3, 156.3, 135.6, 135.0, 135.0, 131.9, 130.2, 129.8, 126.1, 122.5, 
120.1, 120.1, 118.4, 115.1, 112.7, 56.1, 29.3, 17.3; HRMS: m/z NSI+ [Found (M+H)+ 384.1013 
C19H17N3O4S requires (M+H)+ 384.0940]; HPLC: Retention time (system A): tR= 6.04 min. Purity: 
>95%. 
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7-Methoxyquinoline-3-carbaldehyde (155) Prepared according to the procedure of Meth-Cohn 
et al starting from 94 (6 g, 36.3 mmol) to give the title compound (4.82 g, 25.8 mmol, 71%) as a 
pale yellow solid: 1H NMR (500 MHz, CDCl3): δ ppm 10.53 (1H, s), 8.68 (1H, s), 7.87 (1H, d, J = 9.1 
Hz), 7.40 (1H, d, J = 2.5 Hz), 7.29 (2H, dd, J = 9.1, 2.5 Hz), 4.01 (3H, s); 13C NMR (126 MHz, CDCl3): δ 
ppm 189.1, 164.2, 152.0, 151.1, 139.5, 130.8, 124.4, 121.8, 121.6, 106.3, 55.9. The above data is in 
agreement with that previously reported in the literature. 94 
 
7-Methoxy-2-oxo-1,2-dihydroquinoline-3-carbaldehyde (156) 155 (3.0 g, 13.5 mmol, 1 eq.) 
was suspended in HCl (6.0 M, 45 mL) and heated at reflux for 6 hours. The suspension was allowed 
to cool to RT and filtered. The precipitate was washed with H2O and dried to give the title 
compound (1.76 g, 8.68 mmol, 64%) as a brown solid: 1H NMR (500 MHz, DMSO-d6): δ ppm 12.01 
(1H, s), 8.43 (1H, s), 7.78 – 7.71 (1H, m), 7.66 (1H, d, J = 8.8 Hz), 6.90 - 6.82 (2H, m), 3.85 (3H, s); 13C 
NMR (126 MHz, DMSO-d6): δ ppm 162.3, 161.1, 141.5, 141.0, 130.4, 126.8, 122.6, 113.5, 111.8, 97.5, 
55.5. 
 
7-Methoxy-3-methylquinolin-2(1H)-one (157) To a solution of 156 (1.50 g, 7.39 mmol, 1 eq.) in 
allowed to warm to RT, stirred overnight and then poured onto ice (~250 g). The resulting 
precipitate was filtered, washed with H2O, triturated with Et2O and dried to provide the title 
compound (796 mg, 4.21 mmol, 57%) as a pale yellow solid: mp 180 – 181°C (TFA-water); 1H NMR 
(500 MHz, DMSO-d6): δ ppm 11.60 (1H, br. s.), 7.68 (1H, s), 7.49 (1H, d, J = 8.5 Hz), 6.81 - 6.75 (2H, 
m), 3.79 (3H, s), 2.05 (3H, d, J = 0.9 Hz); 13C NMR (126 MHz, DMSO-d6): δ ppm 162.7, 160.1, 139.5, 
136.2, 128.3, 126.3, 113.6, 110.2, 97.9, 55.2, 16.3. 
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7-Methoxy-1,3-dimethylquinolin-2(1H)-one (158) Prepared according to general procedure B 
from 157 (750 mg, 3.97 mmol). Purified by column chromatography (acetone:hexane ; 1:9) to 
provide the title compound (652 mg, 3.21 mmol, 81%) as a colourless solid: mp 144 - 145 °C 
(acetone-hexane); 1H NMR (400 MHz, CDCl3):  ppm 7.40 (1H, s), 7.33 (1H, d, J = 8.6 Hz), 6.77–6.67 
(2H, m), 3.84 (3H, s), 3.64 (3H, s); 13C NMR (126 MHz, CDCl3): δ ppm 163.3, 160.7, 140.6, 135.5, 
129.1, 126.7, 115.0, 109.4, 98.5, 55.6, 29.7, 17.2. 
 
6-Bromo-7-methoxy-1,3-dimethylquinolin-2(1H)-one (159) 158 (812 mg, 4 mmol 1 eq.) was 
dissolved in DMF (4 mL) and N-bromosuccinimide (855 mg, 4.8 mmol, 1.2 eq.) was added in one 
portion. The solution was stirred overnight at RT. Cold water (30 mL) was added and the resulting 
precipitate was filtered off to give the title compound (826 mg, 2.93 mmol, 73%) as a colourless 
solid: 1H NMR (500 MHz, CDCl3):  ppm 7.68 (1H, s, C4H), 7.40 (1H, s, C5H), 6.75 (1H, s, C8H), 4.03 
(3H, s, C13H), 3.75 (3H, s, C11H), 2.25 (3H, s, C12H); 13C NMR (126 MHz, CDCl3): δ ppm 162.9, 156.5, 
139.8, 134.4, 131.7, 128.0, 115.6, 105.7, 97.0, 56.5 , 29.9, 17.5. 
 
6-Amino-7-methoxy-1,3-dimethylquinolin-2(1H)-one (160) Prepared by general procedure J 
from 159 (500 mg, 1.77 mmol). Purified by column chromatography (acetone:hexane ; 2:8 – 6:4) to 
give the title compound as a solution in NMP that was used without further purification. 
 
N-(7-methoxy-1,3-dimethyl-2-oxo-1,2-dihydroquinolin-6-yl)benzenesulfonamide (161) 
Prepared by general procedure E from a solution of 160 in NMP (38 mg, 0.18 mmol). Purified by 
column chromatography (acetone:hexane ; 2:8 – 3:7) to give the title compound (36 mg, 0.10 mmol, 
57% over 2 steps) as a colourless solid: 1H NMR (500 MHz, DMSO-d6):  ppm 9.60 (1H, br. s, NH), 
7.72–7.66 (3H, m, C15H/C4H), 7.63–7.59 (1H, m, C17H), 7.55–7.47 (3H, m, C16H/ C5H), 6.81 (1H, s, 
C8H), 3.60 (3H, s, C13H), 3.57 (3H, s, C11H), 2.08 (3H, s, C12H); 13C NMR (126 MHz, DMSO-d6): δ ppm 
161.8, 154.4, 140.4, 138.4, 135.2, 132.5, 128.7, 126.6, 126.1, 125.2, 120.2, 113.2, 97.4, 55.7, 29.6, 
17.1; HRMS: m/z ESI- [Found (M-H)- 357.0920, C18H18N2O4S requires (M-H)- 357.0909]; HPLC: 
Retention time (system A): tR= 9.02 min. Purity: >95%. 
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4-Cyano-N-(7-methoxy-1,3-dimethyl-2-oxo-1,2-dihydroquinolin-6-yl)benzenesulfonamide 
(162) Prepared by general procedure E from a solution of 160 in NMP (38 mg, 0.18 mmol). Purified 
by column chromatography (acetone:hexane ; 2:8 – 6:4) to give the title compound (35 mg, 0.09 
mmol, 49% over 2 steps) as a pale pink solid: 1H NMR (500 MHz, DMSO-d6):  ppm 9.98 (1H, br. s, 
NH), 8.03 (2H, d, J = 8.5 Hz, C15H), 7.82 (2H, d, J = 8.2 Hz, C16H), 7.74 (1H, s, C4H), 7.51 (1H, s, C5H), 
6.81 (1H, s, C8H), 3.61 (3H, s, C13H), 3.53 (3H, s, C11H), 2.09 (3H, s, C12H); 13C NMR (126 MHz, DMSO-
d6): δ ppm 161.8, 154.7, 144.8, 138.8, 135.2, 133.0, 127.4, 126.5, 126.2, 119.4, 117.8, 114.8, 113.3, 
97.5, 55.6, 29.6, 17.1; HRMS: m/z ESI- [Found (M-H)- 382.0862, C19H17N3O4S requires (M-H)- 
382.0862]; HPLC: Retention time (system A): tR= 9.19 min. Purity: >95%. 
 
4-Cyano-N-(7-methoxy-1,3-dimethyl-2-oxo-1,2-dihydroquinolin-6-yl)-2-
methylbenzenesulfonamide (163) Prepared by general procedure E from a solution of 160 in 
NMP (38 mg, 0.18 mmol). Purified by column chromatography (acetone:hexane ; 2:8 – 4:6) to give 
the title compound (26 mg, 0.07 mmol, 37% over 2 steps) as a pale yellow solid: mp 274 – 275 °C 
(acetone-hexane); 1H NMR (500 MHz, DMSO-d6): δ ppm 9.97 (1H, s, NH), 7.95 (1H, s, C16H), 7.74 - 
7.66 (3H, m, C4H/C18H/C19H), 7.50 (1H, s, C5H), 6.78 (1H, s, C8H), 3.59 (3H, s, C13H), 3.52 (3H, s, C11H), 
2.70 (3H, s, C20H), 2.08 (3H, s, C12H); 13C NMR (126 MHz, DMSO-d6): δ ppm 161.8, 155.1, 142.9, 
139.0, 138.8, 135.6, 135.1, 129.6, 129.4, 127.2, 126.2, 118.9, 117.7, 114.7, 113.3, 97.4, 55.5, 29.6, 
19.5, 17.1; HRMS: m/z ESI- [Found (M+CO2-)- 441.0743, C20H19N3O4S requires (M+CO2-)- 441.0995]; 
HPLC: Retention time (system A): tR= 11.04 min. Purity: >95%. 
 
4-Cyano-2-methoxy-N-(7-methoxy-1,3-dimethyl-2-oxo-1,2-dihydroquinolin-6-
yl)benzenesulfonamide (164) Prepared by general procedure E from a solution of 160 in NMP 
(114 mg, 0.54 mmol). Purified by column chromatography (acetone:hexane ; 2:8 – 1:1) to give the 
title compound (81 mg, 0.20 mmol, 37% over 2 steps) as an off-white solid: mp 259 – 261 °C 
(acetone-hexane); 1H NMR (400 MHz, DMSO-d6): δ ppm 9.35 (1H, br. S, NH), 7.76 (1H, s,  C4H), 7.70 
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(2H, m, C15/18H), 7.46 (1H, s, C5H), 7.43 (1H, dd, J = 8.0, 1.4 Hz, C16H), 6.81 (1H, s, C8H), 3.97 (3H, s, 
C20H), 3.65 (3H, s, C13H), 3.60 (3H, s, C11H), 2.07 (3H, d, J = 0.8 Hz, C12H); 13C NMR (126 MHz, DMSO-
d6): δ ppm 161.8, 156.7, 154.6, 138.5, 135.1, 132.4, 130.0, 126.1, 126.0, 123.6, 119.8, 117.7, 116.3, 
116.2, 113.2, 97.3, 56.9, 55.9, 29.5, 16.8; HRMS: m/z NSI+[Found (M+H)+ 414.1113, C20H19N3O5S 
requires (M-H)- 414.1112]; HPLC: Retention time (system A): tR=  min. Purity: >95%. 
 
4-Cyano-2-ethoxy-N-(7-methoxy-1,3-dimethyl-2-oxo-1,2-dihydroquinolin-6-
yl)benzenesulfonamide (165) Prepared by general procedure E from a solution of 160 in NMP 
(38 mg, 0.18 mmol). Purified by column chromatography (acetone:hexane ; 2:8 – 1:1) to give the 
title compound (16 mg, 0.04 mmol, 22% over 2 steps) as an orange solid: mp 220 – 223 °C 
(acetone-hexane); 1H NMR (500 MHz, DMSO-d6) δ ppm 9.05 (1H, s, NH), 7.75 (1H, d, J = 1.1 Hz, 
C16H), 7.74 (1H, d, J = 8.1 Hz, C19H), 7.71 (1H, s, C4H), 7.50 (1H, s, C5H), 7.43 (1H, dd, J = 8.0, 1.3 Hz, 
C18H), 6.84 (1H, s, C8H), 4.26 (2H, q, J = 7.0 Hz, C20H), 3.67 (3H, s, C13H), 3.61 (3H, s, C11H), 2.07 (3H, 
d, J = 0.8 Hz, C12H), 1.35 (4H, t, J = 7.0 Hz, C21H) ; 13C NMR (126 MHz, DMSO-d6): δ ppm 161.8, 156.0, 
154.2, 138.3, 135.1, 132.3, 130.3, 126.2, 125.0, 123.5, 120.0, 117.7, 116.9, 116.4, 113.2, 97.3, 65.3, 
55.9, 29.6, 17.1, 14.0; HRMS: m/z ESI- [Found (M-H)- 426.1133, C21H21N3O5S requires (M-H)- 
426.1124]; HPLC: Retention time (system A): tR= 10.44 min. Purity: >95%. 
 
2-Methoxy-N-(7-methoxy-1,3-dimethyl-2-oxo-1,2-dihydroquinolin-6-yl)benzenesulfonamide 
(166)  Prepared by general procedure E from a solution of 160 in NMP (38 mg, 0.18 mmol). 
Purified by column chromatography (acetone:hexane ; 2:8 – 3:7) to give the title compound (35 mg, 
0.09 mmol, 51% over 2 steps) as a colourless solid: mp 246 - 247 °C (acetone-hexane); 1H NMR 
(400 MHz, DMSO-d6): δ ppm 8.82 (1H, s, NH), 7.67 (1H, s, C4H), 7.61 - 7.53 (2H, m, C19H/ C17H), 7.48 
(1H, s, C5H), 7.21 (1H, d, J = 7.8 Hz, C16H), 6.95 (1H, td, J = 7.6, 1.0 Hz, C18H), 6.83 (1H, s, C8H), 3.92 
(3H, s, C21H), 3.73 (3H, s, C13H), 3.59 (3H, s, C11H), 2.06 (3H, d, J = 1.0 Hz, C12H); 13C NMR (126 MHz, 
DMSO-d6): δ ppm 161.7, 156.6, 153.5, 137.8, 135.2, 134.8, 129.5, 127.1, 126.1, 123.5, 120.8, 119.6, 
113.1, 112.5, 97.2, 56.1, 56.1, 29.5, 17.1; HRMS: m/z ESI- [Found (M-H)- 387.1024, C19H2N2O5S 
requires (M-H)- 387.1014]; HPLC: Retention time (system A): tR= 9.33 min. Purity: >95%. 
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N-(7-methoxy-1,3-dimethyl-2-oxo-1,2-dihydroquinolin-6-yl)-2-
(trifluoromethoxy)benzenesulfonamide (167) Prepared by general procedure E from a solution 
of 160 in NMP (38 mg, 0.18 mmol). Purified by column chromatography (acetone:hexane ; 2:8) to 
give the title compound (38 mg, 0.09 mmol, 49% over 2 steps) as a pale yellow solid: mp 189 – 190 
°C (acetone-hexane); 1H NMR (500 MHz, DMSO-d6): δ ppm 9.69 (1H, br. s), 7.78-7.72 (2H,m , C19H, 
C17H), 7.71(1H, s, C4H), 7.56 (1H, d, J = 7.6 Hz, C16H), 7.49 (1H, s, C5H), 7.44 (1H, t, J = 7.6 Hz, C18H), 
6.81 (1H, s, C8H), 3.61 (3H, s, C13H), 3.56 (3H, s, C11H), 2.07 (3H, s, C12H); 13C NMR (126 MHz, DMSO-
d6): δ ppm 161.2, 154.9, 145.3, 145.3, 138.7, 135.1, 134.8, 132.6, 130.4, 126.8, 126.6, 126.1, 120.4, 
120.9 (q, J = 90.7 Hz), 113.2, 97.4, 55.6, 29.6, 17.0; HRMS: m/z ESI- [Found (M-H)- 441.0734, 
C19H17N2O5SF3 requires (M-H)- 441.0732]; HPLC: Retention time (system A): tR= 11.02 min. Purity: 
>95%. 
 
N-(7-methoxy-1,3-dimethyl-2-oxo-1,2-dihydroquinolin-6-yl)-4-nitrobenzenesulfonamide 
(168) Prepared by general procedure E from a solution of 160 in NMP (76 mg, 0.36 mmol). Purified 
by column chromatography (acetone:hexane ; 1:9 – 1:4) to give the title compound (94 mg, 0.23 
mmol, 66% over 2 steps) as a bright yellow solid: mp 260 - 262 °C (acetone-hexane); 1H NMR (500 
MHz, DMSO-d6): δ ppm 10.06 (1H, s, NH), 8.37 (2H, d, J = 8.8 Hz, C16H), 7.91 (2H, d, J = 8.8 Hz, C15H), 
7.74 (1H, s, C4H), 7.51 (1H, s, C5H), 6.82 (1H, s, C8H), 3.61 (3H, s, C13H), 3.52 (3H, s, C11H), 2.09 (3H, s, 
C12H); 13C NMR (126 MHz, DMSO-d6): δ ppm 161.8, 154.8, 149.5, 146.2, 138.9, 135.2, 128.2, 126.6, 
126.2, 124.1, 119.2, 113.3, 97.5, 55.4, 29.4, 17.2; HRMS: m/z ESI- [Found (M-H)- 402.0768, 
C18H17N3O6S requires (M-H)- 402.0760]; HPLC: Retention time (system A): tR= 10.98 min. Purity: 
>95%. 
 
N-(7-methoxy-1,3-dimethyl-2-oxo-1,2-dihydroquinolin-6-yl)-4-methylbenzenesulfonamide 
(169): Prepared by general procedure E from a solution of 160 in NMP (38 mg, 0.18 mmol). 
Purified by column chromatography (acetone:hexane ; 1:9 – 3:7) to give the title compound (40 mg, 
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0.11 mmol, 60% over 2 steps) as a pale yellow solid: 1H NMR (500 MHz, DMSO-d6): δ ppm 9.51 (1H, 
s, NH) 7.71 (1H, s, C4H) 7.58 (2H, d, J = 8.2 Hz, C15H) 7.48 (1H, s, C5H) 7.32 (2H, d, J = 8.2 Hz, C16H) 
6.82 (1H, s, C8H) 3.60 (3H, s, C13H), 3.54 (3H, s, C11H), 2.35 (3H, s, C18H) 2.08 (3H, s, C12H); 13C NMR 
(126 MHz, DMSO-d6): δ ppm 161.8, 154.1, 142.7, 138.2, 137.6, 135.2, 129.2, 126.7, 126.1, 124.6, 
120.5, 113.2, 97.5, 55.8, 29.6, 20.9, 17.1; HRMS: m/z ESI- [Found (M-H)- 371.1070, C19H20N2O4S 
requires (M-H)- 371.1066]; HPLC: Retention time (system A): tR= 9.06 min. Purity: >95%. 
 
4-Amino-N-(7-methoxy-1,3-dimethyl-2-oxo-1,2-dihydroquinolin-6-yl)benzenesulfonamide 
(25) 168 (25 mg, 0.06 mmol, 1 eq.) and palladium on carbon (5% by weight, 13 mg, 0.006 mmol, 
0.1 eq.) were placed in a sealed rbf and backfilled with nitrogen 2 times and then EtOH (40 mL) was 
added. The flask was fitted with a balloon of hydrogen and purged and then backfilled 5 times. The 
resulting suspension was stirred at RT overnight, purged with nitrogen for 20 mins and then 
filtered through a pad of Celite ® eluting with EtOH. The filtrate was concentrated under reduced 
pressure to give the title compound (17 mg, 0.05 mmol, 75%) as a beige solid: 1H NMR (500 MHz, 
DMSO-d6): δ ppm 8.98 (1H, s), 7.69 (1H, s), 7.33 (2H, d, J = 8.5 Hz), 6.84 (1H, s), 6.50 (2H, d, J = 8.5 
Hz), 5.92 (1H, s), 3.72 (3H, s), 3.63 (3H, s), 2.08 (3H, s). 
 
(E)-2-methyl-3-phenylacryloyl chloride (172) Prepared according to the procedure of 
Aggarwaal et al starting from (E)-2-methyl-3-phenylacrylic acid (), oxalyl chloride () and DMF () to 
give the title compound (19 % DMF by 1H NMR) which was used without further purification in the 
next step. Relevant 1H NMR (400 MHz, CDCl3): δ ppm 8.06 (1H, d, J = 1.3 Hz), 7.51 - 7.40 (5H, m), 
2.22 (3H, d, J = 1.3 Hz). The above data is in agreement with that previously reported in the 
literature. 130 
 
(E)-N-(2-fluorophenyl)-2-methyl-3-phenylacrylamide (173)  Prepared by general procedure K 
from 2-fluoroaniline (2.5 g, 22.5 mmol) to give the title compound (5.05 g, 19.8 mmol, 88%) as a 
colourless solid which was used without further purification. 
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8-Fluoro-3-methylquinolin-2(1H)-one (174) Prepared by general procedure L from 173 (5 g, 
19.6 mmol) to give the title compound (2.91 g, 16.47 mmol, 84%) as a pale pink solid:  1H NMR (400 
MHz, DMSO-d6): δ ppm 11.73 (1H, br. s.), 7.81 (1H, s), 7.41 (1H, d, J = 7.8 Hz), 7.32 (1H, dd, J = 10.7, 
8.5 Hz), 7.17 - 7.08 (1H, m), 2.11 (3H, s); mp 199 - 202 °C (chlorobenzene-water);13C NMR (126 
MHz, DMSO-d6): δ ppm 162.1, 147.9 (d, J = 244.7 Hz), 135.9 (d, J = 1.8 Hz), 131.3, 126.3 (d, J = 13.7 
Hz), 122.7 (d, J = 2.7 Hz), 121.6 - 121.4 (2C signals), 114.3 (d, J = 17.4 Hz), 16.6. 
 
8-Fluoro-1,3-dimethylquinolin-2(1H)-one (175) Prepared by general procedure B from 174 
(1.0 g, 5.65 mmol). Purified by column chromatography (acetone:hexane 1:9) to give the title 
compound (410 mg, 2.15 mmol, 38%) as a pale pink solid: mp 104 - 105 °C (acetone-hexane); 1H 
NMR (500 MHz, DMSO-d6): δ ppm 7.76 (1H, s), 7.43 (1H, d, J = 7.6 Hz), 7.37 (1H, dd, J = 15.1, 7.9 Hz), 
7.20 (1H, d, J = 4.1 Hz), 3.78 (3H, d, J = 8.2 Hz), 2.11 (3H, s); 13C NMR (126 MHz, CDCl3): δ ppm 
163.2, 150.1 (d, J = 245.6 Hz), 135.4 (d, J = 2.7 Hz), 131.0, 128.2 (d, J = 6.4 Hz), 123.7 (d, J = 3.7 Hz), 
123.5 (d, J = 2.7 Hz), 122.3 (d, J = 8.2 Hz), 116.6 (d, J = 23.8 Hz), 33.5 (d, J = 15.6 Hz), 17.7. 
 
8-Fluoro-1,3-dimethyl-5-nitroquinolin-2(1H)-one (176) Prepared by general procedure C from 
175 (350 mg, 1.81 mmol). Residue crystallised from EtOH to give the title compound (307mg, 1.30 
mmol, 71%) as yellow needles: 1H NMR (400 MHz, DMSO-d6): δ ppm 8.06 - 8.02 (1H, m, C3H), 7.91 
(1H, dd, J  = 8.8, 3.8 Hz, C6H), 7.62 (1H, dd, J = 14.0, 9.0 Hz, C7H), 3.83 (3H, d, J = 9.6 Hz, C11H), 2.20 
(3H, d, J = 1.3 Hz, C12H); 13C NMR (126 MHz, CDCl3): δ ppm 161.9, 152.0 (d, J = 254.8 Hz), 143.0, 
135.1, 129.4 (d, J = 7.3 Hz), 129.0, 119.6 (d, J = 9.2 Hz), 117.0, 115.6 (d, J = 26.6 Hz), 34.0 (d, J = 16.5 
Hz), 18.4. 
 
(E)-N-(4-bromo-2-fluorophenyl)-2-methyl-3-phenylacrylamide (178) Prepared by general 
procedure K from 2-fluro-4-bromoaniline (2.50 g, 13.2 mmol) to give the title compound (4.32 g, 
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12.94 mmol, 98%) as a colourless solid: 1H NMR (500 MHz, DMSO-d6): δ ppm 9.81 (1H, s), 7.65 - 
7.55 (2H, m), 7.50 - 7.33 (7H, m), 2.12 (3H, d, J = 1.3 Hz); 13C NMR (126 MHz, DMSO-d6): δ ppm 
167.9, 155.3 (d, J = 253.9 Hz), 135.7, 134.1, 131.8, 129.4, 128.5, 128.0, 127.9 (d, J = 1.8 Hz), 127.3 (d, 
J = 3.7 Hz), 125.7 (d, J =11.9 Hz), 119.1 (d, J = 23.8 Hz), 117.1 (d, J = 9.2 Hz), 14.2. 
 
6-Bromo-8-fluoro-3-methylquinolin-2(1H)-one (179) Prepared by general procedure L from 
178 (3.5 g, 10.5 mmol). The title compound (443 mg, 1.73 mmol, 17 % yield) was isolated as a waxy 
red solid which was used without further purification in the next step: Relevant 1H NMR (400 MHz, 
DMSO-d6): δ ppm 11.91 (1H, br. s.), 7.78 (1H, t, J = 1.3 Hz), 7.68 (1H, t, J = 2.0 Hz), 7.62 (1H, dd, J = 
10.4, 2.0 Hz), 2.11 (3H, d, J = 1.0 Hz). 
 
6-Bromo-8-fluoro-1,3-dimethylquinolin-2(1H)-one (180) Prepared by general procedure B 
from 179 (430 mg, 1.68 mmol) to give the title compound (112 mg, 0.41 mmol, 25 %) as a dark red 
solid: 1H NMR (400 MHz, CDCl3): δ ppm 7.43 (1H, t, J=1.8 Hz), 7.42 - 7.40 (1H, m), 7.36 (1H, dd, J = 
13.6, 2.3 Hz), 3.92 (3H, d, J = 8.1 Hz), 2.27 (3H, d, J = 1.0 Hz). 
 
6-Amino-8-fluoro-1,3-dimethylquinolin-2(1H)-one (181) Prepared by general procedure J from 
180 (75 mg, 0.28 mmol). Purified by column chromatography (acetone:hexane ; 3:7 – 4:6) to give a 
solution of the title compound in NMP which was used without further purification in the next step.  
 
4-Cyano-N-(8-fluoro-1,3-dimethyl-2-oxo-1,2-dihydroquinolin-6-yl)benzenesulfonamide 
(182) Prepared by general procedure E from 181 (29 mg, 0.14 mg). Purified by column 
chromatography (acetone:hexane ; 3:7 -6:4) to give the title compound (11 mg, 0.03 mmol, 21% 
over 2 steps) as a colourless solid: mp 265 – 266 °C (acetone-hexane); 1H NMR (400 MHz, DMSO-
d6): δ ppm 8.04 (2H, d, J = 8.1 Hz, C14H), 7.92 (2H, d, J = 8.3 Hz, C15H), 7.73 (1H, s, C4H), 7.13 (1H, d, J 
= 0.8 Hz, C5H), 7.08 (1H, dd, J = 15.7, 2.0 Hz, C7H), 3.72 (3H, d, J = 8.3 Hz, C11H), 2.09 (3H, s, C12H); 13C 
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NMR (126 MHz, DMSO-d6): δ ppm 161.6, 149.1 (d, J = 246.5 Hz), 143.1 (d, J = 1.8 Hz), 135.1, 133.6, 
131.0, 127.7, 124.9 (d, J = 7.3 Hz), 123.0 (d, J = 3.7 Hz), 117.5, 115.5, 115.1 (d, J = 2.7 Hz), 110.1 (d, J 
= 26.6 Hz), 32.7 (d, J = 14.7 Hz), 17.2; HRMS: m/z ESI- [Found (M-H)- 370.0659, C18H14N3O3SF 
requires (M-H)- 370.0662]; HPLC: Retention time (system A): tR= 8.68 min. Purity: >95%. 
 
4-Cyano-N-(8-fluoro-1,3-dimethyl-2-oxo-1,2-dihydroquinolin-6-yl)-2-
methoxybenzenesulfonamide (183) Prepared by general procedure E from 181 (29 mg, 0.14 
mg). Purified by column chromatography (acetone:hexane ; 2:8) to give the title compound (7 mg, 
0.02 mmol, 13% over 2 steps) as a colourless solid: mp 214 -215 °C (acetone-hexane); 1H NMR 
(500 MHz, DMSO-d6) δ ppm 10.54 (1H, s), 7.94 (1H, d, J = 8.0 Hz, C18H), 7.75 (1H, d, J = 1.1 Hz, C15H), 
7.72 (1H, s, C4H), 7.52 (1H, dd, J = 8.1, 1.3 Hz, C17H), 7.12 (1H, d, J = 2.3 Hz,  C5H), 7.09 (1H, dd, J = 
16.0, 2.4 Hz, C7H), 3.71 (3H, d, J = 8.1 Hz, C11H), 2.08 (3H, s, C12H) 13C NMR (126 MHz, DMSO-d6): δ 
ppm 161.6, 156.3, 149.0 (d, J = 246.5 Hz), 135.1, 131.7, 131.6, 131.1, 130.7 (d, J = 58.7 Hz), 124.5 (d, 
J = 6.4 Hz), 124.2, 122.9 (d, J = 3.7 Hz), 117.4, 117.1, 116.9, 114.2 (d, J = 2.7 Hz), 109.4 (d, J = 27.5 
Hz), 57.0, 32.7 (d, J = 14.7 Hz), 17.2; HRMS: m/z ESI- [Found (M-H)- 400.0765, C19H16N3O4SF 
requires (M-H)- 400.0767]; HPLC: Retention time (system A): tR= 9.95 min. Purity: >95%.  
 
4-Cyano-N-methyl-N-(1-methyl-2-oxo-1,2-dihydroquinolin-6-yl)benzenesulfonamide (184) 
Prepared by general procedure H from 23 (50 mg, 0.15 mmol). Purified by column chromatography 
(acetone:hexane ; 3:7) to give the title compound (33 mg, 0.09 mmol, 63%) as a colourless solid: 
mp 217 – 218 °C (DCM); 1H NMR (400 MHz, DMSO-d6) δ ppm 8.08 (2H, d, J = 8.3 Hz, C15H), 7.85 (1H, 
d, J = 9.6 Hz, C4H), 7.70 (2H, d, J = 8.6 Hz, C14H), 7.54 - 7.49 (2H, m, C5H/ C8H), 7.37 (1H, dd, J = 9.1, 
2.5 Hz, C7H), 6.65 (1H, d, J = 9.6 Hz, C3H), 3.61 (3H, s, C11H), 3.22 (3H, s, C12H); 13C NMR (151 MHz, 
DMSO-d6) δ ppm 161.0, 139.7, 138.9, 138.8, 134.4, 133.5, 129.1, 128.3, 126.3, 121.9, 120.3, 117.7, 
115.8, 115.5, , 38.2, 29.2; HPLC: Retention time (system A): tR= 7.59 min. Purity: >95% 
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4-Cyano-N-(7-methoxy-1-methyl-2-oxo-1,2-dihydroquinolin-6-yl)-N-
methylbenzenesulfonamide (185) Prepared by general procedure H from 102 (20 mg, 0.05 
mmol). Purified by column chromatography (acetone:hexane ; 3:7) to give the title compound (13 
mg, 0.03 mmol, 63%) as a colourless solid: mp 231– 233 °C (acetone-hexane); 1H NMR (400 MHz, 
DMSO-d6): δ ppm 8.09 (1H, d, J = 8.6 Hz, C15H), 7.86 (1H, d, J = 9.6 Hz, C4H), 7.82 (2H, d, J = 8.6 Hz, 
C16H), 7.66 (1H, s, C5H), 6.89 (1H, s, C8H), 6.49 (1H, d, J = 9.3 Hz, C3H), 3.62 (3H, s, C12H), 3.50 (3H, s, 
C11H), 3.19 (3H, s, C13H); 13C NMR (126 MHz, DMSO-d6): δ ppm 161.3, 157.7, 142.7, 141.3, 138.6, 
133.2, 131.3, 127.9, 123.0, 118.5, 117.8, 115.1, 113.5, 98.1, 55.6, 37.9, 29.3; HRMS: m/z ESI- [Found 
(M+Cl)- 418.0862, C19H17N3O4S requires (M+Cl)- 418.0628]; HPLC: Retention time (system A): tR= 
9,39 min. Purity: >95%. 
 
 
4-Cyano-N-(1,3-dimethyl-2-oxo-1,2-dihydroquinolin-6-yl)-2-methoxy-N-
methylbenzenesulfonamide (186) Prepared according to general procedure H from NI-57 (50 
mg, 0.13 mmol). Purified by column chromatography (acetone:hexane ; 1:9) to give the title 
compound (32 mg, 0.08 mmol, 62%) as a yellow solid: mp 227 – 229 °C (acetone-hexane); 1H NMR 
(500 MHz, DMSO-d6): δ ppm 7.82 (1H, d, J = 0.9 Hz), 7.75 - 7.72 (2H, m), 7.50-7.47 (2H, m), 7.45 - 
7.41 (3H, m), 7.36 (3H, d, J = 2.2 Hz), 3.88 (3H, s), 3.61 (3H, s), 3.34 (3H, s), 2.11 (3H, s); 13C NMR 
(126 MHz, DMSO-d6): δ ppm 161.5, 156.6, 137.5, 135.0, 134.5, 131.7, 130.4, 129.8, 127.6, 125.1, 
124.1, 120.1, 117.5, 117.0, 116.9, 115.0, 56.8, 29.5, 17.3; HPLC: Retention time (system A): tR= 9.98 
min. Purity: >95%. 
 
4-Cyano-N-(1,3-dimethyl-2-oxo-1,2-dihydroquinolin-6-yl)-N-ethyl-2-
methoxybenzenesulfonamide (187) Prepared according to general procedure H from NI-57 (50 
mg, 0.13 mmol). Purified by column chromatography (acetone:hexane ; 1:9) to give the title 
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compound (44 mg, 0.11 mmol 82%) as a pale yellow solid: mp 187 – 188 °C (acetone-hexane); 1H 
NMR (500 MHz, DMSO-d6) δ ppm 7.85 (1H, s, C17H), 7.75 (1 H, s, C4H), 7.66 (1H, d, J = 7.9 Hz, C20H), 
7.46 - 7.42 (3H, m, C8H/C5H/C19H), 7.26 (1H, dd, J = 9.0, 2.4 Hz, C7H), 4.00 (3H, s), 3.83 (2H, q, J = 6.9 
Hz), 3.61 (3H, s), 2.11 (3H, s), 1.03 (3H, t, J = 7.1 Hz); 13C NMR (126 MHz, DMSO-d6): δ ppm 162.3, 
161.6, 156.5, 138.0, 135.0, 131.5, 131.2, 129.8, 129.8, 127.9, 124.0, 120.2, 117.6, 116.9, 116.7, 115.3, 
56.9, 46.6, 29.5, 17.3, 14.6; HRMS: m/z ESI- [Found (M+Cl)- 446.0942 C21H21N3O4S requires (M+Cl)- 
446.0943]; HPLC: Retention time (system A): tR= 10.69 min. Purity: >95%. 
 
4-Cyano-N-(1,3-dimethyl-2-oxo-1,2-dihydroquinolin-6-yl)-N-isopropyl-2-
methoxybenzenesulfonamide (188) Prepared according to general procedure H from NI-57 (50 
mg, 0.13 mmol). Purified by column chromatography (acetone:hexane ; 1:9) to give the title 
compound (27 mg, 0.06 mmol, 49%) as a pale yellow solid: mp 213 – 214 °C (acetone-hexane); 1H 
NMR (500 MHz, DMSO-d6): δ ppm 7.88 (1H, d, J = 0.9 Hz, C17H), 7.77 (1H, s, C4H), 7.66 (1H, d, J = 8.2 
Hz, C20H), 7.50 - 7.40 (2H, m, C19H/ C20H), 7.30 (1H, d, J = 2.2 Hz, C5H), 7.08 (1H, dd, J = 8.8, 2.2 Hz, 
C7H), 4.65 (1H, spt, J = 6.6 Hz, C13H), 4.08 (3H, s, C21H), 3.62 (3H, s, C11H), 2.11 (3H, s, C12H), 1.07 (6H, 
d, J = 6.6 Hz, C14H); 13C NMR (126 MHz, DMSO-d6): δ ppm 161.6, 156.3, 138.6, 135.1, 133.0, 132.3, 
131.2, 131.2, 129.7, 127.4, 124.0, 120.0, 117.6, 116.9, 116.6, 115.0, 56.8, 51.4, 29.5, 22.2, 17.3; 
HRMS: m/z ESI- [Found (M+Cl)- 460.1093 C22H23N3O4S requires (M+Cl)- 460.1094]; HPLC: 
Retention time (system A): tR= 11.14 min. Purity: >95%. 
 
4-Cyano-N-(3-ethyl-1-methyl-2-oxo-1,2-dihydroquinolin-6-yl)-2-
methoxybenzenesulfonamide (191) Prepared according to general procedure E from 136 (30 
mg, 0.15 mmol). Purified by column chromatography (acetone:hexane; 1:9-2:8) to give the title 
compound (23 mg, 0.06 mmol, 39%, or 12% over 2 steps) as a yellow solid: mp 198 – 199 °C 
(acetone-hexane); 1H NMR (400 MHz, DMSO-d6): δ ppm 10.37 (1H, s, NH), 7.92 (1H, d, J = 8.1 Hz, 
C19H), 7.80 (1H, d, J = 1.3 Hz, C16H), 7.71 (1H, s, C4H), 7.54 (1H, dd, J = 8.1, 1.5 Hz, C18H), 7.47 - 7.40 
(2H, m, C5H/ C8H), 7.31 (1H, dd, J = 9.0, 2.4 Hz, C7H), 4.04 (3H, s, C20H), 3.61 (3H, s, C11H), 1.20 (3H, t, 
J = 7.3 Hz, C13H) NB CH2 overlaps with DMSO; 13C NMR (126 MHz, DMSO-d6): δ ppm 160.7, 156.3, 
156.3, 135.7, 135.2, 133.5, 131.1, 130.7, 124.1, 123.0, 120.3, 119.4, 117.5, 116.8, 116.7, 115.3, 57.0, 
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29.3, 23.7, 12.6.; HRMS: m/z ESI- [Found (M-H)- 396.1032 C20H19N3O4S requires (M-H)-  396.1013]; 
HPLC: Retention time (system A): tR= 9.85 min. Purity: >95%. 
 
3-Chloro-N-phenylpropanamide (192) To a solution of aniline (9.3 g, 100 mmol, 1 eq.) in acetone 
(100 mL) and water (200 mL) was added K2CO3 (20.8 g, 150 mmol, 1.5 eq.). The suspension was 
cooled to 0 °C and 3-chloropropanoyl chloride (15.9 g, 125 mmol, 1.25 eq.) was added dropwise. 
The solution was maintained at 0 °C and stirred for 1 hour before being poured onto ice (~200 g). 
The precipitate was collected by filtration and dried under reduced pressure. To afford the desired 
compound, (18.1 g 97 mmol, 97%), as a white solid: 1H NMR (400 MHz, CDCl3): δ ppm 7.54 (2H, d, J 
= 7.8 Hz), 7.46 - 7.30 (3H, m), 7.15 (1H, t, J = 7.6 Hz), 3.91 (2H, t, J = 6.3 Hz), 2.84 (2H, t, J = 6.4 Hz); 
13C NMR (101 MHz, CDCl3): δ ppm 167.8, 137.4, 129.1, 124.7, 120.1, 40.5, 39.9. The above data is in 
agreement with that previously reported in the literature. 131 
 
3,4-Dihydroquinolin-2(1H)-one (193) AlCl3 (43 g, 328 mmol, 4 eq.) was added to 192 (15 g, 82 
mmol, 1 eq.) under an argon atmosphere and the mixture was heated slowly to 120 °C and 
maintained at this temperature for 3 hours. The solution was allowed to cool to ~ 60 °C and then 
poured onto ice (~500 g) and stirred for 30 mins. The precipitate was filtered, washed with water 
and dried to provide the crude title product. Crystallisation of the crude material from MeOH gave 
the pure title compound (5.8 g, 39 mmol, 48%) as an off-white solid: 1H NMR (400 MHz, CDCl3): δ 
ppm 8.66 (1H, br. s.), 7.23 - 7.13 (2 H, m), 7.01 (1H, td, J = 7.5, 1.0 Hz), 6.83 (1H, d, J = 7.8 Hz), 3.00 
(2H, t, J = 7.6 Hz), 2.67 (2H, t, J = 7.3 Hz); 13C NMR (101 MHz, CDCl3): δ ppm 171.6, 137.3, 128.0, 
127.5, 123.7, 123.1, 115.7, 30.7, 25.3. The above data is in agreement with that previously reported 
in the literature. 132 
 
3-Isopropyl-3,4-dihydroquinolin-2(1H)-one (194) To a solution of 193 (1.5 g, 10 mmol, 1 eq.) in 
dry THF (50 mL) under an argon atmosphere at – 78 °C was added freshly prepared LDA (2.0M in 
THF, 25 mmol, 2.5 eq.) and the solution was stirred at – 78 °C for 1 hour. After this time 2-
bromopropane (1.5 g, 12 mmol, 1.2 eq.) was added dropwise and stirred at this temperature for a 
further 30 minutes before being allowed to warm to RT. The solution was quenched with sat. NH4Cl 
and extracted with EtOAc (3 × 50 mL). The organic fractions were pooled, dried over anhydrous 
MgSO4, filtered and concentrated under reduced pressure. Purification of the residue by column 
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chromatography (ethyl acetate:hexane 1:9 – 3:7) gave the title compound (912 mg, 4.8 mmol, 48%) 
as a colorless solid: mp 152 – 153 °C (ethyl acetate-hexane); 1H NMR (400 MHz, CDCl3): δ ppm 8.63 
(1H, br. s.), 7.23 - 7.13 (2H, m), 6.99 (1H, td, J = 7.5, 1.0 Hz), 6.80 (1H, dd, J = 8.1, 1.0 Hz), 3.04 – 2.84 
(2H, m), 2.40 (1H, dt, J = 8.3, 6.2 Hz), 2.27 - 2.16 (1H, m), 1.07 (3H, d, J = 6.8 Hz), 1.00 (3H, d, J = 6.8 
Hz); 13C NMR (101 MHz, CDCl3): δ ppm 172.1, 140.3, 127.9, 127.3, 125.8, 122.6, 114.3, 47.0, 29.7, 
27.2, 26.6, 20.9, 19.1. 
 
3-Isopropyl-1-methyl-3,4-dihydroquinolin-2(1H)-one (195) Prepared by general procedure B 
from 194 (280 mg, 1.48 mmol). Purified by column chromatography (hexane:EtOAc 1:9 – 2:8) gave 
the title compound (237 mg, 1.17 mmol, 79%) as a pale yellow oil:  1H NMR (400 MHz, CDCl3): δ 
ppm 7.17 (1H, td, J = 7.8, 1.0 Hz), 7.09 (1H, d, J = 7.1 Hz), 6.93 (1H, t, J = 7.1 Hz), 6.88 (1H, d, J = 8.1 
Hz), 3.29 (3H, s), 2.85 (1H, dd, J=15.7, 5.6 Hz), 2.73 (1H, dd, J = 16.1, 8.3 Hz), 2.27 (1H, dt, J = 8.2, 6.0 
Hz), 2.08 - 2.02 (1 H, m), 0.92 (3H, d, J = 6.8 Hz), 0.85 (3H, d, J = 6.8 Hz); 13C NMR (101 MHz, CDCl3): 
δ ppm 172.1, 140.3, 127.9, 127.3, 125.8, 122.6, 114.3, 47.0, 29.6, 27.2, 26.6, 20.8, 19.0. 
 
3-Isopropyl-1-methylquinolin-2(1H)-one (196) Prepared by general procedure I from 195 (520 
mg, 2.56 mmol). 3 addition equivalents of DDQ added after 24 hours. Purified by column 
chromatography (hexane:EtOAc 1:9 – 2:8) gave the title compound (117 mg, 0.58 mmol, 23%) as a 
colourless oil: 1H NMR (400 MHz, CDCl3): δ ppm 7.59 - 7.48 (3H, m), 7.35 (1H, d, J = 8.3 Hz), 7.24 
(1H, td, J = 7.5, 1.0 Hz), 3.77 (3H, s), 3.33 (1H, spt, J = 7.1 Hz), 1.29 (6H, d, J = 6.8 Hz); 13C NMR (101 
MHz, CDCl3): δ ppm 162.2, 139.9, 138.8, 132.2, 129.3, 128.2, 121.9, 120.8, 113.7, 29.7, 28.2, 21.8.  
 
3-Isopropyl-1-methyl-6-nitroquinolin-2(1H)-one (197) To a solution of 196 (104 mg, 0.52 
mmol) in AcOH (5 mL) at 0 °C was added  KNO3 (52 mg, 0.52 mmol, 1 eq.) in 1 portion and the 
resulting solution was stirred at 5 °C for 2 hours and then poured onto ice. The resulting 
suspension was filtered, washed with H2O and dried to give the crude compound. Crystallisation 
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(EtOH) of the crude material provided the title compound (81 mg, 0.33 mmol, 63%) as pale yellow 
needles: mp 174 - 175 °C (ethanol); 1H NMR (400 MHz, CDCl3): δ ppm 8.49 (1H, d, J = 2.5 Hz, C5H), 
8.37 (1H, dd, J = 9.3, 2.5 Hz, C7H), 7.60 (1H, s, C4H), 7.43 (1H, d, J = 9.3 Hz, C8H), 3.81 (3H, s, C11H), 
3.32 (1H, spt, J = 7.1 Hz, C12H), 1.30 (6H, d, J = 7.1 Hz, C13H); 13C NMR (101 MHz, CDCl3): δ ppm 
161.9, 142.7, 142.5, 142.0, 131.8, 124.0, 124.0, 120.2, 114.3, 30.3, 28.4, 21.6. 
 
6-Amino-3-isopropyl-1-methylquinolin-2(1H)-one (198) Prepared according to general 
procedure D from 197 (75 mg, 0.30 mmol) to give the title compound as a yellow oil which was 
used without further purification. 
 
4-Cyano-N-(3-isopropyl-1-methyl-2-oxo-1,2-dihydroquinolin-6-yl)benzenesulfonamide 
(199) Prepared according to general procedure E  from 198 (33 mg, 0.15 mmol). Purified by 
column chromatography (acetone:hexane; 2:8 – 4:6) to give the title compound (20 mg, 0.05 mmol, 
34% over 2 steps) as a colourless solid: mp 209 – 210 °C (acetone-hexane); 1H NMR (400 MHz, 
DMSO-d6): δ ppm 10.54 (1H, s, NH), 8.04 (2H, d, J = 8.6 Hz, C16H), 7.88 (2H, d, J = 8.3 Hz, C15H), 7.67 
(1H, s, C4H), 7.44 (1H, d, J = 2.5 Hz, C5H), 7.40 (1H, d, J = 9.1 Hz, C8H), 7.22 (1H, dd, J = 9.0, 2.4 Hz, 
C7H), 3.57 (3H, s, C11H), 3.11 (1H, spt, J = 6.9 Hz, C12H), 1.17 (6H, d, J = 7.1 Hz, C13H); 13C NMR (126 
MHz, DMSO-d6): δ ppm 160.6, 143.4, 139.6, 135.9, 133.5, 131.8, 130.7, 127.4, 123.6, 120.5, 120.4, 
117.5, 115.4, 115.3, 29.4, 27.8, 21.5; HRMS: m/z ESI- [Found (M-H)- 380.1063 C20H19N3O3S requires 
(M-H)-  380.1069]; HPLC: Retention time (system A): tR= 10.78 min. Purity: >95%. 
 
4-Cyano-N-(3-isopropyl-1-methyl-2-oxo-1,2-dihydroquinolin-6-yl)-2-
methoxybenzenesulfonamide (200) Prepared according to general procedure E  from 198 (20 
mg, 0.11 mmol). Purified by column chromatography (acetone:hexane ; 2:8 – 4:6) to give the title 
compound (18 mg, 0.04 mmol, 29 % over 2 steps) as a colourless solid: mp 197 - 198 °C (acetone-
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hexane); 1H NMR (400 MHz, DMSO-d6): δ ppm 10.27 (1H, s, NH), 7.86 (1H, d, J = 8.1 Hz, C19H), 7.74 
(1H, d, J = 1.3 Hz, C16H), 7.63 (1H, s, C4H), 7.47 (1H, dd, J = 8.1, 1.5 Hz, C18H), 7.40 (1H, d, J = 2.3 Hz, 
C5H), 7.37 (1H, d, J = 9.1 Hz, C8H), 7.25 (1H, dd, J = 9.0, 2.4 Hz, C7H), 3.99 (3H, s, C20H), 3.56 (3H, s, 
C11H), 3.10 (1H, spt, J = 6.8 Hz, C12H), 1.16 (6H, d, J = 7.1 Hz, C13H); 13C NMR (126 MHz, DMSO-d6): δ 
ppm 160.5, 156.3, 139.5, 135.6, 131.8, 131.0, 130.8, 124.1, 123.1, 120.2, 119.7, 117.5, 116.8, 116.7, 
115.2, 57.0, 29.4, 27.9, 21.5; HRMS: m/z ESI- [Found (M-H)- 410.117 C21H21N3O4S requires (M-H)- 
410.1175]; HPLC: Retention time (system A): tR= 10.60 min. Purity: >95%. 
 
 
1,3-Diethyl-6-nitroquinolin-2(1H)-one (201) Prepared according to general procedure B from 
135 (300 mg 1.38 mmol) to give the title compound (222 mg, 0.90 mmol, 65%) as a brown solid 
that was used without further purification. 
 
1,3-Diethyl-6-aminoquinolin-2(1H)-one (202) Prepared according to general procedure B  from 
201 (210 mg, 0.85 mmol) to give the title compound as a brown oil that was filtered through a silica 
plug (acetone:hexane ; 7:3) to give a yellow oil (81 mg, 38 mmol, 44%) that was used without 
further purification. 
 
4-Cyano-N-(1,3-diethyl-2-oxo-1,2-dihydroquinolin-6-yl)benzenesulfonamide (203) Prepared 
according to general procedure E  from 202 (40 mg, 0.18 mmol). Purified by column 
chromatography (acetone:hexane ; 1:9 – 2:8) to give the title compound (37 mg, 0.09 mmol, 14% 
over 3 steps) as a pale yellow solid: mp 273 - 274 °C (acetone-hexane); 1H NMR (500 MHz, DMSO-
d6): δ ppm 10.56 (1H, s), 8.04 (2H, d, J = 8.5 Hz, C17H), 7.89 (2H, d, J = 8.5 Hz, C116H), 7.68 (1H, s, C4H), 
7.46 (1H, d, J = 8.8 Hz,  C8H), 7.41 (1H, d, J = 2.5 Hz, C5H), 7.23 (1H, dd, J = 9.1, 2.5 Hz, C7H), 4.22 (2H, 
q, J = 6.9 Hz, C11H), 1.21 - 1.10 (6H, m, C12H/ C14H) NB C13H overlaps with DMSO ; 13C NMR (126 MHz, 
DMSO-d6): δ ppm 160.5, 143.4, 135.3, 134.9, 133.6, 133.5, 130.7, 127.4, 123.6, 120.7, 120.3, 117.5, 
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115.3, 115.2, 36.9, 23.5, 12.7, 12.5; HRMS: m/z ESI- [Found (M-H)- 380.1057 C20H19N3O3S requires 
(M-H)-  380.1069]; HPLC: Retention time (system A): tR= 10.36 min. Purity: >95%. 
 
4-Cyano-N-(1,3-diethyl-2-oxo-1,2-dihydroquinolin-6-yl)-2-methoxybenzenesulfonamide 
(204) Prepared according to general procedure E  from 202 (40 mg, 0.18 mmol). Purified by 
column chromatography (acetone:hexane ; 1:9 – 2:8) to give the title compound (51 mg, 0.12 mmol, 
20% over 3 steps) as a colorless solid: mp 210 °C (acetone-hexane); 1H NMR (500 MHz, DMSO-d6): 
δ ppm 10.30 (1H, s, NH), 7.88 (1H, d, J = 8.2 Hz, C20H), 7.75 (1H, d, J = 0.9 Hz, C17H), 7.64 (1H, s, C4H), 
7.48 (1H, dd, J = 8.2, 1.3 Hz, C19H), 7.43 (1H, d, J = 8.8 Hz, C8H), 7.36 (1H, d, J = 2.2 Hz, C5H), 7.26 (1H, 
dd, J = 9.1, 2.5 Hz, C7H), 4.20 (2H, q, J = 7.1 Hz, C11H), 3.98 (3H, s, C21H), 1.15 (6H, app. t, J = 7.4 Hz, 
C12H/C14H); 13C NMR (126 MHz, DMSO-d6): δ ppm 160.4, 156.3, 135.2, 134.6, 133.6, 131.0, 131.0, 
130.9, 124.1, 123.1, 120.6, 119.5, 117.5, 116.8, 116.7, 115.0, 56.9, 36.9, 23.5, 12.7, 12.5; HRMS: m/z 
ESI- [Found (M-H)- 410.1185 C21H21N3O4S requires (M-H)-  410.1253]; HPLC: Retention time 
(system A): tR= 10.54 min. Purity: >95%. 
 
N-Methyl-2-(4-bromophenyl)acetamide (206a) To a solution of 4-bromophenylacetic acid (5.0 
g, 23.3 mmol, 1 eq.) and DMF (170 mg, 2.33 mmol, 0.1 eq.) in dry Toluene (12 mL) under an argon 
atmosphere was added thionyl chloride (3.32 g, 27.90 mmol, 1.2 eq.) dropwise. The solution was 
heated to 40 °C for 30 minutes and allowed to cool to RT. A solution of aqueous methylamine (40% 
by weight, 3.603 g, 10.0 mL, 116.25 mmol, 5 eq.) was cooled to 5 °C and the solution from the 
previous step was added dropwise with vigorous stirring at such a rate that the temperature of the 
solution did not exceed 25 °C. The resulting precipitate was filtered, washed with water (50 mL) 
and dried at 50 °C at 200 mbar to give the title compound (5.20 g, 22.8 mmol, 98%) as a colourless 
solid: 1H NMR (500 MHz, DMSO-d6): δ 8.00 (1H, br. s.), 7.49 (2H, d, J = 8.20 Hz), 7.21 (2H, d, J = 8.20 
Hz), 3.38 (2H, s), 2.57 (3H, d, J = 4.41 Hz). The above data is in agreement with that previously 
reported in the literature. 97 
 
N-Methyl-2-(4-nitrophenyl)acetamide (206b) Prepared as per Compound 206a from 4-
nitrophenylacetic acid (5.0 g, 27.6 mmol) to give the title compound (4.73 g, 24.9 mmol, 90%) as a 
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colourless solid: 1H NMR (400 MHz, DMSO-d6): δ 8.17 (2H, d, J = 8.6 Hz), 8.06 (1H, s), 7.53 (2H, d, J = 
8.6 Hz), 3.58 (2H, s), 2.60 (3 H, d, J = 4.5 Hz); 13C NMR (126 MHz, DMSO-d6): δ 169.3, 146.2, 144.5, 
130.3, 123.3, 41.9, 25.6. The above data is in agreement with that previously reported in the 
literature. 97 
 
7-Bromo-2-methyl-1,4-dihydroisoquinolin-3(2H)-one (207) To a 3 necked 100 mL flask fitted 
with  a reflux condenser, 50 mL dropwise addition funnel and a thermomemter was added Eaton’s 
Reagent (25 mL) followed by  206a (5 g, 21 mmol, 1 eq.) in portions. Paraformaldehyde (756 mg, 
25.2 mmol, 1.2 eq.) was added and the solution was heated to 80 °C for 2 hours. After cooling to RT 
water (25 mL) was added dropwise and the resulting suspension was cooled to -5 °C. Sodium 
hydroxide (19 M, ~12 mL) was added and the suspension was filtered and the filtrate extracted 
with ethyl acetate (3 × 50 mL). The organic fractions were combined, concentrated under reduced 
pressure and the residue purified by column chromatography (EtOAc) to give the title compound 
(3.56 g, 14.8 mmol, 70%) as a colourless solid: 1H NMR (500 MHz, CDCl3): δ 7.39 (1H, dd, J = 8.2, 1.9 
Hz), 7.33 (1H, s), 7.04 (1H, d, J = 8.2 Hz), 4.47 (2H, s), 3.57 (2H, s), 3.11 (3H, s); 13C NMR (126 MHz, 
CDCl3): δ 168.2, 133.0, 131.3, 130.7, 129.0, 128.1, 120.2, 52.3, 36.4, 34.4. The above data is in 
agreement with that previously reported in the literature. 97 
 
7-Bromo-2,4-dimethyl-1,4-dihydroisoquinolin-3(2H)-one  (208): To a solution of 
diisopropylamine (632 mg, 6.25 mmol 1 eq.) in dry THF (12 mL) at -78 °C was added n-butyllithium 
(1.6 M in Hexane, 6.25 mmol, 1 eq.) dropwise. The solution was stirred for 25 minutes and  207 (1.5 
g, 6.25 mmol, 1 eq.) in dry THF (6 mL) was added dropwise. Iodomethane (1.0 g, 7.5 mmol, 1.2 eq.) 
was added dropwise and stirred overnight. The solvent was removed under reduced pressure and 
the residue purified by column chromatography (6:4 – 10:0 ; EtOAc:hexane) to give the title 
compound (612 mg,  41 %) as a pale yellow oil: 1H NMR (400 MHz, CDCl3): δ 7.34 (1H, dd, J = 8.3, 
1.8 Hz), 7.25 (1H, s), 7.01 (1H, d, J = 8.3 Hz), 4.37 (2H, dd, J = 35.1, 15.9 Hz), 3.43 (1H, q, J = 7.3 Hz), 
3.03 (3H, s), 1.40 (3H, d, J=7.3 Hz); 13C NMR (126 MHz, CDCl3): δ 171.7, 137.0, 132.8, 130.8, 128.1, 
128.1, 120.1, 51.6, 40.8, 34.7, 18.3. 
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4-Cyano-N-(2,4-dimethyl-3-oxo-1,2,3,4-tetrahydroisoquinolin-7-yl)benzenesulfonamide 
(210) The required amine was prepared by general procedure J from 208 (77 mg, 0.30 mmol). 
Purified by column chromatography (EtOAc:hexane ; 9:1). Coupling carried out via general 
procedure E and purified by column chromatography (acetone:hexane ; 2:8) to give the title 
compound (17 mg, 0.05 mmol, 16% over 2 steps) as a pale yellow solid: mp 229 - 230 °C (acetone-
hexane); 1H NMR (400 MHz, DMSO-d6): δ 10.55 (1H, br. s NH), 8.05 (2H, d, J = 8.8 Hz, C15H), 7.92 
(2H, d, J = 8.6 Hz, C14H), 7.13 (1H, d, J = 8.1 Hz, C5H), 7.03 – 6.96 (2H, m, C6H/C8H), 4.47 (1H, d, J = 
16.2 Hz, C1H), 4.38 (1H, d, J = 16.2 Hz, C8H), 3.38 (1H, q, J = 7.2 Hz, C4H), 2.93 (3H, s, C11H), 1.29 (3H, 
d, J = 7.3 Hz, C12H); 13C NMR (126 MHz, DMSO-d6): δ 170.7, 143.5, 135.0, 134.2, 133.5, 132.9, 127.4, 
126.8, 119.6, 117.5, 117.4, 115.3, 50.8, 33.9, 17.0; HRMS: m/z ESI- [Found (M-H)- 354.0922 
C18H17N3O3 requires (M-H)- 354.0912]; HPLC: Retention time (system A): tR= 7.85 min. Purity: 89%. 
 
6-Nitroquinoxalin-2(1H)-one (212) Prepared according to general procedure C from quinaxalin-
2(1H)-one (2.50 g, 17.1 mmol) to give the title compound (3.00 g, 15.8 mmol, 92%) as a pale brown 
solid: 1H NMR (500 MHz, DMSO-d6): δ ppm 12.92 (1H, br. s.), 8.55 (1H, d, J = 2.5 Hz), 8.39 (1H, dd, J 
= 9.1, 2.5 Hz), 8.33 (1H, s), 7.45 (1H, d, J = 9.1 Hz); 13C NMR (126 MHz, DMSO-d6): δ ppm 154.7, 
154.2, 142.5, 137.2, 130.8, 125.3, 124.3, 116.7. The above data is in agreement with that previously 
published in the literature. 133  
 
1-Methyl-6-nitroquinoxalin-2(1H)-one (213) Prepared according to general procedure B from 
212 (1.0 g, 5.2 mmol). Crude product crystallised from EtOH to give the title compound (836 mg, 
4.1 mmol, 78%) as orange needles: 1H NMR (500 MHz, CDCl3): δ ppm 8.79 (1H, d, J = 2.5 Hz), 8.48 
(1H, dd, J = 9.1, 2.5 Hz), 8.44 (1H, s), 7.48 (1H, d, J = 9.1 Hz), 3.78 (3H, s); 13C NMR (126 MHz, CDCl3): 
δ ppm 154.5, 152.5, 143.4, 137.9, 132.5, 126.3, 125.6, 114.5, 29.3. The above data is in agreement 
with that previously published in the literature. 134  
 
4-Cyano-N-(1-methyl-2-oxo-1,2-dihydroquinoxalin-6-yl)benzenesulfonamide (215) Amine 
prepared by general procedure D from 213 (100 mg, 0.48 mmol). The crude amine was then 
coupled via general procedure E. Purified by column chromatography (acetone:hexane ; 4:6 – 6:4)  
to give the title compound (14 mg, 0.04 mmol, 8% over 2 steps) as a yellow solid: mp 247 °C 
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(decomposed); 1H NMR (500 MHz, DMSO-d6): δ ppm 10.77 (1H, br. s. NH), 8.21 (1H, s, C3H), 8.06 
(2H, d, J = 8.8 Hz, C14H), 7.92 (2H, d, J = 8.5 Hz, C13H), 7.52 (1H, d, J = 8.8 Hz, C8H), 7.49 (1H, d, J = 2.2 
Hz, C5H), 7.39 (1H, dd, J = 9.0, 2.4 Hz, C7H), 3.52 (3H, s, C11H); 13C NMR (126 MHz, DMSO-d6): δ ppm 
154.0, 151.2, 143.2, 133.6, 132.7, 132.4, 130.5, 127.4, 124.6, 120.8, 117.5, 116.0, 115.5, 28.6; HRMS: 
m/z ESI- [Found (M-H)- 339.0562, C16H12N4O3S requires (M-H)- 339.0552]; HPLC: Retention time 
(system A): tR= 6.99 min. Purity: >95%. 
 
2-Bromo-6-chloropyridin-3-amine (217) Prepared according to the procedure of Grongsaard et 
al from 6-chloropyridin-3-amine (5.0 g, 45.0 mmol) to give the title compound (7.65 g, 36.9 mmol, 
82%) as a brown solid: 1H NMR (500 MHz, CDCl3): δ ppm 7.11 (1H, d, J = 8.2 Hz), 7.01 (1H, d, J = 8.2 
Hz), 4.17 (2H, br. s.); 13C NMR (126 MHz, CDCl3): δ ppm 140.5, 137.7, 126.7, 124.4, 123.9. The above 
data is in agreement with that previously published in the literature. 98 
 
Tert-butyl (2-bromo-6-chloropyridin-3-yl)carbamate (218) Prepared according to the 
procedure of Grongsaard et al  from 217 (3.25 g, 15.7 mmol) to give the title compound (3.32 g, 
10.8 mmol, 69%) as a colourless solid: 1H NMR (500 MHz, CDCl3): δ ppm 8.39 (1H, d, J = 8.5 Hz), 
7.19 (1H, d, J = 8.8 Hz), 6.92 (1H, br. s.), 1.47 (9H, s); 13C NMR (126 MHz, CDCl3): δ ppm 151.9, 
142.5, 133.5, 129.7, 129.2, 123.8, 82.2, 28.2. The above data is in agreement with that previously 
published in the literature. 98 
 
 
Tert-butyl (4-bromo-2-formylpyridin-3-yl)carbamate (219)  Prepared according to the 
procedure of Grongsaard et al from 218 (1.5 g, 4.88 mmol) to give the title compound (603 mg, 2.00 
mmol, 41%) as a colourless solid: 1H NMR (500 MHz, CDCl3): δ ppm 10.11 (1H, br. s.), 9.92 (1H, s), 
8.81 (1H, d, J = 9.1 Hz), 7.40 (1H, d, J = 9.1 Hz), 1.47 (9H, s); 13C NMR (126 MHz, CDCl3): δ ppm 
195.7, 152.5, 143.3, 138.3, 135.8, 129.9, 129.8, 82.2, 27.2. The above data is in agreement with that 
previously published in the literature. 98 
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6-Chloro-1,5-naphthyridin-2(1H)-one (220) Prepared according to general procedure M from 
219 (400 mg, 1.56 mmol) to give the title compound (106 mg, 0.59 mmol, 38%) as yellow needles: 
1H NMR (500 MHz, DMSO-d6): δ ppm 12.39 (1H, br. s.), 8.64 (1H, d, J = 8.9 Hz), 8.31 (1H, d, J = 9.6 
Hz), 7.92 (1H, d, J = 9.0 Hz), 7.01 (1H, d, J = 9.6 Hz). 
 
6-Chloro-1-methyl-1,5-naphthyridin-2(1H)-one (221) Prepared according to general procedure 
B from x (125 mg, 0.69 mmol). Purified by column chromatography (acetone:hexane ; 2:8) to give 
the title compound (87 mg, 0.45 mmol, 65%) as a pale yellow solid: 1H NMR (500 MHz, DMSO-d6): δ 
ppm 8.47 (1H, d, J = 8.8 Hz), 8.21 (1H, d, J = 9.5 Hz), 7.85 (1H, d, J = 9.0 Hz), 7.11 (1H, d, J = 9.5 Hz), 
3.74 (3H, s). 
 
Tert-butyl (6-chloropyridin-3-yl)carbamate (222) Prepared according to the procedure of 
Rewcastle et al from 6-chloropyriding-3-amine (3.5 g, 27.3 mmol) to give the title compound (5.49 
g, 24.0 mmol, 88%) as an orange solid: 1H NMR (500 MHz, CDCl3): δ ppm 8.26 (1H, d, J = 2.8 Hz), 
7.99 (1H, br. s.), 7.28 (1H, d, J = 8.5 Hz), 6.61 (1H, br. s.), 1.54 (9H, s); 13C NMR (126 MHz, CDCl3): δ 
ppm 152.3, 144.8, 139.4, 134.3, 128.5, 124.2, 81.6, 28.2. The above data is in agreement with that 
previously published in the literature. 135  
 
Tert-butyl (6-chloro-4-formylpyridin-3-yl)carbamate (223) Prepared according to the 
procedure of Leivers et al from 222 (4.0 g, 17.5 mmol) to give the title compound (1.66 g, 6.47 
mmol, 37%) as a pale yellow solid: 1H NMR (500 MHz, CDCl3): δ ppm 9.97 (1H, s), 9.79 (1H, br. s.), 
9.64 (1H, s), 7.57 (1H, s), 1.57 (9H, s); 13C NMR (126 MHz, CDCl3): δ ppm 193.4, 152.0, 143.8, 142.3, 
134.7, 127.2, 126.9, 82.1, 28.2. The above data is in agreement with that previously published in the 
literature. 136  
 
6-Chloro-1,7-naphthyridin-2(1H)-one (224) Prepared according to general procedure M from 
223 (750 mg, 2.93 mmol) to give the title compound (265 mg, 1.46 mmol, 50%) as yellow needles: 
mp 109 -111 °C (DMF-water); 1H NMR (500 MHz, DMSO-d6): δ ppm 12.10 (1H, br. s.), 8.44 (1H, s), 
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7.92 (1H, d, J = 9.8 Hz), 7.83 (1H, s), 6.83 (1H, d, J = 9.5 Hz); 13C NMR (126 MHz, DMSO-d6): δ ppm 
161.2, 141.5, 137.6, 137.4, 133.9, 128.4, 126.7, 120.5. 
 
6-Chloro-1-methyl-1,7-naphthyridin-2(1H)-one (225) Prepared according to general procedure 
B from 224 (250 mg, 1.38 mmol). Purified by column chromatography (acetone:hexane ; 2:8) to 
give the title compound (215 mg, 1.11 mmol, 80%) as a pale yellow solid: mp 217 – 218 °C 
(acetone-hexane); 1H NMR (500 MHz, CDCl3): δ ppm 8.59 (1H, s), 7.61 (1H, d, J = 9.5 Hz), 7.49 (1H, 
s), 6.96 (1H, d, J = 9.5 Hz), 3.78 (3H, s); 13C NMR (126 MHz, CDCl3): δ ppm 161.0, 143.9, 136.3, 
135.9, 134.6, 128.3, 128.1, 120.9, 29.2. 
 
4-Cyano-2-methoxybenzenesulfonamide (227) 4-mercapto-3-methoxybenzonitrile (2.0 g, 12.1 
mmol, 1 eq.) and ZrCl4 (2.8 g, 12.1 mmol, 1eq.) were suspended in dry MeCN (60 mL) under an 
argon atmosphere and then stirred until homogenous. The resulting solution was cooled to 0 °C and 
H2O2 (30% w/w in H2O, 3.7 mL, 36.4 mmol, 3 eq.) was added dropwise, stirred for 2 hours at 0 °C 
and then allowed to warm to RT. The suspension was quenched with H2O (20 mL) and extracted 
with EtOAc (3 × 50 mL). The organic fractions were combined, dried over anhydrous sodium 
sulfate, filtered and concentrated under reduced pressure to give crude 4-cyano-2-
methoxybenzenesulfonyl chloride which was used without purification in the next step. 
The crude 4-cyano-2-methoxybenzenesulfonyl chloride was dissolved in conc. NH4OH (10 mL) and 
stirred overnight. The solvent was concentrated under reduced pressure, the residue dissolved in 
EtOH (50 mL) and the resulting suspension filtered. The filtrate was concentrated under reduced 
pressure  and the residue crystallised (EtOH:H2O ; 2:1) to give the title compound (582 mg, 2.72 
mmol, 23% over 2 steps) as pale yellow needles: mp 221 - 223 °C (ethanol-water); 1H NMR (500 
MHz, DMSO-d6): δ 7.88 (1H, d, J = 8.2 Hz), 7.75 (1H, d, J = 1.3 Hz), 7.55 (1H, dd, J = 7.9, 1.3 Hz), 7.39 
(2H, s), 3.97 (3H, s); 13C NMR (126 MHz, DMSO-d6): δ 156.0, 135.4, 128.5, 124.0, 117.8, 116.4, 115.7, 
56.8. 
 
3-Bromo-5-chloropyridin-2-amine (229a) Prepared according to the procedure of Murtiashaw 
et al from 5-chloropyridine-2-amine (3.0 g, 23.4 mmol) to give the title compound (3.0 g, 14.5 
mmol, 62%) as a brown solid: 1H NMR (400 MHz, CDCl3): δ ppm 8.00 (1H, d, J = 2.0 Hz), 7.68 (1H, d, 
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J = 2.3 Hz), 4.94 (2H, br. s.); 13C NMR (126 MHz, CDCl3): δ ppm 153.6, 145.4, 139.6, 119.6, 102.8. The 
above data is in agreement with that previously published in the literature. 137 
 
5-Bromo-3-iodopyridin-2-amine (229b) Prepared according to the procedure of Hibi et al from 
4-bromo-2-aminopyridine (5.0 g, 28.9 mmol) to give the title compound (4.04 g, 13.58 mmol, 47%) 
as an orange solid: 1H NMR (500 MHz, CDCl3): δ ppm 8.08 (1H, d, J = 2.2 Hz), 7.97 (1H, d, J = 1.9 Hz), 
5.03 (2H, br. s.); 13C NMR (126 MHz, CDCl3) δ ppm 156.4, 148.5, 148.2, 107.3, 77.6. The above data 
is in agreement with that previously published in the literature. 138  
 
Ethyl (E)-3-(2-amino-5-chloropyridin-3-yl)acrylate (230a) Prepared according to general 
procedure P from 229a (2.2 g, 10.6 mmol). Purification by column chromatography (EtOAc:hexane 
; 1:1) gave the title compound (1.41 g, 6.27 mmol, 59%) as a bright yellow solid: 1H NMR (500 MHz, 
CDCl3): δ ppm 8.08 (1H, d, J = 2.2 Hz), 7.61 (1H, s), 7.60 (1H, d, J = 15.6 Hz), 6.40 (1H, d, J = 15.8 Hz), 
4.79 (2H, br. s.), 4.30 (2H, q, J = 7.3 Hz), 1.36 (3H, t, J = 7.1 Hz); 13C NMR (126 MHz, CDCl3): δ ppm 
166.3, 154.8, 148.2, 137.5, 135.3, 121.7, 121.4, 115.5, 60.5, 14.2. The above data is in agreement 
with that previously published in the literature. 139 
 
Methyl (E)-3-(2-amino-5-bromopyridin-3-yl)acrylate (230b) Prepared according to general 
procedure P from 229b (3.0 g, 10.1 mmol). Purified by column chromatography (EtOAc:hexane ; 
1:9 – 3:7) to give the title compound (1.68 g, 6.5 mmol, 65 %) as a bright yellow solid: 1H NMR (500 
MHz, CDCl3): δ ppm 8.07 (1H, d, J = 2.2 Hz), 7.64 (1H, d, J = 2.2 Hz), 7.50 (1H, d, J = 15.8 Hz), 6.30 
(1H, d, J = 15.8 Hz), 4.68 (2H, br. s.), 3.75 (3H, s); 13C NMR (126 MHz, CDCl3): δ ppm 166.6, 155.0, 
150.5, 137.9, 137.7, 120.8, 116.0, 108.8, 52.0. 
 
6-Chloro-1,8-naphthyridin-2(1H)-one (231a) Prepared by general procedure Q from 230a (1.0 
g, 4.72 mmol) to give the title compound (747 mg, 4.15 mmol, 88%) as a colourless solid: mp >300 
°C (methanol-water); 1H NMR (500 MHz, DMSO-d6): δ ppm 8.51 (1H, d, J = 2.5 Hz), 8.22 (1H, s), 7.83 
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(1H, d, 9.5 Hz), 6.59 (1H, d, 9.5 Hz); 13C NMR (126 MHz, DMSO-d6): δ ppm 169.8, 165.5,156.1, 148.3, 
137.4, 134.8, 124.2, 116.9, 106.8. 
 
6-Bromo-1,8-naphthyridin-2(1H)-one (231b) Prepared by general procedure Q from 230b (1.0 
g, 3.89 mmol) to give the title compound (665 mg, 2.96 mmol, 76%) as a colourless solid: mp >300 
°C (methanol-water); 1H NMR (500 MHz, DMSO-d6): δ ppm 8.39 (1 H, d, J=2.8 Hz), 8.01 (1 H, d, J=2.5 
Hz), 7.55 (1 H, d, J=9.1 Hz), 6.38 (1 H, d, J=8.8 Hz); 13C NMR (126 MHz, DMSO-d6): δ ppm 170.8, 
165.7, 156.5, 149.5, 136.2, 135.0, 123.3, 116.6, 106.7. 
 
 
6-Chloro-1-methyl-1,8-naphthyridin-2(1H)-one (232a)  Prepared by general procedure B from 
231a (250 mg, 1.39 mmol). Purified by column chromatography (EtOAc:hexane ; 3:7) to give the 
title compound (191 mg, 0.98 mmol, 71%) as a colourless solid: 1H NMR (500 MHz, CDCl3): δ ppm 
8.39 (1H, d, J = 2.0 Hz), 7.98 (1H, d, J = 2.0 Hz), 7.33 (1H, d, J = 9.5 Hz), 6.59 (1H, d, J = 9.8 Hz), 3.89 
(3H, s); 13C NMR (126 MHz, CDCl3): δ ppm 161.9, 152.5, 148.0, 135.2, 132.9, 124.9, 116.8, 114.0, 
28.2. 
 
6-Bromo-1-methyl-1,8-naphthyridin-2(1H)-one (232b)  Prepared by general procedure B from 
231b (300 mg, 1.33 mmol). Purified by column chromatography (EtOAc:hexane ; 3:7) to give the 
title compound (258 mg, 1.08 mmol, 81%) as a colourless solid: 1H NMR (500 MHz, CDCl3): δ ppm 
8.64 (1H, d, J = 2.2 Hz), 8.01 (1H, d, J = 2.2 Hz), 7.59 (1H, d, J = 9.5 Hz), 6.82 (1H, d, J = 9.8 Hz), 3.82 
(3H, s); 13C NMR (126 MHz, CDCl3): δ ppm 162.7, 150.5, 148.7, 137.9, 135.8, 124.3, 116.9, 113.1, 
28.4. 
 
4-Cyano-N-(1-methyl-2-oxo-1,2-dihydroquinoxalin-6-yl)benzenesulfonamide (234) Amine 
prepared by general procedure J from 232b (100 mg, 0.42 mmol). The crude amine was then 
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coupled via general procedure E. Purified by column chromatography (acetone:hexane ; 4:6 – 6:4)  
to give the title compound (18 mg, 0.05 mmol, 13% over 2 steps) as a yellow solid: mp 283 – 284 °C 
(acetone-hexane); 1H NMR (500 MHz, DMSO-d6): δ ppm 10.80 (1H, br. s. NH), 8.28 (1H, d, J = 2.5 Hz, 
C7H), 8.05 (2H, d, J = 8.5 Hz, C14H), 7.97 (1H, d, J = 9.8 Hz, C4H), 7.92 (1H, d, J = 2.5 Hz, C5H), 7.90 (2H, 
d, J = 8.5 Hz, C13H), 6.71 (1H, d, J = 9.8 Hz, C3H), 3.61 (3H, s, C11H); 13C NMR (126 MHz, DMSO-
d6): δ ppm 161.8, 147.2, 144.2, 142.9, 137.3, 133.6, 130.0, 128.1, 127.4, 123.0, 
117.5, 115.5, 115.2, 27.8; HRMS: m/z ESI- [Found (M-H)- 339.0553, C16H12N4O3S requires (M-
H)- 339.0552]; HPLC: Retention time (system A): tR= 6.21 min. Purity: >95%. 
 
5-Nitro-1,3-dihydro-2H-benzo[d]imidazol-2-one (236)  Prepared according to the procedure of 
Belvagi et al from  1,2-diamino-4-nitrobenzene (2.50 g, 16.3 mmol) to give the title compound (2.69 
g, 15.0 mmol, 90%) as an orange solid that was used without further purification. Analytical sample 
prepared by crystallisation (EtOH:H2O ; 1:1). 380 mg of crude gave 300 mg of pure compound: 1H 
NMR (500 MHz, DMSO-d6): δ 11.41 (1H, br. s.), 11.18 (1H, br. s.), 7.95 (1H, dd, J = 8.7, 2.4 Hz), 7.71 
(1H, d, J = 2.2 Hz), 7.11 (1H, d, J = 8.5 Hz); 13C NMR (126 MHz, DMSO-d6): δ 155.3, 141.2, 135.8, 
129.5, 117.8, 108.0, 103.6. The above data is in agreement with that previously reported in the 
literature.140 
 
1,3-Dimethyl-5-nitro-1,3-dihydro-2H-benzo[d]imidazol-2-one (237) Prepared according to 
general procedure B from 236 (1.50 g, 8.30 mmol). Crude residue crystallised from EtOH to give 
the title  compound (798 mg, 3.85 mmol, 46%) as yellow needles: 1H NMR (500 MHz, CDCl3): δ 8.14 
(1H, dd, J = 8.7, 2.0 Hz), 7.91 (1H, d, J = 2.2 Hz), 7.05 (1H, d, J = 8.8 Hz), 3.52 (3H, s), 3.51 (3H, s); 13C 
NMR (126 MHz, CDCl3): δ 154.7, 142.6, 134.9, 129.7, 118.5, 106.5, 103.2 , 27.6, 27.6.The above data 
is in agreement with that previously reported in the literature. 141 
 
5-Amino-1,3-dimethyl-1,3-dihydro-2H-benzo[d]imidazol-2-one (238) 237 (500 mg, 2.41 
mmol, 1 eq.) and  palladium on carbon (5% by weight, 514 mg, 0.24 mmol, 0.1 eq.) were placed in a 
sealed rbf and backfilled with nitrogen 2 times and then EtOH (40 mL) was added. The flask was 
fitted with a balloon of hydrogen and purged and then backfilled 5 times. The resulting suspension 
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was stirred at RT overnight, purged with nitrogen for 20 mins and then filtered through a pad of 
Celite ® eluting with EtOH. The filtrate was concentrated under reduced pressure to give the title 
compound (350 mg, 1.98 mmol, 82%) as a white solid: 1H NMR (500 MHz, CDCl3): δ 6.76 (1H, d, J = 
8.2 Hz), 6.47 (1H, dd, J = 8.2, 1.9 Hz), 6.39 (1H, d, J = 1.9 Hz), 3.61 (2H, br. s.), 3.38 (3H, s), 3.37 (3H, 
s); 13C NMR (126 MHz, CDCl3): δ 154.8, 141.5, 131.1, 123.0, 108.2, 107.9, 95.6, 27.1, 27.1. The above 
data is in agreement with that previously reported in the literature. 141 
 
4-Cyano-N-(1,3-dimethyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-5-yl)-2-
methoxybenzenesulfonamide (239) Prepared by general procedure E from 238 (20 mg, 0.11 
mg). Purified by column chromatography (acetone:hexane ; 4:6) to give the title compound (23 mg, 
0.06 mmol, 55%) as a pale yellow solid: mp 251 – 252 °C (acetone-hexane); 1H NMR (400 MHz, 
DMSO-d6): δ 10.04 (1H, s, NH), 7.80 (1H, d, J = 7.8 Hz, C17H), 7.73 (1H, d, J = 1.3 Hz, C14H), 7.45 (1H, 
dd, J = 8.0, 1.4 Hz, C16H), 6.95 (1H, d, J = 8.3 Hz, C7H), 6.85 (1H, d, J = 1.8 Hz, C4H), 6.71 (1H, dd, J = 
8.3, 1.8 Hz, C6H), 4.01 (3H, s, C18H), 3.23 (3H, s, C10H or C11H), 3.23 (3H, s, C10H or C11H); 13C NMR 
(126 MHz, DMSO-d6): δ 156.2, 153.7, 131.1, 130.8, 130.5, 129.8, 127.1, 124.0, 117.5, 116.7, 116.5, 
114.7, 107.7, 102.1, 56.9, 26.9, 26.8; HRMS: m/z ESI- [Found (M-H)- 371.0821 C17H16N4O4S requires 
(M-H)- 371.0814]; HPLC: Retention time (system A): tR= 7.64 min. Purity: >95%. 
 
5-Bromo-6-methoxy-1,3-dihydro-2H-benzo[d]imidazol-2-one (241) : 5-methoxy-1,3-dihydro-
2H-benzo[d]imidazol-2-one (400 mg, 2.44 mmol, 1 eq.) was dissolved in DMF (10 mL) and NBS 
(434 mg, 2.44 mmol, 1 eq.) was added in one portion. The solution was stirred overnight and 
poured onto crushed ice (~ 100 g). The resulting precipitate was filtered and dried to give the title 
compound (498 mg, 2.05 mmol, 84%) as a pale brown solid: mp 276 - 278 °C (decomposed);1H 
NMR (500 MHz, DMSO-d6): δ 10.74 (1H, s), 10.52 (1H, s), 7.05 (1H, s), 6.71 (1H , s), 3.79 (3H, s); 13C 
NMR (126 MHz, DMSO-d6): δ 155.2, 150.2, 130.1, 124.4, 112.1, 101.3, 95.0, 56.6. 
 
5-Bromo-6-methoxy-1,3-dimethyl-1,3-dihydro-2H-benzo[d]imidazol-2-one (242) Prepared 
according to general procedure B from 241 (300 mg, 1.23 mmol, 1 eq.). Product precipitated and 
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was filtered, washed with H2O and dried to give the title compound (327 mg, 1.20 mmol, 98%) as a 
brown solid: 1H NMR (500 MHz, DMSO-d6): δ ppm 7.40 (1H, s), 7.07 (1H, s), 3.87 (3H, s), 3.29 (3H, 
m) NB NCH3 peak overlaps with DMSO H2O peak;  13C NMR (126 MHz, DMSO-d6): δ ppm 153.9, 150.7, 
129.9, 124.2, 111.6, 101.8, 94.6, 56.9, 27.1, 27.1. 
 
4-Bromo-N-(7-methoxy-1-methyl-2-oxo-1,2-dihydroquinolin-6-yl)-2-
methylbenzenesulfonamide (243) Prepared by general procedure E from a solution of 93 in NMP 
(78 mg, 0.38 mmol). Purified by column chromatography (acetone:hexane ; 2:8 – 4:6) to give the 
title compound (37 mg, 0.08 mmol, 22% over 2 steps) as a brown solid: mp 207 - 208 °C (acetone-
hexane); 1H NMR (500 MHz, DMSO-d6): δ ppm 9.78 (1H, s, NH), 7.84 (1H, d, J = 9.5 Hz, C4H), 7.68 
(1H, s, C15H), 7.59 (1H, s, C5H), 7.47 (1H, d, J = 8.5 Hz, C18H), 7.44 (1H, d, J = 8.5 Hz, C17H), 6.82 (1H, s, 
C8H), 6.45 (1H, d, J = 9.5 Hz, C3H), 3.59 (3H, s, C12H), 3.57 (3H, s, C11H), 2.66 (3H, s, C19H); 13C NMR 
(126 MHz, DMSO-d6): δ ppm 161.2, 155.9, 139.9, 139.9, 138.7, 137.8, 134.5, 130.8, 128.6, 127.5, 
126.1, 119.5, 118.3, 113.3, 97.5, 55.7, 29.2, 19.5; HRMS: m/z ESI- [Found (M+H)+ 435.0013, 
C18H17N2O4SBr requires (M+H)+ 435.0014]; HPLC: Retention time (system A): tR= 10.40 min. Purity: 
>95%. 
 
4-Cyano-2-methoxy-N-(7-methoxy-1-methyl-2-oxo-1,2-dihydroquinolin-6-
yl)benzenesulfonamide (244) Prepared by general procedure E from a solution of 93 in NMP (78 
mg, 0.38 mmol). Purified by column chromatography (acetone:hexane ; 1:9 – 1:1) to give the title 
compound (24 mg, 0.06 mmol, 16% over 2 steps) as a yellow solid: mp 211 - 213 °C (acetone-
hexane); 1H NMR (500 MHz, DMSO-d6): δ ppm 9.43 (1H, s, NH), 7.83 (1H, d, J = 9.5 Hz, C4H), 7.78 
(1H, d, J = 0.9 Hz, C15H), 7.70 (1H, d, J = 7.9 Hz, C18H), 7.58 (1H, s, C5H), 7.43 (1H, dd, J = 8.2, 1.3 Hz, 
C17H), 6.84 (1H, s, C8H), 6.44 (1H, d, J = 9.5 Hz, C3H), 3.98 (3H, s, C12H), 3.65 (3H, s, C12H), 3.58 (3H, s, 
C1H); 13C NMR (126 MHz, DMSO-d6): δ ppm 161.2, 156.8, 15, 5.6, 139.7, 138.7, 132.4, 130.0, 127.1, 
123.6, 119.9, 118.3, 117.7, 116.3, 116.2, 113.3, 97.4, 56.9, 55.9, 29.2; HRMS: m/z ESI- [Found (M-H)- 
398.0803, C19H17N3O5S requires (M-H)- 398.0811]; HPLC: Retention time (system A): tR= 8.22 min. 
Purity: >95%. 
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4-Bromo-2-fluoro-5-nitrobenzaldehyde (246) Prepared according to the procedure of Kusakabe 
et al from 2-fluoro-4-bromobenzaldeyde (5.00 g, 24.6 mmol) to give the title compound (5.44 g, 
21.9 mmol, 89%) as a pale yellow solid: 1H NMR (500 MHz, CDCl3): δ ppm 10.33 (1H, s), 8.43 (1H, d, 
J = 6.3 Hz), 7.69 (1H, d, J = 9.1 Hz); 13C NMR (126 MHz, CDCl3): δ ppm 183.9 (d, J = 5.5 Hz), 164.1 (d, 
J = 269.4 Hz), 126.1 (d, J = 3.7 Hz), 124.1, 123.9, 123.5 (d, J = 10.1 Hz), 122.6 (d, J = 11.0 Hz). The 
above data is in agreement with that previously reported in the literature. 101 
 
2-Ethyl-4,4-dimethyl-4,5-dihydrooxazole (247) Prepared as per compound 133 from propionic 
acid (5.0 g, 67.6 mmol) to give the title compound (4.72 g, 37.1 mmol, 55%) as a colourless oil: 1H 
NMR (400 MHz, CDCl3): δ ppm 3.90 (2H, s), 2.28 (2H, q, J = 7.5 Hz), 1.28 (6H, s), 1.16 (3H, t, J = 7.5 
Hz) . 
 
 
7-Bromo-3-methyl-6-nitroquinolin-2(1H)-one (248)  Prepared according to general procedure 
F from 2-fluoro-4-nitro-5-bromo-benzaldehyde (4.20 g, 16.8 mmol, 1 eq.) and 247 (2.13 g, 16.8 
mmol, 1 eq.) to give the title compound (3.92 g, 13.8 mmol, 82%) as a black solid that was used 
without further purification: Relevant 1H NMR (500 MHz, DMSO-d6) δ ppm 12.22 (1H, br. s.), 8.46 
(1H, s), 7.90 (1H, s), 7.63 (1H, s), 2.10 (3H, d, J=0.9 Hz). 
 
7-Bromo-1,3-methyl-6-nitroquinolin-2(1H)-one (249) Prepared by general procedure B from 
248 (1.2 g, 4.2 mmol). Product precipitated on addition of H2O and was filtered, washed with H2O 
and dried to give the title compound (983 mg, 3.30 mmol, 78%) as a brown solid that was used 
without further purification: Relevant  1H NMR (500 MHz, DMSO-d6) δ ppm 8.57 (1H, s), 8.04 (1H, 
s), 8.00 (1H, s), 3.77 (3H, s), 2.23 (3H, s). 
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1,3-Methyl-6-nitro-7-(pyrrolidin-1-yl)quinolin-2(1H)-one (250) - 249 (100 mg, 0.35 mmol, 1 
eq.), CuI (7 mg, 0.04 mmol, 0.1 eq.) and pyrrolidine (125 mg, 1.75 mmol, 5 eq.) were dissolved in 
dry DMF and heated at 80 °C for 3 hours. After cooling to RT the solution was poured onto ice (~50 
g) stirred for 10 mins and filtered to give the title compound (62 mg, 0.22 mmol, 65%)  as a brown 
solid: mp 184 °C (decomposed); 1H NMR (500 MHz, CDCl3): δ ppm 7.96 (1H, s), 7.43 (1H, s), 6.51 
(1H, s), 3.70 (3H, s), 3.41 - 3.21 (4H, m), 2.23 (3H, s), 2.11 – 1.98 (4H, m) ; 13C NMR (126 MHz, 
CDCl3): δ ppm 163.5, 143.1, 142.7, 135.0, 133.6, 126.8, 126.7, 110.7, 98.3, 50.9, 29.8, 25.8, 17.5. 
 
6-Amino-1-methyl-7-(pyrrolidin-1-yl)quinolin-2(1H)-one (251) Prepared by general 
procedure D from 250 (40 mg, 0.11 mmol). Compound precipitated on basification to pH 11 and 
was filtered, washed with H2O and dried to give the title compound (24 mg,  0.1 mmol, 91%) as a 
dark red solid: 1H NMR (500 MHz, CDCl3): δ ppm 7.40 (1H, s), 6.84 (1H, s), 6.81 (1H, s), 3.85 - 3.70 
(5H, m), 3.31 – 3.14 (4H, m), 2.24 (3H, s), 2.07 – 1.98 (4H, m) ; 13C NMR (126 MHz, CDCl3): δ ppm 
162.7, 135.7, 134.7, 133.4, 131.2, 127.2, 116.3, 112.7, 102.8, 50.8, 29.6, 24.3, 17.8. 
 
2-Methoxy-N-(1-methyl-2-oxo-7-(pyrrolidin-1-yl)-1,2-dihydroquinolin-6-yl)benzamide 
(252) Prepared by general procedure E from 251 (20 mg, 0.08 mmol). Purified by column 
chromatography (acetone:hexane 2:8) to give the title compound (12 mg, 0.03 mmol, 36%) as an 
orange solid: mp 193 - 196 °C (acetone-hexane); 1H NMR (500 MHz, CDCl3): δ ppm 10.12 (1H, s), 
8.36 (1H, s), 8.30 (1H, dd, J = 7.7, 1.7 Hz), 7.48 - 7.42 (2H, m), 7.10 (1H, t, J = 7.1 Hz), 6.99 (1H, d, J = 
8.5 Hz), 6.82 (1H, s), 3.98 (3H, s), 3.66 (3H, s), 3.22 - 3.15 (4H, m), 2.16 (3H, d, J = 0.9 Hz), 1.98 - 1.92 
(4H, m);  13C NMR (126 MHz, CDCl3): δ ppm 163.3, 163.1, 157.4, 144.1, 136.8, 135.8, 133.2, 132.7, 
127.2, 126.2, 121.8, 121.7, 121.7, 115.7, 111.5, 102.4, 56.0, 51.6, 29.6, 24.8, 17.7; HRMS: m/z NSI+ 
[Found (M+H)+ 392.1958 C23H25N3O3 requires M+ 392.1896]; HPLC: Retention time (system A): tR= 
10.40 min. Purity: 91%. 
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1,3-Dimethyl-6-(pyrrolidin-1-yl)quinolin-2(1H)-one (254)  129a (100 mg, 0.53 mmol, 1 eq.) 
was dissolved in dry DMF (2 mL) under argon. Cs2CO3 (690 mg, 2.12 mmol, 4 eq.) and 1,4 
diiodobutane (198 mg, 0.64 mmol, 1.2 eq.) was added and the resulting suspension was heated to 
80 °C overnight.  After cooling to RT the reaction was diluted with H2O (20 mL) and extracted with 
EtOAc (3×50 mL). The organic fractions were pooled, dried over anhydrous sodium sulfate, filtered 
and evaporated under reduced pressure to give a residue which was purified by column 
chromatography (acetone:hexane ; 1:9 – 3:7) to give the title compound (73 mg, 0.30 mmol, 57%) 
as a bright yellow solid: mp 136 - 137 °C (acetone-hexane); 1H NMR (500 MHz, CDCl3): δ 7.40 (1H, 
s), 7.15 (1H, d, J = 8.8 Hz), 6.77 (1H, dd, J = 9.1, 2.5 Hz), 6.51 (1H, d, J = 2.5 Hz), 3.30 - 3.18 (4H, m), 
1.97 (4H, s); 13C NMR (126 MHz, CDCl3): δ 162.2, 143.6, 135.4, 130.5, 130.2, 121.9, 114.9, 114.8, 
108.1, 48.0, 29.6, 25.5, 17.9. 
 
7-Bromo-1,3-dimethyl-6-(pyrrolidin-1-yl)quinolin-2(1H)-one (255)   254 (50 mg, 0.21 mmol, 
1 eq.) was dissolved in dry DMF (2 mL) and freshly recrystallized NBS (39 mg, .22 mmol, 1.05 eq.) 
was added in 1 portion and stirred overnight. Further NBS (78 mg, 0.42 mmol, 2.1 eq.) was added 
and the solution was stirred for a further 24 hours. The solution was diluted with H2O (10 mL) and 
extracted with EtOAc (3×20 mL). The organic fractions were pooled, dried over anhydrous sodium 
sulfate, filtered and evaporated under reduced pressure to give a residue which was purified by 
column chromatography (acetone:hexane 1:9 – 3:7) to give the title compound (8 mg, 0.025 mmol, 
12%) as a bright yellow solid: mp 105 - 106 °C (acetone-hexane); 1H NMR (400 MHz, CDCl3): δ 8.06 
(1H, d, J = 1.3 Hz), 7.17 (2H, app. s), 3.66 (3H, s), 3.29 - 3.21 (4H, m), 2.23 (3H, d, J = 1.3 Hz), 1.91 
(4H, s); 13C NMR (126 MHz, CDCl3): δ 162.1, 134.4, 131.5, 121.1, 120.2, 115.6, 113.6, 51.8, 30.1, 
24.9, 18.2.  
 
7-Bromo-6-nitroquinolin-2(1H)-one (257)  Prepared according to general procedure G from 
246 (2.5 g, 10.2 mmol) to give the title compound (1.80 g, 6.79 mmol, 66%) as a black solid that 
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was used without further purification Relevant 1H NMR (500 MHz, DMSO-d6): δ 12.21 (1 H, br. s.), 
8.58 (1H, s), 8.05 (1H, d, J = 9.8 Hz), 7.66 (1H, s), 6.70 (1H, dd, J = 9.6, 1.7 Hz). 
 
7-Bromo-1-methyl-6-nitroquinolin-2(1H)-one (258) Crude 257 (1.2 g, 4.46 mmol, 1 eq.) 
methylated according to general procedure B. Purification by column chromatography 
(acetone:hexane 1:20 – 2:8) followed by trituration of product fractions with cold acetone gave the 
title compound (213 mg, 0.76 mmol, 17%) as a pale yellow solid: mp 227 – 229 °C (acetone-
hexane); 1H NMR (400 MHz, CDCl3): δ 8.24 (1H, s), 7.71 (1H, d J = 9.6 Hz), 6.85 (1H, d, J = 9.6 Hz), 
3.75 (3H, s); 13C NMR (126 MHz, CDCl3): δ 161.5, 143.1, 142.7, 137.7, 126.4, 124.3, 120.5, 119.3, 
117.0, 29.4. 
 
1-Methyl-6-nitro-7-(pyrrolidin-1-yl)quinolin-2(1H)-one (259) – 258 (100 mg, 0.35 mmol, 1 
eq.), CuI (7 mg, 0.04 mmol, 0.1 eq.) and pyrrolidine (125 mg, 1.75 mmol, 5 eq.) were dissolved in 
dry DMF and heated at 80 °C for 3 hours. After cooling to RT the solution was poured onto ice (~50 
g) stirred for 10 mins and filtered to give the title compound (74 mg, 0.27 mmol, 77%)  as a brown 
solid: mp 212 °C (decomposed); 1H NMR (500 MHz, CDCl3): δ 8.01 (1H, s), 7.56 (1H, d, J = 9.5 Hz), 
6.58 - 6.47 (2H, m), 3.67 (3H, s), 3.42 - 3.28 (4H, m), 2.17 – 1.98 (4H, m); 13C NMR (126 MHz, CDCl3): 
δ 162.8, 143.8, 143.5, 133.4, 127.7, 118.4, 110.7, 98.4, 50.9, 29.4, 25.8. 
 
6-Amino-1-methyl-7-(pyrrolidin-1-yl)quinolin-2(1H)-one (260) Prepared by general 
procedure D from 259 (50 mg, 0.18 mmol). Compound precipitated on basification to pH 11 and 
was filtered, washed with H2O and dried to give the title compound (34 mg,  0.14 mmol, 77%) as a 
dark red solid: 1H NMR (400 MHz, CDCl3): δ 7.41 (1H, d, J = 9.3 Hz), 6.75 (1H, s), 6.74 (1H, s), 6.46 
(1H, d, J = 9.3 Hz), 3.67 - 3.55 (5H, m), 3.24 - 3.10 (4H, m), 1.95 – 1.93 (4H, m); 13C NMR (126 MHz, 
CDCl3): δ 162.3, 142.4, 137.8, 135.5, 134.6, 118.7, 115.8, 113.4, 102.5, 50.6, 29.4, 24.4. 
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2-Methoxy-N-(1-methyl-2-oxo-7-(pyrrolidin-1-yl)-1,2-dihydroquinolin-6-yl)benzamide 
(261) Prepared by general procedure E from 260 (20 mg, 0.083 mmol). Purified by column 
chromatography (acetone:hexane 2:8) to give the title compound (31 mg, 0.082 mmol, quant) as a 
pale yellow solid: mp 209 - 211 °C (acetone-hexane); 1H NMR (500 MHz, CDCl3): δ 10.11 (1H, s), 
8.41 (1H, s), 8.39 (1H, dd, J = 7.9, 1.9 Hz), 7.65 (1H, d, J = 9.5 Hz), 7.55 (1H, td, J = 8.8, 1.9 Hz), 7.20 
(1H, t, J = 7.9 Hz), 7.09 (1H, d, J = 8.2 Hz), 6.89 (1H, s), 6.59 (1H, d, J = 9.5 Hz), 4.08 (3H, s), 3.73 (3H, 
s), 3.35 - 3.30 (4H, m), 2.07 - 2.02 (4H, m); 13C NMR (126 MHz, CDCl3): δ 163.4, 162.7, 157.4, 145.6, 
138.9, 138.0, 133.3, 132.8, 125.5, 123.3, 121.7, 121.6, 118.7, 115.2, 111.5, 102.0, 56.0, 51.3, 29.3, 
24.9; HRMS: m/z ESI- [Found (M-H)- 376.1662, C22H23N3O3 requires (M-H)- 376.1661]; HPLC: 
Retention time (system A): tR= 9.97 min. Purity: >95%. 
 
4-(N-(1,3-dimethyl-2-oxo-1,2-dihydroquinolin-6-yl)sulfamoyl)-3-methoxybenzamide (262) 
To a suspension of NI-57 (45 mg, 0.12 mmol, 1 eq.) and potassium carbonate (65 mg, 0.37 mmol, 3 
eq.) in dry DMSO (250 μL) was added hydrogen peroxide (30% w/w aqueous solution, 0.24 mmol, 
2 eq.) in 1 portion and the resulting suspension was stirred overnight. Water (10 mL) was added 
and the aqueous layer was extracted with EtOAc (3 × 15 mL). The combined organic extracts were 
pooled, washed with brine (20 mL), dried with Na2SO4, filtered and the solvent was removed under 
reduced pressure to give the title compound (41 mg, 0.10 mmol, 87%) as a colourless solid: mp 285 
°C (ethyl acetate); 1H NMR (500 MHz, DMSO-d6): δ ppm 10.12 (1H, s), 8.11 (1H, s), 7.78 (1H, d, J = 
8.2 Hz), 7.69 (1H, s), 7.62 - 7.51 (2H, m), 7.45 (1H, dd, J = 8.0, 1.4 Hz), 7.36 (1H, d, J = 9.1 Hz), 7.31 
(1H, d, J = 2.5 Hz), 7.27 (1H, dd, J = 9.1, 2.2 Hz), 3.97 (3H, s), 3.55 (3H, s), 2.08 (3H, s); 13C NMR (126 
MHz, DMSO-d6): δ ppm 166.4, 161.3, 156.1, 140.3, 135.7, 135.0, 131.6, 130.3, 129.8, 128.4, 122.6, 
120.2, 119.0, 118.6, 115.2, 111.6, 56.3, 29.3, 17.3;  HRMS: m/z ESI- [Found (M-H)- 400.0968 
C19H19N3O5S requires (M-H)- 400.0967]; HPLC: Retention time (system A): tR= 6.35 min. Purity: 
>95%. 
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9. Appendices 
 9.1 Spectra for NI-57 and NI-42 
9.1.1  NI-42 1H NMR 
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9.1.2  NI-42 13C NMR 
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9.1.3  NI-42 HPLC 
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9.1.4  NI-57 1H NMR 
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9.1.5  NI-42 13C NMR 
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9.1.6  NI-57 HPLC 
 
 9.2 DSF (Thermal Shift Data) for bromonome wide screeining of NI-42, NI-
57 and 164 
9.2.1  NI-42  
BRD Tm (°C) BRD Tm (°C) BRD Tm (°C) 
ASH1L 0.5 BRDT92) -0.3 PB1(4) 0.0 
ATAD2 -0.4 BRPF1A 0.2 PB1(5) 0.2 
BAZ1A -0.9 BRPF1B 7.8 PB1(6) 0.0 
BAZ1B 0.2 BRPF3 2.4 PCAF 0.3 
BAZ2A -0.8 BRWD3(2) 0.5 PHIP(2) -0.8 
BAZ2B -0.5 CECR2 0.4 SMARCA2 0.2 
BRD1 4.2 CREBBP 0.5 SMARCA4 -0.3 
BRD2(1) 0.4 EP300 0.8 SP140 -0.4 
BRD2(2) -0.2 FALZ 0.3 TAF1(2) -0.6 
BRD3(1) 0.6 GCN5L2 -0.3 TAF1(1) 0.0 
BRD3(2) -0.2 ATAD2B -0.1 TAF1L(1) 0.7 
BRD4(1) 0.4 SP140L -0.2 TAF1L(2) -1.9 
BRD4(2) 0.3 MLL 0.0 TIF1-bromo 0.4 
BRD7 4.8 PB1(1) -0.1 TIF1-phd-bromo 0.3 
BRD9 1.8 PB1(2) 0.0 TRIM28 -1.0 
BRDT(1) 0.0 PB1(3) 0.2 WDR9(2) -0.2 
 
 
 
 
 
 
 
 
9.2.2  NI 57 
BRD Tm (°C) BRD Tm (°C) BRD Tm (°C) 
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ASH1L -0.5 BRDT(2) 0.2 PB1(4) 0.6 
ATAD2 -0.5 BRPF1A 0.9 PB1(5) 0.3 
BAZ1A -0.3 BRPF1B 10.7 PB1(6) 0.3 
BAZ1B 0 BRPF3 5.3 PCAF 0.5 
BAZ2A -0.4 BRWD3(2) 1.5 PHIP(2) -0.4 
BAZ2B 0 CECR2 0.3 SMARCA2 0.5 
BRD1 5.6 CREBBP 1.1 SMARCA4 0.2 
BRD2(1) 0.4 EP300 1.1 SP140 0.9 
BRD2(2) 0 FALZ 0.3 TAF1(2) 0.5 
BRD3(1) 0.8 GCN5L2 0.3 TAF1(1) 0.4 
BRD3(2) 0.2 ATAD2B -0.1 TAF1L(1) 0.7 
BRD4(1) 0.8 SP140L 0.5 TAF1L(2) 0.7 
BRD4(2) -0.1 MLL 0.3 TIF1-bromo 2 
BRD7 6.6 PB1(1) 0.5 TIF1-phd-bromo 1.6 
BRD9 3.1 PB1(2) 0.4 TRIM28 0.8 
BRDT(1) 0.2 PB1(3) 0.1 WDR9(2) 0.7 
 
9.2.3  Compound 164 
BRD Tm (°C) BRD Tm (°C) BRD Tm (°C) 
ASH1L 0.8 BRDT(2) 1 PB1(4) 1 
ATAD2 0.2 BRPF1A 0.6 PB1(5) 0.8 
BAZ1A 1.1 BRPF1B 10.9 PB1(6) 0.6 
BAZ1B 1 BRPF3 5.6 PCAF 0.9 
BAZ2A -0.3 BRWD3(2) 0.7 PHIP(2) 0.2 
BAZ2B 0.2 CECR2 0.6 SMARCA2 0.3 
BRD1 6 CREBBP 2.2 SMARCA4 0.6 
BRD2(1) 2.2 EP300 2.2 SP140 1.5 
BRD2(2) 0.5 FALZ 1.9 TAF1(2) 0.7 
BRD3(1) 2.3 GCN5L2 1 TAF1(1) 0.6 
BRD3(2) 0.9 ATAD2B 0.4 TAF1L(1) 1.1 
BRD4(1) 2.6 SP140L 1.5 TAF1L(2) 1.7 
BRD4(2) 0.3 MLL 1 TIF1-bromo 2.5 
BRD7 8.9 PB1(1) 0.9 TIF1-phd-bromo 1.5 
BRD9 6.5 PB1(2) 0.7 TRIM28 0.3 
BRDT(1) 1.1 PB1(3) 0.3 WDR9(2) 0.8 
 
 
 9.3 Data from NCI-60 Cancer panel, AZ CLIMB Panel and Cerep Safety 
Panel 
9.3.1  NCI-60 Panel for NI-57 
Conc (M) Cancer Type Cell Line Growth Percentage (%) 
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0.00001 Leukemia CCRF-CEM 
89.9 
0.00001 Leukemia HL-60(TB) 
95.7 
0.00001 Leukemia K-562 
77.0 
0.00001 Leukemia MOLT-4 
86.3 
0.00001 Leukemia RPMI-8226 
79.3 
0.00001 Leukemia SR 
82.0 
0.00001 Non-Small Cell Lung Cancer A549/ATCC 
87.5 
0.00001 Non-Small Cell Lung Cancer EKVX 
89.7 
0.00001 Non-Small Cell Lung Cancer HOP-62 
88.6 
0.00001 Non-Small Cell Lung Cancer HOP-92 
91.8 
0.00001 Non-Small Cell Lung Cancer NCI-H226 
85.7 
0.00001 Non-Small Cell Lung Cancer NCI-H23 
92.8 
0.00001 Non-Small Cell Lung Cancer NCI-H322M 
93.9 
0.00001 Non-Small Cell Lung Cancer NCI-H460 
102.6 
0.00001 Non-Small Cell Lung Cancer NCI-H522 
73.3 
0.00001 Colon Cancer COLO 205 
114.7 
0.00001 Colon Cancer HCC-2998 
96.7 
0.00001 Colon Cancer HCT-116 
95.9 
0.00001 Colon Cancer HCT-15 
106.6 
0.00001 Colon Cancer HT29 
100.5 
0.00001 Colon Cancer KM12 
92.7 
0.00001 Colon Cancer SW-620 
100.0 
0.00001 CNS Cancer SF-268 
101.7 
0.00001 CNS Cancer SF-295 
90.6 
0.00001 CNS Cancer SF-539 
103.7 
0.00001 CNS Cancer SNB-19 
105.2 
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0.00001 CNS Cancer SNB-75 
82.0 
0.00001 CNS Cancer U251 
92.9 
0.00001 Melanoma LOX IMVI 
95.4 
0.00001 Melanoma MALME-3M 
93.8 
0.00001 Melanoma M14 
97.9 
0.00001 Melanoma MDA-MB-435 
96.2 
0.00001 Melanoma SK-MEL-2 
98.5 
0.00001 Melanoma SK-MEL-28 
108.2 
0.00001 Melanoma SK-MEL-5 
93.0 
0.00001 Melanoma UACC-257 
92.1 
0.00001 Melanoma UACC-62 
82.9 
0.00001 Ovarian Cancer IGROV1 
97.0 
0.00001 Ovarian Cancer OVCAR-3 
103.4 
0.00001 Ovarian Cancer OVCAR-4 
77.0 
0.00001 Ovarian Cancer OVCAR-5 
99.3 
0.00001 Ovarian Cancer OVCAR-8 
94.8 
0.00001 Ovarian Cancer NCI/ADR-RES 
97.2 
0.00001 Ovarian Cancer SK-OV-3 
106.2 
0.00001 Renal Cancer 786-0 
96.9 
0.00001 Renal Cancer A498 
107.6 
0.00001 Renal Cancer ACHN 
95.6 
0.00001 Renal Cancer CAKI-1 
85.2 
0.00001 Renal Cancer RXF 393 
101.8 
0.00001 Renal Cancer SN12C 
92.1 
0.00001 Renal Cancer TK-10 
90.8 
0.00001 Renal Cancer UO-31 
75.2 
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0.00001 Prostate Cancer PC-3 
84.0 
0.00001 Prostate Cancer DU-145 
99.8 
0.00001 Breast Cancer MCF7 
83.4 
0.00001 Breast Cancer MDA-MB-231/ATCC 
97.1 
0.00001 Breast Cancer HS 578T 
97.2 
0.00001 Breast Cancer BT-549 
99.3 
0.00001 Breast Cancer T-47D 
77.2 
0.00001 Breast Cancer MDA-MB-468 
76.2 
 
Table 50. Data for tne NCI-60 cancer panel screen of NI-57. Work carried out at the National Institute of 
Health 
9.3.2  AZ CLIMB Panel 
Label, Species, cell line, GI50 (μM) NI-57 NI-42 
IT16707 Hu SW48 Prolif Cell Panel Mean GI50 (µM) 
30 1.2 
IT16718 Hu OCI-AML2 Prolif Cell Panel Mean GI50 (µM) 
10 1.3 
IT13873 Hu NUGC-4 Prolif Cell Panel Mean GI50 (µM) 
30 1.6 
IT13884 Hu HepG2 prolif Cell Panel Mean GI50 (µM) 
30 2.0 
IT16634 Hu COLO 205 Prolif Cell Panel Mean GI50 (µM) 
30 2.6 
IT13872 Hu OCUM-1 Prolif Cell Panel Mean GI50 (µM) 
30 2.7 
IT21518 Hu HUP-T4 Prolif cell panel Mean GI50 (µM) 
30 3.0 
IT16702 Hu LOVO Prolif Cell Panel Mean GI50 (µM) 
30 4.2 
IT17872 Hu C-99 Prolif Cell Panel Mean GI50 (µM) 
30 4.3 
IT19190 Hu 22Rv1 Prolif cell panel Mean GI50 (µM) 
30 4.4 
IT16706 Hu SK-CO-1 Prolif Cell Panel Mean GI50 (µM) 
30 4.5 
IT16716 Hu Nomo-1 Prolif Cell Panel Mean GI50 (µM) 
10 4.6 
IT16730 Hu MOLP-8 Profil Cell Panel Mean GI50 (µM) 
10 5.1 
IT21527 Hu QGP-1 Prolif cell panel Mean GI50 (µM) 
30 5.2 
IT13914 Hu AGS Prolif Cell Panel Mean GI50 (µM) 
30 5.3 
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IT16710 Hu THP-1 Prolif Cell Panel Mean GI50 (µM) 
10 5.7 
IT21515 Hu Hs 766T Prolif cell panel Mean GI50 (µM) 
30 6.1 
IT13924 Hu SNU-5 Prolif Cell Panel Mean GI50 (µM) 
30 6.3 
IT16715 Hu SW948 Prolif Cell Panel Mean GI50 (µM) 
30 6.3 
IT16705 Hu RKO Prolif Cell Panel Mean GI50 (µM) 
30 6.7 
IT16647 Hu OCI-LY-19 Prolif Cell Panel Mean GI50 (µM) 
10 6.8 
IT16692 Hu KG-1 Prolif Cell Panel Mean GI50 (µM) 
10 7.0 
IT21521 Hu Panc02.03 Prolif cell panel Mean GI50 (µM) 
30 7.5 
IT16713 Hu SW403 Prolif Cell Panel Mean GI50 (µM) 
30 7.6 
IT17314 Hu HCC1187 Prolif Cell Panel Mean GI50 (µM) 
30 7.7 
IT16672 Hu NCI-H1437 Prolif Cell Panel Mean GI50 (µM) 
30 8.1 
IT16673 Hu IM-9 Profil Cell Panel Mean GI50 (µM) 
10 8.2 
IT21504 Hu AsPC-1 Prolif cell panel Mean GI50 (µM) 
30 8.4 
IT16711 Hu SW620 Prolif Cell Panel Mean GI50 (µM) 
30 8.8 
IT16704 Hu LS 180 Prolif Cell Panel Mean GI50 (µM) 
30 9.9 
IT18016 Hu MV-4-11 Prolif Cell Panel Mean GI50 (µM) 
10 9.9 
IT16709 Hu Molm 16 Prolif Cell Panel Mean GI50 (µM) 
10 10.0 
IT16712 Hu MonoMac6 Prolif Cell Panel Mean GI50 (µM) 
10 10.0 
IT16714 Hu Reh Prolif Cell Panel Mean GI50 (µM) 
10 10.0 
IT16729 Hu L-363 Profil Cell Panel Mean GI50 (µM) 
10 10.0 
IT16734 Hu RPMI-8226 Profil Cell Panel Mean GI50 (µM) 
10 10.0 
IT18014 Hu Hel92.1.7 Prolif Cell Panel Mean GI50 (µM) 
10 10.0 
IT18015 Hu Molm 13 Prolif Cell Panel Mean GI50 (µM) 
10 10.0 
IT18017 Hu RS411 Prolif Cell Panel Mean GI50 (µM) 
10 10.0 
IT16630 Hu JEKO-1 Prolif Cell Panel Mean GI50 (µM) 
10 10.0 
IT16643 Hu JVM-3 Prolifl Cell Panel Mean GI50 (µM) 
10 10.0 
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IT16645 Hu MEC-1 Prolif Cell Panel Mean GI50 (µM) 
10 10.0 
IT16646 Hu NAMALWA Prolif Cell Panel Mean GI50 (µM) 
10 10.0 
IT16648 Hu Raji Prolif Cell Panel Mean GI50 (µM) 
10 10.0 
IT16654 Hu Ramos Prolif Cell Panel Mean GI50 (µM) 
10 10.0 
IT16656 Hu CMK Prolif Cell Panel Mean GI50 (µM) 
10 10.0 
IT16657 Hu SC-1 Prolif Cell Panel Mean GI50 (µM) 
10 10.0 
IT16664 Hu Jurkat Prolif Cell Panel Mean GI50 (µM) 
10 10.0 
IT16666 Hu K-562 Prolif Cell Panel Mean GI50 (µM) 
10 10.0 
IT16668 Hu AMO-1 Profil Cell Panel Mean GI50 (µM) 
10 10.0 
IT16669 Hu ARH-77 Profil Cell Panel Mean GI50 (µM) 
10 10.0 
IT16670 Hu JJN-3 Profil Cell Panel Mean GI50 (µM) 
10 10.0 
IT16677 Hu U937 Prolif Cell Panel Mean GI50 (µM) 
10 10.0 
IT16679 Hu WSU DLCL2 Prolif Cell Panel Mean GI50 (µM) 
10 10.0 
IT16662 Hu HT-29 Prolif Cell Panel Mean GI50 (µM) 
30 12.3 
IT17322 Hu MDA-MB-157 Prolif Cell Mean GI50 (µM) 
30 12.4 
IT13920 Hu SNU-1 Prolif Cell Panel Mean GI50 (µM) 
30 12.4 
IT13891 Hu SNU-878 Prolif Cell Panel Mean GI50 (µM) 
30 12.7 
IT21514 Hu HPAF-II Prolif cell panel Mean GI50 (µM) 
30 12.7 
IT13893 Hu SNU-449 Prolif Cell Panel Mean GI50 (µM) 
30 12.8 
IT13913 Hu 23132/87 Prolif Cell Panel Mean GI50 (µM) 
30 13.4 
IT18616 Hu KU-19-19 Prolif Cell Panel Mean GI50 (µM) 
30 14.0 
IT21525 Hu Panc10.05 Prolif cell panel Mean GI50 (µM) 
30 14.1 
IT13876 Hu BEL7405 Prolif Cell panel Mean GI50 (µM) 
30 14.3 
IT17316 Hu HCC1419 Prolif Cell Panel Mean GI50 (µM) 
23.44 14.3 
IT16641 Hu Calu-3 Prolif Cell Panel Mean GI50 (µM) 
30 14.4 
IT18618 Hu RT4 Prolif Cell Panel Mean GI50 (µM) 
30 15.4 
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IT17876 Hu HRA-19 Prolif Cell Panel Mean GI50 (µM) 
15.62 15.7 
IT13908 Hu SNU-638 Prolif Cell Panel Mean GI50 (µM) 
30 15.8 
IT13919 Hu NCl-N87 Prolif Cell Panel Mean GI50 (µM) 
30 16.2 
IT16639 Hu Calu-6 Prolif Cell Panel Mean GI50 (µM) 
30 16.4 
IT17874 Hu CCK-81 Prolif Cell Panel Mean GI50 (µM) 
30 16.4 
IT16640 Hu DMS 114 Prolif Cell Panel Mean GI50 (µM) 
14.67 16.6 
IT19867 Hu LUDLU-1 Prolif cell panel Mean GI50 (µM) 
30 16.7 
IT19904 Hu RERF-LC-Sq1 Prolif Mean GI50 (µM) 
16.57 17.2 
IT13902 Hu HLE Prolif Cell panel Mean GI50 (µM) 
30 17.2 
IT13911 Hu SNU-484 Prolif Cell Panel Mean GI50 (µM) 
30 17.2 
IT13972 Hu Hep3B Prolif Cell Panel Mean GI50 (µM) 
30 17.4 
IT13907 Hu SNU-620 Prolif Cell Panel Mean GI50 (µM) 
30 17.6 
IT13910 Hu SNU-601 Prolif Cell Panel Mean GI50 (µM) 
30 18.0 
IT21513 Hu HPAC Prolif cell panel Mean GI50 (µM) 
30 18.5 
IT18636 Hu SW780 Prolif cell panel Mean GI50 (µM) 
30 19.1 
IT16674 Hu NCI-H1869 Prolif Cell Panel Mean GI50 (µM) 
30 19.8 
IT16652 Hu NIH:OVCAR-3 Prolif Mean GI50 (µM) 
30 20.4 
IT13900 Hu HuH-7 Prolif Cell Panel Mean GI50 (µM) 
30 20.8 
IT18641 Hu 5637 Prolif cell panel Mean GI50 (µM) 
30 21.1 
IT13898 Hu SNU-354 prolif Cell Panel Mean GI50 (µM) 
30 21.6 
IT16694 Hu NCI-H226 Prolif Cell Panel Mean GI50 (µM) 
30 21.6 
IT16650 Hu MDA-MB-231 Prolif CellPanel Mean GI50 (µM) 
30 21.9 
IT21517 Hu HUP-T3 Prolif cell panl Mean GI50 (µM) 
30 22.1 
IT19899 Hu NCI-H2286 Prolif cell panel Mean GI50 (µM) 
30 22.1 
IT14567 Hu NUGC-3 Prolif Cell Panel Mean GI50 (µM) 
30 22.9 
IT14028 Hu PAMC82 Prolif Cell Panel Mean GI50 (µM) 
30 22.9 
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IT16633 Hu HCT 116 Prolif Cell Panel Mean GI50 (µM) 
30 23.0 
IT16632 Hu HX147 Prolif cell panel Mean GI50 (µM) 
30 23.5 
IT18627 Hu BFTC-905 Prolif cell panel Mean GI50 (µM) 
30 23.6 
IT19856 Hu EBC-1 Prolif cell panel Mean GI50 (µM) 
30 23.8 
IT13894 Hu SNU-398 prolif Cell Panel Mean GI50 (µM) 
30 24.1 
IT21526 Hu PANC-89 Prolif cell panel Mean GI50 (µM) 
30 24.4 
IT21522 Hu Panc03.27 Prolif cell panel Mean GI50 (µM) 
30 24.9 
IT18619 Hu SCaBER Prolif cell panel Mean GI50 (µM) 
30 25.7 
IT21510 Hu Capan-2 Prolif cell panel Mean GI50 (µM) 
30 25.7 
IT13896 Hu SNU-368 Prolif Cell Panel Mean GI50 (µM) 
30 26.3 
IT18628 Hu HT1197 Prolif cell panel Mean GI50 (µM) 
30 26.5 
IT17984 Hu OE33 Prolif Cell Panel Mean GI50 (µM) 
30 26.6 
IT17321 Hu JIMT-1 Prolif Cell Panel Mean GI50 (µM) 
30 26.9 
IT16637 Hu NCI-H1299 Prolif Cell Panel Mean GI50 (µM) 
30 27.2 
IT16708 Hu SW480 Prolif Cell Panel Mean GI50 (µM) 
30 27.2 
IT17323 Hu ZR-75-1 Prolif Cell Panel Mean GI50 (µM) 
30 27.3 
IT18640 Hu VM-CUB-1 Prolif cell panel Mean GI50 (µM) 
30 27.5 
IT13887 Hu SNU-886 Prolif Cell Panel Mean GI50 (µM) 
30 27.9 
IT16689 Hu HCT-8 Prolif Cell Panel Mean GI50 (µM) 
30 28.5 
IT17873 Hu CC20 Prolif Cell Panel Mean GI50 (µM) 
30 28.7 
IT19859 Hu HCC-15 Prolif cell panel Mean GI50 (µM) 
30 28.7 
IT21519 Hu KP-4 Prolif cell panel Mean GI50 (µM) 
30 28.8 
IT19192 Hu PNT1A Prolif cell panel Mean GI50 (µM) 
30 29.9 
IT18642 Hu 647V Prolif cell panel Mean GI50 (µM) 
30 30.0 
IT16697 Hu COLO 320DM Prolif Mean GI50 (µM) 
30 30.0 
IT16698 Hu NCI-H358 Prolif Cell Panel Mean GI50 (µM) 
30 30.0 
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IT16699 Hu NCI-H522 Prolif Cell Panel Mean GI50 (µM) 
30 30.0 
IT16701 Hu NCI-H838 Prolif Cell Panel Mean GI50 (µM) 
30 30.0 
IT16703 Hu PC9 Prolif Cell Panel Mean GI50 (µM) 
30 30.0 
IT13874 Hu MKN74 Prolif Cell Panel Mean GI50 (µM) 
30 30.0 
IT13875 Hu BEL7404 Prolif cell panel Mean GI50 (µM) 
30 30.0 
IT13878 Hu HCCC9810 Prolif Cell Panel Mean GI50 (µM) 
30 30.0 
IT13880 Hu MKN1 Prolif Cell Panel Mean GI50 (µM) 
30 30.0 
IT13881 Hu IM95m Prolif Cell Panel Mean GI50 (µM) 
30 30.0 
IT13883 Hu SK-HEP-1 Prolif Cell Panel Mean GI50 (µM) 
30 30.0 
IT13888 Hu SNU-761 prolif Cell Panel Mean GI50 (µM) 
30 30.0 
IT13889 Hu MHCC97L Prolif Cell panel Mean GI50 (µM) 
30 30.0 
IT13890 Hu QGY7703 Prolif Cell panel Mean GI50 (µM) 
30 30.0 
IT13892 Hu SNU-739 prolif Cell Panel Mean GI50 (µM) 
30 30.0 
IT17311 Hu BT-20 Prolif Cell Panel Mean GI50 (µM) 
30 30.0 
IT13897 Hu SMMC7721 Prolif Cell panel Mean GI50 (µM) 
30 30.0 
IT17312 Hu BT-549 Prolif Cell Panel Mean GI50 (µM) 
30 30.0 
IT17313 Hu CAMA-1 Prolif Cell Panel Mean GI50 (µM) 
30 30.0 
IT13901 Hu HuH-1 prolif Cell Panel Mean GI50 (µM) 
30 30.0 
IT17315 Hu HCC1395 Prolif Cell Panel Mean GI50 (µM) 
30 30.0 
IT17317 Hu HCC1569 Prolif Cell Panel Mean GI50 (µM) 
30 30.0 
IT13903 Hu HLF Prolif Cell panel Mean GI50 (µM) 
30 30.0 
IT17318 Hu HCC1806 Prolif Cell Panel Mean GI50 (µM) 
30 30.0 
IT17319 Hu HCC1937 Prolif Cell Panel Mean GI50 (µM) 
30 30.0 
IT17320 Hu HCC1954 Prolif Cell Panel Mean GI50 (µM) 
30 30.0 
IT13909 Hu SNU-668 Prolif Cell Panel Mean GI50 (µM) 
30 30.0 
IT17324 Hu T47D Prolif Cell Panel Mean GI50 (µM) 
30 30.0 
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IT13912 Hu SNU-216 Prolif Cell Panel Mean GI50 (µM) 
30 30.0 
IT17326 Hu MDA-MB-436 Prolif Cell Mean GI50 (µM) 
30 30.0 
IT17327 Hu SUM52PE Prolif Cell Panel Mean GI50 (µM) 
30 30.0 
IT17328 Hu MDA-MB-453 Prolif Cell Mean GI50 (µM) 
26.72 30.0 
IT13915 Hu GTL-16 Prolif Cell Panel Mean GI50 (µM) 
30 30.0 
IT13916 Hu HGC27 Prolif Cell Panel Mean GI50 (µM) 
30 30.0 
IT13917 Hu KATO III Prolif Cell Panel Mean GI50 (µM) 
30 30.0 
IT17875 Hu HCA-7 Prolif Cell Panel Mean GI50 (µM) 
30 30.0 
IT17983 Hu OE19 Prolif Cell Panel Mean GI50 (µM) 
30 30.0 
IT13925 Hu SNU-16 Prolif Cell Panel Mean GI50 (µM) 
30 30.0 
IT14575 Hu HS746T Prolif Cell Panel Mean GI50 (µM) 
30 30.0 
IT18615 Hu J82 Prolif Cell Panel Mean GI50 (µM) 
30 30.0 
IT16631 Hu A549 Prolif cell panel Mean GI50 (µM) 
30 30.0 
IT18617 Hu RT112/84 Prolif Cell Panel Mean GI50 (µM) 
30 30.0 
IT16635 Hu HCT-15 Prolif Cell Panel Mean GI50 (µM) 
30 30.0 
IT16636 Hu Calu-1 Prolif Cell Panel Mean GI50 (µM) 
30 30.0 
IT18629 Hu HT1376 Prolif cell panel Mean GI50 (µM) 
30 30.0 
IT18630 Hu 1A6 [PTA-556] Prolif panel Mean GI50 (µM) 
30 30.0 
IT18633 Hu MGH-U3 Prolif cell panel Mean GI50 (µM) 
30 30.0 
IT18634 Hu 97-7 Prolif cell panel Mean GI50 (µM) 
30 30.0 
IT18635 Hu T24 Prolif cell panel Mean GI50 (µM) 
30 30.0 
IT18637 Hu SW1710 Prolif cell panel Mean GI50 (µM) 
30 30.0 
IT16644 Hu LNCaP clone FGC Prolif Mean GI50 (µM) 
30 30.0 
IT18638 Hu TCC-SUP Prolif cell panel Mean GI50 (µM) 
30 30.0 
IT18639 Hu UM-UC-3 Prolif cell panel Mean GI50 (µM) 
30 30.0 
IT16649 Hu MCF7 Cell Panel Mean GI50 (µM) 
30 30.0 
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IT19191 Hu LNCap-CasRes(AZ) cell panel Mean GI50 (µM) 
30 30.0 
IT16651 Hu NCI-H23 Prolif Cell Panel Mean GI50 (µM) 
30 30.0 
IT16653 Hu MIA PaCa-2 Prolif CellPanel Mean GI50 (µM) 
30 30.0 
IT19858 Hu HARA Prolif Cell Panel Mean GI50 (µM) 
30 30.0 
IT16655 Hu PANC-1 Prolif Cell Panel Mean GI50 (µM) 
30 30.0 
IT19861 Hu HCC95 Prolif cell panel Mean GI50 (µM) 
30 30.0 
IT19864 Hu LK-2 Prolif cell panel Mean GI50 (µM) 
30 30.0 
IT16658 Hu SK-BR-3 Prolif Cell Panel Mean GI50 (µM) 
30 30.0 
IT19897 Hu NCI-H2170 Prolif cell panel Mean GI50 (µM) 
30 30.0 
IT16663 Hu MDA-MB-468 Prolif CellPanel Mean GI50 (µM) 
30 30.0 
IT19900 Hu NCI-H520 Prolif cell panel Mean GI50 (µM) 
30 30.0 
IT19901 Hu NCI-H596 Prolif cell panel Mean GI50 (µM) 
30 30.0 
IT16665 Hu NCI-H460 Prolif Cell Panel Mean GI50 (µM) 
30 30.0 
IT19902 Hu NCI-H647 Prolif cell panel Mean GI50 (µM) 
30 30.0 
IT19903 Hu RERF-LC-AI Prolif Mean GI50 (µM) 
30 30.0 
IT16667 Hu NCI-H460 dnp53 Prolif Mean GI50 (µM) 
30 30.0 
IT19905 Hu SK-MES-1 Prolif cell panel Mean GI50 (µM) 
30 30.0 
IT19906 Hu SW 900 Prolif cell panel Mean GI50 (µM) 
30 30.0 
IT21507 Hu BxPC-3 Prolif cell panel Mean GI50 (µM) 
30 30.0 
IT21509 Hu Capan-1 Prolif cell panel Mean GI50 (µM) 
30 30.0 
IT21511 Hu CFPAC-1 Prolif cell panel Mean GI50 (µM) 
30 30.0 
IT16675 Hu MCF7/mdr+ Prolif Cell Panel Mean GI50 (µM) 
30 30.0 
IT16678 Hu PC-3 Prolif Cell Panel Mean GI50 (µM) 
30 30.0 
IT16680 Hu NCI-H1703 Prolif Cell Panel Mean GI50 (µM) 
20.65 30.0 
IT16681 Hu NCI-H526 Prolif Cell Panel Mean GI50 (µM) 
10.41 30.0 
IT16684 Hu NCI-H1793 Prolif Cell Panel Mean GI50 (µM) 
30 30.0 
214 
 
IT16686 Hu DU 145 Prolif Cell Panel Mean GI50 (µM) 
30 30.0 
IT16687 Hu A2058 Prolif Cell Panel Mean GI50 (µM) 
30 30.0 
IT21523 Hu Panc04.03 Prolif cell panel Mean GI50 (µM) 
30 30.0 
IT16690 Hu NCI-H1975 Prolif Cell Panel Mean GI50 (µM) 
30 30.0 
IT16691 Hu NCI-H2085 Prolif Cell Panel Mean GI50 (µM) 
30 30.0 
IT21529 Hu SU.86.86 Prolif cell panel Mean GI50 (µM) 
30 30.0 
IT16693 Hu NCI-H2126 Prolif Cell Panel Mean GI50 (µM) 
30 30.0 
IT21530 Hu SW1990 Prolif cell panel Mean GI50 (µM) 
30 30.0 
IT21531 Hu T3M-4 Prolif cell panel Mean GI50 (µM) 
30 30.0 
IT16695 Hu NCI-H2291 Prolif Cell Panel Mean GI50 (µM) 
30 30.0 
IT21533 Hu YAPC Prolif cell panel Mean GI50 (µM) 
30 30.0 
IT16696 Hu NCI-H322 Prolif Cell Panel Mean GI50 (µM) 
30 30.0 
IT21927 Hu Panc08.13 Prolif cell panel Mean GI50 (µM) 
30 30.0 
Table 51. Data from the AZ CLIMB cancer panel screen of NI-57 and NI-42. Work carried out at AZ. ’10’ 
indicates a GI50 >10 μM, ‘30’ indicates a GI50 >30 μM.  
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 9.4 Cerep Panel 
 
Assay 
Test 
Concentration 
(M) 
% 
Inhibition 
of Control 
Specific 
Binding 
Reference Compound 
norepinephrine transporter (h)  (antagonist radioligand) 1.0E-05 39 protriptyline 
A1 (h)  (antagonist radioligand) 1.0E-05 38 DPCPX 
kappa  (KOP)  (agonist radioligand) 1.0E-05 20 U 50488 
CB1 (h)  (agonist radioligand) 1.0E-05 13 CP 55940 
MT1 (ML1A) (h)  (agonist radioligand) 1.0E-05 13 melatonin 
EP4 (h)  (agonist radioligand) 1.0E-05 12 PGE2 
D2S (h)  (antagonist radioligand) 1.0E-05 10 (+)butaclamol 
NTS1 (NT1) (h)  (agonist radioligand) 1.0E-05 10 neurotensin 
5-HT5a (h)  (agonist radioligand) 1.0E-05 8 serotonin 
Cl- channel  (GABA-gated)  (antagonist radioligand) 1.0E-05 8 picrotoxinin 
NK3 (h)  (antagonist radioligand) 1.0E-05 7 SB 222200 
Na+ channel (site 2)  (antagonist radioligand) 1.0E-05 6 veratridine 
NOP (ORL1) (h)  (agonist radioligand) 1.0E-05 5 nociceptin 
5-HT2B (h)  (agonist radioligand) 1.0E-05 5 (±)DOI 
mu  (MOP) (h)  (agonist radioligand) 1.0E-05 4 DAMGO 
5-HT7 (h)  (agonist radioligand) 1.0E-05 4 serotonin 
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dopamine transporter (h)  (antagonist radioligand) 1.0E-05 4 BTCP 
CCK1 (CCKA) (h)  (agonist radioligand) 1.0E-05 3 CCK-8s 
delta 2 (DOP) (h)  (agonist radioligand) 1.0E-05 3 DPDPE 
5-HT6 (h)  (agonist radioligand) 1.0E-05 3 serotonin 
Ca2+ channel  (L, verapamil site)  (phenylalkylamine)  (antagonist radioligand) 1.0E-05 3 D 600 
B2 (h)  (agonist radioligand) 1.0E-05 2 NPC 567 
MC4 (h)  (agonist radioligand) 1.0E-05 2 NDP-alpha -MSH 
A3 (h)  (agonist radioligand) 1.0E-05 0 IB-MECA 
ETA (h)  (agonist radioligand) 1.0E-05 0 endothelin-1 
5-HT1A (h)  (agonist radioligand) 1.0E-05 0 8-OH-DPAT 
alpha 1 (non-selective)  (antagonist radioligand) 1.0E-05 -2 prazosin 
CCR1 (h)  (agonist radioligand) 1.0E-05 -2 MIP-1alpha 
A2A (h)  (agonist radioligand) 1.0E-05 -3 NECA 
H1 (h)  (antagonist radioligand) 1.0E-05 -4 pyrilamine 
M3 (h)  (antagonist radioligand) 1.0E-05 -4 4-DAMP 
5-HT1B  (antagonist radioligand) 1.0E-05 -4 serotonin 
KV channel  (antagonist radioligand) 1.0E-05 -4 alpha -dendrotoxin 
beta 1 (h)  (agonist radioligand) 1.0E-05 -5 atenolol 
5-HT3 (h)  (antagonist radioligand) 1.0E-05 -5 MDL 72222 
beta 2 (h)  (agonist radioligand) 1.0E-05 -7 ICI 118551 
CXCR2 (IL-8B) (h)  (agonist radioligand) 1.0E-05 -7 IL-8 
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V1a (h)  (agonist radioligand) 1.0E-05 -7 
[d(CH2)51,Tyr(Me)2]-
AVP 
SKCa channel  (antagonist radioligand) 1.0E-05 -7 apamin 
AT1 (h)  (antagonist radioligand) 1.0E-05 -8 saralasin 
GAL2 (h)  (agonist radioligand) 1.0E-05 -10 galanin 
GABA  (non-selective)  (agonist radioligand) 1.0E-05 -11 GABA 
Y2 (h)  (agonist radioligand) 1.0E-05 -11 NPY 
5-HT2A (h)  (antagonist radioligand) 1.0E-05 -11 ketanserin 
VPAC1 (VIP1) (h)  (agonist radioligand) 1.0E-05 -11 VIP 
alpha 2 (non-selective)  (antagonist radioligand) 1.0E-05 -12 yohimbine 
D1 (h)  (antagonist radioligand) 1.0E-05 -12 SCH 23390 
sst (non-selective)  (agonist radioligand) 1.0E-05 -12 somatostatin-14 
5-HT transporter (h)  (antagonist radioligand) 1.0E-05 -12 imipramine 
BZD (central)  (agonist radioligand) 1.0E-05 -13 diazepam 
NK2 (h)  (agonist radioligand) 1.0E-05 -13 [Nleu10]-NKA (4-10) 
M2 (h)  (antagonist radioligand) 1.0E-05 -17 methoctramine 
Y1 (h)  (agonist radioligand) 1.0E-05 -17 NPY 
M1 (h)  (antagonist radioligand) 1.0E-05 -21 pirenzepine 
H2 (h)  (antagonist radioligand) 1.0E-05 -24 cimetidine 
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